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Abstract 
It is important to account for all sources of uncertainty when evaluating the clinical or 
cost-effectiveness of health care technologies. Therefore, this thesis takes as its basis 
a cost-effectiveness study in liver transplantation and identifies two previously 
unexplored issues that can arise in clinical and cost-effectiveness studies. A literature 
review of studies evaluating the effectiveness, costs or cost-effectiveness of solid 
organ transplantation confirmed that these issues were important and relevant to other 
transplantation studies. 
The first issue concerns the selection of an appropriate method for estimating mean 
study costs in the presence of incomplete (censored) data. Twelve techniques were 
identified and their accuracy was compared across artificially created mechanisms and 
levels of censoring. Lin's method with known cost histories and short interval lengths is 
recommended for accurately estimating mean costs and their uncertainty. It is 
assumed that these findings are generalisable to any solid organ transplant study 
where censoring is an issue. 
The second issue explored in this thesis relates to methods for measuring uncertainty 
around survival, HRQL and cost estimates derived from prognostic models in the 
absence of observed data. Probabilistic sensitivity analysis is recommended for 
measuring prognostic model parameter uncertainty and estimating individual patient 
outcomes and their uncertainties, as it is able to incorporate the additional uncertainty 
from using prognostic models to estimate control group outcomes. 
This thesis shows the quantitative importance of these issues and the methodological 
guidance offered should enable decision makers to have more confidence in clinical 
and cost-effectiveness estimates. Providing decision makers with a fuller estimate of 
the uncertainty around clinical and cost effectiveness estimates will aid them in 
decisions about the necessity of conducting further research in to the clinical or cost-
effectiveness of health care technologies. 
Publications and Authorship 
The research presented in Chapter 2 denote the starting point for the work presented in 
this thesis and the results in Chapter 2 are the result of a collaborative effort on the part 
of a multi-disciplinary research team [Longworth et aI, 2002; Longworth et aI, 2003]. I 
played a substantive role in this research team, performing the statistical analysis and 
contributing to the cost-effectiveness analysis, writing and dissemination of the study 
results. Whilst acknowledging the contribution of my colleagues, it should be 
emphasised that for all of the research presented in the thesis, I have been the lead 
researcher, designing the main component studies and undertaking all analyses. 
The research presented in Chapter 4 of this thesis has been presented in 
Pharmacoeconomics [Young, 2005]. The results in Chapter 4 differ from those in the 
paper as they contain additional methods for estimating costs in the presence of 
censoring, they compare methods for different levels of censoring (e.g.10%, 30% and 
50%) and compare methods for differing interval lengths (dividing the study in to 
alternative interval lengths). This resulted in slightly different conclusions to those 
published in the paper. 
The research presented in Chapter 5 of this thesis has been published in the 
International Journal of Technology Assessment in Health Care [Young & Thompson, 
2004]. 
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CHAPTER 1 
INTRODUCTION 
1.1 MEASURING UNCERTAINTIES IN ECONOMIC EVALUATIONS OF HEALTH 
CARE TECHNOLOGIES 
Guidelines on the analysis of economic evaluations of health care technologies 
encourage analysts to include information on the "uncertainty associated with clinical 
and cost-effectiveness information" [National Institute for Health and Clinical 
Excellence (NICE), 2004; See: Drummond & Jefferson, 1996; NICE, 2004; Canadian 
Agency for Drugs and Technologies in Health (CADTH), 2006]. 
These guidelines state that uncertainty should be dealt with "both systematically and 
thoroughly" so that informed decisions can be made for new and existing health care 
technologies [CADTH, 2006]. Results based on patient level data should include details 
of the statistical tests performed and confidence intervals (CI) should be presented 
around the main outcomes of interest [Drummond & Jefferson, 1996; CADTH, 2006]. 
Further, guidelines recommend that the uncertainty around economic evaluation results 
1 
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be presented in the form of "confidence ellipses, scatter plots on the cost-effectiveness 
plane and cost effectiveness acceptability curves" [NICE, 2006]. 
In economic evaluations, uncertainties in sample estimates are usually expressed by 
standard errors or confidence intervals around point estimates. Briggs et ai, classify 
this type of uncertainty as sampling variation [Briggs et ai, 1994]. This is also referred 
to in the literature as first order uncertainty or stochastic uncertainty [Briggs, 2000; 
Coyle et ai, 2003]. 
In addition to sampling variation, Briggs and colleagues classify three further types of 
uncertainty in stochastic analysis - studies where observed data are available [Briggs 
et ai, 1994]. The first type of uncertainty that arises is methodological uncertainty, 
which occurs due to the assumptions made in the process of estimating the outcome of 
interest, for example choosing a discount rate for future costs and effects of 3.5% when 
rates of 0% or 6% may be equally applicable. The second source of uncertainty occurs 
when generalising the study results to alternative populations or settings. 
Typically, economic evaluation studies are concerned with observing the lifetime costs 
and effects of health care technologies, however, the majority of studies only collect 
information over a fixed (short-term) time period. Therefore, methods are required for 
extrapolating results beyond the study time period and Briggs and colleagues note that 
the third source of uncertainty arises from the need to credibly extrapolate results over 
a longer time frame. 
"The process of extrapolating the results of economic evaluations is invariably 
undertaken using modelling exercises" [Briggs & Gray, 1999]. Further, economic 
evaluations of health care technologies usually apply some form of mathematical 
modelling "to progress from the within-trial results to the economic results of interest" 
[Briggs, 2000]. This introduces three further sources of uncertainty, namely: model 
parameter uncertainty, model structure uncertainty and uncertainties in the model 
process [Manning et ai, 1996]. Model input values, also known as model parameters, 
might include the probability of an event occurring, unit cost estimates or regression 
coefficients for a prognostiC model for estimating patient survival and these values are 
subject to (model parameter) uncertainty. Uncertainties in the model structure arise 
when selecting the mathematical structure of the model. For example, a researcher 
aiming to model the hazard or risk of death needs to decide between analysing survival 
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at a fixed time point (using logistic regression or a similar model) and analysing the 
actual survival time (using Cox regression or a similar model). Model process 
uncertainties arise because there is more than one solution to a problem. For example, 
if a problem is assigned to two (or more) analysts to solve independently, the analysts 
may use different approaches (processes) to derive a solution to the problem. 
Guidelines on measuring uncertainties in economic evaluations of health care 
technologies recommend the use of deterministic and probabilistic sensitivity analysis 
to explore methodological, extrapolation and modelling uncertainties [Drummond & 
Jefferson, 1996; NICE, 2004; CADTH, 2006]. When sensitivity analysis is conducted 
"details should be given of the approach used ... and justification given for the choice 
of variables and the ranges over which they are varied" [Drummond & Jefferson, 1996]. 
It is important to identify and measure all sources of uncertainty in economic 
evaluations and various methodological techniques for measuring sources of 
uncertainty in economic evaluations have been presented in the literature. Probably the 
most well debated problem pertains to measuring the sampling variation around 
incremental cost-effectiveness ratios (ICER), the ratio of the difference in costs to 
difference in effects between two or more treatment and control groups in a study. 
Methods for estimating CI include: confidence boxes [O'Brien et ai, 1994; Polsky et ai, 
1997], confidence ellipses [van Hout et ai, 1994], Taylor series [O'Brien et ai, 1994], 
Fieller's theorem [Fieller, 1932; Fieller, 1954; Willan & O'Brien, 1996], sampling 
[Mullahy & Manning, 1995] and bootstrapping [Efron & Tibshirani, 1993; Manning et ai, 
1996; Briggs et ai, 1997]. These techniques have been discussed thoroughly in the 
literature [See: Briggs & Fenn, 1997; Briggs & Gray, 1999] and will not be dealt with in 
more detail here. 
It is not the focus of this thesis to identify and review all the methodology that has been 
proposed in the literature for identifying and measuring uncertainty in economic 
evaluations. However, from the analyst's perspective there are still unresolved issues 
pertaining to the methodology for measuring various forms of uncertainty in economic 
evaluations. A recent economic evaluation study in liver transplantation [Longworth et 
ai, 2003] identified two such issues, neither of which are unique to this one study. From 
the analysts perspective this created an ongoing problem that hindered the ideal of 
allowing for all uncertainty associated with a study, and consequently formed the 
motivation for this thesis. 
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1.2 FOCUS OF THIS THESIS 
This thesis takes as its basis a cost-effectiveness study in liver transplantation and 
explores some specific methodological, model parameter estimate and model 
uncertainty issues that arose during the course of this study, namely: 
• the selection of an appropriate method for estimating mean total costs in the 
presence of censoring 1 (methodological uncertainty) 
• methods for estimating uncertainty around non-transplant survival, quality 
adjusted life years (QAl Y) and cost estimates derived from a prognostic model2 
(methodological, model parameter estimate and model uncertainty) 
This thesis first reviews a series of methods proposed in the literature for estimating 
mean total costs in the presence of censoring. The comparison of methods aids 
researchers by providing a guide to the most appropriate technique to use under 
particular circumstances. Although the methods of estimation set under censoring are 
not themselves original, this is the first time any study has statistically compared the 
existing methods in an empirical application and attempted to derive recommendations 
that can be applied in future economic evaluations where censoring is an issue. 
The second contribution of this thesis is to provide original methodology for 
incorporating prognostic model uncertainty in to cost and effectiveness estimates in 
studies where no observed control group is available. These uncertainties can be 
incorporated in to economic evaluations in organ transplantation and the results 
presented to decision makers to aid their decisions. The application of these prognostic 
model techniques is generalisable beyond the area of organ transplantation to other 
studies where there is an absence of an obvious control group. 
1.3 STRUCTURE OF THIS THESIS 
This study has been divided in to seven further chapters, as set out below. 
Chapter 2 introduces the United Kingdom (UK) cost-effectiveness in liver 
transplantation (CELT) study and presents the original study methodology and results 
over a 2.25 year time frame [Longworth et aI, 2003]. Consideration is then given to 
1 Censoring occurs when a number of patients in a study do not have the end-point of interest within the 
study period and are lost to follow-up prior to the end of the study. 
2 PrognostiC models are mathematical models that can be used to estimate patients outcomes, e.g. 
survival, in the absence of observed data (See Chapter 5 for further details of prognostic models). 
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extending the CELT study over a five-year time frame and this chapter identifies two 
areas of concern in extending the study: 1) selecting an appropriate method that 
accurately estimates mean study costs in the presence of censoring and 2) measuring 
prognostic model uncertainty when estimating control group effectiveness and costs in 
the absence of an observed control group. These two issues will be taken forward in 
the remainder of this thesis. 
Solid organ transplantation is currently considered as the treatment of choice for 
certain patients with end-stage organ failure and has never been the subject of a 
randomised controlled trial (RCT). Chapter 3 discusses alternatives to the RCT study 
design for cost studies, effectiveness studies or cost-effectiveness studies in solid 
organ transplantation. The chapter highlights some of the problems in applying an 
observational study design within solid organ transplantation. This chapter also reviews 
the literature on solid organ transplant studies, focussing on studies where 
transplantation is compared with an alternative treatment for patients with end-stage 
organ failure. The aim of this review was to confirm that the two areas of uncertainty, 
identified in the CELT study and taken forward in this thesis, were general statistical 
issues arising in solid organ transplantation studies. The review identifies that the 
majority of studies are poorly designed and fail to either acknowledge or incorporate 
uncertainties associated with their choice of study design. 
Chapter 4 compares a series of methods proposed in the literature for estimating the 
mean total costs in the presence of censoring. The methods are compared across 
different levels of censoring and different censoring mechanisms, since the accuracy of 
methods may vary according to the proportion of censored cases and the reason for 
censoring. Censoring is simulated for an observed cohort of patients for whom 
complete liver transplant costs over a 2.25 year study period have been observed. 
Censored estimates of mean total costs and standard errors are compared with the 
observed mean estimates and their standard errors over the 2.25 year study period 
prior to censoring. This chapter makes recommendations on the most appropriate 
censored cost techniques to use, based upon the nature of the study cost data. 
Chapter 5 sets out a simulation technique that accounts for prognostiC model 
parameter uncertainties. The impact of parameter uncertainty on non-transplant 
survival and the survival gain from liver transplantation are compared and the effect of 
allowing for model uncertainty is discussed. This chapter also considers a series of 
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steps for selecting an appropriate prognostic model that can be applied to a series of 
transplant patients in order to estimate, what would have been, their survival in the 
absence of transplantation. The implementation of model uncertainty in to the model 
selection process is also considered. Three models for predicting survival in patients 
with end-stage primary biliary cirrhosis (PSC), a type of liver disease, are used to 
demonstrate these methods. 
Although the prognostic models applied in the original CELT study estimate individual 
patient survival lengths they did not estimate patient specific outcomes (survival/death) 
over the 2.25 year study period. Chapter 6 proposes a series of techniques for 
estimating individual patient outcomes over a fixed time period. The need to estimate 
individual outcome predictions may arise due to: estimating patient level survival, 
QAl Ys or costs at the individual level, estimating survival, QAl Y or cost gains at the 
individual level, or adjusting for costs or health related quality of life (HRQl) data for a 
time period prior to death. Any approach for estimating outcomes should maximise the 
use of the control group information that is available and, given that the individual 
patient outcome is an estimate, should allow for uncertainties around the estimate. This 
chapter also investigates the impact of estimating patient level outcomes on QAl Y and 
cost estimates. 
Chapter 5 and 6 considered three types of prognostic model uncertainty; prognostic 
model parameter uncertainty, prognostic model outcome uncertainty, and prognostic 
model selection uncertainty. Additionally, estimates of individual patient survival are 
conditional on the survival predictions obtained from prognostic models and Chapter 7 
investigates the impact of all three sources of prognostic model uncertainty on non-
transplant survival, QAl Y and cost estimates using probabilistic sensitivity analysis 
(PSA) over a five-year study period for a possible extension of the CELT study. 
In Chapter 8 the emerging methodological themes are brought together. The 
contribution of this research to the evaluation of transplantation and its wider 
application within health services research are discussed. 
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COST-EFFECTIVENESS OF LIVER TRANSPLANTATION: 
A CASE STUDY 
2.1 INTRODUCTION 
Liver transplantation is a medical intervention that has become the accepted standard 
treatment for end-stage liver failure across several liver disease groups. Despite this, 
there are still issues and controversies that remain in this area. Section 2.2 explains 
how liver transplantation has become a treatment of choice despite a lack of ReTs 
evaluating the effectiveness, costs or cost-effectiveness of liver transplantation. Section 
2.2 also considers how the assessment of the clinical effectiveness and cost-
effectiveness of liver transplantation has had to address this. 
This chapter provides the reader with a brief overview of the original eEL T study. 
Sections 2.3 to 2.5 introduce the original study and describe the study methodology, 
results, sensitivity analysis and conclusions over the 2.25 year study period. In the 
absence of an observed control group it is inevitable that particular uncertainties exist 
when estimating the cost-effectiveness of liver transplantation and Section 2.6 
7 
Chapter 2 Cost-effectiveness of liver transplantation 
discusses the areas of uncertainty that were addressed within the original CELT study. 
Section 2.6 also considers the implications of extending the study time frame and the 
potential impact of the statistical uncertainties on the cost-effectiveness of liver 
transplantation over an extended period. 
2.2 LIVER TRANSPLANTATION: BACKGROUND 
The first successful human liver transplant was performed in 1963 by Thomas E. Starzl 
in Denver, Colerado, United States (US) [Starzl et ai, 1963]. Five years later Sir Roy 
Caine successfully performed the first UK liver transplant in Cambridge [Caine & 
Williams, 1968]. Unfortunately, early liver transplantations often resulted in a relatively 
poor outcome for reasons such as poor donor organ quality, technical complications 
and frequent graft failure [Foster & Burton, 1989; Neuberger & lucey, 1994]. 
Postoperative complications were frequent with patients having a poor tolerance to the 
immunosuppressive regime required following transplantation, which commonly led to 
biliary complications and sepsis. 
By the 1980s several factors had led to both an increase in the number of liver 
transplants being performed throughout the world and an increase in survival following 
this procedure [Neuberger & lucey, 1994]. Improvements in surgical techniques and 
the introduction of the immunosuppressive drug cyclosporine A led to large 
improvements in survival after liver transplantation. Furthermore, the general adoption 
of brain stem death as acceptable grounds for instigating liver donation lead to an 
increase in both the number and the condition of donor organs becoming available 
[Neuberger & lucey, 1994]. In the early years of transplantation, an organ could be 
retrieved from the donors only after the donor heart had stopped beating, by which 
point a liver may already be damaged due to the human deterioration or "shutting 
down" process. The acceptance of the definition of brain stem death improved the 
condition of donor organs, which are now retrieved from donors earlier [Hockerstedt, 
1990]. Additionally, the 1983 National Institute of Health Consensus Development 
Conference recommended that liver transplantation should no longer be regarded as 
an experimental procedure, but be considered as a "therapeutic modality for end-stage 
liver disease" [National Institute of Health, 1984]. 
The number of liver transplants in Europe has therefore increased dramatically over the 
last 25 years. The number of transplants in Europe was 49 in 1980, increasing to 2,107 
in 1990 and 4,624 in the year 2000 [European Liver Transplant Registry (El TR) 
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website, 2006]. Prior to 1985, one-year and five-year survival rates were 34% and 21 % 
respectively. These rates had more than doubled to 83% at one-year and 71 % at five 
years for the period 1995 to 1999 [EL TR website, 2006]. 
Liver transplantation is currently considered the treatment of choice for patients with 
end-stage liver disease. It is also recognised as being a costly procedure due to the 
nature of the surgery involved, the need for intensive care post surgery, the cost of the 
immunosuppressive drug regimes and the necessity and frequency of clinical 
monitoring post transplant [Hockerstedt & Kankaanpaa, 1986; O'Grady & Williams, 
1986; Foster & Burton, 1989; Neuberger & Lucey, 1994]. Several authors have 
recognised the necessity of exploring the cost-effectiveness of liver transplantation 
[See: Hockerstedt & Kankaanpaa, 1986; Burroughs et aI, 1991]. Burton and Heyse 
noted the following: 
"Biomedical progress makes it possible to save more lives than ever before: 
however, costly medical innovations such as liver transplantation are 
sophisticated, but expensive, new diagnostic technologies are bringing us 
to the point where somebody, not just the physician, but economists, 
planners, the public, and their elected political leaders will have to make 
decision on how to distribute the limited material and fiscal resources for 
health care among the competing medical technologies and treatments 
needed for and desired by the patient population and health care providers 
alike." [Burton & Heyse, 1985] 
2.2.1 Impracticalities of the RCT Study Design for an Economic Evaluation in 
Liver Transplantation 
It is currently considered unethical to withhold liver transplantation from patients who 
are eligible for it [Neuberger & Lucey, 1994]. For this reason a RCT in liver 
transplantation has never been undertaken. In addition to this, there are practicalities in 
the design of a theoretical RCT that seeks to randomise patients to either a treatment 
(liver transplant) or control group given the current allocation system of donor livers in 
the UK [UK Transplant, 2005a]. 
In the UK, the listing of transplant patients and allocation of donor organs is co-
ordinated by UK Transplant [UK Transplant, 2005a]. At point of listing, patients are 
9 
Chapter 2 Cost-effectiveness of liver transplantation 
classified as either emergency cases 1 or elective (routine) cases, and in the donor 
allocation system priority is given to emergency patients. When a suitable donor liver 
becomes available it is matched to recipients as closely as possible by blood group (A, 
S, AS or 0), age and size of liver, in order to increase the likelihood of a successful 
transplant (minimising the possibility of rejection and complications post 
transplantation). This matching is performed by a computer programme that has been 
set up by UK Transplant [UK Transplant, 2006]. 
Once a liver has been matched it is firstly offered to emergency patients at any of the 
transplant centres in the UK. If no suitable recipient is available the organ is then 
offered to elective patients in the transplant centre in the zone where the donor organ 
originated2 . If there is still no suitable match it is offered to the remaining transplant 
centres, where the centre with the highest points total gets priority3. Finally if no 
suitable match is found in the UK the liver is offered to transplant centres in the 
European Community and worldwide. 
Clearly, the selection of patients for liver transplantation is anything but random and a 
randomised study design would therefore need to fit within the current allocation of 
donor livers in the UK. Current figures suggest that at anyone time point there are 
approximately 270 patients on the waiting list for a liver transplant [UK Transplant, 
2005]. It is reasonable to argue that a sample size of 270 patients is sufficient to use in 
a randomised controlled trial. However, patients need to be stratified by blood group 
(four groups), age and size or organ. For illustrative purposes let us assume that 
patients are stratified in to five age groups and five size groups, let us also assume that 
the probability of appearing in any group is equally likely across blood group, age and 
size. Thus, if an RCT in liver transplantation were conducted, patients would need to be 
stratified in to 100 groups (4x5x5) with two to three patients in each stratum. The 
randomisation of patients to receive transplantation or not, would then take place within 
each stratum. In reality, the probability of being in a particular stratum will not be evenly 
distributed across the 100 strata, with some strata having more patients in than others. 
Further, if more than one potential recipient existed the patients would additionally 
need to be in retrieval zones with equal point allocation for randomisation to take place. 
1 Emergency cases are patients who clinicians expect to die if they do not receive a transplant within three 
days of listing. 
2 For liver transplantation the UK is divided in to seven organ retrieval zones (one in Scotland and the 
remaining six in England and Wales). each zone contains one liver transplant centre. 
3 "A centre is awarded a point if it passes on a liver it cannot use to one of the other centres. There is a 
corresponding loss of a point when any centre receives a liver from outside the areaft [UK Transplant. 
2007]. 
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Given the current system for matching and allocating donor organs, and the related 
lack of donor livers, it is easy to appreciate that the number of scenarios where there 
are more than one suitable recipient for randomisation are rare. 
Two additional and foreseeable problems with a potential RCT in liver transplantation 
will be recruitment of patients and it is likely that patients would be reluctant to 
participate in a trial where they might not receive life saving treatment. Furthermore any 
patients who do agree to participate are likely to withdraw if they were randomised to a 
non-transplant group. Additionally, it would clearly be impossible to design a study in 
such a way that patients and their assessors were unaware of their allocated treatment 
arm (awareness of treatment is acknowledged as a source of study bias [Pocock, 
1983]). 
Therefore, an RCT in liver transplantation is considered to be both unethical and 
impractical to conduct and any evaluation needs to be based on a non-randomised 
design, comparing liver transplant patients with non-transplant patients. This raises the 
question of who to use as an appropriate non-transplant control group for comparing 
liver transplantation within an economic evaluation. 
2.2.2 Commissioning of the CELT Study 
In 1995, the UK Department of Health (DoH) commissioned the CELT study to attempt 
to estimate the clinical effectiveness and the cost-effectiveness of the National Health 
Service (NHS) liver transplant programme in England and Wales. Given the suggestive 
evidence that liver transplantation is a life saving procedure and the impracticalities of 
conducting an RCT, an RCT design where transplantation would be withheld from a 
randomly selected control group, was rejected and a non-randomised study design was 
used. This approach is described in Section 2.3 and 2.4. 
2.3 THE eEL T STUDY 
Between December 1995 and December 1997, a total of 755 adult patients (aged 16 
years or older) with various end-stage liver diseases were assessed for their suitability 
for transplantation at one of the six DoH liver transplant centres in England and Wales. 
The six centres were: the Queen Elizabeth Hospital, Birmingham; Addenbrooks 
Hospital, Cambridge; The Freeman Hospital, Newcastle; St. James' Hospital, leeds; 
Kings College Hospital, london; and The Royal Free Hospital, london. 
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The study focused on reporting the effectiveness, costs and cost-effectiveness of liver 
transplantation on a per patient basis. Patients were excluded from the study if they 
had received a previous liver transplant prior to the beginning of the studio However, 
patients who went on to receive a second or subsequent transplant during the study 
period, were included in the study. 
Patients entered the study at the point they were admitted to the transplant centre for 
assessment. As a result of the assessment a patient was either: 
• listed as a suitable transplant candidate and placed on the transplant waiting list 
until a suitable liver became available 
• deferred and assessed again at a later date 
• not listed as a suitable liver transplant candidate 
Listed patients were classified as either an emergency or elective case. 
Of the 755 transplanted patients, 550 were listed for transplantation, of whom 477 went 
on to receive a liver transplant. Patients who were listed but did not receive a transplant 
either died on the waiting list or were removed from the waiting list. Reasons for 
removal included the patient's condition having improved or having deteriorated, 
medical reasons, psychological reasons, or the patient's own choice. The patients who 
received a transplant were followed from point of transplant for two years or until time 
of death if sooner, 383 patients were alive at two years post transplant, 86% of the 
transplanted cohort. Data collection for the study ended in December 1999. 
Five reports were produced from the original study results; each addressed different 
aspects of the evaluation. The focus of these reports was: survival [Young et a', 2001], 
HRQL [Ratcliffe et a', 2001], costs [Longworth et a', 2001], patient costs [Mistry et a', 
2003] and cost-effectiveness [Longworth et a', 2002]. All reports present the results of 
the analysis across all end-stage liver disease groups, the exception being the cost-
effectiveness report which focused on the cost-effectiveness of liver transplantation for 
4 The GEL T study team took the decision to exclude these patients as it was difficult to identify the point 
that assessment first started, thus potentially underestimating these patients' costs. The GEL T study team 
also felt that the clinical data would differ from those patients seen for a first liver transplant. However, 
exploration of the re-transplant costs for GEL T study patients (those patients who underwent two or more 
transplants within the GEL T study) suggests that the average re-transplantation costs £52K, which is 
similar to the transplant costs of a first transplant (mean = £53K). Therefore excluding these patients 
should not unduly effect the estimation of transplantation. 
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three major liver disease groups: alcoholic liver disease (AlD), PBC, and primary 
sclerosing cholangitis (PSC). Sections 2.4 and 2.5 describe the main cost-effectiveness 
study, that is the cost-effectiveness of liver transplantation for AlD, PBC and PSC 
patients, in greater detail. 
2.4 CELT STUDY METHODOLOGY 
The perspective taken in the main cost-effectiveness study was that of the NHS 
transplant centres. The CELT study time period was 2.25 years (27 months), which 
represented the two-year follow-up period post transplant plus the average time a 
patient spent waiting for a transplant (three months). 
An electronic Microsoft® Access database was used for data collection. Databases 
were installed at each of the six centres participating in the study. A research nurse 
was employed at each centre to collect prospective information on patient 
demographics, disease characteristics and resource use attributed to the liver 
transplant programme. 
The research nurse also administered the study questionnaire to patients. The 
questionnaire contained some demographic questions and two instruments used for 
measuring HRQl; the short form (SF) 36 [Ware et ai, 1993] and EuroQOl EQ-5D 
[Brooks, 1996]. The study questionnaire was administered to all English speaking 
patients listed for a liver transplant at point of listing, and at three monthly intervals until 
point of transplant, then at 3, 6, 12 and 24 months post transplant. Questionnaires were 
not sent to patients who, in the opinion of the research nurse based at each centre, 
were too ill to complete the questionnaire. Reminders were sent to non-responders 
approximately three weeks after the first questionnaire was sent. 
The costs and effects for each patient who received a transplant were compared with 
the estimated costs and effects for that patient had they not received a transplant. The 
only difference in costs and benefits, with and without the transplant programme, for 
patients who died or were removed from the waiting list, were the costs of assessment. 
Therefore, patients who were listed for transplantation but removed from the waiting 
list, or who died before transplantation, were excluded from the cost-effectiveness 
cohort. However, the assessment costs for the listed patients who did not receive a 
liver transplant were incorporated in to the cost and cost-effectiveness results for the 
transplant cohort (See Appendix A2.1 for further details). 
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2.4.1 The Intervention Group - Liver Transplant Cohort 
A total of 347 patients with end-stage AlD (N = 155), PBC (N = 122) or PSC (N = 70) 
were assessed for their suitability as liver transplant candidates at one of the six 
centres participating in the study. Patients were followed from assessment, through 
candidacy (the time between listing and transplantation), their transplant hospital stay 
and a two-year period post liver transplantation. 247 patients were listed for liver 
transplantation of whom 208 received a liver transplant during the CELT study period 
(AlD: N = 82, PBC: N = 81, PSC: N = 45). 
Methods for estimating survival, HRQl, QAl Y and costs for the transplant cohort are 
detailed below. 
2.4.1.1 Survival 
Observed information on survival was available for the majority of ALD, PBC and PSC 
patients from point of assessment up to 2.25 years post-assessment. Patients who did 
not die during the study were censored 2.25 years after the date of their liver transplant 
assessment or at the end of the study period for those patients who did not have 
complete 2.25 year follow-up. Follow-up was incomplete (censored) for 13 out of 208 
transplanted cases (6% ) - in all 13 cases the study ended before 2.25 years of data 
had been collected. The mean survival time for the cohort over the 2.25-year study 
period was estimated from the area under the Kaplan-Meier survival curve [Kaplan & 
Meier, 1958; Collett, 1994]. 
In this thesis individual patient survival lengths are calculated in years. 
2.4.1.2 HRQL 
The EuroQOl EQ-5D is a non-disease specific HRQl questionnaire that asks a series 
of five questions concerning HRQl (mobility, self care, ability to perform usual 
activities, pain or discomfort, and anxiety or depression) [Brooks, 1996]. Questionnaire 
responses can be transformed in to a single index score where a score of one indicates 
full health and a score of zero indicates death. 
The results from the EQ-5D were used in the main CELT analysis as a measure of 
HRQL. The scoring tariff applied to the CELT cohort is known as the York tariff, where 
the scoring tariff is based on a representative sample from the UK population [Dolan, 
1997]. 
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Using CELT data Ratcliffe et al showed that there was no significant change in HRQl 
over time on the waiting list for liver transplantation [Ratcliffe et al. 2005]. As HRQl 
was not measured at the time of transplantation it was assumed that each patient's 
HRQl at this point would be the same as it was at their last known pre-transplant 
response. Similarly, each patient's HRQl score at assessment was assumed to be the 
same as the score observed at listing. HRQl was assumed to increase or decrease 
linearly between all other time points. 
In a dataset such as this, it is inevitable that HRQl data are not be available for all 
patients' across all time points. For example, data is regarded as missing for non-
English speaking patients and those considered too ill to complete the questionnaire. 
Mean HRQl was estimated for individuals who had missing data, but had available 
responses either side of the missing point. Where values either side of the missing 
value were unavailable the prior or subsequent value was carried forward or backward. 
A Monte Carlo simulation technique, known as multiple imputation, was used to impute 
missing values when no EQ-50 data were available5 [Little & Rubin, 1987; Schafer, 
1999]. 
2.4.1.3 Quality Adjusted Life Years (QAL Ys) 
Individual patient QAl Ys were estimated by plotting each patient's EQ-50 values over 
time from point of assessment to 2.25 years post assessment. The number of QAl Ys 
for each liver transplant patient was then estimated from the area under the curve. 
2.4.1.4 Costs 
Comprehensive resource use information was collected prospectively for each patient 
in the study beginning at the time each patient was assessed for listing. Resource use 
details were collected on inpatient stay (categorised as ward or intensive therapy unit 
stay), out-patient visits, the length of the transplant operation, high cost/high volume 
5 Patient's with AlD, PSC or PSC did not complete the EO-50 at any time point during the study in 13% of 
cases and multiple imputations were used to impute these miSSing cases. Multiple imputation is a Markov 
chain Monte Carlo simulation technique, in which a number of possible values, which are drawn from the 
predictive distribution of the missing data, are imputed for each missing observation. Multiple imputation 
assumes that data are missing at random (MAR), which means that the values of the variable(s) which 
contain the missing data are not a sub-sample of the sampled observations but are a random sample of 
variables that depend on the values of observed variable(s). In the CELT study it is possible that patient's 
did not respond to the OOl questionnaire for reasons related to the severity of their underlying liver 
disease, thus violating the MAR assumption. However, Schafer states that multiple imputation methods do 
not "require or assume that nonresponse is ignorable. Imputations may in principle be created under any 
kind of assumptions or model for the missing-data mechanism. and the resulting inferences will be valid 
under that mechanism" [Schafer, 2007]. Therefore, in the CELT study, although the missing data pattern 
may not be MAR, imputations were carried out mainly because ignoring the incomplete case would have 
reduced, an already small, sample size for the study. 
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drugs, blood products, tests and treatments, dietician sessions, physiotherapy sessions 
and nutritional support. For each item of resource use the dates of administration were 
collected. Quantities of blood products, drugs and nutritional support were also 
collected for costing purposes. 
Unit costs for the 1998/9 financial year were obtained from the six centres participating 
in the study. Unit cost information was not available for all items of resource use from 
all centres, therefore, a weighted mean cost was calculated, weighted by the number of 
transplants performed at each centre. Weighted mean costs were applied to each item 
of resource use. 
The British National Formulary [BNF 38, 1999] was used to obtain drug costs. Staff 
costs for medical and inpatient staff were attributed over the transplant programme 
activity. 
2.4.2 The Control Group - Medical Management of End Stage Liver Disease 
Due to ethical and practical considerations it was not feasible to use a ReT design to 
evaluate the cost-effectiveness of liver transplantation (Section 2.2). Therefore, the 
eEL T study team considered the possibility of collecting data for a non-ReT based 
control group. Quasi-experimental control groups, intervention delay groups, historical 
control groups and expert opinions were considered as possible sources of information 
on non-transplant survival, costs and HRQL. 
The eEL T study team considered the possibility of collecting information on a cohort of 
UK patients with end-stage liver disease treated at NHS centres that did not refer 
patients for transplantation (quasi-experimental group). However, this group of non-
transplant patients was rejected because the number of patients who fell in to this 
category was not deemed large enough to meaningfully compare survival, costs and 
QAl Y outcomes with a concurrent transplant group. An intervention delay group, 
consisting of patients on the waiting list for liver transplantation, was dismissed owing 
to concerns over selection bias. If the intervention delay group contained patients who 
died on the waiting list these patients could be sicker than patients who survive to the 
point of transplant, exaggerating the survival benefit from transplantation [Gail, 1972]. 
Conversely, if the control group included the non-transplant (waiting list) experience of 
transplanted patients then the survival affect from transplantation will be 
underestimated. This later situation is comparable to sicker patients being given priority 
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to transplantation. Chapter 3 Section 3.3.2.1 discusses weaknesses of the intervention 
delay group in further detail. 
The use of a simple historical control group was also rejected by the CELT study team. 
It was considered impractical to retrospectively collect clinical and resource use 
information from patient records, problems were envisaged in locating the records for 
all eligible patients and in the completeness of the records at the level of detail required 
for a cost-effectiveness study. Finally, expert opinions were discarded due to concerns 
over the reliability of collecting information from experts [Black et aI, 1999]. 
After discarding these four possible control groups the CELT study team chose to 
model the expected non-transplant survival, HRQl and costs of the transplant patients, 
as if these patients continued with the medical management of end-stage liver failure. 
Prognostic models were used to estimate non-transplant survival; these models were 
based on historical cohorts of patients with end-stage liver diseases. HRQl and costs, 
in the absence of transplantation, were estimated from the waiting list experience of the 
transplant patients. Details of the methods used to estimate non-transplant survival, 
HRQl and costs are outlined below. 
2.4.2.1 Survival 
A literature search revealed that several prognostiC models based on historical cohorts 
of patients with end stage liver diseases existed and could potentially be used to 
estimate survival in the absence of transplantation for the CELT study. In each case, a 
prognostic model had been fitted to a historical cohort of patients undergoing medical 
treatments for liver disease. All prognostiC models were based on a Cox Proportional 
Hazards (PH) model. The concept of the Cox PH model is to estimate the hazard, 
which is the risk of death, at any time among patients who remain alive and under 
follow-up. Using baseline covariates the model can incorporate several explanatory 
variables that influence patient survival, for example patient age at time of treatment, or 
levels of serum bilirubin. Further details of the Cox PH model will be presented in 
Chapter 5 where prognostiC models are considered in more detail. 
PrognostiC models can be applied to concurrent data using information on the clinical 
and patient characteristics for the current cohort to give an estimate of survival. The 
minimum amount of information required from a prognostiC model to predict survival in 
another cohort of patients are the regression coefficients and hazard function from the 
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prognostic model and patient specific clinical and demographic data for the cohort the 
model is to be applied to. Given this information, it is possible to compare the mean 
observed survival for patients who have received the new treatment with their expected 
survival if they had not. Thus, the survival gain of the new treatment may be estimated. 
A key assumption that is made when fitting a prognostic model is that it adequately 
represents the cohort of patients to whom it is fitted. With this in mind, an appropriate 
prognostic model must be selected. A choice of prognostic models existed for each of 
the three liver disease groups evaluated in the main cost-effectiveness study (AlD -
two models, PBC - three models; PSC - two models). Table 2.1 outlines each of the 
prognostic models that could be applied to the CELT cohort to predict non-transplant 
survival. 
A three step process was used to select the most appropriate model for each liver 
disease group. Firstly, models were chosen if they were shown to be statistically 
superior to alternative models using criteria set out by Altman and Royston [Altman & 
Royston, 2000]. These criteria state that models should: 
• be validated on both internal and external data sets 
• be based on adequate samples of patients 
• for each variable fitted in the model the number of events, in this case deaths, 
should be in the ratio of one explanatory variable for every 10 to 20 deaths 
• make clinical sense 
• be applied to appropriate cohorts 
The second step, for those models that appeared to be statistically valid, was to 
incorporate models where the historical cohort included UK patients. These patients 
would be more likely to have similar characteristics and be treated in a similar manner 
to those in the CELT study, in the absence of transplantation, thus minimising this 
potential source of bias. Finally, if no disease specific model was superior to the other 
models after applying the first two steps the final step was to take an average estimate 
of survival from the remaining models. 
At step one, only the Beclere AlD model showed statistical superiority over the 
Birmingham model. The Birmingham model was not validated on other internal data 
sets nor was it validated extemally. Additionally, the Birmingham model was based on 
18 
Chapter 2 Cost-effectiveness of liver transplantation 
a relatively small sample of patients (N = 76) and the number of deaths (N = 38)6 for 
each of the five variables included in the models was less than the 50 deaths 
recommended for a five parameter model. Therefore, the Beclere model was chosen 
as the best model for estimating non-transplant survival in patients with ALD. 
Step two resulted in the elimination of the PBC Mayo model and the PSC Mayo model, 
which did not include UK patients and left the PSC Intemational model and two PBC 
models, the Royal Free and European models. Given that two PBC models remained, 
the average survival estimates across these models were applied in the main CELT 
analysis of PSC patients. 
The three models that were not selected for the main CELT analysis (AlD: Birmingham 
model, PBC Mayo and PSC Mayo) were applied in deterministic sensitivity analysis in 
order to assess the reliability of the results to model choice. 
Survival in the absence of transplantation is observed from point of assessment until 
point of transplant. Survival in the absence of transplantation is unobserved from point 
of transplant onwards and needs to be estimated from this point. Clinical information 
was collected in the CELT cohort at one time point only, immediately prior to 
transplantation? This information was used to estimate, what would have been, 
survival in the absence of transplantation using the four disease specific published 
prognostic models chosen above. 
The prognostic models were used to obtain individual patient survival probabilities over 
time. The survival probabilities can be plotted to obtain individual patient survival 
curves, where the area under the curve gives an estimate of survival in the absence of 
transplantation. Further details of this process are given in Chapter 5. 
6 The number of deaths for the Anand model cohort is not stated in the paper, though. from other 
information that is given, we estimate the proportion to be approximately 49% (38 deaths), which is lower 
than the 50 required when fitting a 5 variable model. . 
7 In 21% of cases clinical information needed to predict survival in the absence of transplantation was 
missing and ignoring patients with missing information would reduce the sample size of t~e non-~ransplant 
cohort and potentially bias the comparison with the transplant cohort. Therefore. multiple Imputations were 
used to impute missing clinical values [Rubin, 1997; Schafer, 1997]. 
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Table 2.1 Summary of prognostic models that could be applied to the CELT cohort to estimate non-transplant survival 
Disease Model Publication details Sample Population Predictors of survival 
I Group name Size 
ALD Beclere Poynard et aI, 1994 787 France Serum bilirubin, serum albumin, the presence or absence of 
Poynard et aI, 1999 encephalopathy, age 
ALD Birmingham Anand et al,1997 76 UK Serum bilirubin, serum albumin, blood urea, the presence 
or absence of spontaneous bacterial peritonitis (SSP) 
PBC European Christensen et aI, 1985 248 Australia, Belgium, Serum bilirubin, serum albumin, age, the presence or 
Christensen et aI, 1993 Denmark, France, absence of ascities, the presence of gastrointestinal 
Spain, UK, USA bleeding 
PBC Royal Free Hughes et aI, 1992 289 UK Serum bilirubin, serum albumin, age, the presence or 
absence of ascities 
PBC PBC Mayo Dickson et aI, 1989 312 USA Serum bilirubin, serum albumin, age, prothrombin time, 
Murtaugh et aI, 1994 oedema score* 
PSC International Dickson et aI, 1992 392 UK & USA Serum bilirubin, age, histological stage, the presence or 
absence of splenomegaly 
--- -- --- --------
PSC PSC Mayo Wiesner et aI, 1989 174 USA Serum, bilirubin, age, haemoglobin levels, the presence or 
absence of inflammatory bowel disease, histological stage 
• Oedema score: 0 = oedema and no diuretic therapy for oedema, 0.5 = oedema without diuretic therapy, 1 = oedema resolved by diuretic therapy 
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2.4.2.2 HRQL 
Each patient's HRQL score at assessment was assumed to be the same as the score 
observed at listing. Observed EQ-50 scores were used to estimate HRQL in the 
absence of transplantation from point of listing to point of transplant. Each patient's last 
known pre-transplant score was assumed constant over time from point of transplant 
until death or 2.25 years post-assessment. 
2.4.2.3 QAL Ys 
QAL Ys were estimated in exactly the same way as done for the transplant cohort. EQ-
50 values were plotted over time up to 2.25 years post assessment and the area under 
the curve was calculated in order to measure the number of non-transplant QAL Ys for 
each patient. 
2.4.2.4 Costs 
Costs in the absence of transplantation were estimated by multiplying the average cost 
per patient per day on the waiting list by each patients estimated survival length, where 
patient non-transplant survival lengths were estimated from prognostic models. An 
examination of the cost data for all patients who died on the waiting list revealed that 
costs increased in the month prior to death (Appendix A2.2). Therefore, an adjustment 
was made to the cost estimate for those patients who were not expected to survive the 
full 2.25 year study period. 
Equation 2.1 presents the formula used to estimate non-transplant costs for the 2.25 
year study period. 
where 
Expected costs without transplantation 
= At(CtSi) + (1 - Ai)*[Ci*(Si - 30) + (Xi)] 
i denotes the ith patient in the cohort, where i = {1 , ... ,N} 
Equation 2.1 
Ai denotes whether patient i was expected to be alive or dead at the end 
of the study period (1 = alive, O=dead) 
Ci is the average daily cost on the waiting list for patient i 
Si is the predicted survival length (in days) of patient i in the absence of 
transplantation (time on the waiting list + expected survival time predicted 
by the prognostic model) 
Xi is the predicted cost of patient i for the 30 days prior to death (if the 
patient was predicted to die), as estimated by the regression model for 
death costs [Appendix A2.2 Table A2.3.2] 
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2.4.3 Incremental Cost-Effectiveness of Liver Transplantation 
QAL Ys were discounted at 1.5% and costs at 6% in accordance with NHS guidelines 
available at the time of analysis [NHS National Institute for Clinical Excellence, 2003]. 
Given that both cost and QAL Y data had skewed distributions, bias adjusted non-
parametric bootstrapping was performed in order to generate 95% CI around mean 
cost and QALY estimates8 [Manly, 1997]. A total of 1,000 repeated samples were taken 
to estimate 95% CI around mean costs, QAL Ys and incremental cost effectiveness 
ratios. 
The incremental costs were calculated by subtracting each patient's expected costs in 
the absence of transplantation from their observed costs with transplantation. Similarly, 
incremental QAL Ys were estimated by subtracting each patient's predicted non-
transplant QAL Y from their observed transplant QAL Y. The individual patient 
incremental cost per QAL Y, also known as the ICER, was then calculated by dividing 
the incremental costs by the incremental QAL Ys for each patient. Bootstrapping was 
again performed to obtain 95% CI around the mean cohort incremental costs, QAL Ys 
and ICERs. 
2.4.4 Sensitivity AnalysiS 
To assess the various assumptions that were made during the CELT study a series of 
one-way sensitivity analysis were performed across all three liver disease groups; 
these assumptions are listed in Table 2.2 below. 
8 In the absence of information from the population it is reasonable to make inferences using inf~rmati~n 
obtained from a random sample. In the absence of being able to sample from the population It ~s 
reasonable to resample from the random sample and make inferences about the population from t~IS 
[Manly. 1997]. Bootstrapping takes repeated samples of size N from a cohort of the same size with 
replacement. For each random sample the parameterls of interest, for example mean transplant costs, are 
estimated. 
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Table 2.2 Details of the one-way sensitivity analysis undertaken in the CELT 
study 
One-way Sensitivity Analysis Reason the analysis was undertaken 
Alternative prognostic models The three models that were discarded in the 
main analysis could predict non-transplant 
survival as accurately or more accurately 
than the models used in the main analysis 
Assume HRQL deteriorated linearly from last In the main analysis HRQL was assumed 
known pre-transplant score to zero at point of constant from last known pre-transplant 
death in the non-transplant group observation until death and this was felt to 
overestimate QAL Ys 
Organ retrieval costs (estimated at £7,200)* These were not included in the transplant 
group costs in the main analysis, owing to 
the difficulty in obtaining a reliable estimate 
Lowest set of unit costs used for key items of Unit cost estimates varied considerably 
resource use (inpatient stay, outpatient visits, across the six transplant centres 
transplant operation) 
Highest set of unit costs used for key items of Unit cost estimates varied considerably 
resource use (inpatient stay, outpatient visits, across the six transplant centres 
transplant operation) 
Increase daily non-transplant costs (50%) Assumed that the daily costs in the absence 
of transplantation would be the same as the 
mean daily cost on the waiting list, but may 
be an underestimate as any care provided 
locally to patients is excluded 
Decrease daily non-transplant costs (50%) Assumed that the daily costs in the absence 
of transplantation would be the same as the 
mean daily cost on the waiting list, but may 
be an overestimate as patients might be 
treated more resource intensively on the 
waiting list 
* Data from Royal College of Surgeons and Englneenng and Physical SCiences Research CounCil 
[Engineering and Physical Sciences Research Council, 2002; The Royal College of Surgeons. 2002] 
2.5 SUMMARY OF THE MAIN CELT RESULTS AND CONCLUSIONS 
Table 2.3 presents key demographic details for the transplant cohort. Although the 
percentage of male patients varies by disease group, the percentage is typical for each 
disease, where the incidence of ALD and PSC is higher in males and the incidence of 
PBC higher in females. Only one patient, a PBC case, was classified as an emergency 
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case. Survival at two years post transplant was 80% or more for all three disease 
groups. 
Table 2.3 Demographic details of transplanted patients in the main CELT 
study 
AlD (N = 82) PBC (N = 81) PSC (N = 45) 
Median Age (IQR)* 50 (45 to 57) 56 (51 to 62) 49 (38 to 56) 
Males (%) 67 (82%) 8 (10%) 31 (69%) 
Emergency cases (%) o (0%) 1 (10/0) o (0%) 
Retransplantations (%) 6 (7%) 9(11%) 7 (16%) 
Survival to 2-years post 67 (82%) 69 (85%) 36 (80%) 
transplant (%) 
• lOR - Inter-quartile range 
The main cost-effectiveness results for the eEL T study are presented below for the 
three liver disease groups; AlD, PSC and pse (Table 2.4). Mean incremental survival 
differs across disease groups and is greatest for AlD patients. However, once HRQl is 
adjusted for, there is little difference in QAl Ys across disease groups, where the 
quality adjusted survival gain for transplanted patients over a 2.25 year period is 
approximately six months in each group. The observed costs of the liver transplant 
programme for AlD patients (£66K) were higher than the costs for pse (£52K) or pse 
(£61 K) and the incremental costs of transplantation were over £10K more for AlD 
patients than pse or pse patients. 
Table 2.4 Summary of main CELT results (mean with 95% Bootstrapped CI) 
[Longworth et ai, 2003] 
AlD (N = 82) PBC (N = 81) PSC (N = 45) 
Mean Incremental 
Survival in years 0.59 0.37 0.23 
(95% CI) (0.38 to 0.74) (0.18 to 0.55) (0.01 to 0.41) 
Mean Incremental 0.55 0.54 0.58 
QAl Y (95% CI) (0.40 to 0.69) (0.39 to 0.69) (0.40 to 0.75) 
Mean Incremental £25,712 £15,224 £12,182 
Cost (95% CI) (£7K to £41 K) (£0 to £28K) (-£13K to £33K) 
Mean leER £48,355 £28,716 £21,332 
(95% CI) (£ 12K to £83K) (£ 1 K to £59K) (-£23K to £60K) 
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Figure 2.1 shows the distribution of bootstrapped net costs and QAL Y differences on 
the incremental cost effectiveness plane. There are no negative incremental QAL Y 
gains. However, there is some evidence to suggest that liver transplantation is cost 
saving over a 2.25 year period (negative incremental cost estimates) for PSC patients, 
where over 15% of the bootstrapped incremental costs fall in the south east quadrant 
of the cost-effectiveness plane. 
The mean ICER was highest for the ALD group (£4BK) and lowest for the PSC group 
(£21 K). If an NHS bench mark of £30,000 were assumed to be what the NHS could 
afford to pay for additional QAL Ys, then the liver transplant programme would be an 
acceptable cost-effective intervention for PSC and PSC patients but not for ALD 
patients. However, the time frame of this study was relatively short at 2.25 years and 
the cost per QAL Y for ALD patients would almost certainly decrease over an extended 
time period. 
Figure 2.1 
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Figure 2.2 shows the cost-effectiveness acceptability curves for the probability of liver 
transplantation being cost effective for different values of the maximum acceptable 
incremental cost per CAL Y for each liver disease group. The curves show that the 
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cost-effectiveness of liver transplantation is most likely to be acceptable in patients with 
PSC, then PSC and least likely to be acceptable for ALD patients. 
Figure 2.2 
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2.5.1 Sensitivity Analysis 
The mean incremental cost-effectiveness results for a series of one-way sensitivity 
analyses are presented in Table 2.5. The incremental cost-effectiveness ratios for the 
alternative PSC prognostic model (PSC Mayo model) were very similar to the ICER for 
the averaged Royal Free and European models. However, the ICERs for ALD and PSC 
were highly sensitive to the choice of prognostic models, where the alternative models 
increased the average incremental cost per CAL Y gained. The mean ICER was also 
sensitive to the assumption that HRQL remained constant over time and assuming that 
HRQL in the non-transplant group decreased linearly over time resulted in a decrease 
in the leER for all disease groups, although the mean ICER for ALD patients was still 
greater than the £30K NHS benchmark. The reality for patients in the absence of 
transplant is likely to lie somewhere between the two extremes. 
Including an estimated cost for organ procurement increased the ICER across all 
groups. Estimates of the ICER were sensitive to changes in unit cost estimates for key 
items of resource use. Using the £30K NHS benchmark liver transplantation might be 
funded if the lowest sets of unit costs are observed for key resource use items PBC 
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might not be funded if the highest set of unit costs are observed with an leER greater 
than the £30K benchmark. Results were also sensitive to changes in the cost per day 
on the waiting list. 
The impact on the leERs when varying unit cost estimates in sensitivity analysis was 
larger than the impact on the leERs when varying the assumption related to changes 
in non-transplant HRQl over time. Variation in leER's was smaller than that when 
increasing or decreasing the non-transplant daily costs by 50%. 
Table 2.5 Mean ICER's (in £1000s) with 95% bootstrapped CI for one-way 
sensitivity analysis for AlD, PBC and PSC 
ALD PBe pse 
(N = 82) (N = 81) (N = 45) 
Main analysis £48 £29 £21 
(£12 to £83) (£1 to £59) (-£23 to £60) 
Alternative prognostic models £119 £30 £35 
(£21 to £242) (£0 to £63) (£8 to £55) 
Linear deterioration of non-transplant groups £38 £22 £15 
HRQL (£10 to £65) (£0 to £45) (-£16 to £41) 
Organ retrieval costs £62 £43 £34 
(£25 to £101) (£14 to £76) (-£15 to £69) 
Lowest unit costs £29 £10 £6 
(£1 to £53) (-£14 to £30) (-£27 to £32) 
Highest unit costs £56 £32 £22 
(£5 to £102) (-£8 to £73) (-£42 to £77) 
Increase non-transplant cost per day (50%) £14 -£4 -£19 
(-£40 to £49) (-£52 to £29) (-£92 to £31) 
Decrease non-transplant cost per day (50%) £82 £61 £62 
(£53 to £126) (£40 to £95) (£32 to £94) 
2.5.2 Summary of CELT Conclusions 
By making a series of plausible assumptions, the eEL T study illustrates that it is 
possible to estimate the costs of the medical management of end-stage liver disease 
and the cost-effectiveness of liver transplantation using published prognostic models as 
a basis for the non-transplant estimation of survival, HRQl and costs. 
The incremental QAl Y gain of liver transplantation over 2.25 years was approximately 
six months across all disease groups. However, the cost-effectiveness of liver 
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transplantation in the UK differed by disease group and was poorest for AlD9. The 
results raised questions concerning the cost-effectiveness of liver transplantation as an 
intervention for patients with AlD and the authors suggested extending the analysis 
over a longer time frame so that the mid to long term benefits of liver transplantation 
could be measured. Liver transplantation might prove to be a cost effective intervention 
over a longer time frame for all liver disease groups. 
2.6 ISSUES OF STATISTICAL UNCERTAINTY IN THE CELT STUDY 
The results from the main CELT study for the 2.25 year study period for AlD, PSC and 
PSC patients have been published and were presented to the sponsors of the study, 
the DoH. Although there was evidence to suggest that liver transplantation was a cost 
effective treatment for PSC and PSC patients the DoH were concerned with the 
relatively short study time period and felt the benefits of transplantation would be more 
evident over a longer time frame. A five-year time frame was suggested. The proposed 
extended time frame raised two areas of concem; 1) the selection of an appropriate 
method for estimating mean study costs in the presence of censoring and 2) measuring 
uncertainty around the prognostic model, non-transplant estimates in the absence of a 
control group. These issues will be raised in Section 2.6.2 and explored in the 
remainder of this thesis. Section 2.6.1 will first consider sources of uncertainty that 
were addressed within the CELT study when using prognostic models in the absence 
of an observed non-transplant control group. 
2.6.1 Uncertainties Addressed in the Main eEL T Study 
In the absence of information from an observed control cohort of non-transplant 
patients, prognostic models were used to estimate, what would have been, the 
transplant cohort's expected survival in the absence of transplantation. The prognostic 
models are the pivotal step in estimating the non-transplant survival, HRQl and costs. 
Non-transplant costs and QAl Y estimates depend on the length of time a patient with 
end-stage liver disease is predicted to survive without transplantation. One particular 
concern was that the patient cohorts on which the prognostic models were derived 
were not representative of the CELT cohort in terms of waiting list criteria, given that 
more than one prognostic model existed for each liver disease group. It was therefore 
important to select the most statistically robust and appropriate models for estimating 
non-transplant survival. The importance of this choice was evident in the sensitivity 
results. Whilst it was reassuring that the PSC models gave similar survival and ICER 
9 This was felt to be mainly due to the high cost of assessing a large number of patients with ALD (N = 55) 
who were ultimately unsuitable liver transplant candidates. 
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estimates, the alternative AlD Birmingham model and PSC Mayo model showed 
markedly different ICER estimates from the results of the main analysis. Although the 
justification of model choice appeared reasonable, one can never be totally sure that 
the most appropriate model has been selected. 
In the absence of an observed non-transplant cohort, information on HRQl and costs 
in the absence of transplantation were estimated from each transplant patient's HRQl 
and cost experiences on the waiting list. One-way sensitivity analyses were conducted 
that increased or decreased the average daily cost of the waiting list by 50%. The rates 
of cost variation used in the one-way sensitivity analysis were arbitrarily chosen and 
could be argued as being extreme choices. Cost-effectiveness ratios doubled across all 
disease groups when daily costs were decreased by 50%, and when daily costs were 
increased by 50% the cost-effectiveness ratios decreased by £30K or more, in 
comparison with the main analysis. 
The main CELT study was not the only organ transplant study to assume that non-
transplant costs remained constant over time [Bonsel et al. 1990a; Van Enckevort et al. 
1997; Anyanwu et al. 2002]. Therefore, it appeared reasonable to assume that costs 
remained constant over time in the CELT study. An alternative approach could be to 
assume that non-transplant costs vary over time. If data were available on the daily or 
weekly costs incurred on the waiting list conventional modelling work could explore 
time dependent changes in non-transplant costs over time. Daily costs were not varied 
further in the main CELT study and uncertainty in these estimations could perhaps 
have been explored further. 
Unit costs were treated as fixed parameters in the CELT study and varied using the 
minimum and maximum set of unit costs provided by the six transplant centres for key 
items of resource use (ward and ITU inpatient stay, out-patient visits and transplant 
operation). This type of sensitivity analysis is referred to in the literature as extreme 
scenario analysis [Briggs & Gray, 1999]. The application of the lowest set of unit costs 
reduced the cost-effectiveness ratio, in favour of liver transplantation, for all three 
disease groups and the application of the highest set of unit costs increased the cost-
effectiveness ratio. An altemative approach to exploring the uncertainty around unit 
costs would be PSA. In PSA, statistical distributions are assigned to each unit cost 
estimate and Monte Carlo simulations are run to re-estimate both the outcome of 
interest and the uncertainty around it [Doubilet et ai, 1985; Critchfield et ai, 1986]. The 
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application of PSA to unit cost uncertainty is well established and will not be explored 
further in this thesis [See: lord & Asante, 1999; Briggs, 2001]. 
Non-transplant HRQl was assumed to be the same as that observed at point of listing 
for transplantation, this assumption was not varied in sensitivity analysis. However, the 
assumption that non-transplant HRQl remained constant over time was varied, where 
one-way sensitivity analysis assumed HRQl deteriorated linearly to point of death, "the 
best estimate probably lies between these two extremes" [Longworth et aI, 2003]. 
2.6.2 Remaining Issues of Uncertainty 
For the transplant cohort the potential extension of the study period to five years simply 
involved the additional collection of survival, HRQl and resource use information for up 
to five years post assessment. Censoring was anticipated as being an issue within the 
CELT study if it was extended to five years as a larger proportion of patients would be 
expected to be lost to follow-up and thus have incomplete data over the study period10. 
Methods for allowing for censoring are well established in time to event (survival) data, 
however, these methods should not be applied to censored costs and QAl Y data and 
a series of alternative methods for estimating mean study costs and QAl Ys in the 
presence of censoring exist. Faced with a choice of possible methods, it is not obvious 
which method will produce the most accurate estimate of mean total costs or QAl Ys 
and their uncertainty. This thesis focuses on methods for estimating mean total costs in 
the presence of censoring, however, the twelve techniques explored in Chapter 4 can 
also be applied to studies where QAl Ys are censored. 
The second area of uncertainty, results from using prognostic models to estimate non-
transplant survival and the subsequent impact of the model estimates on the non-
transplant cost and QAl Y estimates. Chapters 5 to 7 explore methods for estimating 
prognostic model uncertainties in further detail. Chapter 5 introduces a Monte Carlo 
simulation technique that incorporates prognostic model parameter uncertainty. 
Chapter 5 also considers how estimates of prognostic model uncertainty could be 
incorporated in to selection criteria for choosing an appropriate prognostic model, when 
more than one model exists. 
Although the prognostic models used in the CELT study estimate survival length they 
do not estimate patient specific outcomes. In the CELT study this information was 
10 Over the 2.25 year study period 6% of the CELT cohort of AlD, PSC and PSC patients dropped out of 
the study prior to its end, censoring was therefore ignored in the main CELT analysis. 
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necessary, in order to estimate the individual survival gain of transplantation, and if a 
patient died during the study period, to estimate the non-transplant costs in the month 
prior to death (Equation 2.1). PSA is proposed as a technique for estimating individual 
patient outcomes and the uncertainty around the outcome predictions (Chapter 6). 
Finally, Chapter 7 explores the impact of prognostic model uncertainty on non-
transplant costs and QAL Ys over the five-year study period. 
The two issues that have been selected for further exploration in the remainder of this 
thesis were chosen as matters specifically pertinent to a particular cost-effectiveness 
study in liver transplantation. Therefore, it seemed sensible to conduct a literature 
review to confirm that the methodology for estimating costs in the presence of 
censoring and techniques for estimating uncertainty around prognostic model 
estimates were issues that had been adequately addressed in other solid organ 
transplant studies. The results of this literature review are presented in Chapter 3. 
31 
CHAPTER 3 
DIFFICUL TIES ARISING IN SOLID ORGAN 
TRANSPLANT STUDIES 
3.1 INTRODUCTION 
This thesis takes as its basis a cost-effectiveness study in liver transplantation and 
explores two issues of uncertainty that are pertinent to this study. The CELT study is an 
observational study, and Chapter 2 (Section 2.2) explained why it is currently 
considered unethical to randomise patients to a control group where the alternative to 
liver transplantation is to withhold treatment. Chapter 2 also illustrated how the 
randomisation of patients was likely to yield a sample size too small to establish the 
clinical or cost-effectiveness of liver transplantation. In the UK the practical difficulties in 
conducting an RCT to evaluate the clinical or cost-effectiveness of solid-organ 
transplantation arise from the stratification process that would be necessary to account 
for donor/recipient matching criteria and current donor organ allocation procedures [UK 
Transplant, 2005a]. 
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The ethical and practical considerations that have prevented the conduct of RCT in 
liver transplantation are also applicable to solid organ transplantation in general. 
Therefore, alternative study designs to the RCT are needed to evaluate the 
effectiveness, costs or cost-effectiveness of solid-organ transplantation. 
The CELT study chose a prognostic model approach for estimating, what would have 
been, survival in the absence of liver transplantation [Longworth et aI, 2003]. 
Prognostic models were based on historical cohorts of patients with end-stage liver 
diseases. Non-transplant costs and HRQl were estimated from the non-transplant 
experience of patients on the waiting list for transplantation (intervention delay). 
However, this is just one approach to estimating non-transplant survival, HRQl and 
costs and alternative approaches exist for observing or estimating a non-transplant 
cohort which could also produce adequate estimates of non-transplant survival, HRQl 
or costs. Therefore, the first half of this Chapter (Section 3.2) presents a more 
complete list of alternative study designs to the RCT that could be used in clinical or 
cost-effectiveness studies in solid organ transplantation. Section 3.2 also discusses the 
strengths and limitations of each study design within the context of economic 
evaluations in solid organ transplantation. 
The problems of uncertainty identified in the CELT study are not unique to this one 
study and are common problems that are characteristic of solid organ transplantation 
studies. The remainder of the chapter presents the results of a literature review of 
evaluative studies of solid organ transplantation (Section 3.3). The literature review 
describes and critically appraises the study designs used when attempting to estimate 
the clinical or cost-effectiveness of solid organ transplantation. The review was 
conducted to confirm the methodological issues that were pertinent to the CELT study 
(accurately estimating mean study costs in the presence of censored costs and 
prognostic model uncertainty) were relevant to other solid organ transplant studies. The 
review also sought to establish what approaches had been taken by other researchers 
to overcome the issues of estimating mean costs in the presence of censoring or to 
measure prognostic model uncertainty. Section 3.4 discusses the implications of the 
chapter findings and highlights how this thesis will contribute to the methodology on 
techniques for estimating statistical uncertainty in evaluation studies. 
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3.2 ALTERNATIVE STUDY DESIGNS TO THE RCT 
Various study designs have been proposed to evaluate a medical intervention. The 
NHS Centre for Reviews and Disseminations categorised these in to six categories and 
presented them in a "hierarchy" of scientific credibility [NHS Centre for Reviews and 
Dissemination, 2006]. These designs are, in order: 
• experimental studies with randomisation (RCT) 
• experimental studies without randomisation 
• cohort observational studies 
• case-control observational studies 
• observational studies without a control group 
• expert opinion 
This section explores the five altemative types of study designs that could be used as a 
substitute to the RCT, i.e. experimental studies without randomisation, cohort 
observational studies, case-control observational studies, observational studies without 
a control group and expert opinion. A definition of each type of study design, and the 
steps that should be considered to minimise potential bias and uncertainty within the 
study design are presented in Sections 3.2.1 to 3.2.5. The weaknesses of each 
experimental design are also considered. Section 3.2.6 describes a possible extension 
to experimental studies without randomisation, observational studies and observational 
studies without a control group using modelling. 
Each approach is presented within the context of solid organ transplantation, where the 
primary outcome of interest is effectiveness, costs or cost-effectiveness. It is assumed 
that studies in transplantation for end-stage organ failure consist of an observed 
consecutive series of transplant patients, with the intention being to compare their 
outcomes to those of patients treated with non-transplant management of end-stage 
organ failure over a study period of interest. 
3.2.1 Experimental Study without Randomisation 
The NHS Centre for Reviews and Dissemination defines an experimental study without 
randomisation as "the allocation of patients to different interventions [ ... ] managed by 
the researcher [where] the method of allocation falls short of genuine randomisation 
e.g. altemative or even-odd allocation" [NHS Centre for Reviews and Dissemination, 
2006]. 
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3.2.1.1 Weaknesses 
In solid organ transplantation studies the same ethical and practical implications that 
prevent RCT studies from being conducted also hold true for experimental studies 
without randomisation. It is still likely to be considered unethical to withhold organ 
transplantation from a cohort of patients with end-stage organ failure, regardless of 
what the allocation process is. Further, the practical difficulties from the stratification 
process that would be necessary to account for donor/recipient matching criteria and 
current donor organ allocation procedures still apply (see Section 2.2.1 for a brief 
description of these issues in liver transplantation). Additionally, any non-randomised 
experimental study is likely to struggle to recruit patients and could have high 
withdrawal rates, especially in the control cohort (Section 2.2.1). 
Therefore, experimental studies without randomisation are not considered as a 
plausible alternative to the RCT for evaluating the clinical, cost or cost-effectiveness of 
solid organ transplantation and will not be considered further in this chapter. 
3.2.2 Observational Study with Control Group - The Cohort Study 
An observational study in solid organ transplantation occurs when the survival, HRQL 
or costs from an observed cohort of patients receiving solid organ transplantation are 
compared with survival, HRQL or costs from an observed cohort of non-transplant 
patients managed for end-stage organ failure. Two possible non-transplant cohorts 
exist: a concurrent cohort and a historical cohort. The remainder of Section 3.2.2 
defines concurrent and historical cohorts, within the context of solid organ transplant 
studies and considers the potential weaknesses with each type of non-transplant 
controls. 
3.2.2.1 Concurrent Control Group 
In an observational study with a concurrent control group, information is collected on a 
cohort of patients who present with end-stage organ failure during the same time 
period as the patients who are transplanted. Patients in this cohort are not transplanted 
and so form the control group against which to assess the outcome of those who are 
transplanted. Thus, the control group may consist of patients with end-stage organ 
failure who are not listed for transplantation or the waiting list experience of patients 
with end-stage organ failure. 
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There are several reasons why patients might not be transplanted and hence be 
considered as a "control" patient, including: 
• transplantation might not be a referral option at the treatment centre 
• the patient has contraindications to transplantation (Box 3.1 presents a list of 
contraindications for liver transplantation [Neuberger & Lucey, 1994]) 
• the patient is considered too ill for transplantation 
• the patient is considered too well for transplantation 
• the patient refuses treatment 
• the patient is psychologically unsuitable 
• the patient dies whilst being assessed for transplantation 
• the patient dies whilst on the waiting list for transplantation 
• the patient is removed from the waiting list prior to transplantation 1 
Box 3.1 Contraindications to liver transplantation 
• active alcohol abuse 
• active sepsis 
• advanced cardiac or pulmonary diseases 
• cardiac diseases 
• current metastatic or extrahepatic cancers or previous malignancies 
• diabetes 
• diagnosis of AIDS or HIV infection 
• hepatitis B 
• patient age 
• previous biliary surgery 
• previous psychiatric illnesses 
• severe pulmonary hypertension 
In other words, the patient may not be deemed suitable for transplantation (by the 
clinician) or may themselves choose not to undergo transplantation, or may be unable 
to access transplantation. 
, Common reasons for patients being removed from the waiting list include either an improvement or 
deterioration in health. 
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To avoid potential differences in outcomes between the treatment and control cohorts 
the reason for not transplanting a patient should be independent of what their survival 
outcome might be post-transplant. For example, patients considered too ill for 
transplantation should be excluded from the control group, as the decision not to 
transplant is dependent upon (anticipated) survival post transplant. On the other hand, 
a patient who refuses treatment might be included, so long as the factors that lead to 
the decision not to transplant would not have influenced the expected outcome post 
transplant. 
There are two possible populations that can be used as control cohorts in 
transplantation studies: quasi-experimental control groups and intervention delay 
groups. These two patient groups are discussed in detail below. 
Quasi-Experimental Control Group 
Within the framework of transplantation, a quasi-experimental control group consists of 
those patients who are suitable for transplantation but do not receive it for reasons that 
are independent of what their survival might be post transplant. For example, patients 
might refuse treatment for personal reasons or be treated at a centre that does not 
refer patients for transplantation. 
Weaknesses 
Quasi-experimental control groups were considered by Buxton et al in an economic 
evaluation of a heart transplant programme in two UK hospitals and by Michel et al in 
an economic evaluation of the Dutch liver transplant programme [Buxton et aI, 1985; 
Michel et aI, 1994]. Both sets of authors reject the quasi-experimental method and 
state the reason for this is because the sample of patients are liable to be too small to 
provide a suitable sample size to enable the study to detect a significant difference 
between groups, if one exists. Published results from Anand et al suggest that a quasi-
experimental study consisting of patients refusing treatment for personal reasons are 
likely to yield a small sample size, where 7 of 137 ALD cases (5%) assessed for liver 
transplantation over a seven year period refused to be listed for transplantation for 
personal reasons [Anand et aI, 1997]. 
Moreover, there could also be problems in obtaining adequate information on a quasi-
experimental control group. Patients who refuse transplantation or are cared for at a 
centre where patients are not referred for transplant may return to the care of their local 
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hospital or GP and would be more difficult to follow-up and might be lost to follow-up 
altogether. 
Intervention Delay Group 
There is a general shortage of suitable donors in solid organ transplantation and so 
organ supply does not meet organ demand [UK Transplant, 2004]. In liver 
transplantation, for example, there are approximately 270 patients with end-stage liver 
diseases on the UK waiting list at anyone time point and in the United States (US) this 
figure is in excess of 17,000 patients [UK Transplant, 2005; The organ procurement 
and transplant network, 2005]. Patients who remain on the waiting list may therefore 
provide a control group against which to compare the outcomes of the transplanted 
patients. 
There are three possible definitions of the cohort of patients that might be used as an 
intervention delay group. Cohort I: includes all patients on the waiting list who die or 
are removed from the waiting list before transplantation. Cohort II: includes all patients 
that are transplanted, collecting details on survival and costs both pre-transplantation 
and post-transplantation. The survival of patients in the pre-transplant cohort would be 
censored at point of transplant. Cohort III: combines cohorts I and II, thus the cohort 
would include patients who were removed from the waiting list and the waiting list 
experience of patients who went on to receive a transplant. 
Weaknesses 
A drawback of Cohort I is that, typically, only a small number of patients are withdrawn, 
leading to a control group too small for meaningful comparisons to be based on. 
Furthermore, this group may be an unrepresentative control group, since the subset of 
patients who improve, deteriorate or die do not mirror the population of potential 
transplant patients. Therefore, this choice of control group is problematic for both 
practical and theoretical reasons. 
Gail argues that comparing Cohort I to transplanted patients is analogous to comparing 
transplant patients with non-transplant patients in a situation where transplant priority is 
given to healthier patients, thus patients who die on the waiting list are sicker than 
those patients who survive to point of transplant [Gail, 1972]. In this situation, the 
survival effect from transplantation will be exaggerated: selecting patients that are more 
likely to survive the transplant operation implies that those who remain on the waiting 
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list have poorer health and are more likely to die before a suitable donor becomes 
available. 
An attractive appeal of using Cohort II is that no further information need be collected 
from a second cohort of patients, and within-patient comparisons (in which patients act 
as their own controls) usually need fewer patients to demonstrate a treatment 
difference. However, Cohort II is still unlikely to be representative of a population of 
patients with end-stage liver disease, as patients are censored at point of transplant 
and their expected survival in the absence of transplantation, from point of transplant, 
remains unknown. 
Using cohort II as a comparison group for transplanted patients would be compromised 
if Gail's argument above is true, since if low-risk patients are given priority for 
transplants then their post-transplant survival prognosis may be expected to be good 
due to their prognosis (rather than the treatment). Conversely, if transplant priority is 
given to sicker patients over healthier patients then the survival effect from 
transplantation will be underestimated because the sicker transplant patients will be 
more likely to die during the transplant operation and the healthier patients will be more 
likely to remain alive on the waiting list. 
Box 3.2 illustrates how the two alternative selection strategies; Strategy 1 giving 
transplant priority to healthier patients (Le. non-transplant Cohort I) and Strategy 2 
giving transplant priority to sicker patients (Le. non-transplant Cohort II) could affect the 
survival outcome of patients with and without transplantation. 
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An illustration of the possible outcomes of two alternative 
transplantation strategies of patients on the transplant waiting list 
Let us take two patients, A and B, both of whom have waited three months for a 
suitable transplant organ. Patient B has a better prognosis than patient A. An organ 
becomes available and both patient A and B are suitable matches. 
Strategy 1: Transplant priority given to healthier patients (Patient B) 
Patient B is given the transplant organ and survives to two years post transplant, 
whereas patient A dies four months after being placed on the waiting list. 
The survival gain for transplantation is estimated by the survival of patient B 
compared to that of patient A, and is equal to 2.25 years (including the time spent 
on the waiting list) minus 0.33 years, giving 1.92 years. 
Strategy 2: Transplant priority given to sicker patients (Patient A) 
Patient A is given the transplant organ, but develops post operative complications 
and dies one month after transplantation. Patient B dies six months after being 
placed on the waiting list. 
The survival gain for transplantation is 0.33 years for the transplanted patient A 
(including the time spent on the waiting list) minus 0.5 years for patient B, giving 
-0.17 years. 
What this means is that bias may occur when making a comparison between transplant 
and non-transplant cohorts, depending on whether donated organs are offered as 
priority to well patients (leading to bias in favour of transplant), sicker patients (leading 
to bias against transplant), or regardless of prognosis (no bias). In practice it is not 
known if either of these biases occur, although both have been suggested [Gail, 1972; 
Longworth et a', 2003a]. It is certainly impossible to fully adjust the comparison for the 
impact of this treatment selection. 
In truth, the transplant selection process is likely to include a mixture of these two 
scenarios i.e. Cohort III a non-transplant cohort combining Cohorts I and II. Thus, the 
selection effect (and hence the bias) cannot be quantified and removed from the 
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comparison of transplant and non-transplant patients. Moreover, it is difficult to predict 
the direction in which the bias operates. 
Several authors have proposed alternative survival methods for adjusting for potential 
differences between an intervention delay group and a concurrent transplant cohort 
[See: Turnbull et aI, 1974; Aitkin et aI, 1983]. These authors argue that Cohort III, which 
they assume to be homogeneous, will give a more reliable estimate of non-transplant 
survival than estimates from each of the Cohort I or II (Box 3.2). However, estimates 
are unlikely to be representative of survival in the absence of transplantation given that 
those patients who are censored at the point of transplant (Cohort II) have incomplete 
non-transplant observations (it is unknown how long they would have lived had they not 
received a transplant), potentially underestimating what these censored patients' non-
transplant survival would have been. 
3.2.2.2 Historical Cohorts 
The historical comparator cohort should consist of patients with the same medical 
condition as those receiving the new treatment. In studies in transplantation, a 
historical cohort should consist of non-transplant patients receiving treatment for end-
stage organ failure, who would have met the criteria for acceptance on to the transplant 
waiting list. Data on a clinically defined group of patients can then be obtained from 
previously collected datasets or collected retrospectively, and a comparison made 
between patients who are listed for transplantation and the historical cohort who would 
have been listed for transplant, had it been available at an earlier date. 
Weaknesses 
The first problem when using a historical control group arises in deciding which patients 
it should comprise of. In order to illustrate some of the difficulties in selecting an 
unbiased historical cohort of non-transplant patients, consider the current UK NHS 
protocol for listing patients with end-stage liver failure and some of the difficulties in 
identifying similar patients retrospectively. Patients with end-stage liver diseases are 
accepted on to the liver transplant waiting list if a) their survival in the absence of liver 
transplantation is expected to be less than one year or b) their HRQL is very poor [UK 
Transplant, 2005]. Further, a patient should have a reasonable chance of survival after 
transplantation. There are many contraindications to liver transplantation, some of 
which are more stringent than others (Box 3.1). 
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In addition to the above criteria a patient should, in general, be healthy enough to 
undergo extensive surgery - liver transplantation is a lengthy operation usually taking 
several hours - and be psychologically capable of undergoing the intense 
immunosuppressive regime that normally follows transplantation for the remainder of 
the patient's life. It is easy, retrospectively, to identify whether a patient meets some of 
the contraindications for liver transplantation (Box 3.1), for example, the presence of 
pulmonary hypertension might well be available from patient notes. However, other 
factors, such as HRQL and the ability to undertake an immunosuppressive regime, will 
be difficult (if not impossible) to ascertain in this way. 
An additional but related problem arises when attempting retrospectively to identify 
whether a patient had illness of sufficient severity for transplantation to be considered. 
It is problematic to make a comparison of survival or costs post-transplantation 
between transplanted and non-transplanted patients, since (among other issues) the 
date of transplant is by definition unknown for patients in the control group. It is more 
reasonable to compare survival and costs from the time at which the patient is either 
listed for transplant or not listed. Thus, the time at which the historical patients would 
have been eligible for listing must be estimated. As noted previously, this is not 
necessarily the date of diagnosis; patients with end-stage liver disease in the UK would 
be listed for transplantation when they were expected to survive for less than one-year 
without liver transplantation. Estimating the point at which to include an historical 
patient is difficult, and involves ignoring the retrospective knowledge of any death. The 
expected outcome of a historical cohort of patients might differ from the actual 
outcome, with some patients surviving longer than predicted and others less. If 
available, prognostic models2 could be used to predicted survival to one year, provided 
that clinical information relating to disease characteristics is also available 
retrospectively. 
The quality of historical are likely to have evolved over time, where today more and 
more information is held on computers. Missing clinical information could result in the 
exclusion of patients where case mix factors cannot be adjusted for. In cost and cost-
effectiveness studies missing resource information might result in an underestimation 
of non-transplant costs and thus an over estimation of the incremental costs of 
transplantation. Worst still, older notes may even have been destroyed or lost. In 
2 Prognostic models are described in greater detail in Chapter 5. 
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summary, patient notes may not be of sufficient quality to allow a historical comparison 
to be made. 
Moving away from such practical considerations, it should also be remembered that 
there may be differences between the historical control group and the concurrent 
treatment group that are due to differences in the experimental environment of the 
study [Pocock, 1983]. Of particular note are developments in treatment practice over 
time. For example, in liver transplantation the drug ursodeoxycholic acid has been 
administered to patients with PSC in order to delay the onset of end-stage liver disease 
and the consequent need for transplantation [Goulis et aI, 1999]. Within this context, 
patients considered for transplantation may differ in terms of characteristics (such as 
age at time of listing) to those from a historical cohort where the drug was not available, 
if the drug does in fact postpone the onset of end-stage disease. Other medical 
advances, such as improvement in palliative care, are also likely to increase both the 
survival and the cost of transplant patients over and above that which was observed for 
the historical cohort, potentially exaggerating the effectiveness or cost-effectiveness of 
transplantation. 
The selection criteria for organ transplantation will differ by organ and by country, and 
ideally the historical non-transplant cohort should come from the same centre as the 
transplant cohort. Otherwise, potential biases will arise due to differences in the 
selection of patients, where the type of patient selected is likely to vary due to 
differences in selection criteria between cohorts [Pocock, 1983]. However, using a 
historical cohort from another centre or country might be an attractive option if the data 
are already available, or are more complete than any data that are available for the 
country or centre in question. 
The points mentioned above should be taken in to consideration before collecting 
retrospective information on a historical cohort or using existing historical datasets. It is 
possible to adjust for differences in patient or clinical characteristics by matching3 
historical controls with concurrent transplant patients using the characteristics of the 
transplant patients on the waiting list. Mathematical models can be applied (e.g. 
regression models) to adjust for differences in the clinical and demographic information 
between cohorts, provided that this information has been collected in both groups. 
3 Each transplant patient is matched to one or more non-transplant historical controls "such that they are 
alike with regard to the major prognostic factors" [Pocock, 1983]. 
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However, it is very difficult to adjust for uncertainty caused by experimental differences 
and selecting a historical comparator group presumes the untestable assumption that 
there is no effect of time on prognosis. This assumption is unlikely to be met, but any 
attempt to adjust for a time effect will be speculative, because any time effects on the 
historical cohort are, by definition, irretrievably confounded with the effect of 
transplantation and hence not measurable. 
3.2.3 Observational Study with Control Group - The Case-Control Study 
The case-control study is a retrospective study that seeks to examine factors affecting 
the health and illness of individuals [Crombie, 1996] The NHS Centre for Reviews and 
Dissemination define the case-control study as "a comparison of exposure to 
interventions between participants with the outcome of interest (cases) and those 
without the outcome (controls)" [NHS Centre for Reviews and Dissemination, 2006]. 
For example, a case-control study seeking to establish whether smoking is a causal 
factor in bladder cancer would compare the proportion of smokers amongst a cohort of 
patients with bladder cancer (cases) with the proportion of smokers amongst a cohort 
of patients without bladder cancer [See: Kunze et aI, 1992]. 
3.2.3.1 Weaknesses 
There are two possible ways of defining a case-control study within the context of solid 
organ transplantation. The first approach is to identify a group of transplant cases and 
compare these cases with a group on non-transplant controls. Within the definition of 
the case-control study the focus of the study is to identify whether there are any causal 
factors that explained why the cases received a transplant and the controls do not. 
However, the effectiveness, costs or cost-effectiveness of solid organ transplantation 
can not be evaluated under this definition of the case-control study, unless the aim of 
the study is to illustrate that a patient's survival, HRQL, costs or cost effectiveness 
results in transplantation. In this chapter we are considering the appropriateness of 
alternative non-RCT study designs in the evaluation of the effectiveness or cost-
effectiveness of solid organ transplantation, therefore, this approach is not considered 
further here. 
The second approach to the case-control study is to define a population of interest, for 
example the population of patients who have had end-stage liver disease in England 
and Wales over the last ten years. The next step is to define the outcome of interest, 
for example survival, and one or more causal factors, here the causal factor of interest 
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is liver transplantation. The cases are then defined as those patients with end-stage 
liver disease who have died during the study period and the controls are defined as 
patients who are alive. In order to have similar cohorts of cases and controls each case 
might be matched in terms of patient and disease characteristics to a control patient. 
The next step is to calculate the proportion of transplants that occurred in the case and 
control groups and calculate an odds ratio: the odds of having a transplant and 
subsequently dying compared to the odds of having a transplant and surviving. The 
practicalities of this second approach will be considered in further detail in the 
remainder of this section. 
The first difficulty in conducting a case-control study in solid organ transplantation is 
identifying the population. For example, is it possible to identify the population of 
patients with end-stage liver failure, can this be done from records at transplant 
centres, hospitals or GPs or is there a proportion of the population that remain 
undiagnosed and thus will not be captured easily? It is likely that a proportion of the 
population will be missed, for example patients with end-stage organ failure who are 
not referred for transplantation as they are not treated at a centre who refer patients for 
transplantation, leading to a bias which is hard to quantify. 
The next concern is how to define a study that will evaluate survival over time, HRQL 
or costs and how to examine how transplantation affects these outcomes. In principle it 
would be possible to define the outcome of a case-control study as being either dead 
within two years of diagnosis of end-stage organ failure (case) or alive two or more 
years after end-stage organ failure (control), and compare the proportion of transplant 
operations in each cohort. However, a cohort defined in such a way is likely to be 
confounded by the health of the patient. The difficulties in making case and control 
groups similar (but not too similar) with regards to aspects other than the outcomes are 
well recognised in case-control studies [See: Meirik, 1993]. Even ignoring such 
confounding, retrospective studies cannot conclude causality: a treatment may have 
lead to an increase in deaths, or may have been given specifically because the patient 
was deemed as being at high risk of death (which subsequently occurred). In 
examining these factors within a case-control study design it would not be known which 
of these was the real reason for any association. 
Further difficulties arise when attempting to use a case-control study to examine the 
effect of transplant on HRQL or costs. To illustrate this, consider a cohort of patients 
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with end-stage organ failure where the cost of organ failure for each patient is known. 
Cases would need to be defined as those who cost more than a cut off value (£30K, for 
example), and controls would be defined as patients with end-stage organ failure who 
cost less than this amount. There are two issues here: firstly how the cut off value is 
meaningfully defined and who decides what this value should be? Secondly, questions 
are raised as to whether the results actually answer a question pertaining to the 
effectiveness, cost or cost-effectiveness of organ transplantation in a way that is 
meaningful to decision makers. It is generally accepted that decisions which take costs 
in to account should focus on the total actual cost of the treatment and not the 
proportion of patients whose treatment costs more than some threshold. 
The final problem with the case control study relates to the availability of HRQL and 
cost data. It is unlikely that HRQL data would have been routinely collected at the time, 
and retrospective collection is likely to be either biased or, in the case of patients who 
died, practically impossible. For cost studies, resource use data would also need to be 
gathered retrospectively and this raises concerns about the quality and completeness 
of retrospective data (as identified with historical control groups in Section 3.2.2.2). 
On a more general note, the major weakness of the case-control study is that they 
cannot "provide information on incidence rates of disease" [Meirik, 1993]. The case-
control study will establish whether a causal factor (in this case transplantation) 
increases or decrease the risk of death in the population, but it will not give enough 
information to establish how the risk of death might change. For example, a case 
control study may estimate an odds ratio of 0.33 (suggesting that transplant is 
associated with a two-thirds reduction in the odds of death), but can not estimate the 
absolute magnitude of this benefit in the population (e.g. whether the odds have 
reduced from one in three thousand to one in a thousand, or from three in ten to one in 
ten). For this reason, case-control studies are principally ''first-step'' tools to investigate 
whether there may be any association between a treatment and outcome which, if 
apparent in the study, should ideally be followed up with more rigorous studies of 
alternative study designs. 
To summarise, in principle it is possible to conduct a case-control study to evaluate the 
effectiveness, costs or cost-effectiveness of solid organ transplant. However, there are 
problems obtaining a useful interpretation of the results for decision makers, and 
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additionally any apparent benefit from transplantation would need investigating further 
using alternative study designs. 
3.2.4 Observational Studies without Control Groups 
The fourth type of study design listed by the NHS Centre for Reviews and 
Disseminations is the observational study without a control group, where three possible 
studies exist: cross-sectional study, before and after study and the case series [NHS 
Centre for Reviews and Dissemination, 2006]. The possibilities of using each of these 
three designs within the context of evaluating the effectiveness, costs or cost 
effectiveness of solid organ transplantation will be considered in Sections 3.2.4.1 to 
3.2.4.3. 
3.2.4.1 Cross-Sectional Study 
The cross-sectional study is similar to the case-control study where a population of 
patients with end-stage organ failure are identified and an investigation of the 
relationship between end-stage organ failure and other variables of interest are carried 
out. The difference between the cross-sectional study and the case-control study is the 
case-control study collects information retrospectively whereas the cross-sectional 
study takes a snap-shot of what is happening at one point in time. 
Weaknesses 
The cross-sectional study can not be used to evaluate the survival benefits, costs or 
cost-effectiveness of end-stage organ failure because information is only collected at 
one time point and this will not capture the longer-term costs or survival attributable to 
transplantation. 
However, a cross-sectional study could be used to compare the HRQL of patients who 
had received a transplant with patients who had not received a transplant at a 
particular point in time. Adjustments would need to be made to allow for differences in 
demographic and clinical characteristics between the pre-transplant cohort and the 
post-transplant cohort. 
3.2.4.2 Before-and-after Study 
A before and after study in to the survival, HRQL or costs of solid organ transplantation 
would compare the findings of study participants before and after solid organ 
transplantation. Patients would probably be followed from either point of assessment 
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for transplantation or from point of listing until point of transplant (the "before-
transplant" phase) and for a period of time after transplantation ("after-transplant" 
phase"). 
Weaknesses 
The problems of the before-and-after study are similar to those listed for the 
intervention delay group using Cohort II described in Section 3.2.2.1. Patients are only 
included in a before and after study if they survive the "before" phase, and hence this 
cohort of patients are guaranteed to have survived until point of transplant. The pre-
transplant experience would be analogous to the waiting list experience of transplanted 
patients censored at point of transplant. As outlined in Section 3.2.2.1 this is likely to 
underestimate the survival and HRQL effect of transplantation and exaggerate the 
costs of the transplant cohort in comparison with the pre-transplant costs. 
3.2.4.3 Case Series/Uncontrolled Trial 
A case series (also known as an uncontrolled trial) is a study in which a cohort of 
patients all receive the new treatment or technology, and there is no control group with 
which to compare these patients. Thus, in solid organ transplantation, all patients 
would receive a transplant. A comparison is made (sometimes implicitly) between this 
case series and a second cohort of patients who have received the alternative 
treatment(s) in previous studies, i.e. non-transplant management of end-stage organ 
failure. 
Weaknesses 
The most obvious weakness of the uncontrolled trial is that there is no control group to 
compare the costs and effects of organ transplantation with. A comparison with the 
results from a published study consisting of a second cohort of non-transplant patients 
may be made4, but the comparison will be deeply flawed. The case series of transplant 
patients mayor may not be similar to those in any non-transplant comparison cohort, 
since the two cohorts may be from different countries, different time eras, or different 
risk groups. The extent to which any of these issues confound the impact of the new 
therapy is unknown. 
4 The comparison with previous studies would not use the original data from previous studies, only their 
results. 
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It is possible that less seriously ill patients are likely to be accepted in to an 
uncontrolled trial, as these patients are more likely to respond favourably and therefore 
provide the investigator with more favourable results. This concern was pointed out by 
Gail in the context of heart transplantation, where less seriously ill patients were felt to 
achieve favourable outcomes post transplantation [Gail, 1972]. On the other hand, in 
some instances patients in the most serious need of treatment are enrolled in the 
study. In either case, these patients are unlikely to be representative of the general 
population of patients needing organ transplantation. The extent and indeed direction, 
that these biases will act is unknown. 
Since this thesis is concerned with measuring the uncertainty in the comparison 
between two treatments, and since the case study/uncontrolled trial is unable to 
provide any such comparison, this thesis will not consider the case series/uncontrolled 
trial further. 
3.2.5 Expert Opinions 
An alternative method for collecting information on a non-transplant cohort of patients 
would be to ask a series of experts to estimate the survival, HRQL and resource usage 
of each patient had they not received a transplant. These experts should be the same 
people who assess patients for their suitability for transplantation, i.e. the transplant 
clinicians. When eliciting expert opinions experts should be blinded to the identity of the 
patients. 
Black et aI, reviewed methods for obtaining consensus from a series of experts and list 
three approaches for doing this [Black et aI, 1999]. The first method is the Delphi 
technique [Dalkey & Helmer, 1963]. Each expert is presented with a series of disease, 
clinical and possibly HRQL information. The experts then predict the non-transplant 
survival, HRQL or resource use should that patient not receive transplantation. Experts 
may also be asked to place ranges of uncertainty around their estimate. Each expert 
acts independently of the other experts. 
After each expert has returned their initial opinions (known as a round) they may be 
presented with their own results and the results from the other participants and asked 
whether they wish to revise their prediction. This process may be repeated until 
consensus is reached across all experts. Alternatively, the process may be run over a 
predefined number of rounds, or experts may only be asked once. 
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The second method is known as the nominal group method, in which a series of 
experts initially express an independent prediction of non-transplant survival, HRQL or 
resource use [Oelbecq & Van de Ven, 1971]. These opinions are collected, the group 
of experts would meet, and each expert's predictions are fed back to the group for 
discussion. The experts are then asked to record a revised prediction, these are 
aggregated and summarised at the group level 
The third technique is the consensus development conference, where a series of 
experts are brought together and are presented with evidence and opinions from 
various sources [Fink et aI, 1984]. The experts then retire as a group to consider the 
evidence and attempt to reach a consensus. 
3.2.5.1 Weaknesses 
There are three areas of concern when using expert opinions to simulate a control 
group of non-transplant patients. Firstly, and most importantly, there is a lack of 
evidence to show the reliability of consensus methods, where consensus can vary 
depending on the method used, the way the evidence is phrased or presented, the 
composition of the group of experts, the number of participants and the meeting 
environment [Black et aI, 1999]. 
Secondly, all human decisions are influenced by emotional factors, which can cause 
under or over optimistic estimates of the outcome of interest [Poses et aI, 1991]. It 
would be difficult to account for the factors that influence these decisions, although it is 
possible to ask the expert to explain why they came up with a particular estimate and 
revise it accordingly if consensus argues against reasoning. 
Finally, the three consensus techniques demand that the experts estimate survival, 
HRQL or resource use in the absence of transplantation. This creates a logistical 
problem for the nominal group method and the consensus development conference 
technique since it requires co-ordinating the meeting of a team of experts and a 
discussion of the expected medical needs and outcomes of a (potentially sizeable) 
number of patients would require several meetings. 
3.2.6 Estimating Control Group Endpoints using Modelling 
An extension to the observational cohort study with a concurrent or historical control 
group and the observational study without a control group is to use statistical modelling 
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to estimate what patients' costs and effectiveness would have been in the absence of 
transplantation. These models can range from simple regression models [Bonsel et aI, 
1991], Markov models [Sagmeister et aI, 2002], or even complex discrete event 
simulation models [Ratcliffe et aI, 2001]. Any modelling approach used will be based 
upon one or more sources of data that will originate from: 
• intervention delay groups 
• quasi-experimental control groups 
• historical cohorts 
• non-transplant controls in case-control studies or cross-sectional studies 
• the pre-transplant experience of transplant patients 
• a combination of all of the above listed sources of data 
There are arguments as to why modelling is an attractive option to estimate non-
transplant survival, HRQL or resource use. Firstly, modelling can be used to allow for 
uncertainty in estimates by assigning distributions around them. Secondly, modelling 
can be used in the absence of observed information from a non-transplant cohort of 
patients (prognostic modelling). Prognostic models based upon historical cohorts of 
patients can be used to estimate non-transplant outcomes whilst incorporating the 
characteristics of the current cohort of transplant patients (and estimating their 
outcomes had they not been transplanted). 
3.2.6.1 Weaknesses 
Model data will be subject to many of the same cautions, strengths and weaknesses 
mentioned in sections 3.3.2 to 3.3.5 above. The modelled cohort should be 
representative of the population of patients with end-stage organ failure who are 
eligible for transplantation, selective (Le. patients should not be included in the non-
transplant cohort because they are too ill/well for transplantation), and based on an 
adequate number of patients to achieve reliable non-transplant estimates. 
Further, as described in Chapter 1, the modelling of control group data will introduce 
modelling uncertainties, i.e. model parameter uncertainty, model structure (choice) 
uncertainty and model process uncertainty. Therefore, any study that uses a modelling 
approach should carry out extensive deterministic and probabilistic sensitivity analysis 
to explore the effects of model uncertainties on the study results and conclusions in 
accordance with health technology guidelines [See: NICE, 2004; CADTH, 2006]. 
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3.2.7 Summary 
Section 3.2 has presented alternative study designs to the RCT for estimating the costs 
or benefits in the absence of solid-organ transplantation. For each choice of design 
there are potential problems with uncertainty caused by the bias in the selection of a 
control group of patients. It should however be noted that RCTs are not always the 
most appropriate design to use, since they too have potential problems, for example 
ethical issues or inadequate sample sizes due to rare diseases or events. 
Studies should be designed so that they minimise the potential biases arising from the 
study design. As Black points out "there is no such thing as a perfect method; each 
method has its strengths and weaknesses. The two approaches [RCT and 
observational studies] should be seen as complementary" [Black, 1996]. In some cases 
a non-randomised study design might be the most appropriate approach to use for 
estimating the costs or benefits, or both, of new treatments or technologies. 
If every effort is made to minimise study population bias from alternative study designs 
then it is possible to estimate the effectiveness, costs or cost-effectiveness of a new 
treatment or technology, within the limitations of the study design. 
3.3 A REVIEW OF STUDIES EVALUATING SOLID ORGAN 
TRANSPLANTATION 
Section 3.3 presents the results of a literature review of the evaluation of solid organ 
transplantation. The aim of the review is to identify solid organ transplantation studies 
that had compared either the costs, benefits or both the costs and benefits of solid 
organ transplantation with the medical management of end-stage organ failure. The 
following issues are critically appraised for each of the studies identified: 
• the author's source of evidence for the non-transplant management of end-
stage organ failure (e.g. quasi-experimental, intervention delay, historical, case-
control, cross-sectional, before-and-after, expert opinion) 
• whether censoring was an issue, in cost or cost-effectiveness studies, and if it 
was which methods were used to allow for censored cost data 
• whether studies that used prognostic models to estimate non-transplant survival 
HRQL or costs measured the uncertainty around prognostic model estimates 
52 
Chapter 3 Difficulties Arising in Solid Organ Transplant Studies 
• whether other types of modelling, other than prognostic modelling, e.g. Markov 
models, were used to estimate non-transplant survival, HRQL and costs and 
whether uncertainty around model estimates was accounted for 
• whether other sources of uncertainty were identified or accounted for, and 
whether deterministic or probabilistic sensitivity analysis were used to account 
for this uncertainty 
• whether studies had a sample size of less than 30 patients per group5 (these 
studies are unlikely to detect significant differences between groups). Study 
sample size was investigated as a further measure of the quality of the study 
The review focuses on transplantation studies that compared vital organ 
transplantation with the non-transplant management of end-stage organ failure. Studies 
which compared transplantation of the heart, intestine, kidneys, liver, lungs, pancreas 
or a combination of more than one of these organs with alternative (non-
transplantation) management were included in the review. 
The search was limited to six databases: 
• Ovid - Medline [OVID, 2005] 
• Ovid - Cumulative Index to Nursing and Allied Health Limited (CINAHL) [OVID, 
2005] 
• BIDS - International Bibliography of the Social Sciences (IBSS) [BIDS, 2005] 
• NHS Economic Evaluation Database (NHS EED) [Centre for Review and 
Dissemination, 2005] 
• Office of Health Economics Health Economic Evaluations Database (OHE 
HEED) [OHE HEED, 2005] 
• University of Sheffield's online library catalogue (STAR) [University of Sheffield 
Library, 2005] 
To identify articles in solid organ transplantation the search strategy combined the term 
"transplant" or "graft" with any of the solid organs listed above ("heart", "intestine", 
"kidney", "liver", "lung", or "pancreas"). These terms were also combined with those 
5 There is no consensus in the statistical literature on the preferred sample size, in studies where a power 
calculation is inapplicable. A suggested urule of thumb" is that the sample size should be a minimum of 30 
per arm in order for th~ ce~trallimit t~~r~ to apply (Le. for sample means ~o follow a .normal distribution 
irrespective of the distribution of the Individual measurements). Although arbitrary. this IS conventionally a 
minimum sample size and is the rule adopted here. 
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relating to economic evaluation studies or cost studies or studies addressing patient 
benefits (either outcome or HRQL). Search terms included expressions listed on the 
Medical Subject Headings (MESH) database [National Library of Medicine, 2005]. Full 
details of terms searched are listed in Appendix 3.1. 
Databases were searched for the period January 1 st 1980 to May 31 st 2005. Exceptions 
were made for a series of studies examining survival in the Stanford heart transplant 
series published prior to 1980. These studies were felt to contain important 
methodological contributions to the literature on allowing for bias in survival for 
intervention delay groups [Clark et aI, 1971; Turnbull et aI, 1974]. Reviews were 
excluded, though review articles were obtained to identify sources for original studies. 
One unpublished study (grey literature) known to the author of this thesis was included 
as it was felt to address important methodological issues in accounting for uncertainties 
in non-RCT studies [Longworth et aI, 2003a]. Studies had to be in English to be 
included in the review. 
An initial screen of the articles was performed, in which the author rejected articles if 
the article title and abstract (when available) clearly indicated that the article did not 
compare transplantation with the non-transplant management of vital organ failure. If 
the title or abstract stated that the article compared the effectiveness, costs or cost-
effectiveness of transplantation with the non-transplant management of organ failure 
the original articles were sought and reviewed to obtain further details of the study 
design and methodology. A total of 678 articles were sought and reviewed to obtain 
further details. Articles were excluded from the analysis if: 
• 
• 
• 
they did not compare transplantation with medical management 
they were a review article 
the article was unobtainable6 
Based upon the article title and abstract, a total of 678 potential articles were listed as 
suitable comparators of transplantation with a non-transplant cohort (Figure 3.1). Nine 
per cent (N = 62) of these articles were unavailable in the British Library or the 
University of Sheffield libraries. This left 616 articles which were obtained and read; of 
these 12% (N = 74) were review articles and 55% (N = 340) did not compare 
6 Articles were sought from the University of Sheffield Libraries, which include access to a number of NHS 
libraries in the South Yorkshire region, including teaching hospital libraries, and the British Library. If 
articles were not found after searching these sources they were considered unobtainable. 
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transplantation with a non-transplant cohort. A total of 202 articles (33% of those read), 
covering 158 studies were accepted as suitable comparisons of transplantation with a 
non-transplant cohort. 
Figure 3.1 Flowchart depicting the exclusion process for the 678 articles that 
were reviewed in the literature review 
62 articles N =678 
-'" were Articles reviewed -
unavailable 
~ 
"' 340 articles 
rejected as they v 74 articles did not compare 
..... 
N = 616 Articles 
rejected as 
transplantation ..... -
review articles 
with medical 
" 
management 
,~ 
N =202 
Articles accepted 
Table 3.1 details the articles included or excluded in the review by organ. Few studies 
were found in the area of intestinal transplantation and kidney transplant was the most 
common organ to be studied in this review. 
Table 3.1 Summary of 678 accepted and rejected literature review articles by 
organ 
Accepted Rejected: Rejected: Not Rejected: Total 
Review comparing Tx Unable to find 
Heart 31 10 49 11 101 
Intestinal 4 3 7 2 16 
Kidney 75 22 152 23 272 
Liver 35 18 92 21 166 
Lung 25 6 12 2 45 
Pancreas 3 7 11 3 24 
Pancreas-Kidney 29 8 17 0 54 
Total 202 74 340 62 678 
Tx - Transplantation 
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Appendix A3.2 gives reference details of the 202 articles included within this review. 
The remainder of this chapter presents the study results in terms of the number of 
original studies included in the review (N = 158) and not in terms of the number of 
articles, since some authors published more than one article describing the same 
patients. 
Figure 3.2 presents a Venn diagram to summarise the number of studies by the 
database/s the study was identified in. A total of 145 studies (92%) were identified by 
the Ovid database, 108 from Ovid alone and a further 37 which were identified by Ovid 
and at least one other database (For example Ovid and CINAHL). Of the other five 
databases searched in this literature review; NHS EED identified 25 studies (16%), 
OHE HEED 22 studies (14%), CINAHL 15 studies (9%), STAR 1 study (1%) and BIDS 
no studies. One unpublished study was also included in this review. 
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Figure 3.2 
Difficulties Arising in Solid Organ Transplant Studies 
Venn diagram of number of accepted studies by database (N = 
158) 
3 (20/0) 
Table 3.2 presents a summary of the literature review results by organ and type of 
study; survival, HRQL, survival and HRQL, costs or cost-effectiveness studies. Nearly 
half the studies (470/0) compared HRQL only between transplantation and a non-
transplant cohort, 150/0 looked at survival only and seven studies (4%) considered both 
survival and HRQl. One quarter of the studies presented cost-effectiveness results 
comparing transplantation with a non-transplant control group, and eight per cent of 
studies presented costs only. 
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Table 3.2 
Organ 
Heart 
Intestine 
Kidney 
Liver 
Lung 
Pancreas 
SPK 
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Number of studies included in the review by organ and type of 
study (N = 158) 
Survival HRQL Survival Costs Cost- Total 
&HRQL effectiveness 
(N = 23) (N = 75) (N = 7) (N = 13) (N = 40) (N = 158) 
5 12 4 1 4 26 
0 1 0 0 1 2 
10 25 0 9 20 64 
3 14 0 2 8 27 
2 11 0 0 3 16 
0 2 0 0 1 3 
3 10 3 1 3 20 
SPK - Simultaneous pancreas kidney transplant 
Appendix A3.3 presents a detailed summary of the 158 studies included in this 
literature review by organ. Sections 3.4.1 to 3.4.4 present a summary of the main 
findings of the literature review by type of study (survival, HRQL or survival and HRQL, 
costs or cost-effectiveness). Table 3.3 summarises the different study designs used 
and Table 3.4 summarises whether the studies dealt with censored costs, modelling, 
prognostic modelling, used deterministic or probabilistic sensitivity analysis or had a 
small sample size, by type of study. 
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Table 3.3 
Quasi-
experimental 
cohort 
Intervention 
delay cohort 
Historic cohort 
Case-control 
Cross-section 
Before & After 
Expert opinion 
Other 
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Summary of the study designs used in 158 studies reviewed by 
type of study (Frequency and percentage reported) 
Survival HRQL or Costs Cost- Overall 
survival & effectiveness 
HRQL 
(N = 23) (N = 82) (N = 13) (N = 40) (N = 158) 
14 (61%) 28 (34%) 11 (85%) 28 (70%) 81 (51%) 
8 (35%) 1 (1 %) 1 (8%) 8 (20%) 18 (11%) 
0 (0%) 0 (0%) 0 (0%) 1 (3%) 1 (1%) 
0 (00/0) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
0 (0%) 9 (11%) 0 (0%) 0 (0%) 9 (6%) 
0 (0%) 34 (41 %) 1 (8%) 0 (0%) 35 (22%) 
0 (0%) 1 (1 %) 0 (0%) 0 (0%) 1 (1%) 
1* (4%) 9# (7%) 0 (0%) 3+ (8%) 13 (8%) 
* Historical cohort combined with Intervention delay group 
# Five studies used both quasi-experimental and before and after groups, three studies used cross 
sectional and before and after studies and one study used quasi-experimental and intervention delay 
groups. 
+ Two studies used intervention delay combined with a historical control group and one study used 
intervention delay combined with a historical control group. Of the three studies, one conducted a further 
intervention delay group analysis 
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Table 3.4 
Censoring of 
costs a 
potential issue 
Censored 
costs adjusted 
for 
Prognostic 
models used 
Other models 
used 
Deterministic 
sensitivity 
analysis used 
Small sample 
size 
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Summary of the issues of statistical uncertainty used in 158 
studies reviewed by type of study (Frequency and percentage 
reported) 
Survival HRQL or Costs Cost- Overall 
survival & effectiveness 
HRQL 
(N = 23) (N = 82) (N = 13) (N = 40) (N = 158) 
N/a N/a 13 (100%) 23 (56%) 33 (21 %) 
N/a N/a 0 (0%) 3 (8%) 3 (2%) 
1 (4%) 0 (0%) 0 (0%) 3 (8%) 4 (3%) 
13 (57%) 3 (4%) 2 (15%) 20 (50%) 38 (24%) 
1 (4%) 1 (1 %) 1 (8%) 20 (50%) 23 (15%) 
1 (4%) 29 (35%) 2 (15%) 9 (23%) 41 (26%) 
N/a Not applicable 
3.3.1 Survival Only Studies (N = 23) 
Failure to adjust for case mix factors (Le. factors known to affect the survival outcome) 
which differ between treatment and control groups can bias the survival estimates 
either in favour of, or against, transplantation. Adjustment for case mix factors can be 
made using modelling techniques, for example the Cox PH model. Over 60% of the 
survival studies included in this review made adjustments for case mix factors shown to 
affect survival. The remaining nine studies failed to adjust for case mix factors, 
potentially introducing bias in to their survival estimates. 
Eight studies used an intervention delay waiting list cohort - this cohort is unlikely to be 
representative of the population of patients with end-stage organ failure who are 
eligible for transplantation for the reasons set out in Section 3.2.2.1. Fourteen studies 
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used a quasi-experimental control group. Only one study used a prognostic model 
approach to estimate survival in the absence of transplantation, combining information 
from a historical cohort with an intervention delay group and this study failed to account 
for prognostic model uncertainties. 
3.3.2 HRQL Only (N = 75) and Survival and HRQL Studies (N = 7) 
Over half of the studies (52% [82/158]) included in this review compared HRQL with, 
and in the absence of, transplantation, with seven studies reporting both survival and 
HRQL results. Twenty-eight HRQL studies (34%) compared transplantation with a 
quasi-experimental control group, 34 (41 %) used a before and after study design, 9 
(11 %) a cross sectional study design, one study used an intervention delay group and 
one used expert opinion (the only study in the literature review to use this approach) 
and the remaining nine studies used more than one type of study design. 
The cross sectional studies asked control group and transplant patients about their 
HRQL at one time point only. These studies would not obtain a representative sample 
of non-transplant patients since they do not capture the HRQL of patients who died 
during the study. A similar selection process was true of the before and after studies 
that profiled HRQL over time; many of these studies compared patients who were well 
enough to respond to a questionnaire at all study time points. Only a handful of studies 
included all responders. 
Four of the HRQL studies will be subject to recall bias as transplanted patients were 
asked to recall what their HRQL had been like before transplantation. A further study 
asked experts to value patients HRQL. 
3.3.3 Cost Studies (N = 13) 
Eleven of the 13 cost studies compared transplantation with a quasi-experimental 
control group. Of the remaining two studies, one compared transplantation with an 
intervention delay group and one used the before and after study design. All studies 
used observed data, though one kidney transplant study compared observed transplant 
costs with costs for a hypothetical cohort of dialysis patients, but provided no details 
regarding the characteristics of this cohort. 
None of the cost studies gave details to indicate whether patients were lost to follow-up 
(censored) during the study, therefore, all thirteen studies were potentially subject to 
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censored cost data, yet none of the studies accounted for mean total costs in the 
presence of censoring. Only one study carried out one-way sensitivity analysis to vary 
assumptions made in the main cost analysis. 
3.3.4 Cost-Effectiveness Studies (N = 40) 
Eight studies compared transplantation with an intervention delay group. A further three 
studies combined data from an intervention delay group with historical data. All three 
studies used prognostic models based on historical cohorts to estimate survival in the 
absence of transplantation and information from the waiting list to estimate non-
transplant utilities and costs. A further 15 studies (38% ) used modelling techniques, for 
example Markov modelling or simulation modelling, to estimate the cost effectiveness 
of solid organ transplantation. 
De By and colleagues compared a cohort of transplant patients whose graft had failed 
with a cohort of dialysis patients [De By et ai, 1982]. This study is likely to be biased 
towards the dialysis cohort as patients with graft failure will tend to have higher 
mortality and incur more costs than patients with a non-failing kidney graft. 
Censoring occurs when a proportion of study patients do not experience an event of 
interest (e.g. death) during the study period and have incomplete data for the full study 
period. Ignoring censoring can result in biased estimates of survival, HRQL or costs. 
Statistical methods exist to allow for censoring in time to event survival studies [Collett, 
1994]. However, these techniques are not applicable to cost or HRQL data due to 
underlying methodological assumptions (See Chapter 4 for further details) [Hallstrom & 
Sullivan, 1998]. Three (8%) of the forty cost-effectiveness studies adjusted for 
censored cost data. All three studies used the Kaplan-Meier product limit estimator, 
also known as Lin's method, where mean costs per time period are weighted by the 
Kaplan-Meier probability of survival and summed over time [Lin et ai, 1997]. This 
method is explained in further detail in Chapter 4. 
None of the studies that chose to use prognostic models to estimate non-transplant 
survival made an adjustment for model parameter uncertainty. One paper, which was 
part of Longworth and colleagues' liver transplant study [Longworth et ai, 2003], used 
discrete event simulation modelling to estimate the cost-effectiveness of liver 
transplantation [Ratcliffe et ai, 2001]. In discrete event simulation it is possible to 
specify distributions, central estimates (e.g. means, medians) and uncertainties around 
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distributions using ranges and standard errors, this is analogous to PSA. However, 
although this paper did allow for uncertainty around resource use parameters it 
assumed that prognostic model parameters were fixed and thus failed to account for 
prognostic model uncertainties [Personal communication with authors]. 
The authors of three studies felt that costs increased for a time period immediately prior 
to death and made an adjustment to estimate non-transplant costs accordingly. 
Additionally, Anyanwu and colleagues and Van Enckevort et aI, also adjusted for costs 
for a period prior to death in the transplant cohort; both studies extrapolated data 
beyond the observed study period [Van Enckevort et aI, 1997; Anyanwu et aI, 2002]. 
3.4 DISCUSSION 
The RCT remains the preferred method for evaluating the effects, cost and cost-
effectiveness of medical interventions. Despite this, solid organ transplantation is one 
therapeutic intervention for which this design is inappropriate, both for ethical and 
practical reasons. Alternatives to the RCT that could be used in comparator studies of 
solid organ transplantation with an alternative treatment cohort were presented in 
Section 3.2. For each study design cautions in the application, strengths and 
weaknesses were discussed. Section 3.3 followed this with a review of the current 
literature, giving details on the designs that had been used in practice together with 
details of other issues that were encountered. 
It was disappointing to note that the majority of studies in this review compared 
transplantation with an inappropriate cohort of non-transplant patients. Half of the 
studies included in the literature review compared organ transplantation with a quasi-
experimental control group. The majority of these studies (N = 53) were kidney 
transplant studies where dialysis is offered as an altemative treatment for end-stage 
renal failure. However, few of the studies that included a quasi-experimental control 
group compared cohorts of patients with end-stage organ failure, and instead 
compared cohorts undergoing transplantation or an alternative treatment. For example, 
an obvious alternative treatment to kidney transplantation is dialysis, but dialysis is also 
given to patients who have other (less chronic) kidney diseases. Including these 
patients in a comparison cohort for patients with end-stage organ failure creates a 
control cohort of patients who are likely to be healthier than a cohort of patients 
undergoing transplantation. A number of studies took this approach and therefore 
would have underestimated the effectiveness of kidney transplantation, although some 
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studies did consider this and used concurrent cohorts of dialysis patients listed for 
kidney transplantation [Chantler et a', 1980; Laupacis et a', 1993; Laupacis et a', 1996; 
Fujisawa et a', 2000). 
Only one study used expert opinions to estimate HRQL in the absence of 
transplantation [Mai et a', 1990). Given the lack of evidence of the reliability of expert 
opinions, the results from this study are highly likely to be biased [Black et a', 1999]. No 
study used the case-control study design, which is unsurprising given the difficulties of 
designing and drawing meaningful conclusions from such a study. 
Faced with a choice of possible study designs the approach of preference would be the 
use of a quasi-experimental control group of non-transplant patients with end-stage 
organ failure who meet the criteria for transplantation. However, the expected sample 
size of a quasi-experimental control group should be considered with this type of study, 
and 14 (18%) of 79 concurrent studies used cohorts consisting of less than 30 cases. If 
the sample size is likely to be small the study is unlikely to detect statistical differences 
between groups, or to reliably estimate effectiveness, costs or cost-effectiveness. 
In the absence of a suitable cohort of quasi-experimental controls I would probably 
explore the use of a historical control group over an intervention delay group, and five 
studies in the literature review used this approach [Williams et a', 1987; Bonsel et a', 
1990a; Bonsel et a', 1990b; Christensen et a', 1999; Liemann Garcia et ai, 2001; 
Longworth et ai, 2003; Longworth et ai, 2003a]. I believe such a cohort is still 
preferable to an intervention delay group of patients on the waiting list, an intervention 
delay cohort is unlikely to be representative of the general population of non-transplant 
patients with end-stage organ failure who meet transplant listing criteria (Section 
3.2.2.1 ). 
If the data are available, statistical modelling can be used to adjust for differences 
between the treatment cohort and either the quasi-experimental, intervention delay or 
historical control groups. An alternative strategy would be to individually match patients 
in the treatment group to similar patients in the control arm. A few studies in this review 
did this. However, matching can reduce the sample size of a study, as patients without 
a suitable match are excluded from the analysis. 
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3.4.1 Estimating Mean Total Costs in the Presence of Censoring 
None of the HRQL studies tackled the issue of censored data. Only one study 
considered the HRQL of patients who died, where patients who died during the study 
period were given a value of zero [Ratcliffe et aI, 2001; Longworth & Bryan, 2003]. 
Most of the HRQL studies chose to compare the HRQL of patients who remained alive 
throughout the study and the HRQL of patients who died was ignored, biasing the 
results towards healthier patients. A few studies chose to include patients who dropped 
out of the study and Caine and colleagues used the last value carried forward 
approach to allow for drop outs [Caine et aI, 1996]. 
It has already been highlighted that many of the HRQL studies excluded patients with 
incomplete (censored) data and it can be assumed that many of the cost and cost-
effectiveness studies comparing transplantation with a non-transplant cohort over a 
fixed time period also ignored the issue of censoring. A total of 33 studies could have 
been subject to censored cost data and could have adjusted for it. However, only three 
studies did so, each of which used Lin's method to adjust for the incomplete follow-up 
of a proportion of their patients [Ohi et aI, 1986; Garner & Dardis, 1987; Longworth et 
aI, 2003a]. Numerous techniques have been proposed in the literature for estimating 
mean total costs in the presence of censoring and these will be reviewed in Chapter 4. 
The censored cost methods introduced in Chapter 4 can be applied in any study where 
censoring is an issue (including RCTs) and can also be applied to censored HRQL 
data. 
3.4.2 Measuring Prognostic Model Parameter Uncertainty 
In the absence of a suitable observed control group, four of the studies in this review 
used prognostic models to estimate survival in the absence of transplantation [Bonsel 
et aI, 1990a; Bonsel et aI, 1990b; Christensen et aI, 1999; Liemann Garcia et aI, 2001; 
Longworth et aI, 2003; Longworth et aI, 2003a]. Prognostic models are usually based 
on cohorts other than the one they are being applied to when estimating control group 
survival and prognostic model regression coefficients are actually a mean coefficient 
for a cohort. These model coefficients are therefore estimates and the uncertainty 
around the mean regression coefficients is represented by the regression coefficient 
standard error. All the studies included in this literature review assumed that there was 
no uncertainty around the prognostiC model and applied the mean regression 
coefficients when estimating control group survival. A method is set out in Chapter 5 to 
incorporate prognostiC model parameter uncertainty. 
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3.4.3 Estimating Individual Patient Outcomes from Prognostic Models and the 
Uncertainty Surrounding the Outcomes 
In this review, three studies assumed that costs increase for a time period immediately 
prior to death, where it was assumed that patients were likely to be treated more 
resource intensively and an adjustment was made accordingly [Van Enckevort et aI, 
1997; Anyanwu et aI, 2002; Longworth et aI, 2003]. Methods based upon observed 
data or modelling techniques were applied to estimate costs incurred in the time period 
prior to death. 
Extrapolation techniques must be applied to establish time of death using modelling 
techniques. If a fixed study time period is observed, uncertainties exist in establishing 
methods for defining the exact point of death and uncertainty will exist around the 
estimated time point. Chapter 6 explores a number of techniques for estimating 
uncertainties when predicting outcomes in a control group of patients over a fixed study 
period. 
3.4.4 Collectively Measuring Multiple Sources of Uncertainty Relating to the 
use of Prognostic Models Instead of an Observed Non-transplant Cohort 
A total of 23 studies conducted deterministic sensitivity analysis to test assumptions 
made when estimating the costs, effectiveness or cost effectiveness with and without 
transplantation. In all 23 studies the sensitivity analysis was the basic one-way. 
Occasionally, extreme scenarios were explored within the one-way analysis. However, 
none of the studies included in this literature review considered multi-way or PSA to 
explore the effects of varying more than one assumption at a time. Additionally, no 
study considered whether varying one assumption would have an impact on other 
assumptions made within a study. 
Although this is a complex issue, techniques exist to enable researchers to conduct 
multi-way and PSA [Doubilet et aI, 1985]. Chapter 7 focuses on measuring multiple 
sources of uncertainty from applying a prognostic model approach to estimate survival, 
HRQL and costs in the absence of a suitable observed cohort of non-transplant 
patients. PSA is applied in order to consider the impact of prognostic model 
uncertainties on survival, HRQL and cost estimates. 
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3.5 CONCLUSIONS 
This chapter has identified some of the problems and uncertainties associated with 
non-RCT study designs. More specifically, it has focussed on the problems and 
uncertainties associated with the appropriate selection of a non-transplant cohort of 
patients in the evaluation of the effectiveness, costs or cost-effectiveness of solid organ 
transplantation. It is important that any issues associated with the choice of study 
design are considered at the design stage and failure to do this could result in a non-
transplant cohort of patients that is either unrepresentative of the population of interest 
or not comparable to the transplant cohort (or both). 
The solid organ transplant studies identified in the literature review adopted a number 
of designs and methods to estimate control group survival, HRQl or costs and the 
uncertainties associated with these estimates. However, it was disappointing to 
observe that the majority of studies failed to consider or acknowledge potential bias in 
their studies as a result of the choice of their study design. 
Despite this, it should also be pointed out that some of these problems are not specific 
to the above types of study, since problems with unrepresentative cohorts and low 
sample sizes in particular may arise even in an RCT. Clearly, no solution is going to be 
perfect and any of the comparator groups selected are going to have inherent 
difficulties and so any evaluation will have to make some assumptions in order to 
estimate the effectiveness, costs or cost-effectiveness of solid organ transplantation. 
The best studies will give consideration to the criteria mentioned above, acknowledge 
the difficulties encountered within the study and discuss the possible implications these 
may have on the results. The plausibility of any assumptions made will raise questions 
regarding the reliability of the study results, and as a consequence studies should also 
highlight any assumptions made and perform a deterministic or probabilistic sensitivity 
analysis around any assumptions that are particularly important or controversial. 
The literature review confirmed that estimating costs in the presence of censoring and 
the use of prognostiC models were important issues to be addressed in the CELT study 
and were also common problems inadequately addressed in many solid organ 
transplant studies. Therefore, the remainder of this thesis will specifically explore the 
following issues: 
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• estimating mean total costs in the presence of censoring (Chapter 4) 
• measuring prognostic model parameter uncertainty (Chapter 5) 
• estimating individual patient outcomes from prognostic models and the 
uncertainty surrounding the outcomes (Chapter 6) 
• collectively measuring multiple sources of uncertainty related to the use of 
prognostic models instead of an observed non-transplant cohort (Chapter 7) 
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CHAPTER 4 
ESTIMATING MEAN TOTAL COSTS IN THE PRESENCE 
OF CENSORING 
4.1 INTRODUCTION 
The main findings of the CELT study were based on a follow-up period of 2.25 years 
after point of assessment [Longworth et a', 2003]. In the original study, only six per cent 
of AlD, PSC and PSC transplant patients were lost to follow-up (censored) prior to the 
end of the 2.25 year study period and censoring was ignored. It was anticipated that 
the proposed extension to the CELT study, over a five-year post-assessment follow-up 
period, would increase the proportion of data censored before the end of the study 
rather than censored at five years. It was felt unwise to ignore censoring for the 
extended follow-up data, prompting the question: what methods can be used to 
analyse censored data and which of them work well? This provided the motivation for 
the research carried out and reported in this chapter. 
The simplest method for allowing for censored survival data is the Kaplan-Meier 
product limit method, which makes no assumptions about the underlying distribution of 
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the data [Kaplan & Meier, 1958; Collett, 1994]. However, like most other survival 
methods, including the Cox PH regression model [Cox, 1972]; it does assume that 
survival times are independent of the method or reason of censoring. This means that 
a patient who is censored at a particular time point should be representative of all other 
patients who have survived to that time point. If this assumption does not hold then 
censoring is said to be informative and these survival analysis methods become 
biased, with the degree of bias depending on the proportion of informatively censored 
patients in the study. 
In evaluations of health care interventions the problem of censoring is not unique to 
survival or other health outcomes; it is also relevant to costs where information may be 
similarly censored. Unfortunately, the problem of censoring is not solved simply by 
using methods such as the Kaplan-Meier method and applying it to censored cost data. 
For the Kaplan-Meier methodology to be appropriately applied costs should be 
independent of the method or reason for censoring and a censored cost should be 
representative of all other costs that size or greater. Hallstrom and Sullivan have clearly 
illustrated the problems in using the Kaplan-Meier estimate on a cost scale [Hallstrom 
& Sullivan, 1998]. They illustrate the problem by considering the effect of censoring on 
survival and costs among four hypothetical patients, as demonstrated in Figure 4.1 
(reproduced from their paper with kind permission of the journal Medical Care [Medical 
Care (1998); 36(3): 433-436]). 
Panel A of Figure 4.1 presents the cost and survival histories for four patients: 
• patient A dies after 2 days and incurs costs at a rate of $0.5 per day with a total 
study cost of $1 
• patient B is censored after 5 days and incurs costs at a rate of $1 per day with a 
total study cost of $5 
• patient C is censored after 3 days and incurs costs at a rate of $1.5 per day with 
a total study cost of $4.5 
• patient 0 is censored after 4 days and incurs costs at a rate of $2 per day with a 
total study cost of $8 
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Figure 4.1 
Estimating Mean Total Costs in the Presence of Censoring 
Transcribing the real time costs and survival of four patients (panel 
A) to the failure time scale (panel B) and failure cost scale (panel C) 
and computing the Kaplan-Meier failure time estimates (panel B) 
and the Kaplan-Meier analogue of failure cost estimates (panel C) 
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Panel A of Figure 4.1 depicts the study start time and the time each patient entered 
and left the study. Panel B shows the total time each patient was in the study (as the 
length of the horizontal line) and the Kaplan-Meier probability of survival (St) from time 
zero to five days (Ct will be defined later). All patients remain in the study up to day 2, 
giving a Kaplan-Meier survival probability of one. On day 2 patient A dies, giving a 
Kaplan-Meier survival probability of 0.75. The final panel of Figure 4.1 shows the total 
costs incurred by each patient over the study period, where the horizontal line is equal 
to the total cost (daily cost multiplied by time spent in the study) and St refers here to 
71 
Chapter 4 Estimating Mean Total Costs in the Presence of Censoring 
the probability of incurring a cost greater than or equal to the value on the horizontal 
axis. 
If the Kaplan-Meier method is directly applied to the cost scale, the probability of 
incurring a cost of at least $1 during the study period is one. Thereafter, patient A dies 
leaving three censored patients in the study with total study costs of at least $2, and 
with a probability of incurring a cost of at least $2 of 0.75. The mean costs for the study 
would then be estimated by (St x daily cost): 
(1x1) + (0.75x1) + (0.75x1) + (0.75x1) + (0.75x1) + (0.75x1) + (0.75x1) + (0.75x1) 
= $6.25 
Panel C also shows why the assumption of independent censoring does not hold for 
censored cost data. Consider patient C, whose costs are censored at $4.5. This patient 
is not representative of the two patients, Band 0, who are censored after $4.5, 
because patient B incurs costs at a lower rate than patient C and patient 0 incurs costs 
at a higher rate. 
Hallstrom and Sullivan pointed out that a more accurate estimate of mean total costs 
could be obtained by multiplying the average cost per day (Ct) by the Kaplan-Meier 
survival probability of being alive on that day (Panel B). Thus, the mean study costs for 
patients A to 0 are calculated from time intervals one through to five respectively by: 
(1 x5/4) + (1 x5/4) + (3/4x3/2) + (3/4x3/2) + (3/4x1) = $5.5 
This method is referred to in the literature as either Lin's method or as the Kaplan-
Meier product limit estimator. Note, this method is not the same as calculating the 
Kaplan-Meier estimator on the cost scale directly, which to avoid confusion will 
hereafter be referred to as the Kaplan-Meier cost method. The method of dividing the 
time in to intervals will be referred to as Lin's method, and both will be discussed in the 
subsequent section of this chapter (Section 4.2). 
In the remainder of this chapter, costs are defined as censored if they are incomplete 
for the study period of interest. Costs are defined as complete if either: 
• a patient dies during the study period, or 
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• a patient is alive at the end of a study and has complete costs for the full study 
period 
Otherwise, the cost is deemed censored. 
This chapter describes a series of alternative methods for estimating mean total costs 
in the presence of censoring (Section 4.2), focusing on data that are right censored1• 
An earlier version of this chapter has been published by the author elsewhere [young, 
2005]. 
Examples of censoring mechanisms include patients who decide that they no longer 
wish to participate in a study and thus drop out of the study before it ends, or patients 
who are lost to follow-up as they move away from the region the study is conducted in. 
Although there are several methods in the literature that can be applied to censored 
cost data, there are currently no studies that compare multiple causes of censoring and 
evaluate how different censoring mechanisms may affect the "accuracy" of the estimate 
of the total average costs. Section 4.3 goes on to explore different reasons why cost 
data might be censored. 
To date no review of all existing methods for estimating mean total costs in the 
presence of censoring exists and, faced with a series of methods, it is not obvious 
which one will give the most accurate estimate of mean total costs in the presence of 
censoring. Therefore, Sections 4.4 to 4.6 explore an issue of methodological 
uncertainty. The methods identified in Section 4.2 will be compared across four 
different censoring mechanisms - random censoring, end-of-study censoring, 
informative censoring and partial censoring - by simulating the censoring mechanisms 
from a complete cohort of patients included in the CELT study. Section 4.7 will present 
the results from the simulation study and the findings will be discussed in Section 4.8. 
4.2 A REVIEW OF METHODS FOR ESTIMATING MEAN TOTAL COSTS IN THE 
PRESENCE OF CENSORING 
A literature review was conducted in order to identify existing methods for estimating 
mean total study costs in the presence of censored data. The following databases were 
searched: Ovid Medline [Ovid, 2005]. BIDS Social Science database [BIDS, 2005], 
1 Right censoring occurs when the event of interest occurs at some unknown time point ~to the right of the 
last known survival time" [Collett. 1994]. In the context of cost data. the true (but unobserved) cost is 
therefore greater than the censored (observed) cost. 
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NHS EED [Centre for Review and Dissemination, 2005] and OHE HEED [OHE HEED, 
2005]. 
The same identification strategy detailed in Chapter 3 was applied here; titles were 
assessed and possible relevant articles identified, abstracts from the relevant articles 
were then reviewed and further inappropriate articles were eliminated. Finally, after 
evaluating the abstracts, all possibly relevant articles were obtained and read. Articles 
were included in the review if they proposed original methods for estimating mean 
study costs in the presence of censoring. Articles were rejected if they: 
• reviewed other previously published methods 
• treated censoring as a missing data problem rather than specifically allowing for 
censored data 
• presented methods for estimating QAL Ys in the presence of censoring 
• presented methods for estimating cost-effectiveness in the presence of 
censoring 
References from articles related to censored cost data were followed up and included 
in the review if they proposed original methods for estimating mean study costs in the 
presence of censoring. Appendix A4.1 presents details of the search terms used and 
the search results. 
A total of 12 different methods for handling censored cost data, including methods that 
ignore censoring, were identified. These methods were: ignoring censoring, ignoring 
censored cases, Kaplan-Meier cost method [Fenn, 1995], Cox PH cost method [Fenn, 
1996], the partitioned Cox cost method [Lipscomb et ai, 1998], Lin's methods with 
either known cost histories (KCH)2 or unknown cost history (UCH) [Lin et ai, 1997], the 
weighted cost method with KCH or UCH [Bang & Tsiatis, 2000], Lin's regression 
method with KCH or UCH [Lin, 2000], and Carides' regression method [Carides et ai, 
2000]. These methods are outlined in detail below. 
4.2.1 Ignoring Censoring (IC) 
The average study costs are simply calculated in the same way as one would calculate 
any mean, by ignoring the fact the data are censored and assuming each patient's cost 
2 Cost data are said to have cost histories when the detail of resource collection is such that information on 
the time each resource is used is collected alongside information on the quantity of each resource. 
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was complete. Equation 4.1 presents the mathematical formula for estimating mean 
study costs (C,c) when ignoring censoring, where C is the total cost for patient i 
(where i = 1 ... N), and N denotes the total number of patients in the study. 
_ 1 N 
C,c =-LCi 
N i=1 
4.2.2 Ignoring the Censored Cases (CC) 
Equation 4.1 
A further simple technique for estimating mean study costs is to ignore the censored 
cases. The average cost is calculated across a reduced sample (Nee) of uncensored 
cases (Equation 4.2). 
- 1 ~ Ccc =--LCi 
Ncc i=1 
Equation 4.2 
4.2.3 Kaplan-Meier Cost Method (KM) 
The Kaplan-Meier cost method was briefly introduced in Section 4.1, and is described 
in further detail here. The method has been applied by several authors in order to 
calculate average study costs [See: Hay, 1989, Hiatt et ai, 1990; Fenn et ai, 1995]. The 
Kaplan-Meier cost method uses a cost rather than a time scale and assumes that 
individual costs are independent of each other and that censored costs are 
independent of the censoring mechanism. 
Costs are sorted in to ascending order and divided in to k intervals, where the first 
interval starts at zero and ends at the smallest fully observed (Le. uncensored) cost; 
the smallest cost is included in this interval. The second interval begins immediately 
after the first uncensored cost and ends at the second smallest uncensored cost. This 
process is repeated up to the final interval (k), which begins after the penultimate 
uncensored cost and ends at the largest uncensored cost. Equation 4.3 presents the 
formula for calculating the probability of incurring a cost of at least Ck (k = 1 to K), where 
nk represents the total number of individuals whose cost is at least Ck, and dk 
represents the number of individuals whose cost is known to be between Ck-1 and Ck 
who die during this interval. Individuals with censored costs are included in an interval 
(Ck-1, Ck) only if the censored cost is Ck or greater. 
75 
Chapter 4 Estimating Mean Total Costs in the Presence of Censoring 
Equation 4.3 
The mean cost for the study can then be estimated by multiplying the probability of 
incurring at least cost c in interval k by the additional cost in interval k by the additional 
costs occurring in interval k and summing these over all intervals (Equation 4.4), i.e. 
calculating the area under the Kaplan-Meier cost curve. 
K 
C KM = L K (c k )( C k - C k-\ ) Equation 4.4 
k=l 
4.2.4 Survival Model Method (Cox) 
Several authors have suggested using survival modelling techniques to estimate mean 
total costs in the presence of censoring [Hay, 1989, Dudley et aI, 1993, Fenn et aI, 
1996, Etzioni et aI, 1999]. A number of survival models exist for modelling censored 
data, the most common of which is the Cox PH model. Other choices exist including 
Weibull or Gompertz models, both of which make more distributional assumptions of 
the data. In this chapter the Cox PH model is fitted to illustrate the use of modelling 
techniques when estimating mean total study costs in the presence of censoring. 
One of the attractions of the survival model method is that any explanatory variables 
that are believed to affect survival and costs can be adjusted for within the models. As 
with the Kaplan-Meier cost method (Section 4.2.3), it is possible to fit a Cox PH model, 
using a cost rather than time scale. The hazard of accumulating costs at cost level c 
are related to the explanatory covariates included in the Cox PH model. The probability 
of a patient incurring at least cost c can then be calculated using Equation 4.5. 
Equation 4.5 
where Rc denotes a patients "risk" of incurring costs and is calculated using Equation 
4.6. 
Equation 4.6 
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where X1, X2 , .'" Xp are the explanatory variables (also known as prognostic variables 
or covariates) included in the model and ~1' ~2' ... , ~p are the regression coefficients. 
Returning to Equation 4.5, Reo corresponds to a hypothetical individual with the 
average values for covariates X1, ••. , Xp and Ko(c) is the cost function for the 
hypothetical patient with risk cost Reo. An individual patient profile of costs against the 
probability of incurring cost c can be plotted and the area under the profile calculated to 
obtain the individual patient's expected total study cost. The average total cost for a 
cohort can then be calculated. 
The following assumptions should hold for the Cox model: 
• individual costs should be independent of each other 
• censored costs should be independent of the censoring mechanism 
• censoring must also be independent of costs within each level of the covariates 
fitted in the models (e.g. if gender is included as a covariate in the model then 
censoring must be independent for male patients and female patients) 
• the explanatory covariates fitted in the model should be proportional across 
costs, so the hazard of incurring a cost c in female patients should be the same 
proportion as the hazard of incurring costs in male patients for all c 
4.2.5 Partitioned Cox Method (PC) 
Lipscomb and colleagues proposed extending the Cox PH method (Section 4.2.4) 
using a partitioned Cox PH model using details from patients' cost histories [Lipscomb 
et aI, 1998]. The study time period is first divided in to k smaller time intervals, which 
need not have identical interval lengths. A Cox PH model, using a cost rather than a 
time scale, is then fitted within each interval. Costs are censored if they are incomplete 
for the whole interval, but otherwise are complete. The costs of patients who die during 
the study are excluded from the interval when they die but are included in all prior 
intervals. 
The mean total cost is obtained for each interval by plotting individual patient profiles of 
each patient's probability of incurring cost c. The area under each profile is calculated 
to obtain patients expected total interval costs. These costs are summed across 
intervals and the mean study costs in the presence of censoring are obtained (Equation 
4.7). 
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Equation 4.7 
where KkO(C) = exp[ -A kO (c)] and A kO (c) is the baseline cumulative hazard function in 
interval k, Rkc a patients "risk" of incurring costs in interval k (Equation 4.6) and ~co the 
average patient's risk of incurring costs for interval k. 
4.2.6 Lin's Method - KCH (LK) 
Lin's method had previously been used in several studies [See: Hodgson, 1992; Etzioni 
et aI, 1996], before Lin et al published a paper studying its properties [Lin et a', 1997]. 
The method described here assumes that patient cost histories are known. 
The study time period (of length K) is divided in to a series of smaller equal time 
intervals, a1, a2, ... ,ak, k = 1 , ... ,K. For each of the time intervals the average total interval 
" cost (Ck ) incurred by all patients alive at the start of the interval is calculated. The 
" Kaplan-Meier survival function (S k) is also calculated for each interval. The total 
average cost per interval is then multiplied by the survival estimate, and these are 
summed over time intervals in order to estimate the average total cost for the study 
period (Equation 4.8). 
K 
CLK = LSkCk 
Equation 4.8 
k=1 
4.2.7 Lin's Method - UCH (LU) 
In some economic evaluations patient cost histories are unknown and therefore Lin's 
method (KCH) cannot be used to estimate mean study costs in the presence of 
censoring (Section 4.2.6). Lin et al offer an alternative method for estimating mean 
study costs when patient cost histories are unknown [Lin et aI, 1997]. The study period 
is again divided in to k smaller time intervals, k = 1, ... ,K, where K + 1 = 't denotes the 
end of the study period. The costs of patients censored before the end of the study are 
" 
excluded from the mean total cost estimate. Within intervals k = 1 to K, Ak are 
calculated as the average total cost for patients who die in the interval [ak, ak+1)' The 
A 
average total costs (A K +1 ) for interval aK+1 are calculated for patients who die during the 
final interval and those with complete study costs. For each interval the average cost is 
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multiplied by the difference between the Kaplan-Meier survival estimates at the 
beginning (S k ) and end (S k+l ) of the interval - this difference is the probability of dying 
during the interval. The mean study costs are then estimated by summing the weighted 
costs over the complete study time period (Equation 4.9). 
K+l 
CLU = LAkCSk - Sk+l) Equation 4.9 
k=1 
The accuracy of the method improves by increasing the number of time intervals (elk). 
However, there should be a reasonable number of observed deaths per interval in 
order to obtain a reliable average cost estimate for Ak 3. 
4.2.8 Bang and Tsiatis' Weighted Cost Method - UCH (WU) 
In 1997, Zhao and Tsiatis published methodology for estimating mean QAL Ys after 
adjusting for censored QAL Y data [Zhao & Tsiatis, 1997]4. Bang and Tsiatis adapt this 
methodology to censored cost data using a weighted complete case estimator [Bang & 
Tsiatis, 2000]. The method described here is applied when cost histories are unknown. 
The overall study costs (Ci) for patients who died during the study or had complete 
costs information up to the end of the study are weighted by the reciprocal of the 
Kaplan-Meier survival probability estimator (11 SCTj )), using reverse censoring. In 
conventional survival analysis censored observations would have an indicator value of 
zero and deaths a value of one. Here, the censoring pattern is reversed and censored 
observations have an indicator value of one and deaths a value of zero and the 
Kaplan-Meier estimator is calculated on the time scale in the usual way, but calculating 
the time to censoring rather than the time to event. 
Weighted costs are then summed across all patients. The total summed costs are 
divided by the overall study sample size N (where the sample size includes the 
censored cases) to obtain the mean total cost estimate in the presence of censoring 
(Equation 4.10). 
3 Based upon simulation work carried out by the authors they recommend that there should be at least five 
deaths per interval in order to obtain an accurate estimate of mean total costs [Lin et ai, 1997]. 
4 As with cost data, the Kaplan-Meier survival estimator should not be applied directly to a QAL Y scale 
because censoring is not independent of the quality adjusted survival times. 
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Equation 4.10 
~i = J (1'; ~ Vi) is an indicator function that equals one if time to death or the end-of-
study (Ti) is less than or equal to time to censoring (Ui) and equals zero otherwise. 
4.2.9 Bang and Tsiatis' Weighted Cost Method - KCH (WK) 
An extension to the weighted cost method (UCH) makes use of patient cost histories 
over the study period [Bang & Tsiatis, 2000]. As with the partitioned Cox method and 
Lin's method (KCH) the study time period is divided in to a number of smaller intervals 
(k = 1 ... K-1). Within each interval, the interval costs for patients who die during the 
interval or have complete interval costs are weighted by the Kaplan-Meier survival 
estimator for the interval5 using reverse censoring. Weighted estimates are summed 
across intervals and patients and are divided by the total sample size for the cohort (N) 
to obtain an estimate of mean study costs in the presence of censoring (Equation 
4.11 ). 
_ 1 N K ~kC~ 
C =_~"" I I 
WK N ~ ~ S"(T,k) 
I-I k-I I 
Equation 4.11 
where S(T/) is the Kaplan-Meier survival estimator for censoring within each interval 
and c; is the total cost of patient i within interval k. 
4.2.10 Lin's Regression Method - UCH (RU) 
A further estimator of mean total costs in the presence of censoring proposed by Lin 
makes use of covariate information related to patient and clinical characteristics [Lin, 
2000]. Lin sets out an ordinary least squares regression method to predict patient 
costs, whilst making adjustments for the covariates that influence these costs using an 
inverse weighting method. The regression model is fitted to those patients who die or 
have complete study costs. The weights that are used in the model are equal to the 
inverse of the survival probability, which is estimated either by the Kaplan-Meier 
method or by other survival model probability estimates, such as Cox's PH regression 
5 For example, if three monthly interval lengths were used then, for each interval, the Kaplan-Meier 
probability of being alive during that interval would be calculated as if each interval were an independent 
study period. 
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model. A reverse censoring indicator is used in the survival estimates so that deaths 
are denoted as zero and censored cases as one. The regression model is then applied 
to the full study cohort of N patients and the mean total study costs obtained (Equation 
4.12). 
Equation 4.12 
where Z is a vector or covariates thought to influence patient costs, ~ is a vector of 
regression coefficients and SeT;) is the Kaplan-Meier survival estimator at time Ti with 
the roles of the censoring times and survival times reversed, i denotes the ith patient, i = 
1 to N. 
4.2.11 Lin's Regression Method - KCH (RK) 
Lin's regression method can also be adapted to incorporate patient cost histories. The 
study time period is divided in to a series of k smaller subintervals and a weighted 
regression model fitted to the costs within each interval. The regression coefficients for 
the whole study period are then calculated by summing the regression estimates for 
each of the subintervals. The same regression covariates should be included in all 
subinterval models. The predicted costs for the study cohort can then be estimated by 
applying the model and the mean study costs obtained (Equation 4.13). 
Equation 4.13 
where Z is a vector or covariates thought to influence patient costs, ~ is a vector of 
regression coefficients and SeT;) is the Kaplan-Meier survival estimator at time Ti with 
the roles of the censoring times and survival times reversed, i denotes the ith patient, i = 
1 to N. 
4.2.12 Carides' Regression Method (CR) 
The final technique presented in this chapter for estimating mean study costs will be 
referred to as Carides method [Carides et aI, 2000]. The mean total cost is calculated 
in two stages, where the first stage assumes that each patient's total cost Ci can be 
modelled solely from their survival time. The chosen model should be one that 
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produces the best fit to the data. Carides and colleagues suggest selecting a 
multiplicative model (Cj = g(T; )Zj' where Zj = eEl is the exponential function for the 
error term [c j]) to estimate costs if the study has a greater potential for expensive 
events, for example hospitalisations. Otherwise, an additive model (Cj = g(T;) + cj ) is 
assumed. In each case g(Tj) denotes the functional form for modelling survival times 
(Tj). The model is fitted to the uncensored costs only. 
The second stage of calculating the mean total cost involves weighting the cost 
estimates by the Kaplan-Meier probabilities of death for the cohort (Equation 4.14). 
TMA)( 
CCR = f get) I dS T (t) I Equation 4.14 
o 
where T MAX is the longest observed follow-up time. 
The study period is divided in to smaller time intervals and within each interval the 
mean expected total cost for those patients who die in the interval is weighted by the 
" " Kaplan-Meier probability of dying in the interval S k - S k+l (See Section 4.2.7). To 
estimate the average lifetime costs, the weighted mean values are summed over the 
study period. However, if the aim of the study was to estimate costs over a specific 
time period (L), 2.25 years for example, then the mean estimate for the final interval 
should include complete costs for the study period of interest (Equation 4.15). 
L 
CCR = f g(t) I dS T (t) 1+ CnLS(L) Equation 4.15 
o 
where S(L) is the Kaplan-Meier probability of surviving to time L and CT~L is the 
average cost for all patients who have complete costs for the study period of interest. 
4.2.13 An Overview of Published Validation Methods for Estimating Mean Total 
Costs in the Presence of Censoring 
Section 4.2.13 briefly summarises the approaches used to validate mean total cost 
estimates in the presence of censoring by the authors of these proposed methods. 
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Authors compared their proposed estimator with na·ive estimators that ignore censored 
data [Fenn et aI, 1995; Lin et aI, 1997; Lin, 2000], or with estimators proposed by other 
authors [Bang & Tsaitis, 2000; Carides et aI, 2000]. Comparisons were also made 
using both artificially created data sets based on Monte Carlo simulations [Lin et aI, 
1997; Bang & Tsaitis, 2000; Carides et aI, 2000; Lin, 2000] and real data sets that were 
subject to censoring [Fenn et al,1995; Fenn et aI, 1996; Lin et aI, 1997; Lipscomb et aI, 
1998; Bang & Tsaitis, 2000; Carides et aI, 2000; Lin, 2000]. All authors conclude that 
their proposed methods produce a better estimate of mean total costs than the 
methods they are being compared with. 
Additionally, there have been a series of papers that have compared Lin's methods 
with weighted cost methods proposed by Bang and Tsaitis [Lin et aI, 1997; Bang & 
Tsaitis, 2000]. Bang and Tsaitis use artificial and real data sets to compare methods for 
estimating mean total costs and conclude that the methods they propose are as 
reliable as Lin's methods. Raikou and McGuire also compare these methods but under 
conditions of heavy censoring (over 80% cases censored) and state a preference for 
Lin's estimator with KCH and Bang and Tsaitis estimator with KCH [Raikou & McGuire, 
2004]. The authors had a slight preference towards Bang and Tsaitis method as it is 
"not restricted by the censoring pattern." O'Hagan and Stevens and Strawderman 
consider the mathematical properties of these two sets of estimators and conclude that, 
under certain conditions and depending upon the choice of interval lengths in to which 
the study time period has been divided, the methods are equivalent [Strawderman, 
2000; O'Hagan & Stevens, 2004]. 
4.3 FOUR ALTERNATIVE CENSORING MECHANISMS 
Censored cost data may arise due to several different reasons. In this section, reasons 
for censoring are categorised in to four broad groups: random censoring, end-of-study 
censoring, informative censoring and partial censoring. 
4.3.1 Random Censoring 
Censoring is said to occur randomly when patients are lost to follow-up at any time 
point during a study owing to reasons that are unrelated to (Le. independent of) the 
event of interest. There are various reasons why random censoring may arise and 
these include: 
• patients moving away from the area where the study is being conducted 
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• patients dropping out of the study for reasons unrelated to the treatments they 
are receiving 
• patients dying from causes unrelated to the treatment (e.g. being killed in a road 
traffic accident whilst in a study looking at deaths related to diabetes) 
4.3.2 End-of-Study Censoring 
End-of-study censoring is similar to random censoring, except that censoring is 
restricted to a time frame at the end of a study period. The majority of studies run for 
pre-specified time periods and often the patient cohort will be recruited over time rather 
than on the first day of the study. For example, a fixed two-year follow-up study 
beginning on 1st of January and ending on 31 st December the following year would 
have incomplete follow-up data (that is, for less than two years) for all patients who 
entered the study after the start date. End-of-study censoring is also known in the 
literature as type I censoring. Figure 4.2, below, illustrates end-of study censoring. 
Figure 4.2 Illustration of end-of-study censoring 
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4.3.3 Informative Censoring 
Informative censoring occurs when patients withdraw from a study for reasons that are 
related to the event of interest. For example, patients may withdraw from a study 
because they are unwell and the reason they are unwell is related to the treatment they 
are receiving. 
4.3.4 Partial Censoring 
In economic evaluations there are two situations where partial censoring may arise. 
Firstly, individual patient survival and outcome(s) may be known but individual costs 
and HRQl may only be available up to a specific time point. For example, if costs and 
HRQl data are collected over a two-year study period and survival data over a four-
year study period, then cost and HRQl data are censored from the end of year two to 
the end of year four. Secondly, costs or HRQl information may only be collected at 
specific time points. For example, costs are collected every six months during a study 
period, thus a patient dying in month eight will have a six-month cost but censored 
costs for month seven onwards. 
4.4 THE CELT COHORT 
The objective of this chapter is to compare 12 methods for estimating mean study costs 
in the presence of censoring, across four censoring mechanisms. Censoring 
mechanisms will be simulated from a complete cohort of costs collected from point of 
assessment over a 2.25 year study period for CELT patients. 
In the CELT study complete data were available for 726 liver disease cases over a 2.25 
year study period. The costs for the 29 patients with incomplete study costs were 
censored 1.83 to 2.17 years after assessment. All 29 patients entered the study 
towards the end of the recruitment phase and were censored as a result of the study 
ending before complete 2.25 year data could be observed (Le. end-of-study censoring). 
This analysis takes as its basis the 726 complete cases, and for these a known mean 
total cost and standard error can be calculated. 
The data collection process described in Chapter 2, applied in the main CELT analysis 
for three liver disease groups (AlD, PSC, and PSC), also applies to the complete 
CELT cohort of 726 patients used here. For those 197 patients (27%) who were not 
listed as suitable transplant candidates, only the assessment costs are included in the 
transplant patient costs. Patients listed for transplantation who did not receive a liver 
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transplant during the study period (N = 73 [10%]) were followed up to the point they 
were removed from the waiting list. 
Covariates that significantly affect costs were incorporated in to the calculation of mean 
study costs in the presence of censoring for the Cox cost method, partitioned Cox cost 
method, Lin's regression method KCH and Lin's regression method UCH. Table 4.1 
presents demographic patient characteristics for the 726 "complete" CELT cases that 
were considered in the four methods for estimating mean study costs listed above. 
Table 4.1 Demographic patient characteristics for the 726 "complete" CELT 
patients 
Age in years Mean (SO) 49.3 (12.1) 
Gender (%) Males 334 (46%) 
Centre (0/0) 1 160 (22%) 
2 50 (7%) 
3 118 (16%) 
4 54 (7%) 
5 90 (12%) 
6 254 (35%) 
Transplant group (%) Not listed 197 (27%) 
Elective 396 (55%) 
Emergency 75 (10%) 
Re transplant < 14 days 7 (1%) 
Re transplant> 14 days 51 (7%) 
Disease group (%) Cholestatic 372 (51 %) 
Parenchymal 204 (28%) 
Fulminant 78(11%) 
Other 72 (10%) 
Number of listed patients (%) 529 (73%) 
Number of transplanted patients (%) 456 (63%) 
EQ-50 score at listing Mean (SO) 0.48 (0.25) 
.. so: Standard deviation 
In each of the four models where covariate information was included, covariates with a 
p-value less than or equal to 0.05 were maintained in statistical models. Patient age, 
gender, transplant centre, disease group and whether a patient received a transplant 
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were significant predictors of costs in the Cox cost model. Transplant centre, transplant 
group and whether a patient received a transplant were significant predictors of costs in 
the partitioned Cox cost model. Type of transplant and whether a patient received a 
liver transplant were significant predictors of costs in linear regression models (Lin's 
regression methods with KCH and UCH). 
4.5 CREATING ARTIFICIAL CENSORED DAT ASETS FOR THE CELT COHORT 
Simulation methods are used to create artificial data sets for each of the four censoring 
mechanisms introduced in Section 4.3: random, end-of-study, informative and partial 
censoring. The methods for creating these data sets are described in further detail 
below. 
4.5.1 Random Censoring 
Artificial data sets containing randomly censored data were created from the CELT 
cohort using simulation methods. Random number generators were used to select 
which patients were to be censored and at what time points the censoring were to 
occur. Censoring was simulated assuming a binomial distribution and the time of 
censoring was simulated assuming a uniform distribution over the time period 0 to 2.25 
years. Observed CELT study deaths were artificially censored if the randomly 
generated censoring time was less than the observed time of death. If the censoring 
time was greater than or equal to the observed time of death, the observed data 
remained unchanged. Each patient's study costs are censored at the randomly 
selected censoring time. 
A total of five thousand simulated data sets were created6 for each of three different 
censoring levels: 10% censoring (representing a low level of censoring), 30% 
censoring (representing a medium level of censoring) and 50% censoring (representing 
a high level of censoring). These three alternative censoring levels were simulated in 
order to investigate how the level of censoring affected the accuracy of the mean total 
cost estimates for the twelve methods described in Section 4.2. 
4.5.2 End-of-study Censoring 
As with random censoring, simulation methods were used to create 5,000 artificial data 
sets for analysis at each of 10%, 30% and 50% end-of-study censoring. The binomial 
6 A total of 5,000 simulations were required to estimate the mean cost estimate to within £60 pounds of the 
true mean with 95% uncertainty. 
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distribution was used to create censoring and the uniform distribution to generate 
censored survival times. To create end-of-study censoring the randomly generated 
censoring times were restricted to the last six months of the study period. This period 
was chosen as it reflected the censoring pattern of the 29 patients who were censored 
in the GEL T study (see Section 4.4). 
Further data sets were created for the same three censoring levels where the end-of 
study censoring was restricted to the final year of the study. This choice was made in 
order to vary the period of time where censoring occurred. The choice of time period 
was essentially arbitrary. 
Thus for end-of study censoring six sets of simulations were run: 
• at the 10% censoring level with censoring restricted to the final 0.5 years of the 
study 5,000 simulated data sets were created 
• at the 300/0 censoring level with censoring restricted to the final 0.5 years of the 
study 5,000 simulated data sets were created 
• at the 50% censoring level with censoring restricted to the final 0.5 years of the 
study 5,000 simulated data sets were created 
• at the 10% censoring level with censoring restricted to the final year of the study 
5,000 simulated data sets were created 
• at the 30% censoring level with censoring restricted to the final year of the study 
5,000 simulated data sets were created 
• at the 50% censoring level with censoring restricted to the final year of the study 
5,000 simulated data sets were created 
4.5.3 Informative Censoring 
In the GEL T study, utilities were measured using the EQ-50, which was administered 
to patients as part of a postal questionnaire at point of listing and at three monthly 
intervals from point of listing up to point of transplant. After transplantation the 
questionnaire was administered to patients at 0.25, 0.5, 1 and 2 years post transplant. 
The responses from the EQ-50 are used to create artificial data sets that simulate 
informative censoring. 
Oatasets based on informative censoring were created by considering two alternative 
scenarios, the first hypothesises that the sickest patients would drop out of the study 
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due to ill health and the second hypothesises that patients who were well would drop 
out of the study. The percentile distribution of the EQ-5D was examined across all the 
time points that the questionnaire was administered and information from the 10th 
(utility = 0.16), 20th (utility = 0.36), 80th (utility = 0.85) and 90th (utility = 1.00) percentiles 
were used to create four data sets that simulated informative censoring. 
Two data sets were created to simulate informative censoring due to ill health. To 
create a censored data set simulating informative censoring using the 10th percentile of 
the EQ-5D distribution, each patient profile of EQ-5D scores over time were examined 
and patients were censored at the point their utility score first fell below 0.16. For 
example, patient A might have a profile of utility values 0.38, 0.25, 0.12 and 0.08 at 
times 0, 0.5, 1 and 2 years for the study period; this patient's utility falls below 0.16 at 
one-year and they are therefore assumed censored in terms of both costs and survival 
after this time point. Patients whose profiles never drop below 0.16 remain uncensored. 
This process is repeated to create a second censored dataset simulating informative 
censoring using the 20th percentile of the utility distribution, except here patients are 
censored when their utility score first falls below 0.36, which occurs at 0.5 years for 
patient A. Using this method to simulate informative censoring due to ill health resulted 
in 13% censoring at the 10th percentile level, and 31 % censoring at the 20th percentile 
level. 
Data sets three and four were created to simulate informative censoring due to good 
health. In set three patients are censored at the time point where their utility first 
exceeds the 80th percentile (utility = 0.85) of the EQ-5D distribution. For example, 
suppose patient B has utilities of 0.42, 0.54, 0.74 and 1.00 at 0, 0.5, 1, and 2 years for 
the study period; this patient's utility exceeds 0.85 at two years and they are therefore 
assumed to be censored in terms of survival and costs after this time point. Patients 
whose profiles never exceed 0.85 remain uncensored. This process is repeated to 
create the final data set using the 90th percentile of the utility distribution (utility = 1.00). 
Using this method to simulate informative censoring due to good health resulted in 21 % 
censoring at the 80th percentile level and 14% censoring at the 90th percentile level. 
4.5.4 Partial Censoring 
Two partially censored cohorts were simUlated. In the first data set it was assumed that 
resource use and costs were collected at one time point only during the CELT study 
period, 31 st March 1998,2.25 years after data collection for the CELT study first began. 
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This type of censoring is referred to in this chapter as one time resource collection 
censoring. Any costs incurred after this time point were set to zero and costs were 
censored as of this date (80% of the data were censored). 
In the second data set it was assumed that resource use and cost information were 
collected up to 2.25 years after the end of a one-year recruitment period in each 
transplant centre (3.25 years after data collection first began at each centre). The 
second type of censoring is referred to here as fixed resource collection censoring. In 
the second partially simulated data set 15% of the data were censored. 
Survival times were observed over the full study period for partial censoring for both 
one time resource collection and fixed time resource collection. 
4.6 STATISTICAL METHODS FOR EXPLORING THE ACCURACY OF 
METHODS FOR ESTIMATING MEAN TOTAL COSTS IN THE PRESENCE OF 
CENSORING 
4.6.1 Varying Interval Lengths 
The partitioned Cox cost method, Lin's method KCH and UCH, the weighted cost 
method with KCH, Lin's regression method with KCH and Carides' method all require 
the division of the study time period in to a series of smaller time intervals. The six 
methods can then be applied in order to estimate mean total study costs in the 
presence of censoring. Three monthly interval lengths were used to estimate mean 
total costs for these methods. 
Lin et al and O'Hagan and Stevens recommend using the smallest possible choice of 
interval length to obtain accurate estimates of Lin's methods (KCH and UCH) [Lin et aI, 
1997; O'Hagan & Stevens, 2004]. O'Hagan and Stevens also state that the weighted 
cost method (with KCH) of Bang and Tsiatis is likely to produce more accurate 
estimates of mean total costs with smaller interval lengths in comparison with larger 
ones [Bang & Tsiatis, 2000; O'Hagan & Stevens, 2004]. To observe whether these 
assumptions were true for the CELT data, the interval lengths were varied for the six 
methods where it was necessary to divide the study time period in to interval lengths. 
The accuracy of Lin's method (KCH and UCH), and Carides' method were compared 
over interval lengths of one month, two months, three months, six months, and twelve 
months across random, end-of-study, informative and partial censoring. The accuracy 
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of the partitioned Cox cost method, the weighted cost method KCH and Lin's 
regression method with KCH were compared over interval lengths of two months, three 
months, six months and twelve months across random, end-of-study, informative and 
partial censoring? 
4.6.2 Estimating Standard Errors 
The methods of ignoring costs, the complete case method, Cox cost method, 
partitioned Cox cost method and Lin's regression methods (KCH and UCH) use the 
conventional method of estimating the standard error of the mean total cost based on 
the assumption of normally distributed data (Equation 4.16). 
Standard Error = (SD/-rn) Equation 4.16 
Greenwood's formula was used to estimate the standard error for the Kaplan-Meier 
method [Collett, 1994]. Non-parametric bootstrapping was applied to estimate the 
standard errors for the remaining five methods (Lin's methods [KCH and UCH], the 
weighted cost methods [KCH and UCH] and Carides' method) [Manley, 1997]. 
4.6.3 Comparing the Accuracy of Methods from the Estimated Means and 
Standard Errors 
The primary focus of any researcher selecting a method to estimate mean total costs in 
the presence of censoring, is to select a method that accurately measures the mean 
costs. The accuracy of the 12 methods was assessed by measuring the magnitude 
(distance) between the estimated means and the true mean for the "complete" data set, 
prior to censoring. 
Standard errors are calculated in order to make inferences about the results to the 
general population and in statistical tests for comparing potential differences between 
the costs of two or more treatments. Therefore, it is also important that methods which 
can estimate the mean total costs accurately also estimate the uncertainty around the 
mean estimates (standard errors) accurately. The magnitude between the estimated 
standard errors and the observed standard error are also calculated. 
7 In this thesis CELT survival has been measured using monthly units of time. For the partitioned Cox cost, 
Lin's regression (KCH) and the weighted cost methods (KCH) the time interval is divided in to a series of 
smaller intervals and Kaplan-Meier or Cox survival probabilities are estimated for the N patients alive at the 
beginning of the interval. Thus, it is not possible to estimate survival probabilities for these three methods 
using one monthly interval lengths. 
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Methods for estimating mean total costs are ranked in order of magnitude, where the 
smaller the magnitude the closer the estimate is to the observed mean or standard 
error. Methods are ranked separately in terms of the accuracy of the mean and the 
accuracy of the standard error. Rankings are assigned separately for each type of 
censoring mechanism (random, end-of-study, informative, partial) and at each level of 
censoring (e.g. 10%,30%, 50% censoring levels). Kendall's concordance statistic was 
used to assess whether methods were consistently ranked as being more (or less) 
accurate in comparison with alternative methods across different censoring 
mechanisms and for different levels of censoring [Kendall & Gibbons, 1990t. For the 
CELT data a significant p-value (p S 0.05) was taken to indicate that the ordering of the 
accuracy of the mean (or standard error) in the presence of censoring does not differ 
and a non-Significant p-value (p > 0.05) was taken to indicate that the ranking of 
methods does differ. In other words, unless significant concordance was demonstrated 
across the ordering of methods, the accuracy of the mean (or standard error) was 
deemed to depend either on censoring mechanism or censoring level. 
4.6.4 Other Statistical Issues 
For Carides' method a non parametric local regression model with smoothing 
[Cleveland & Devlin, 1988] was fitted to estimate individual patient costs from their 
survival times. 
The S-PlUS statistical computer package was used for all analysis [S-PlUS, 2001]. 
4.7 A COMPARISON OF MEAN TOTAL COST ESTIMATES ACROSS 12 
METHODS FOR ESTIMATING MEAN TOTAL COSTS FOR THE CELT 
STUDY 
The mean total cost for the 726 uncensored CELT patients was £36,045 and the 
standard error was £1,517. The median total cost was £27,166 with costs ranging from 
£393 to £311,873 across the sample. This is a typical example of a positive skewed 
distribution of cost data (Figure 4.3). 
Figures 4.4 to 4.8 present the results from random censoring, end-of-study censoring, 
informative censoring and partial censoring across different levels of censoring. All 
graphs are presented as the difference between the estimated mean and standard 
error and the actual mean (£36,045) and standard error (£1,517) for the CELT cohort 
8 Kendall's concordance statistic measures the agreement between two or more sets of ranked data. 
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prior to censoring. In Figures 4.4, 4.5 and 4.6 each point on the graphs represents the 
mean, average total costs and standard errors across 5,000 simulations. In Figures 4.7 
and 4.8 each point represents the average difference between the observed and 
expected mean total cost and the observed and expected standard error for one 
simulation run. The legend for Figures 4.4 to 4.8 is presented in Box 4.1 
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Box 4.1 Legend for Figures 4.4 to 4.9 
D WK: Weighted method (KCH) 
0 RK: Lin's regression method (KCH) 
L LK: Lin's method (KCH) 
+ PC: Partitioned Cox cost method (KCH) 
x C: Carides' method 
<> IC: Ignoring censoring 
"V LU: Lin's method (UCH) 
• RU: Lin's regression method (UCH) 
• WU: Weighted method (UCH) 
A CC: Complete case method 
• Cox: Cox PH cost method 
® KM: Kaplan-Meier cost method 
Figure 4.4 presents the results from applying 12 methods for estimating mean total 
costs under 10% random censoring. The mean cost estimate for the Kaplan-Meier cost 
method (£133,752) is nearly £100,000 greater than the observed mean total cost prior 
to censoring (£36,045) and the mean estimate from the Cox PH cost method (£69,266) 
and the partitioned Cox cost method (£20,321) are approximately £30K greater and 
£15K less than the observed mean estimate, respectively. Mean cost estimates for 
these three methods were consistently poor across the four censoring mechanisms: 
• mean costs for the Kaplan-Meier cost method range: £132K to £160K 
• mean costs for the Cox cost method range: £68K to £75K 
• mean costs for the partitioned Cox cost method range: £19K to £23K 
These three methods have been excluded from Figures 4.5 to 4.8 in order to aid the 
reader in distinguishing between the estimates for the remaining nine methods. Tabular 
versions of these results, including the results for the three omitted methods are found 
in Appendix 4.2. 
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Figures 4.5 to 4.8 show that the majority of methods estimated mean total costs to a 
reasonable level of accuracy. Garides method, the weighted cost method (KGH and 
UGH), Lin's regression method with UGH, Lin's method with UGH and the method of 
ignoring censoring, frequently predicted mean costs to within £1,000. Estimates of 
mean total costs were worst under informative censoring of sicker patients; these 
patients incurred higher costs than other patients, and censoring them earlier resulted 
in a larger under estimation of mean costs in comparison with other censoring 
mechanisms (the underestimation of the mean costs ranged from £925 to £9,251). 
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Figure 4.5 Mean total costs and standard errors estimated for nine censored 
cost methods, assuming random censoring at a) 10%, b) 30% and 
c) 50% 
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Figure 4.6 
Estimating Mean Total Costs in the Presence of Censoring 
Mean total costs and standard errors estimated for nine censored cost methods, assuming end-of-study censoring at a) 100/0 
from 1.75 years, b) 30% from 1.75 years, c) 50% from 1.75 years, d) 10% from 1.25 years, e) 30% from 1.25 years and f) 500/0 
from 1.25 years 
a) 10% from 21 months b) 30% from 21 months c) 50% from 21 months 
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Figure 4.7 
Estimating Mean Total Costs in the Presence of Censoring 
Mean total costs and standard errors estimated for nine censored 
cost methods, assuming informative censoring with EQ-SD scores 
a) less than the 10th percentile, b) less than the 20th percentile c) 
greater than the 80th percentile, or d) greater than the 90 th percentile 
of the utility score distribution 
a) Too ill (10m percentile 13% censoring) b) Too ill (20m percentile 31 % censoring) 
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Figure 4.S 
Estimating Mean Total Costs in the Presence of Censoring 
Mean total costs and standard errors estimated for nine censored 
cost methods, assuming partial censoring where costs are 
collected a) one time resource collection, or b) fixed resource 
collection 
a) One time resource collection (SO% censoring) 
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One time resource collection partial censoring (800/0 censoring) cost estimates for 
Carides method, Lin's method (UCH) and the weighted cost method (UCH) under 
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predicted mean costs by over £25~. The mean study costs, estimated from Lin's 
method (UCH) are based upon the costs of patients who die or have complete costs to 
the end of the study period (censored costs are ignored). Costs are weighted by the 
probability of dying within an interval and the largest weights are given to mean costs 
that occur in the final study interval, which also includes patients who survive the full 
study period (Table 4.2). Under one time resource collection partial censoring, no 
patient incurs costs after 19 months, in other words, no patient has complete follow-up 
data to 2.25 years and the last death occurred at 19 months - 8 months prior to the 
end of the study. Thus, under Lin's method (UCH), given that all patients are censored 
prior to the end of the study, no costs can obtain the largest weight observed in the 
final study interval resulting in a large underestimation in the mean total costs. A similar 
observation is true for Carides' method where the same probabilities of death (listed in 
Table 4.2) are assigned to mean cost estimates for patients who die or have complete 
study costs derived from a non-parametric local regression model. 
Table 4.2 
Month 
N 
Probability of 
death per 
interval 
Cost (£s) 
Cost*Probability 
of death (£s) 
Probabilities of death and mean cost per three month period for 
patients who die during study after simulating partial censoring 
(one time resource collection 80% censoring) 
3 6 9 12 15 18 21 24 27 
86 18 21 12 4 2 1 0 0 
0.12 0.02 0.03 0.02 0.01 0.008 0.008 0.007 0.78 
22,767 51,691 74,952 97,501 72,808 42,328 67,823 0 0 
2,697 1,282 2,374 1,880 903 350 561 0 0 
For the weighted cost method (UCH) mean study costs are again estimated from the 
costs for patients who die or survive the full study period and these costs are weighted 
by the inverse of the Kaplan-Meier estimator, 1/S(t) using reverse censoring. Under 
partial censoring the survival estimates are known for all patients for the full study 
period (only costs are censored). Thus, applying reverse censoring to Kaplan Meier 
estimates results in survival probabilities equal to one for all patients, because under 
reverse censoring no patient has the event of interest. Therefore, for one time resource 
collection partial censoring, we are summing the unweighted uncensored costs for 166 
9 Readers should note the change in scale for Figure 4.8a. 
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patients, and obtain a total cost of £7,027,378. This total cost is divided by the total 
number of patients in the CELT sample (N = 726) to obtain a mean estimate of £9,678. 
Table 4.3 presents the rankings for the magnitudes of the 12 methods for estimating 
mean study costs in the presence of censoring. The first four techniques presented in 
each table are those where cost histories are required to estimate total study costs. 
Cost histories are not required for the remaining eight methods. Table 4.4 presents the 
rankings for the magnitudes of the standard error estimates. Appendix 4.2 presents the 
absolute difference of each mean estimate from the observed mean and the difference 
of the estimated standard error from the observed standard error. 
Lin's method (UCH) consistently gave one of the most accurate estimates of mean 
costs in the presence of censoring, and predicted the mean to within £7 under random 
censoring at 30%, and within £3 under end-of-study censoring during the final year of 
the study at a 10% censoring level. Lin's regression method (UCH) performed well 
under end-of-study censoring, predicting the mean to within £3 (end-of-study censoring 
during the final year, 30% ) and Carides' method performed well under informative 
censoring. Both Carides' method and weighted cost method with KCH consistently 
predicted mean total costs to within £1000 (although were not always the best 
estimates of the mean) and gave reasonably accurate estimates of the standard errors. 
The methods of ignoring censoring and the weighted cost method with KCH 
consistently gave the best estimates of the standard error across all censoring levels 
and mechanisms. 
Surprisingly, the narve method of ignoring censoring was one of the more accurate 
techniques for estimating mean total costs in the presence of censoring and frequently 
predicted mean cost estimates to within £1,000. Under partial censoring (fixed time) 
ignoring censoring was the best estimator of the mean and standard error estimates 
(the mean estimate was out by £10 and the standard error was exact). It is likely that 
this unexpected result is due to the nature of the cumulative costs for a typical patient 
in the CELT study: costs are high at the beginning of the study period when 
transplantation occurs and then level off towards the end of the study when patients 
have stabilised on drugs and typically are seen at outpatient appointments every six to 
twelve months (Figure 4.9). 
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Lin's method (UCH) performed poorly under partial censoring when censoring was 
heavy (80% censoring). The Kaplan-Meier cost method, Cox cost method, the 
partitioned Cox cost method and Lin's method (KCH) consistently gave the poorest 
mean estimates across all censoring mechanisms and levels. Lin's method with UCH 
and Lin's regression method with UCH both gave poor standard error estimates. 
Kendall's concordance test statistic was applied to the rankings of means and standard 
errors to establish whether there were any statistically significant differences in the 
ordering of methods across different levels of censoring, and different censoring 
mechanisms. Unsurprisingly, the ordering of the accuracy of methods differed under 
the two partial censoring mechanisms (one time and fixed time resource collection) for 
both the mean and standard error estimates (Kendall's concordance = 0.833, P = 0.074 
and 0.888, p = 0.052, respectively). However, the rankings of the accuracy of random, 
end-of-study and informative censoring did not vary across censoring levels. The 
rankings for the accuracy of mean cost estimates differed significantly from the 
rankings of the standard error estimate across all censoring levels and mechanisms, 
thus a method that gave accurate cost predictions did not necessarily give accurate 
standard error estimates and visa versa. Appendix A4.3 presents full details of the 
results for Kendall's concordance statistic. 
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Table 4.3 Ranking the methods for estimating mean total costs; ranked in terms of magnitude from the true mean (£36,045) of the 
uncensored CELT data 
Random End-of-study End-of-study Informative Informative Partial 
1.75 years 1.25 years Low EQ-50 High EQ-50 
10% 30% 50% 10% 30% 50% 10% 30% 50% 10m 20tn 80th 90-01 One Fixed 
(13%) (31%) (21%) (14%) Time Time 
(80%) (15%) 
Known Cost Histories 
WK: Weighted costs 7 7 8 7 4 5 7 6 7 7 8 4 3 2 2 
RK: Un's regression 8 3 6 8 8 1 5 5 3 3 6 1 8 1 7 
LK: Lin's method 9 9 7 9 9 9 9 9 9 9 7 9 9 4 8 
PC: Partitioned Cox 10 10 10 10 10 10 10 10 10 10 10 10 10 7 10 
Unknown Cost Histories 
C: Carides 4 4 2 5 6 7 4 4 2 1 1 2 2 8 6 
, 
IC: Ignoring Censoring 6 8 9 2 2 4 3 7 6 8 9 8 7 3 1 · 
LU: Lin's method 1 1 1 4 5 6 1 2 4 2 2 3 1 9 5 
RU: Lin's regression 5 6 4 1 1 2 2 1 1 4 3 6 5 6 =3 
WU: Weighted costs 3 2 3 3 3 3 6 3 5 6 5 7 6 10 9 
CC: Complete cases 2 5 5 6 7 8 8 8 8 5 4 5 4 5 =3 
Cox: Cox regression 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 
KM: Kaplan-Meier 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 
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Table 4.4 Ranking the methods for estimating mean total costs; ranked in terms of magnitude from the true standard error (£1,517) of 
the uncensored CELT data 
Random End-of-study End-of-study Informative Informative Partial 
1.75 years 1.25 years Low EQ-50 High EQ-50 
10% 30% 50% 10% 30% 50% 10% 30% 50% 10m 20m 80u 90In One Fixed 
(13%) (31%) (21%) (14%) Time Time 
(80%) (15%) 
Known Cost Histories 
WK: Weighted costs 1 1 1 2 3 2 3 3 2 2 2 1 2 1 3 
RK: Un's regression 9 9 7 7 8 6 9 7 6 9 9 10 9 6 8 
LK: Lin's method 5 4 5 6 4 3 4 8 4 7 6 6 5 3 6 
PC: Partitioned Cox 10 10 10 10 10 8 10 10 9 10 10 11 11 9 11 
Unknown Cost Histories 
C: Carides 7 2 6 5 2 5 5 1 5 5 3 2 4 11 7 
IC: Ignoring Censoring 2 3 3 1 1 1 1 2 1 3 4 3 1 2 1 
LU: Lin's method 3 6 8 3 5 7 2 5 7 6 8 5 6 7 2 
RU: Lin's regression 8 7 2 8 6 4 8 6 3 8 5 7 8 10 9 
WU: Weighted costs 6 5 4 9 9 10 6 9 11 4 7 8 7 4 4 
CC: Complete cases 4 8 9 4 7 9 7 4 8 1 1 4 3 5 5 
Cox: Cox regression 11 11 11 11 11 11 11 11 10 11 11 9 10 8 10 
KM: Kaplan-Meier 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 
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Figure 4.9 Cumulative mean total costs of the liver transplant programme over 
the 27 month study period in 1998 UK £'s 
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4.7.1 Summary of Results 
The accuracy of the 12 censored cost methods varied by censoring mechanism: 
• Lin's method (UCH) gave the most accurate mean estimates under random 
censoring 
• Lin's regression method (UCH) gave the most accurate estimates under end-of-
study censoring 
• Carides' method gave the most accurate estimates under informative censoring 
• the weighted cost method (KCH) or ignoring censoring gave the most accurate 
estimates under partial censoring 
Carides' method and the weighted cost method (KCH) gave accurate predictions of 
both the mean cost and standard error across censoring levels and censoring 
mechanisms. Generally, the accuracy of mean estimates did not differ by censoring 
level, the exception being partial censoring, where Carides' method, Lin's method 
(UCH) and the weighted cost method (UCH) performed poorly under one time resource 
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collection censoring. Finally, the accuracy of methods differed for the mean and 
standard error estimates. 
4.7.2 The Impact of Covariates on Mean Total Costs in the Presence of 
Censoring 
Mean cost estimates derived from Lin's regression methods, KCH and UCH, Cox cost 
method and partitioned Cox cost method adjust for covariates within the cost 
estimates. In this chapter covariates were selected based upon level of significance (p 
< 0.05) and were not common across the four methods. Thus, Lin's regression 
methods KCH and UCH adjusted for whether transplanted (yes/no), and transplant 
group, the partial Cox cost method adjusted for whether transplanted, transplant group 
and transplant centre, and the Cox cost method adjusted for age, gender, disease 
group, transplant centre and whether transplanted. 
The choice of covariates allowed for in each model might effect mean cost predictions, 
therefore this section explores how mean total cost estimates are effected by covariate 
patterns. 
4.7.2.1 Cox Cost and Partitioned Cox Cost Models 
The Kaplan-Meier method, Cox cost method and partitioned Cox cost method all 
violate the assumption of independence between censoring and costs, where censored 
costs should be representative of all costs that value or greater. This chapter has 
already shown that cost estimates can not be predicted accurately if this assumption is 
ignored (Section 4.7.1). 
When the Kaplan-Meier estimate was applied to the CELT data costs were over 
estimated by almost £100K across all censoring mechanisms. After adjusting for age, 
gender, transplant centre, liver disease group and whether receiving a liver transplant 
(yes/no) mean total cost estimates derived from the Cox cost method were at least 
£60K less than estimates from the Kaplan-Meier method. However, estimates from the 
Cox cost model were still twice the observe cost due to the violation of the 
independence assumption. The partitioned Cox cost method reduced estimates further 
and underestimated mean costs by over £13K. This section briefly explores the impact 
of adjusting for covariates upon cost estimates for the Cox cost method and partitioned 
Cox cost method. Models are explored under 10% random censoring and are 
generalisable to other levels and mechanisms of censoring for the CELT data set. 
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Estimates of mean total costs were compared between the Kaplan-Meier model and 
the Cox cost model under 10% random censoring for each individual covariate in order 
to understand how the covariate pattem from the Cox cost model affects mean cost 
estimates. Under 10% random censoring mean cost estimates under the Kaplan-Meier 
method were approximately £98K greater than the observed mean estimate of £36,045 
(Table 4.5). At the individual covariate level gender and disease group are not 
significant predictors of costs in the Cox cost model but age, centre, transplant group 
and whether transplanted are. Further, whether transplanted lowered mean costs by 
over £61 K and transplant group lowered mean costs by over £45K whereas age, 
gender, centre and disease group had little impact on mean cost estimates. 
Table 4.5 Estimated mean total costs under 10% random censoring for the 
Kaplan-Meier method and Cox cost model for individual covariates 
(univariate models) 
Mean (£) Overall model Difference from 
likelihood ratio KM mean 
(p-value) estimate (£) 
Kaplan-Meier method 134,107 
Cox Cost Method (individual models) 
Age 136,019 5.01 (0.025) 1,912 
Gender 137,000 2.11 (0.146) 2,839 
Centre 130,766 17.3 (0.004) -3,341 
Disease group 137,923 6.54 (0.088) 3,816 
Transplant group 88,629 62.2 « 0.001) -45,478 
Transplanted (YIN) 72,882 205.0 « 0.001) -61,223 
The next step in the investigation was to explore how the five variables included in the 
Cox cost model affected mean cost estimates within a multivariate Cox cost model. 
The process is illustrated under 10% random censoring where the mean cost is 
estimated at £63,383 a £70K reduction in cost estimates under the Kaplan-Meier 
method. A second multivariate model was fitted which included age, gender, centre 
and disease group and predicted the mean costs as £134,034 implying that whether 
transplanted is the only variable that reduces costs significantly in this multivariate 
model when comparing estimates with those from the Kaplan-Meier method. A final 
multivariate Cox cost model was fitted that adjusted transplant centre, transplant group 
and whether transplanted (the three variables adjusted for in the partitioned Cox cost 
107 
Chapter 4 Estimating Mean Total Costs in the Presence of Censoring 
models). Mean cost estimates after adjusting for these three variables were £68,005 
and were similar to estimates after adjusting for age, gender, centre, disease group 
and whether transplanted. 
The partitioned Cox cost method estimated mean costs per three monthly intervals, 
costs are said to be censored per interval if they are incomplete for the interval. 
Individual covariate estimates had similar impact on mean estimates to that for the Cox 
cost model and were most noticeable for transplant group and whether transplanted. 
Estimates of mean total costs for partitioned Cox cost models that included centre 
alone had a small impact on mean cost estimates (Table 4.6). However, multivariate 
partitioned Cox cost models that include variables for whether transplanted and centre 
reduce mean cost estimates by £16K compared to mean cost estimates from the 
partitioned Cox model adjusting for centre alone. Total cost estimates are reduced by a 
further £2K after including transplant group in the multivariate model. 
Table 4.6 
Months 
1 to 3 
4 to 6 
7 to 9 
10 to 12 
13 to 15 
16 to 18 
19 to 21 
22 to 24 
25 to 27 
Total 
Mean observed costs under 10% random censoring and partitioned 
Cox cost estimates of costs per interval for centre, centre + 
transplanted (YIN) and centre + transplanted (YIN) + transplant 
group under 1 0% censoring 
Observed costs (£) Partitioned Cox cost estimates (£) 
Centre Centre + Centre + transplant 
transplant (yIn) (yIn) + transplant group 
20,069 19,625 16,138 15,792 
7,685 8,401 3,419 2,401 
3,807 4,420 1,086 769 
1,899 1,984 411 352 
838 1,260 329 267 
666 1,087 210 216 
500 781 223 202 
299 409 180 180 
282 281 130 142 
36,045 38,248 22,126 20,321 
The proportional hazards assumptions held for all Cox regression models. 
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Mean cost estimates for the Cox cost method and the partitioned Cox cost method 
were highly sensitive to the choice of model covariates, where the more significant the 
covariate the larger the impact on mean cost estimates. Given that these models are 
sensitive to the selection of covariates the level of impact on mean cost estimates will 
not be generalisable to other data sets. However, the assumption of independence 
between censoring and costs are violated for the Kaplan-Meier method, Cox cost 
method and partitioned Cox cost method and as a consequence all three methods fail 
to predict mean costs accurately and should not be used when data is censored. 
4.7.2.2 Lin's Regression Mode/s, KCH and UCH 
Both of Lin's regression methods, KCH and UCH, involve fitting regression models to 
those patients who died or observe complete costs for either for the full study period 
(UCH) or per interval (KCH) [See Section 4.2.10 and 4.2.11]. Predicted costs are 
estimated for all patients (censored and uncensored) for the full study period or per 
interval. Costs are then predicted for all patients and weighted by the reciprocal of the 
Kaplan-Meier probability estimator (with reverse censoring) and a mean cost is then 
estimated. The choice of covariates will affect the predicted costs and the variation 
around the cost estimates but will not have any impact on the Kaplan-Meier weights. 
Therefore the remainder of this section focuses on how the selection of covariates in 
the regression models influences the predicted costs. 
Univariate linear regression models were fitted to the complete (uncensored) costs for 
726 CELT patients, prior to simulating censoring mechanisms. Age, gender and 
disease group were not significant predictors of costs at the individual covariate level, 
however costs differed significantly by centre, transplant group and whether 
transplanted (Table 4.7). The best fitting univariate model was for transplant group 
which explained the most variability in cost estimates and had the lowest root mean 
square error (MSE) in comparison to all other variables1o, costs were highest for 
patients receiving a transplant within 14 days (mean = £122,258) and lowest for 
unlisted patients (mean = £5,368). The model for whether transplanted or not also fitted 
the cost data well in comparison with other models, on average costs were £45,745 
greater for those who received at least one liver transplant during the study compared 
with patients who did not receive one. 
10 The lower the MSE the better the model at predicting costs. 
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All univariate models accurately predicted the "true" mean costs (£36,045). However, 
all models failed to measure the "true" variation in the CELT data (Standard error = 
£ 1,517), with the best estimate of the standard error after adjusting for transplant group 
(£895) which is £622 lower than the observed value. 
Table 4.7 Model goodness of fit statistics for predicting costs for 726 
complete costs: univariate regression models 
F-statistic DF* Rl Root Estimated Estimated 
(p-value) for F- MSE mean SE (£) 
statistic cost (£) 
Age 2.01 1,724 0.003 40,852 36,045 439 
(0.156) 
Gender 0.06 1,724 0.0001 40,908 36,045 13 
(0.813) 
Centre 7.28 5, 720 0.048 40,023 36,045 333 
« 0.001) 
Disease group 0.36 3, 722 0.002 40,935 36,045 59 
(0.780) 
Transplant group 96.17 4, 721 0.348 33,104 36,045 895 
« 0.001) 
Transplanted 299.87 1,724 0.293 34,401 36,045 821 
(YIN) « 0.001) 
*DF - degrees of freedom 
A multivariate linear regression model was fitted to complete costs for all patients and 
variables that reached statistical significance at p < 0.05 were included in the model; 
transplant group and whether transplanted were the only statistically significant 
variables in this model11 . Although this model predicts the mean cost (mean = £36,045) 
the mean variability around predicted costs i.e. the root MSE is high (31,599). Further, 
the model predicts high and low costs poorly with the minimum cost being almost £5K 
greater than the observed minimum cost for the data of £393 and the highest prediction 
almost £200K lower than the observed maximum cost of £311,873. Thus, the model 
under predicts the "true" standard error (£1,517) for the CELT data by £549. 
" These covariates are the same ones as those used to estimate mean costs for lin's regression method 
KCH and UCH after simulating censoring in Section 4.7. 
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In an attempt to improve the estimate of the standard error a further multivariate model 
was fitted to the 726 complete (uncensored) cases which included all covariates (age, 
gender, transplant centre, disease group, transplant group and whether transplanted) 
regardless of level of significance. The hypothesis behind this model was that the 
greater the number of variables in the model, the larger the variation in the predicted 
estimates, thus the more accurate the estimate of the standard error. The root MSE for 
this model remained high at 31,080 and the R2 was 0.434. However, this model gave 
negative predictions of costs for 63 (9% ) patients, these patients were assumed to 
have zero costs. After adjusting for negative costs the mean cost estimate was £36,121 
and the standard error was still £521 less than the observed standard error. Therefore, 
for the GEL T dataset it was reasonable to include only statistically significant variables 
in the regression models given that the inclusion of non-significant variables affected 
mean cost estimates and only marginally improved the standard error estimate. 
So far the regression models fitted have been for complete (uncensored) costs for all 
726 GEL T patients, however, when censoring is present Lin's regression models 
should be fitted to complete (uncensored) costs. Therefore, the next step is to 
investigate whether predicted mean costs are still predicted accurately with models 
under predicting standard errors, after simulating censoring and fitting regression 
models to a reduced set of uncensored cases. Further, the accuracy of regression 
model estimates need to be verified for models fitted under UGH and KGH (Le. fitting 
regression models per interval when the study is divided into a number of time 
periods). This hypothesis was tested by simulating censoring for two censoring 
mechanisms; 30% random censoring and informative censoring too ill (20th percentile) 
and regression models were fitted with UGH and KGH using three monthly intervals 
(Table 4.8). As before mean estimates were exact with UGH and underestimated with 
KGH, presumably due to loss of information when dividing the study period into smaller 
intervals. Standard error estimates remained lower than the observed standard errors. 
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Table 4.8 Mean and standard error estimates from linear regression models 
under 30% random censoring and informative censoring too ill (20th 
percentile) fitted using models UCH and KCH 
Observed Predicted Predicted values 
estimates UGH KGH 
Mean SE Mean SE Mean SE 
Random censoring 38,110 1,934 38,110 1,287 37,797 1,303 
(N = 504) 
Informative censoring 30,977 1,801 30,977 1,204 27,660 1,111 
too ill (20th percentile) 
(N = 500) 
This section has not estimated mean total costs in the presence of censoring and to 
complete this process predicted costs should be weighted by Kaplan-Meier estimates 
with reverse censoring. Instead, this section has focused upon accurately estimating 
mean costs and standard errors from linear regression models and the impact of 
covariates upon these estimates. The choice of covariates included in the regression 
models did not affect mean cost estimates or standard errors. Standard errors were 
poorly predicted, this can be attributed to the skewed nature of the GEL T data (Figure 
4.3) which did not follow assumptions of normality that are assumed when fitting linear 
regression models. The skewed nature of cost distributions is widely recognised and so 
the under prediction of the standard error estimates from fitting Lin's regression method 
are likely to occur in other studies. Further, cost data is bounded at zero and poorly 
fitting models may give negative cost predictions, which when adjusted for will result in 
an over estimation of mean costs. 
4.7.3 Varying Interval Lengths 
In this section the estimates of mean total costs in the presence of censoring are 
compared for a variety of interval lengths, across the six methods where it is necessary 
to divide the study time period in to smaller interval lengths. Given that rankings of the 
accuracy of methods did not vary significantly across censoring levels the methods are 
compared for five censoring mechanisms: 10% random censoring, 10% end-of-study 
censoring, 13% informative censoring too ill (1oth percentile), 140/ 0 informative 
censoring too well (90th percentile) and fixed time resource collection partial censoring. 
Figure 4.10 presents the difference between the observed mean costs (prior to 
censoring) and the estimated mean costs for the six censoring mechanisms, for 
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different interval lengths (See Box 4.2 for legend). Appendix A4.4 presents tabled 
mean and standard error estimates for each of the six methods. 
Box 4.2 Legend for Figure 4.10 
• 10% Random censoring 
x 10% End-of-study censoring (1.75 years) 
~ 13% Informative censoring: too ill (1 oth percentile) 
\l 14% Informative censoring: too well (90th percentile) 
• 15% Partial censoring (fixed) 
4.7.2.1 Weighted Cost Method with KCH 
Mean cost estimates were the most accurate for random censoring and end-of-study 
censoring when interval lengths of six months were used. For informative censoring too 
ill, informative censoring too well and partial censoring, estimates were most accurate 
with three monthly interval lengths. 
The least accurate estimates were from two monthly interval lengths, where mean 
costs were overestimated by between £7K and £12K across the five censoring 
mechanisms. These results contradict the findings of Bang and Tsiatis and O'Hagan 
and Stevens who suggest that a smaller interval length will give a more accurate mean 
cost estimate [Bang & Tsiaits, 2000; O'Hagan & Stevens, 2004]. This apparent 
contradiction is due to the loss of information from estimating Kaplan-Meier survival 
probabilities (with reverse censoring) for small interval lengths. With survival measured 
in monthly units and choosing two monthly interval lengths an event can only occur at 
one of two time points (month one or month two). This choice of interval lengths thus 
results in less accurate estimates of survival over time. 
4.7.2.2 Lin's Regression Method with KCH 
Lin's regression method is subject to the same problem as the weighted cost method 
and information on survival is lost when interval lengths of two months are used (mean 
costs were overestimated by £4K to £ 11 K across censoring mechanisms). The best 
estimates of mean total costs are produced when selecting six monthly intervals and 
the difference between cost estimates and the true mean cost range between -£1,148 
and £1,388 at 6 months. 
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4.7.2.3 Lin's method with KCH 
For Lin's method KCH, the narrower the interval length the more accurate the estimate 
of mean total costs was, with the most accurate estimate occurring for monthly interval 
lengths and the least accurate for yearly interval lengths (underestimating mean costs 
by £6K to £9K). 
4.7.2.4 Partitioned Cox Cost Method 
The partitioned Cox cost method always underestimated mean study costs. The mean 
cost estimates were worst for monthly intervals (underestimated by approximately 
£17K) and best for yearly intervals for the partitioned Cox method. However, even the 
best estimates were approximately £12K less than the observed mean cost (£36,045). 
4.7.2.5 Carides' Method 
The accuracy of the mean estimates varied by censoring mechanism and no 
discernable pattern was observed. 
4.7.2.6 Lin's Method with UCH 
Under random censoring and end-of-study censoring the most accurate estimates of 
mean study costs were observed for monthly interval lengths, for both informative 
censoring mechanisms and partial censoring a three monthly interval length gave the 
best estimates. 
For each of the six methods (weighted [KCH], Lin's regression [KCH], Lin [KCH], 
partitioned Cox cost, Carides' and Lin [UCH]) the results for the interval length that 
gave the most accurate estimate of mean total costs were selected. Mean (and 
standard error) estimates were compared with mean (and standard error) estimates for 
the six methods where it was unnecessary to divide the study period in to intervals 
(ignoring censoring, complete cost method, Kaplan-Meier cost method, Cox cost 
method, weighted cost method (UCH) and Lin's regression method (UCH)). Results 
were then ranked in terms of the accuracy of the mean (and standard error) estimate 
for the 12 censoring methods. Table 4.9 and 4.10 present the rankings for accuracy of 
the mean and standard error estimates. 
Lin's method (KCH) is the most accurate method for estimating mean and standard 
error estimates when monthly interval lengths are selected. Lin's method with KCH 
(monthly interval lengths) showed the most marked improvements in mean cost 
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estimates and changed from being one of the poorest predictors of mean study costs to 
being one of the best predictors of mean study costs. The standard error estimates 
from Lin's method (KCH) under monthly intervals were also more accurate than when 
using three monthly intervals. The rankings for all other methods did not alter by more 
than three places. 
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Figure 4.10 Difference between observed mean costs (prior to censoring) and estimated mean costs (in the presence of censoring) for 
six censoring mechanisms by interval length 
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Table 4.9 Ranking the methods for estimating mean total costs; ranked in terms of magnitude from the true mean (£36,045) of the 
uncensored eEL T data 
10% Random 10% End-of-study 13% Infonnative 14% Infonnative 15% Partial Censoring 
Censoring Censoring Censoring Too III Censoring Too Well 
(1.75 years) (10th percentile) (90th percentile) (Fixed) 
"New" "Old" "New" Rank "Old- "New" Rank "Old" "New" Rank "Old- "New" Rank ·Old" 
Rank Rank Rank Rank Rank Rank 
Known cost histories 
WK: Weighted costs (6 MI·) 6 7 (6 MI) 7 7 (3 MI) 8 7 (3 MI) 4 3 (3 MI) 3 2 
RK: Lin's regression (6 MI) 8 8 (6 MI) 9 8 (6 MI) 2 3 (6 MI) 9 8 (6 MI) 8 7 
LK: Lin's method (1 MI) 2 9 (1 MI) 2 9 (1 MI) 4 9 (1 MI) 3 9 (1 MI) 2 8 
PC: Partitioned Cox (12 MI)10 10 (12MI)10 10 (12 MI) 10 10 (12MI)10 10 (12MI)10 10 
Unknown cost histories 
C: Carides (6 MI) 3 4 (1 MI) 3 5 (3 MI) 1 1 (12 MI) 2 2 (1 MI) 4 6 
IC: Ignoring Censoring 9 6 =4 2 9 8 8 7 1 1 
LU: Lin's method (3 MI) 1 1 (1 MI) =4 4 (6 MI) 3 2 (3 MI) 1 1 (1 MI) 5 5 
RU: Lin's regression 7 5 1 1 5 4 6 5 =6 =3 
WU: Weighted costs 5 3 6 3 7 6 7 6 9 9 
CC: Complete cases 4 2 8 6 6 5 5 4 =6 =3 
Cox: Cox regression 11 11 11 11 11 11 11 11 11 11 
KM: Kaplan-Meier 12 12 12 12 12 12 12 12 12 12 
·N~ rank - using the interval lengths that give the most accurate mean estimates Old" rank - using three monthly interval lengths • MI - Monthly intervals (choice of interval lengths used) 
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Table 4.10 Ranking the methods for estimating mean total costs; ranked in terms of magnitude from the true standard error (£1,517) of 
the uncensored eEL T data 
10% Random 10% End-of-study 13% Infonnative 14% Infonnative 15% Partial Censoring 
Censoring Censoring Censoring Too III Censoring Too Well 
, (1.75 years) (10th percentile) (90th percentile) (Fixed) 
"New" "Old" "New" Rank "Old" "New" Rank "Old" "New" Rank "Old" "New" Rank ·Old" 
Rank Rank Rank Rank Rank Rank 
Known cost histories 
WK: Weighted costs (6 MI·) 5 1 (6 MI) 4 2 (3 MI) 2 2 (3 MI) 3 2 (3 MI) 2 3 
RK: Lin's regression (6 MI) 9 9 (6 MI) 7 7 (6 MI) 9 6 (6 MI) 9 9 (6 MI) 9 8 
LK: Lin's method (1 MI) 1 5 (1 MI) 1 6 (1 MI) 3 4 (1 MI) 2 5 (1 MI) 4 6 
PC: Partitioned Cox (12 MI)11 10 (12 MI) 11 10 (12 MI) 10 10 (12 MI) 11 11 (12MI)10 11 
Unknown cost histories 
C: Carides (6 MI) 7 7 (1 MI) 6 5 (3 MI) 7 5 (12 MI) 5 4 (1 MI) 7 7 
IC: Ignoring Censoring 2 2 2 1 4 3 1 1 1 1 
LU: Lin's method (3 MI) 3 3 (1 MI) 3 3 (6 MI) 5 6 (3 MI) 6 6 (1 MI) 5 2 
RU: Lin's regression 8 8 8 8 8 8 8 8 8 9 
WU: Weighted costs 6 6 9 9 6 4 7 7 3 4 
CC: Complete cases 4 4 5 4 1 1 4 3 6 5 
Cox: Cox regression 10 11 10 11 11 11 10 10 10 10 
KM: Kaplan-Meier 12 12 12 12 12 12 12 12 12 12 
"New" rank - using the interval lengths that give the most accurate mean estimates Old" rank - using three monthly interval lengths * MI - choice of interval lengths used (in months) 
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4.8 DISCUSSION 
Of the 53 cost and cost-effectiveness studies included in the literature review in 
Chapter 3, 20 (38%) modelled the lifetime costs of solid organ transplantation and the 
remaining 33 studies (62%) estimated the cost-effectiveness or costs of solid organ 
transplantation over a fixed time period. Only three of the 33 papers gave enough 
information to establish whether censoring was an issue [Ohi et aI, 1986; Garner & 
Dardis, 1987; Longworth et aI, 2003] and all three studies elected to use Lin's method 
with KCH. In this chapter Lin's method (KCH) gave one of the most accurate estimates 
of mean total costs and standard errors in the presence of censoring when the study 
period was divided in to a series of monthly interval lengths. 
The remaining 30 papers that reported the costs or cost-effectiveness of organ 
transplantation over a fixed time period did not provide enough information to assert 
whether censoring was an issue. We can only hypothese that censoring is likely to 
have occurred in at least a proportion of these 30 studies and has been ignored when 
estimating mean costs. Ignoring censoring will underestimate the mean total cost for a 
study, since any costs incurred by patients beyond the point they are censored are 
ignored. The magnitude of the underestimation is likely to depend on the proportion of 
censored cases, where the larger the proportion of censored cases the higher the 
degree of underestimation. However, the results in this chapter showed that the 
technique of ignoring censoring was one of the more accurate methods for estimating 
mean total costs. Therefore, it is likely that the cost and cost effectiveness estimates 
presented in the 30 studies that potentially ignored the issue of censoring produced 
more accurate mean cost estimates than if they had chosen an inappropriate method 
for accounting for censoring (for example the Kaplan-Meier method). 
4.8.1 Inclusion of Na'ive Methods 
Na'ive methods such as ignoring censoring, the complete case method and survival 
analytic time methods using a cost rather than time scale (Kaplan-Meier, Cox, 
partitioned Cox) were included in this chapter in order to illustrate the magnitude of the 
difference between observed and expected costs in comparison with other proposed 
methods. These methods were included despite the fact that it is now widely 
acknowledged that they will under or over estimate mean total study costs in the 
presence of censoring [Lin et aI, 1997; Hallstrom & Sullivan, 1998]. 
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The technique of ignoring censoring produced fairly accurate estimates of mean total 
costs and standard errors under some scenarios (end-of-study censoring restricted to 
the final six months of the study and partial censoring). It could be argued that, rather 
than applying one of the more complex methods described in this chapter, for example, 
Lin's method with or without cost histories, that simple methods could be used. 
However, ignoring censoring gave more accurate estimates of mean total study costs 
when censoring occurred towards the end of the study period, as was the case with 
end-of-study and partial censoring and the accuracy of this method could be due to the 
nature of the CELT dataset, where on average larger costs were incurred earlier in the 
study period at the point of the transplant operation and stabilised in the later end of the 
study period. Therefore, the results found here might not be generalisable to other 
cohorts where different patterns of resource usage are observed, this analysis should 
be repeated on other datasets to confirm these results. 
Despite being widely criticised in the literature my experience is that the Kaplan-Meier 
cost method and Cox cost methods continue to be applied in practice when estimating 
mean total costs in the presence of censoring. Estimates of mean total study costs 
using the Cox cost method were almost double the observed mean cost and estimates 
from the Kaplan-Meier cost method were almost quadruple the observed mean, 
offering further indication that these methods should not be applied to censored cost 
data. However, it should be pointed out that the Kaplan-Meier method performs poorly 
if applied directly to censored cost data, and when applied to survival data as part of an 
estimation of mean study costs, such as Lin's methods, Lin's regression methods and 
weighted cost methods (KCH and UCH), produces more accurate estimates of mean 
study costs. 
4.8.2 Magnitude for Measuring Accuracy 
Kendall's concordance statistic was used to measure the agreement of the ranking of 
the accuracy of methods across different levels of censoring and different censoring 
mechanisms. The ranking approach was chosen over alternative methods, for example 
mean squared error, as it measured the consistency of methods across alternative 
censoring levels and mechanisms rather than measuring the magnitude of the 
precision of each method in estimating the mean or standard error. 
The ranking of mean cost estimates differed significantly from the ranking of standard 
error estimates. Methods that were accurate at predicting mean costs, for example 
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Lin's method with UCH and Lin's regression method with UCH did not give the best 
estimates of the uncertainty surrounding the mean, as measured by the standard error. 
Researchers are usually interested in the uncertainty surrounding mean cost estimates 
in addition to a reliable estimate of mean total costs. Therefore, this chapter has 
focused upon comparing methods for estimating mean cost estimates and standard 
error estimates independently. In practice one would be more interested in selecting a 
method that accurately estimated mean total costs, with the accuracy of the standard 
error estimate becoming important when the mean estimate has been proven to be 
accurate. Lin's method with KCH with monthly interval lengths and the weighted cost 
method with KCH with three or six monthly interval lengths produced accurate 
estimates of both the mean cost and standard error estimates. 
4.8.3 Interval Choices 
Initially, the twelve methods for estimating mean total costs in the presence of 
censoring were compared and a common three monthly interval length was applied to 
the six methods which required the division of the study time period in to smaller 
interval lengths. Lin's method (UCH), Carides' method and Lin's regression method 
(UCH) were shown to be the best estimates of mean total costs under these 
circumstances. Interval lengths were then varied for the six methods where estimates 
relied upon dividing the study period in to smaller intervals, to investigate how the 
choice of interval length affected mean cost estimates. The most notable improvement 
in mean cost estimates was Lin's methods (KCH) using monthly interval lengths, where 
estimates improved by approximately £2,000 across methods and resulted in Lin's 
method (KCH) being one of the most accurate methods of estimating mean total costs 
in the presence of censoring. 
O'Hagan and Stevens explored the accuracy of Lin's method (KCH) and the weighted 
cost method (KCH) under random censoring and concluded that the accuracy of Lin's 
method improves, the shorter the interval lengths used [O'Hagan & Stevens, 2004). 
Results from the CELT study support these results for Lin's method, which gave 
estimates to within £1 of the mean total cost using monthly interval lengths under 
random censoring (30%). 
Additionally, O'Hagan and Stevens stated that the weighted cost method of Bang and 
Tsiatis will produce similar estimates to Lin's method, though with KCH Lin's estimate 
makes use of information on censored costs per interval, whereas the weighted 
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estimates ignore this data, thus Lin's method will tend to produce more accurate 
estimates. For this study, when estimates using three monthly intervals were compared 
the weighted cost method consistently produced more accurate estimates than Lin's 
method. However, when interval lengths were varied, Lin's method gave a more 
accurate estimate of mean total costs than the weighted cost method did. 
4.8.4 Censoring Mechanisms 
Most of the methods listed here assume that censoring is independent of survival times 
and for informative censoring this assumption does not hold. Estimates of mean total 
costs varied more for informative censoring than for other censoring mechanisms. 
However, for Carides' method and Lin's method with UCH (three monthly intervals) 
estimates were still within £3,000 of the observed mean cost when informative 
censoring was due to ill health (20th percentile 31 % censoring). In reality censoring is 
unlikely to occur due to one type of censoring mechanism only, but through a 
combination of mechanisms, and despite all precautions taken during the study it is not 
always possible to determine why patients are censored during a study period. Future 
research could use a modelling process to combine different types of censoring and 
see how they impact on each of the methods for estimating mean total costs. 
4.8.5 Censoring Levels 
The ordering of the accuracy of methods did not differ significantly across different 
levels of censoring. This was true of all censoring mechanisms except partial 
censoring, where the ranking of methods for heavy censoring (one time resource 
collection censoring 80% ) differed from that for partial censoring (fixed time resource 
collection censoring 15%). The cause of this discrepancy appears to be due to the 
inaccuracy of the mean predictions from Carides' method, weighted cost method 
(UCH) and Lin's method (UCH) under heavy censoring. Based on the results from this 
study it is recommended that alternative methods are used under heavy censoring, for 
example Lin's regression method (UCH), Lin's method (KCH), or the weighted cost 
method (KCH). However, these observations should be validated using other cohorts 
where censoring patterns and patterns of resource use differ from those observed in 
the CELT study. 
4.8.6 Variants on Methods for Estimating Mean Total Costs 
Variants to Lin's method (KCH), the weighted cost methods (KCH and UCH) and Lin's 
regression method (KCH & UCH) have been excluded from this review, despite being 
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published in the literature. Bang and Tsiatis' weighted cost estimators (KCH and UCH) 
belong to a wider class of estimators, the properties of which have been studied by 
several authors [Bang & Tsiatis, 2000; Zhao & Tian, 2001]. These estimators have not 
been used here as they require estimating the variance and covariance for the original 
estimator and we were unable to obtain sensible estimates (> 0) for the CELT data. 
These extensions to the weighted cost methods assume that cost are normally 
distributed, which is not true in the case for the CELT data, which are positively skewed 
(Figure 4.3). Owing to this skewness this confirms the observations of Carides and 
colleagues that "reliance on asymptotic [normality] theory is not recommended" and 
Raikou and McGuire who show that the extensions to the weighted cost estimator were 
unstable [Carides et aI, 2000; Raikou & McGuire, 2004]. 
Lin and colleagues suggest excluding incomplete costs from the interval in which they 
are censored, as an alternative method (Lin's method with KCH). This approach 
assumes that censoring occurs only at the start of intervals, which was not true for the 
CELT study, therefore this method was ignored. 
Huang uses calibration regression, an extension to Lin's regression methods (KCH and 
UCH) to estimate the lifetime costs of treatments or technologies using information 
collected over a limited time period [Huang, 2002]. This method was excluded because 
the aim of this chapter was to compare the accuracy of methods for estimating mean 
study costs over a fixed time period rather than the lifetime of the treatment. Finally, 
Jain and Strawderman suggest a generalisation to Lin's regression method with UCH 
[Jain & Strawderman, 2002]. Lin's regression method assumes that costs are linearly 
related to covariates (PH) whereas Jain and Strawderman's flexible hazards model 
makes no such assumption. However, Jain and Strawderman also note that their 
method is slightly less efficient than Lin's regression method if the PH assumption 
holds, which it did for the CELT data. 
4.8.7 Application of Censored Cost Methods to QAL Y Data 
As with censored cost data, survival analytic methods should not be applied directly to 
QAl Ys to estimate mean study QAl Ys in the presence of censoring. This is because, 
as with censored cost data, the assumption of independence between QAl Ys and the 
underlying censoring mechanism will not hold. However, there is no reason why Lin's 
method (KCH and UCH), Lin's regression method (KCH and UCH), the weighted cost 
method (KCH and UCH) and Carides' method cannot be applied to censored QAl Y 
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data. In fact, Zhao and Tsiatis originally proposed the weighted cost method to 
estimates mean QAl Ys in the presence of censoring [Zhao & Tsiatis, 1997]. Further 
research should be conducted to explore the accuracy of methods applied to QAl Y 
data to establish whether the same methods that produced accurate mean cost 
estimates produce accurate estimates of mean QAl Ys. 
4.8.8 Simulating Censoring from the CELT data set 
The approach taken in this thesis was to simulate censoring from a real data set rather 
than the alternative approach of creating a completely simulated dataset with known 
properties, for example with a known pattern or resource use. Although either approach 
is applicable the one taken was to simulate censoring from a real dataset to explore 
how mean total cost results were affected by censoring in a real observed situation. 
The advantage of taking this approach was to gain an understanding of how censoring 
would affect mean total costs in the extended five year CELT study and thus select an 
appropriate method for adjusting for censoring over a five year period. 
4.8.9 Generalisability 
The recommendations and conclusions that are presented in Chapter 4 are based on 
the data from one cost-effectiveness study in liver transplantation. The CELT study was 
subject to end-of-study censoring and had a distinct pattern of cumulative costs over 
time; costs are high at the beginning of the study period when transplantation occurs, 
and then level off towards the end of the study when patients are stabilised on drugs 
and typically are seen at outpatient appointments every six to twelve months. The 
pattern of resource use is likely to be observed in other solid organ transplant studies. 
Therefore, it is probably reasonable to assume that this pattern of censoring and 
resource use is generalisable to other cost and cost-effectiveness studies in solid 
organ transplantation. 
However, the methods that produced the most accurate estimate of mean total costs 
i.e. Lin's method KCH with small intervals, might not give the most accurate estimates 
of mean costs in other data sets where the pattern of resource use differs to that 
observed in the CELT study. Each of the non-na'ive methods for estimating mean total 
costs (Lin's methods KCH and UCH, weighted cost methods UCH and KCH, Lin's 
regression methods UCH and KCH and Carides' method), applies a form of weighting 
to costs, where for each method the weights are a variation of the Kaplan-Meier 
survival probabilities. Thus, Lin's method KCH weight mean costs per interval by the 
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Kaplan-Meier probability of survival in each interval, with mean costs in later intervals 
weighted lower than mean costs in earlier intervals. If a study observed an increase in 
resource usage over time, for example in studies of chronic conditions, then lower 
weights will be applied to the higher costs at the end of the study which could result in 
an underestimation of mean costs. Lin's method UGH and Garides' methods use a 
similar process and weight cost estimates by the probability of dying, where the largest 
weights occur in intervals with the greatest probability of death. Finally, the weighted 
cost methods and Lin's regression methods weight costs by the inverse of the Kaplan-
Meier survival probability, with reverse censoring, thus inflating costs, with a higher 
level of inflation applied to costs in the later intervals of a study.12 Therefore, the 
weighted cost method and Lin's regression method with UGH might overestimate mean 
cost estimates in studies where costs increase over time by over inflating costs at the 
end of the study period. 
This chapter has explored the accuracy of 12 methods at estimating mean total costs 
for alternative censoring mechanisms for one pattern of resource use and has not 
explored the accuracy of methods for alternative resource use patterns, for example 
increasing costs over time or constant costs over time. Therefore, it is recommended 
that further work is carried out to establish whether the results here are generalisable to 
censored data sets outside the field of organ transplantation where alternative resource 
patterns are likely to be observed. 
Additionally, HRQL is typically measured at one or more fixed time points during a 
study, patients may chose not to respond at particular time points and thus HRQL data 
could have a higher likelihood of informative censoring than resource use data. Given 
that the censoring mechanism may differ to that for resource use data caution is 
advised in generalising the results shown here to QAL Y. Further work should also be 
conducted to establish the generalisability of the results to censored QAL Y and cost-
effectiveness data. 
4.9 CONCLUSIONS 
A number of messages have emerged after exploring an issue of methodological 
uncertainty by comparing 12 methods for estimating mean total costs in the presence 
of censoring. The 12 methods were compared across different censoring mechanisms 
12 If cost histories are known the study period is divided into several intervals and costs will be given a 
larger inflation rate in the later part of each interval in comparison to earlier parts of the interval. 
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and different levels of censoring, ranging from 10% (light censoring) to 80% (heavy 
censoring). It is assumed that the findings in Chapter 4 are generalisable to any study 
in solid organ transplantation where cost censoring is an issue. However, further work 
should be carried out to establish whether these results are generalisable beyond the 
field of organ transplantation and to censored HRQl or QAl Y data. 
The accuracy of mean study cost estimates can vary by censoring mechanism and for 
the CELT study the initial results showed that: 
• Lin's method (UCH) gave the most accurate estimate under random censoring 
• Lin's regression method (UCH) gave the most accurate estimate under end-of-
study censoring 
• Carides' method gave the most accurate estimate under informative censoring 
• the weighted cost method (KCH) or ignoring censoring gave the most accurate 
estimate under partial censoring 
However, the choice of interval length affects the accuracy of mean study cost 
estimates for the six methods where the study time period can be divided in to smaller 
interval lengths (weighted cost method [KCH], Lin's regression method [KCH], Lin's 
method [KCH], partitioned Cox cost method, Carides' method and Lin's method [UCH]). 
Selecting the interval length that resulted in the best mean cost estimate and 
comparing the estimates across all 12 censoring methods showed that Lin's method 
(KCH) with monthly interval lengths gave the most accurate estimate of mean study 
costs across all censoring mechanisms and levels. Therefore, based upon the results 
of the CELT study, it is recommended that in the presence of censored cost data Lin's 
method with short interval lengths (KCH) is used to estimate mean study costs in the 
presence of censoring. 
The results presented in Chapter 4 have also shown that a method that produces an 
accurate mean estimate does not necessarily produce an accurate estimate of the 
uncertainty (standard error) around the mean estimate. For the CELT study, Lin's 
method with short interval lengths (KCH) gave the most accurate estimates of the 
mean and its standard error. The weighted cost method (KCH) also produced accurate 
estimates of both the mean and standard error across all censoring mechanisms and 
levels. 
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In addition to the recommendations on the selection of the most appropriate method for 
estimating mean total costs in the presence of censoring, Chapter 4 has shown that 
three methods should not be applied when costs are not incurred at the end of the 
study period of interest. When no patient has complete costs for the full study period 
Carides' method; Lin's method (UCH) and the weighted cost method (UCH) gave 
estimates that substantially underestimates mean costs. 
Censoring was anticipated as being an issue in the extension of the CELT study from 
2.25 years to five years. Therefore, methodological uncertainties in techniques for 
estimating mean study costs in the presence of censoring were explored further in this 
thesis. The importance of exploring the methodological uncertainty in methods for 
estimating mean study costs in the presence of censoring was verified from the 
literature review conducted in Chapter 3 where 30 studies, potentially, ignored 
censoring when estimating mean study costs 13. However, given that Chapter 4 has 
also shown that ignoring censoring produces one of the more accurate estimates of 
mean study costs, for the CELT study, the cost estimates from the 30 studies identified 
in Chapter 3 may have produced more accurate mean cost estimates than if they had 
selected an alternative method. 
In the CELT study the issue of censored cost data was only relevant to the transplant 
arm of the study. For the non-transplant arm prognostic models were to be applied in 
order to estimate survival over the five-year study period and patients were predicted 
as being alive at five years or to have died during the study. However, prognostic 
models are subject to parameter uncertainty, model selection uncertainty and 
uncertainty in estimating patient specific outcomes. Therefore, the remaining chapters 
of this thesis (Chapters 5 to 7) present methods for estimating prognostic model 
uncertainties. 
13 These 30 studies did not provide enough information to assert whether censoring was an issue. 
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CHAPTER 5 
MEASURING PROGNOSTIC MODEL PARAMETER 
UNCERTAINTY 
5.1 INTRODUCTION 
The previous chapter explored the first of two issues that arose when extending the 
CELT case study from 2.25 to five years: methodological uncertainty pertaining to the 
accuracy of methods for estimating mean study costs in the presence of censoring. 
Chapters 5 to 7 explore the second issue to be addressed in this thesis; measuring 
uncertainty in published prognostic models in the absence of patient specific non-
transplant data. This chapter presents methods for estimating prognostic model 
parameter uncertainty. 
Published prognostic models were used in the main CELT study to estimate survival in 
the absence of liver transplantation over 2.25 years for patients with end-stage AlD, 
PSC or PSC. It is proposed that the same prognostic models will be used to estimate 
non-transplant survival over the extended CELT study period of five years, with a view 
to estimating the longer-term effect of transplantation. 
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The prognostic models that were applied to the CELT cohort to estimate survival in the 
absence of transplantation were all Cox PH regression models. The Cox PH model 
described here is the fixed covariate 1 Cox PH model. The concept of the Cox PH model 
is to describe the survival of a cohort of patients based on additional information 
specific to the individual patient. Mathematically, this is achieved by expressing patient 
survival in terms of the patient's demographic or clinical characteristics, which are 
referred to as explanatory variables. The probability of survival at a particular time point 
t, written S(t), is modelled in terms of a set of p explanatory variables (X1,.'" xp) that 
have some influence on patient survival (e.g. patient age at time of treatment or levels 
of bilirubin as a measure of liver function). These factors are linearly combined to 
create a risk score R, also known as a prognostic index, (Equation 5.1), where larger 
values of the risk score indicate a greater risk or poorer prognosis. 
Equation 5.1 
The terms ~1"" ~p are known as the regression coefficients, where ~j 0 = 1, ... ,p) 
quantifies the effect that the explanatory variable Xj has on the risk score R. The risk 
score is then used to model the probability of surviving to time t (Equation 5.2) 
Probability of surviving to time t = S(t) = So(t)eXP(R -RO) Equation 5.2 
In equation 5.2, Ro is the risk score for a hypothetical patient with average values for Xj 
(for example average age, bilirubin levels etc.) and 8o(t) is the survival probability for 
this hypothetical patient, or the probability of the hypothetical patient surviving to time 
point t. So(t) is often referred to as the baseline survival function. To illustrate this, 
suppose that S(t) were expressed in terms of one explanatory variable, the patient's 
age at transplant and further suppose the average age of the cohort is 50 years. Ro 
would then correspond to the risk score of a 50-year-old patient and 8o(t) would 
correspond to the probability with which a 50-year-old patient survives to a time t. The 
survival probability for patients of other ages can also be calculated. 
1 In the fixed covariate Cox PH model described here the demographic and clinical 
characteristics are collected at one time point only and are assumed to remain constant over 
time. 
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The minimum amount of information required from a prognostic model in order to 
predict survival in another cohort, are the estimates of the regression coefficients, J31' 
.",J3p, and the baseline hazard or survival rates at given time points2. 
Given this information, it is possible to estimate the expected survival of patients had 
they not received the new treatment and compare this with their observed survival for 
patients who have received the new treatment. Thus, the survival gain of the new 
treatment may be estimated. 
It is important to recognise that the degree to which each explanatory variable 
influences survival is not known exactly, but rather is an estimate based on the survival 
of a cohort of patients. As such, there is uncertainty associated with each of the 
estimates of the regression coefficients and the authors of some published prognostic 
models acknowledge this by providing their standard errors. This information is usually 
ignored when estimating control group survival [See: Neuberger et aI, 1986; Bonsel et 
aI, 1990a; Longworth et aI, 2003]. Incorporating these standard errors in to the 
calculation of estimated survival gives a more accurate representation of the model 
uncertainty. Further, these regression coefficients will typically not be independent of 
each other. Therefore, an even more accurate representation of model uncertainty can 
be obtained if, in addition to the standard errors, the correlations between the 
regression coefficients are available. 
In the CELT study, the prognostic models were an essential tool in the estimation of the 
costs, HRQl and QAlYs of the medical management of end-stage liver disease, as the 
estimates of non-transplant costs, HRQl and QAl Ys were all functions of length of 
survival in the absence of transplantation. The main focus of this chapter is to introduce 
methods for estimating model parameter uncertainty; an earlier version of this work has 
been published by the author elsewhere [Young & Thompson, 2004]. A revised version 
of the PSC Mayo model3 is used to illustrate the techniques and methods introduced. 
2 The hazard function h(t) and survival function S(t) are mathematically related 
[h(t) = - :t {log S(t)}] 
3 The Mayo model used in this chapter is based upon unpublished data (provided directly to the author) 
that differs from that used to fit the published prognostic models [Dickson at aI, 1989; Murtaugh at aI, 1994] 
in the main CELT study due to additional follow-up information and the correction of minor data errors in 
patient age and prothrombin times. 
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A secondary issue considered here was whether measures of prognostic model 
parameter uncertainty should be incorporated in to the selection criteria for an 
appropriate prognostic model when more than one prognostic model exists. 
This chapter is divided in to a further nine sections. Section 5.2 presents an overview of 
the literature on model uncertainty. Section 5.3 then introduces the PBC CELT cohort 
in greater detail and presents details of the PBC Mayo clinic data. The section also 
presents results from a direct comparison of survival for two patient cohorts with, and in 
the absence of, liver transplantation. The chapter then goes on to describe how 
prognostic models can be applied to estimate survival in another cohort (Section 5.4). 
Monte Carlo simulation methods for adjusting for model parameter uncertainty are 
introduced in Section 5.5 and 5.6. Section 5.7 compares the levels of parameter 
uncertainty across three PBC prognostiC models. Section 5.B considers whether levels 
of model parameter uncertainty could be used as a model selection criteria, when more 
than one prognostic model is available, on the basis that the less the uncertainty the 
better the model. A discussion of some of the advantages and disadvantages of 
adjusting for model uncertainty are then discussed in Section 5.9. 
5.2 AN OVERVIEW OF THE LITERATURE ON STATISTICAL MODEL 
UNCERT AINTY 
In this section a brief overview of possible sources of model uncertainty is presented. 
Uncertainty is considered at three levels; model choice uncertainty (level 1), variable 
selection uncertainty (level 2), and model parameter uncertainty due to the underlying 
data set the model has been fitted to (level 3) [Figure 5.1]. 
Model uncertainty (also known as structural uncertainty) arises when selecting the 
mathematical structure of the model. For example, a researcher aiming to model the 
hazard or risk of death needs to decide between analysing survival at a fixed point in 
time (using logistiC regression or a similar model) and analysing the actual survival 
times (using Cox regression or a similar model). The choice between these two 
approaches, and the choice of model with which to accomplish it, may not be obvious, 
since either may fit a data set equally well. Bayesian methods have been developed to 
allow for model selection uncertainty [see: Draper, 1995; Kang et a', 2000]. These 
methods involve running "repeated analysis utilising different models and specifying 
prior probabilities of different models across this model space" [Briggs, 2000]. 
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Figure 5.1 The three levels of statistical model uncertainty 
Level 1 Model choice uncertainty 
Level 2 Variable selection uncertainty 
There are several issues that arise when selecting which variables are to be included in 
a mathematical model. Firstly, the variable selection techniques will depend on the 
requirements of the model and often on the analyst. In some cases, some or all 
variables will be included in a model regardless of their statistical Significance, whereas 
in others only variables that are statistically significant will be included. Secondly, the 
analyst needs to select the significance levels for p-values, where variables with a p-
value lower than a chosen level are included in the model. Thirdly, there is the method 
of variable selection. If forward selection is used, each of the variables are fitted to the 
model one at a time, with the single best fitting variable (the one that is the most 
significant predictor) being included in the model. The unselected variables that remain 
are then fitted, one at a time, to the new model, which now includes the best fitting 
variable. If the model is significantly improved by the inclusion of a second variable 
then the model is again updated with the most significant of the variables. The process 
is continued until none of the remaining variables significantly improve the model fit. 
Conversely, in backwards selection all variables are fitted to the model and non-
significant variables are removed one at a time until only significant variables remain . 
The use of forward and backward selection can result in different combinations of 
variables in the final models and choice of technique will depend on the preference of 
the analyst and on the study objectives. Collett states that "there are likely to be a 
number of equally good models, rather than a single 'best' model" and recommends 
that analys consider a number of altemative models based on different combinations 
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of variables [Collett, 1994]. In contrast, Wang et al compared frequentist stepwise 
variable selection methods (including forward and backward stepwise regression) with 
Bayesian model averaging approaches using simulated data sets and conclude that 
the Bayesian approach is a preferable variable selection method [Wang et aI, 2004]. 
The final source of model uncertainty arises from uncertainty in the parameter 
estimates and this can be measured by the standard error of the regression coefficient 
or the covariance matrix for the regression coefficients. Numerous papers in different 
topic areas suggest techniques for allowing for this uncertainty using simulation, 
bootstrapping or Bayesian techniques [See: Gigli et aI, 2000; Babyak, 2004; Bertrand-
Krajewski, 2004; Cox & Popken, 2004; Kawrakow 2004]. 
The above discussion on model uncertainty is not meant to be a comprehensive review 
of the literature but seeks to give an overview of possible sources of statistical model 
uncertainty. The objective of this chapter is to identify techniques for adjusting for 
uncertainty in published mathematical models applied to another data set and all the 
techniques described in this section are derived to measure model uncertainty in an 
observed data set. No literature was found on methods for incorporating model 
uncertainty when fitting an existing model to another data set. Therefore, Sections 5.5 
and 5.6 set out a simulation method that allows for this. 
5.3 A COMPARISON OF OBSERVED SURVIVAL WITH AND IN THE ABSENCE 
OF LIVER TRANSPLANTATION 
This section introduces the PBC Mayo clinic cohort, from whom a prognostiC model is 
derived for estimating survival in the absence of liver transplantation. The model is 
applied to 81 CELT patients with end-stage PBC to estimate, what would have been, 
their survival in the absence of transplantation over the extended five year CELT study 
period. This section also introduces the PBC CELT cohort and compares demographic 
and clinical characteristics for the CELT cohort with the PBC Mayo cohort over five 
years. The remainder of Section 5.3 describes methods for estimating survival with and 
without transplantation and the survival gain from liver transplantation using a historical 
control group to estimate non-transplant survival. 
5.3.1 PBC Mayo Cohort - The Non-Transplant Group 
Between January 1974 and April 1984 a total of 312 patients with PBC participated in 
one of two RCTs at the Mayo Clinic, Rochester, Minnesota. The objective of both trials 
133 
Chapter 5 Measuring Parameter Uncertainty in Prognostic Models 
was to evaluate the therapeutic effect of D-penicillamine as a treatment for PSC in 
comparison with a placebo drug [Dickson et aI, 1985]. The two trials differed in that one 
compared the drug in patients with histological stage 1 or 2 PSC4 , and in the other, 
patients had stage 3 or 4 PSC. Neither trial found a therapeutic difference between the 
treatment and control arms of the trial. 
In both trials, detailed demographic, clinical and biochemical information were collected 
for each patient every time they visited the Mayo clinic for treatment for PSC. The 
patient and clinical characteristics provided in the full Mayo data set consisted of: 
patient age, gender, presence or absence of ascities, presence or absence of 
hepatomegaly, presence or absence of spiders, oedema scores, albumin, serum 
bilirubin, serum cholesterol, alkaline phosphate, serum glutamic-oxaloacetic 
transaminase, platelets, prothrombin time, histological stage, survival length and 
patient outcome. 
Patients were followed up until April 1988, yielding a median follow-up time of 6.3 years 
(IQR: 3.7 years to 8.9 years). Patients had between one and sixteen visits to the Mayo 
clinic during the study period. 
A total of 29 (9.3%) patients received a liver transplant during the two trials. These 
patients were censored in the original studies at point of transplant and no further 
clinical information was collected on these patients. 
5.3.2 PBC CELT Cohort - The Transplant Group 
Eighty-one patients with end-stage PSC underwent liver transplantation during the 
CELT study period. The main CELT study collected survival information up-to two 
years post transplantation. Survival outcome was updated in September 2001 when all 
six transplant centres who participated in the study provided information on survival 
and date of death, if applicable, for all transplanted patients. The median study follow-
up time for the extended study period was 4.8 years (IQR: 4.4 to 5.3 years). 
Information was available on the age and gender of all patients. Clinical information 
was collected on all patients immediately prior to transplantation and included: serum 
4 Histological stage is a categorisation of disease severity based on liver biopsy results; stages 1 and 2 are 
less severe than 3 and 4 where patients have fibrosis or cirrhosis of the liver. 
5 Oedema score: 0 = no oedema and no diuretic therapy for oedema, 0.5 = oedema present without 
diuretic therapy or oedema resolved by diuretics, 1 = oedema present despite diuretic therapy. 
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bilirubin levels, presence or absence of ascities, oedema score, serum albumin levels, 
prothrombin time, urea, creatinine levels, encephalopathy and blood group. 
5.3.3 Estimating the Survival Gain of Liver Transplantation - Kaplan-Meier 
Method 
Given that data were available for a non-transplant cohort of patients (PBC Mayo 
cohort) an intuitive first step in estimating the survival gain of liver transplantation is to 
use the available data. Therefore, Sections 5.3.3 and 5.3.4 explore a series of methods 
for estimating non-transplant survival and the survival gain from transplantation using 
the original Mayo data to estimate non-transplant survival, these results will be 
compared with non-transplant survival estimates using prognostic models. 
The simplest comparison of survival with, and in the absence of, transplantation is to 
estimate the survival for each cohort by the Kaplan-Meier method. 
5.3.3.1 Kaplan-Meier Analysis 1: Comparing PBC CEL T survival from date of 
transplant with PBC Mayo patient survival from date of first visit 
Figure 5.2 presents the Kaplan-Meier survival curves for the PBC Mayo cohort (non-
transplant group) and the PBC CELT transplant group. The survival curves cross at 
approximately 2.5 years, suggesting that the apparent early survival advantage in the 
absence of transplantation ends at this point, and the transplant patients have better 
survival over the remainder of the five-year period. This result is not entirely 
unexpected. The most likely time period for mortality post-liver transplantation is in the 
six-month period that follows transplantation. During this time, patients are more likely 
to suffer from post-operative complications, infections and rejection episodes. 
However, once this period has elapsed, prognosis tends to stabilise. By contrast, 
mortality will occur at a more constant rate over time in the non-transplant group. 
The mean survival for each cohort was calculated from the area under the Kaplan-
Meier survival curves [Collett, 1994]. Greenwoods formula was applied to estimate 
950/0 CI around the two means. The mean survival gain from transplantation is the 
difference between the areas for the non-transplant and transplant survival curves. 
The mean survival time for the transplant group was 4.4 years (95% CI: 4.0 to 4.7 
years) which was similar to the mean survival for the non-transplant group of 4.3 years 
(950/0 CI: 4.1 to 4.4 years). The proportion of deaths over five years post-transplant for 
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the CELT cohort (12 [15%]) was lower than the number of deaths over five years for 
the Mayo cohort (88 [28%]). The mean survival gain from transplantation over five 
years suggested that there was no significant difference in survival between the two 
groups (Mean transplant survival gain = 0.11 years, 95% CI: -0.26 to 0.48 years; 
Wilcoxon Xt2 test = 3.24, P = 0.072). 
Figure 5.2 
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5.3.3.2 Is Kaplan-Meier Analysis 1 providing a fair comparison? 
The above analysis compared survival between transplanted and non-transplanted 
patients. However, it is only valid to interpret this as a comparison between 
transplantation and non-transplantation if the two patient cohorts are themselves 
comparable. To understand the difficulties in making this inference, it is necessary to 
take a step back from the data and to consider the clinical characteristics of PSC and 
the criterion by which the cohorts were defined. 
PSC is a chronic progressive disease consisting of a pre-symptomatic stage that lasts 
approximately twenty years, a symptomatic stage that lasts between five and ten years, 
and a pre-terminal/accelerated phase that lasts approximately two years [Pasha & 
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Dickson, 1997]. Patients in the CELT study have end-stage liver failure and are highly 
likely to be in the pre-terminal phase of PSC. On the other hand, patients in the Mayo 
cohort may be in any of the three stages, though most likely to be in the symptomatic 
or pre-terminal stage. Since the objective of the CELT study was to estimate the impact 
of liver transplantation among patients with end-stage PSC, the study population (and 
the patients to whom this research is directed) are patients with end-stage PSC. An 
appropriate comparator cohort should therefore comprise of PSC patients whose 
disease has progressed towards or in to the pre-terminal stage. 
The Mayo study collected clinical information on study patients over a series of time 
points. Table 5.1 presents the clinical and demographic characteristics of the Mayo 
group at first and final study visit6 • The median time between first and final visits was 
3.7 years (IQR: 1.5 to 7.2 years). During the study the patient's health deteriorated due 
to the progression of the liver disease?; bilirubin levels and prothrombin times increased 
(t = -10.04, P < 0.001, and t = -9.71, P < 0.001, respectively), albumin levels decreased 
slightly (t = 13.13, P < 0.001) and the number of patients with oedema (with or without 
diuretics) increased as did the proportion of patients with ascities (X; = 43.50, P < 
0.001, and X12 = 40.31, P < 0.001, respectively). Furthermore, Table 5.1 shows the 
Mayo patient cohort at their first visit are at less risk of death than the CELT patients, 
but are more similar to the CELT cohort at the time of their final visit. 
6 The clinical characteristics presented in Table 5.1 were commonly collected in both the Mayo and eEL T 
studies. . . ed d th 
7 Higher bilirubin levels, longer prothrombi~ times, lower albumm levels, higher 0 ema scores an e 
presence of ascities suggest more severe disease levels. 
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Table 5.1 Demographic and clinical characteristics for the Mayo non-
transplant cohort at the time of first and final study visits and the 
PBC CELT cohort immediately prior to transplantation 
Mayo cohort Mayo cohort CELT cohort 
First visit Final visit Point of 
transplant 
(N = 312) (N = 312) (N = 81) 
Age in years (SO*) 50.0 (10.6) 54.7 (10.9) 55.2 (8.1) 
Serum bilirubin in mg/dl (SO) 3.2 (4.5) 7.2 (8.2) 8.1 (8.7) 
Serum albumin in g/dl (SO) 3.5 (0.4) 3.1 (0.6) 3.1 (0.7) 
Prothrombin time in seconds (SO) 10.7 (0.9) 12.0 (2.4) 16.0 (4.4) 
Females 296 (89%) 296 (89%) 73 (90%) 
Oedema score 0 247 (79%) 165 (53%) 50 (62%) 
Oedema score 0.5 44 (14%) 79 (25%) 11(14%) 
Oedema score 1 21 (7%) 68 (22%) 20 (26%) 
Ascities present 24 (8%) 84 (27%) 41 (51%) 
5.3.3.3 Kaplan-Meier Analysis 2: Comparing PBC CEL T survival from date of 
transplant with Mayo patient survival from date of last visit 
It was decided that a more appropriate comparison group for the GEL T survival post 
transplant was the survival in the Mayo cohort from final study visit onwards (Figure 
5.3). The remainder of the non-transplant analysis in this chapter uses information from 
each patient's final Mayo study visit. 
In the Mayo cohort, a total of 136 (44%) patients died over the five-year period 
following their final study visit, which is almost triple the proportion that died post-
transplant in the GEL T study (12 [15%]). The Kaplan-Meier survival curve shows that 
survival without transplantation is consistently lower than survival post-transplant over 
the five-year period (Wilcoxon x~test = 31.4, P < 0.001). The mean survival post 
transplant was 4.4 years (95% GI: 4.0 to 4.7 years) and in the absence of 
transplantation was 2.8 years (95% GI: 2.5 to 3.0 years) with a mean transplant 
survival gain of 1.59 years (95% GI: 1.15 to 2.03 years). In contrast to Kaplan-Meier 
Analysis 1, these results imply that transplantation is an effective treatment of choice 
for patients with end-stage PSG. 
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5.3.3.4 Is Kaplan-Meier Analysis 2 providing a fair comparison? 
By comparison to Analysis 1, the above analysis is more realistic, since the patients 
are more alike at the outset. Despite this, Table 5.1 still suggests that there are 
differences between the demographic and clinical characteristics of the PBC CELT 
cohort at point of transplant and the PBC Mayo cohort at final study visit. The two 
cohorts were similar in mean age and the proportion of female patients. However, the 
CELT cohort had significantly higher serum bilirubin levels, prothrombin times and a 
higher proportion of patients had ascities than the Mayo cohort (t = 2.37, P = 0.018; t = 
12.14, P < 0.001; Xt2 = 16.64, P < 0.001, respectively), suggesting that at time of 
transplant the CELT patients were at worse prognosis than the Mayo cohort, even at 
their final study visit. 
The survival curves, as estimated by the Kaplan-Meier method, do not take in to 
account the differences in patient characteristics between the Mayo and CELT cohorts. 
Consequently, it is quite likely that even the second analysis is underestimating the true 
139 
Chapter 5 Measuring Parameter Uncertainty in Prognostic Models 
benefit of transplantation over the medical management of end-stage liver failure. In 
Chapter 3, we discussed how differences between historical and concurrent cohort 
populations can cause biases in the results and that it is possible (to some extent) to 
adjust for these differences provided that the information on the differences is 
collected. There appears to be a difference in disease severity between the CELT and 
Mayo cohorts and it is possible to adjust for such differences using approaches such as 
Cox PH regression analysis. 
5.3.4 Estimating the Survival Gain of Liver Transplantation - Cox Method 
The patient specific data from the PBC CELT and PBC Mayo cohorts were combined in 
to one data set to adjust for the differences in patient characteristics between cohorts. 
A Cox PH regression model was employed to obtain an adjusted estimate of survival in 
the absence of transplantation and this estimate was used to calculate the survival gain 
from transplantation. Variables that were common to both data sets were adjusted for 
in the Cox model: patient age, gender, serum bilirubin levels, prothrombin time, serum 
albumin, oedema score and presence or absence of ascities. The assumptions of 
proportionality were checked and held for each variable. Appendix A5.1 presents the 
Cox PH model results. 
Figure 5.4 below, presents the unadjusted survival curve for the PBC CELT cohort 
(transplant group) and the predicted survival curve for the PBC Mayo cohort (non-
transplant group) from date of final study visit, adjusted for the demographic and 
clinical characteristics using the Cox PH model described above. The mean survival for 
transplant patients was 4.4 years (95% CI: 4.0 to 4.7 years). The mean estimate of 
survival over five years in the absence of transplantation was 2.6 years (95% CI: 2.4 to 
2.9 years), slightly lower than the unadjusted estimate presented in Section 5.3.3.3 (2.8 
years). This resulted in an estimated increase in the mean survival gain over five years 
from transplantation (Mean = 1.72 [95% CI: 1.68 to 1.76 years]). 
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5 years for the Mayo Cohort from final study visit (non-transplant 
group; N = 312, dashed line) and the CELT Cohort (transplant 
group; N = 81, solid line) 
i._ 
i . ., 
:....1., 
:...·T~ 
. ...:.!.~ 
:...._., 
._-:...._.- -"'-.'!~-"'I 
i._._._._._._., '1'- '1'-
"·'t-·-·-·--·--·-·-t--:·-·-·-·-i.~ ','-
~ .. ~ 
0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 
Survival time in years 
5.0 
5.3.5 Summary of Results 
No significant gain in survival after transplantation was evident over five years when 
using non-transplant Mayo data from first study visit. However, there was evidence of a 
mean survival gain of 1.59 to 1.72 years when using Mayo data from final study visit, 
both with and without adjustment for clinical and demographic patient characteristics. 
The most reliable of the three estimates of the survival gain was 1.72 years, since this 
estimates the difference in survival between transplantation and medical management 
after adjusting for differences in clinical and demographic data between the transplant 
and non-transplant cohorts. 
However, it is not always possible to collect person-specific data from a historical 
cohort of patients and this was the case in the CELT study, where historical non-
transplant data became available for the PSC group (Mayo non-transplant cohort) only 
after the main CELT analysis had been published. The CELT study therefore used a 
different approach, although one that still relies on the Cox PH regression model. In 
this, published prognostic models were used to estimate the non-transplant survival of 
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patients with end-stage liver disease and consequently QAL Ys and costs in the 
absence of transplantation. The use of prognostic models to estimate non-transplant 
survival is described in detail below. 
5.4 USING PROGNOSTIC MODELS TO PREDICT NON·TRANSPLANT 
SURVIVAL 
A prognostic model is essentially a mathematical formula that attempts to predict an 
outcome such as length of survival. This formula is derived on the basis of observed 
data from previous patients, with the intention of providing a prognosis for future 
patients. It is possible to use the information from a prognostic model to estimate the 
survival for a particular treatment or condition. It is also possible to compare survival 
estimates from a prognostic model with observed survival for patients from a 
comparator cohort, for example, comparing survival with, and in the absence of, liver 
transplantation. Thus, assuming the patients on whom the prognostic model was 
derived can be generalised to the present cohort (other than in their therapeutic 
treatment), the survival gain of a new treatment or technology may be estimated. 
The remainder of this section illustrates this process in detail. The prognostic model 
described here was derived from fitting a fixed covariate Cox PH model to the person 
specific PSC Mayo data, from point of final study visit. Patient age, gender, bilirubin 
levels, albumin levels, prothrombin time, oedema score and the presence or absence 
of ascities were included in the model. The assumptions of proportionality were 
checked and held for each variable (Appendix A5.1). Table 5.2 presents the prognostic 
model regression coefficients and standard errors and Table 5.3 presents the baseline 
survival [So(t)] over five years in 0.25 year increments. 
Bilirubin levels, age, albumin levels, oedema scores and gender were significant 
predictors of non-transplant survival in the Mayo cohort, whereas prothrombin time and 
ascities were not significant. The probability of survival without transplantation 
decreases with increasing age, increasing bilirubin levels and decreasing albumin 
levels. Patients with an oedema score of 0.5 or 1 were less likely to survive than 
patients with a score of 0 and female patients had a greater probability of surviving 
than male patients. The variables were included in the model regardless of the level of 
statistical significance. 
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Table 5.2 Regression coefficients and their standard errors for a fixed 
covariate Cox PH model fitted to the PBC Mayo cohort (N = 312) 
Regression Standard Z p-value 
coefficient error 
Loge(bilirubin in mg/dl) 0.87 0.11 7.65 < 0.001 
Albumin in g/dl -0.93 0.22 -4.31 < 0.001 
Oedema score 0.5* 0.45 0.23 1.93 0.053 
Oedema score 1 0.52 0.25 2.06 0.040 
Ascities present 0.19 0.22 0.86 0.390 
Gender: female -0.64 0.25 -2.59 0.010 
Age in years 0.03 0.01 2.96 0.003 
Loge(prothrombin time in seconds) 1.10 0.66 1.67 0.096 
* Oedema scores: 0 - no oedema and no diuretic therapy for oedema; 0.5 - oedema present without 
diuretics or oedema resolved by diuretics; 1 - oedema present despite diuretics (score 0 used as a base 
score in the model) 
The baseline risk score (Ro) for an average patient from the PSC Mayo cohort (a 54 
year old female, with a serum bilirubin level of 7.2, a serum albumin level of 3.07 and a 
prothrombin time of 12 seconds with no oedema [score 0] and no ascities) is 2.41. 
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Baseline survival estimates So(t) up to five years for a fixed 
covariate Cox PH model fitted to the PBC Mayo cohort (N = 312) 
Time in years So(t) 
0.25 0.917 
0.50 0.835 
0.75 0.782 
1.00 0.734 
1.25 0.686 
1.50 0.644 
1.75 0.644 
2.00 0.632 
2.25 0.547 
2.50 0.547 
2.75 0.547 
3.00 0.489 
3.25 0.489 
3.50 0.489 
3.75 0.489 
4.00 0.489 
4.25 0.462 
4.50 0.462 
4.75 0.435 
5.00 0.379 
This prognostic model, detailed in Table 5.2 and 5.3, can now be fitted to the PSC 
CELT cohort in order to estimate their survival in the absence of liver transplantation. 
The model is applied to each patient in the CELT cohort to obtain individual prognostic 
scores. For example, a 55-year-old female patient with a serum bilirubin level of 
8.1 mg/dl, a serum albumin level of 3.1 g/dl, with a prothrombin time of 16 seconds with 
no oedema and ascities has a risk score of 3.02 (Equation 5.3) and an adjusted risk 
score (R - Ro) of 0.61 (3.02 - 2.41). 
R = (0.03x55) - 0.64 + (0.87xloge(8.1)) - (0.93x3.1 0) 
+ (1.1 Oxloge(16.0)) + 0.19 = 3.02 
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This score can be transferred in to the expected probability of surviving to time point t, 
using Equation 5.2 and the baseline survival results presented in Table 5.3. Table 5.4 
presents the 1, 2, 3, 4 and 5-year survival probabilities for the example patient. Here, 
the patient has a 57% probability of surviving one-year without a transplant, which 
decreases to 17% at five years. 
Table 5.4 Survival probabilities at 1, 2, 3, 4 and 5 years for a 55-year-old 
female patient with a bilirubin level of 8.1 mg/dl, albumin level of 
3.1 g/dl and prothrombin time of 16 seconds, no oedema, with 
ascities 
1 year 2 years 3 years 4 years 5 years 
Probability of surviving 0.566 0.430 0.268 0.268 0.168 
These probabilities can be plotted over time to give an individual profile of expected 
survival in the absence of transplantation and the area under the curve denotes the 
patients expected survival length (Figure 5.5). The example patient has a predicted 
non-transplant survival of 2.10 years over the five-year time period. 
Using this approach, non-transplant survival can be calculated for each patient in the 
cohort. Overall, the estimated average length of survival in the absence of 
transplantation for the CELT cohort is 2.5 years (95% CI: 2.2 to 2.8 years) over the 
five-year period. More importantly, each individual patient in the cohort now has a 
survival duration estimated in the absence of transplantation with which to compare to 
his or her observed survival time following transplantation. It is possible to estimate 
each patient's individual survival gain by subtracting the estimated non-transplant 
survival from each patients observed transplant survival. The mean survival gain over 
five years from transplantation is 1.69 years (95% CI: 1.24 to 2.13 years). 
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Estimated survival in the absence of transplantation for a 55-year-
old female patient with a bilirubin level of 8.1 mg/dl, albumin level of 
3.1 g/dl and prothrombin time of 16 seconds, no oedema, with 
ascities 
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The Kaplan-Meier transplant survival curve for the PSC CELT cohort and the mean 
non-transplant survival estimates, derived from the PSC Mayo prognostic model, are 
presented in Figure 5.6 with 95% CI to show cohort uncertainty at 1, 2, 3, 4 and 5 
years. It is important to note that the CI represent cohort uncertainty, but not model 
parameter uncertainty. In other words, the variability between patients is accounted for 
by the CI, but the non-transplant survival estimates are assumed to be a fixed quantity. 
The CI does not incorporate any of the uncertainty in the prognostic models estimates. 
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Kaplan-Meier transplant survival (solid line) and non-transplant 
survival estimated from the PBe Mayo prognostic model (dotted 
line) for 81 PBe eEL T patients (with 95% el for cohort uncertainty) 
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So far this chapter has presented summary statistics such as the mean sample 
estimates of survival with and without transplantation, or the mean survival gain from 
transplantation. These are supplemented with a 95% CI, which represents the 
uncertainty around the estimate and allows inferences to be drawn as to how close the 
sample mean is likely to be to the population mean [Bland, 2000]. The basic logic is as 
follows: whenever a sample mean is estimated, it is highly unlikely that this number will 
be exactly equal to the true population mean value. The CI allows a plausible range to 
be proposed within which the true population mean is expected to lie. The same 
process and logic is true when fitting statistical models. Just as the sample mean is an 
estimate of the population mean, the regression coefficient used in a prognostic model 
is not the true effect of that prognostic factor, but is an estimate of it. It is possible (and 
wise) to derive CI in order to represent uncertainty for each of the estimated regression 
coefficients (fi j) that are included in a statistical model. For example, using the 
standard errors for the Mayo prognostic model for bilirubin (Standard error = 0.11 see 
Table 5.2) a 95% CI can be constructed around the estimated regression coefficient of 
0.87 (95% CI: 0.65 to 1.09). 
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The authors of some published prognostic models provide information on the standard 
errors of the regression coefficients, which can be used to estimate CI around the 
regression coefficients [See: Dickson et ai, 1989; Christensen et ai, 1993, Poynard et 
ai, 1999]. Typically, authors applying models for estimating control group survival have 
ignored this additional information. 
5.5 MEASURING MODEL PARAMETER UNCERTANTY USING 
INFORMATION FROM STANDARD ERRORS 
This section presents a simple Monte Carlo simulation method to adjust for model 
parameter uncertainty. This technique is applied to allow for uncertainty in the PSC 
Mayo model's parameter estimates over a series of five steps. The computer syntax for 
this method can be found in Appendix A5.2. 
In Step 1, 3,000 sets of regression coefficients are randomly generated from a normal 
distribution. For each coefficient, the mean across 3,000 simulations, is equal to the 
value of the coefficient estimated for the PSC Mayo cohort (see Table 5.2), and the 
standard deviation is equal to its standard error. The simulations are performed using 
the rmvnorm statistical function in the S-PlUS statistical computer package [S-PlUS 
6, 2001]. The simulations provide an empirical distribution of regression coefficients 
that would have been observed had the original model been derived from 3,000 
random patient samples, instead of just one. 
In Step 2, each of the 3,000 sets of regression coefficients is applied to the PSC CELT 
data set and used to derive 3,000 sets of prognostic risk scores (Equation 5.1). Each 
set of scores is adjusted for the base line risk score of the average patient in the Mayo 
cohort (Ro = 2.41). Step 3 uses these adjusted scores to calculate the individual 
patients' probabilities of surviving to time t for all CELT patients (Equation 5.2), 
generating 3,000 sets of individual estimated survival probabilities in the absence of 
liver transplantation at three monthly intervals. In other words, this step provides insight 
to how the predicted non-transplant survival of CELT patients would have varied had 
the original prognostic model been derived on different patient samples. 
In Step 4, each set of probabilities is plotted against time to obtain the patient's overall 
expected survival. The area under each profile is the expected non-transplant survival 
time to five years for a patient in the CELT cohort. Finally, in Step 5 the average 
survival gain for each of the 3,000 simulated data sets is calculated, by subtracting the 
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expected non-transplant survival over five years from the average observed post 
transplant survival over five years, obtained from the observed post-transplant survival 
for the CELT cohort (4.4 years [53 months]). 
Box 5.1 summarises the simulation process. 
Box 5.1 Summary of the Monte Carlo simulation method for incorporating 
prognostic model parameter uncertainty in to survival estimates 
The uncertainty in the regression model's predictive accuracy was estimated using 
the following algorithm: 
Step 1: Simulate 3,000 sets of regression coefficients 
Step 2: Calculate the risk score for each patient in each of the 3,000 simulations 
Step 3: From the risk scores, calculate the predicted survival for each patient in each 
of the 3,000 simulations 
Step 4: Calculate the expected non-transplant survival over five years for each 
patient in each of the 3,000 simulations 
Step 5: For each of the 3,000 simulations, calculate the average survival gain from 
tra nspl a ntation 
These simulations allow the incorporation of the PBC Mayo model parameter 
uncertainty in to the estimates of the survival gain from liver transplantation. A 95% CI 
for the survival gain from transplant can be calculated from the 2.5th and 97.5th 
percentiles from the simulated mean non-transplant survival and the simulated mean 
survival gain from liver transplantation. The point estimate (mean) is defined 
analogously as the average of the 1500th and 1501 st largest values. 
The expected non-transplant survival was 2.5 years (95% CI: 0.3 to 4.8 years) over five 
years, after allowing for model parameter uncertainty. This CI is much wider than the CI 
for cohort uncertainty presented in Section 5.4 (average non-transplant survival 2.5 
years: 95% CI: 2.2 to 2.8 years). 
Figure 5.7 presents the prognostic model uncertainty graphically, having applied the 
Mayo model to the CELT cohort, after allowing for the uncertainty from the regression 
coefficients of the prognostic model. The estimated survival gain over five years from 
transplantation is 1.9 years (950/0 CI for model uncertainty: -0.4 to 4.1 years). Note that 
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these CI are much wider that the intervals calculated for cohort uncertainty only (i.e. 
assuming perfect model predictions) and imply that the mean survival gain after liver 
transplantation is not statistically significant. 
Figure 5.7 Mean non-transplant (shadow) survival (solid line) with 95% CI 
(blue shaded area) estimated from the PBC Mayo model using 
Monte Carlo simulations for 81 PBC CELT patients - using the 
standard errors (se) of the regression coefficients to account for 
model parameter uncertainty 
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5.5.1 Computational Considerations 
When adjusting for any uncertainty, whether it is in parameter estimates or in 
estimating individual patient outcomes, the number of simulations run should be 
specific to the type of uncertainty and the convergence of the mean estimates. Figure 
5.8 illustrates that mean regression coefficient estimates converge to the mean, before 
the end of the 3,000 simulation runs. Thus, it appears that 3,000 simulation runs is a 
reasonable number of runs for obtaining convergence of mean regression coefficients 
for prognostiC model parameter uncertainty. 
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Figure 5.8 Mean regression coefficients adjusting for model parameter uncertainty over 3,000 simulations runs for a) 10ge bilirubin 
levels, b) albumin levels, c) oedema score 0.5, d) oedema score 1, e) ascities, f) gender, g) age and h) loge prothrombin time 
a) Loge(Bilirubin levels) b) Albumin levels c) Oedema score 0.5 d) Oedema score 1 
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5.6 MEASURING MODEL PARAMETER UNCERT~NTY USING 
INFORMATION FROM THE COVARIANCE MATRIX 
In Section 5.5 it was assumed that the prognostic model parameters were fully 
independent of each other (for example, the coefficient for patient age is unrelated to 
the coefficient for bilirubin levels). This assumption is relaxed in Section 5.6 and the 
inclusion of extra information on the covariance matrix of the regression coefficients is 
included in the simulation runs for measuring prognostic model parameter uncertainty. 
The extra information on the covariance matrix of the regression coefficients could 
narrow the CI for prognostic model uncertainty, albeit only marginally. This would 
enable coefficients to be sampled from a multivariate normal distribution in which the 
estimated effect of one prognostic factor could take in to account the estimates of 
others, rather than it being assumed that the effects would be estimated independently 
of each other. 
The majority of published prognostic models provide the standard errors of the 
regression coefficients, and to date, none that I am aware of, have provided details of 
the correlation (or covariance) matrix. In order to obtain information on the correlation 
between regression coefficients the authors of each of the three prognostic models 
used in the PBC CELT study; PBC Mayo, Royal Free and European models, were 
contacted and asked if they would be willing to provide this extra information. The 
Mayo Clinic provided the person specific data used to fit their PBC prognostic model, 
enabling the covariance matrix to be estimated. 
A second set of 3,000 Monte Carlo simulations are subsequently run, accounting for 
both the standard errors of, and the correlations between, the estimated coefficients in 
the Mayo prognostic model8 • The convergence of the mean regression coefficients was 
verified over 3,000 simulations for each of the variables included in the Mayo model 
using the same convergence checks detailed in Section 5.5.1. All variables converged 
prior to 3,000 simulations. 
The average non-transplant survival probability to time t are plotted over time, and the 
average non-transplant survival and the transplant survival gain over five years is 
calculated, in the same way as described in Steps 1 to 5 of Section 5.5 (Box 5.1). 
8 The covariance matrix is derived by multiplying the correlation matrix by the standard errors. 
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Table 5.5 presents the correlations between regression coefficients for the PSC Mayo 
model. There is a strong correlation between age and gender, and between bilirubin 
and prothrombin time; and there is moderate correlation between prothrombin time and 
albumin, oedema and ascities; between age and bilirubin, oedema and ascities, 
between oedema and gender, and between oedema and ascities. There is poor to 
slight correlation between the remaining variables included in the model. 
After accounting for both the standard errors and the correlations between the 
regression coefficients, the expected non-transplant survival over five years was 2.5 
years (95% CI: 0.3 to 4.8 years), and the survival gain from transplantation was 1.9 
years (95% CI: -0.4 to 4.2 years). Adjusting for the correlation between regression 
coefficients very slightly increases the model parameter uncertainty, in this case, as 
can be seen in Figure 5.9. 
153 
Chapter 5 Measuring Parameter Uncertainty in Prognostic Models 
Table 5.5 Correlation between regression coefficients for the PBC Mayo prognostic model presented in Table 5.2 
Loge(bilirubin} Albumin Oedema: 0.5 Oedema: 1 Ascities Gender Age Loge(prothrombin) 
L0ge(bilirubin) 1.00 -0.19 -0.03 0.05 0.09 0.19 0.39 -0.79 
Albumin 1.00 -0.07 -0.09 0.10 -0.19 0.01 0.33 
Oedema: 0.5 1.00 0.85 -0.38 -0.45 -0.36 -0.24 
Oedema: 1 1.00 -0.51 -0.52 -0.31 -0.30 
Ascities 1.00 -0.00 -0.38 -0.30 
Gender 1.00 0.82 -0.04 
Age 1.00 -0.01 
Loge(proth rombin) 1.00 
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model using Monte Carlo simulations for 81 PBC CELT patients -
using the standard errors (se) and the correlations (corr) between 
the regression coefficients to account for model parameter 
uncertainty 
+se 
+ corr 
~~ 
Shadow survival 
+ se 
Survival Tim e in Years 
Table 5.6 summarises the results from using Monte Carlo simulation methods to 
predict model uncertainty using information from the standard errors of the regression 
coefficients, and the standard errors and correlation between regression coefficients, 
from a prognostic model fitted to a cohort of patients with PBC treated at the Mayo 
Clinic. 
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Table 5.6 Summary of results: Average survival estimates (with 95% CI) over 
five years in PBC CELT patients and estimated survival gain from 
liver transplantation 
Average Estimated survival 
survival (years) gain (years) 
Observed post-transplant survival 4.4 (4.0 to 4.7) 
-
(CEl T patients) 
Observed non-transplant survival 2.8 (2.5 to 3.0) 1.6 (1.2 to 2.0) 
(Mayo patients) 
Observed adjusted non-transplant 2.6 (2.4 to 2.9) 1 .7 (1 .7 to 1.8) 
survival (Mayo patients) 
Predicted non-transplant survival in CELT patients from Mayo data prognostic model 
Coefficients alone 2.5 (2.2 to 2.8) 1.9 
Coefficients and standard errors 2.5 (0.3 to 4.8) 1.9 (-0.4 to 4.1) 
Coefficients, standard errors and 2.5 (0.3 to 4.8) 1.9 (-0.4 to 4.2) 
correlations 
5.7 COMPARING MODEL PARAMETER UNCERTAINTY ACROSS THREE PBC 
PROGNOSTIC MODELS 
In their analysis of the CELT data Longworth et al used three published prognostic 
models to estimate non-transplant survival for patients with end-stage PSC: the PSC 
Mayo model (detailed above), the Royal Free model, and the European model 
[Longworth et aI, 2003]. The Royal Free model predicts survival using information on 
patient age, serum bilirubin, serum albumin and the presence or absence of ascities 
[Hughes et aI, 1992]. This model applies Cox PH assumptions to a cohort of 289 
patients referred to the Royal Free Hospital, london UK, with PSC between 1977 and 
1989. 
The European prognostic model is based upon a cohort of patients with PSC who took 
part in a multi-centre RCT between 1971 and 1983 (56.9% of patients were from UK 
centres), in which 248 patients were randomised to receive either azathioprine or 
placebo [Christensen et aI, 1985; Christensen et aI, 1993]. Clinical data were collected 
every six months and were included in a time dependent covariate Cox PH model. 
Serum bilirubin, serum albumin, age, the presence of ascities and the presence of 
gastrointestinal bleeding were found to be significant predictors of survival. All three 
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models result in similar predictions of non-transplant survival estimates when applied to 
the PSC CELT cohort (Figure 5.10). 
Figure 5.10 Estimated non-transplant survival for 81 PBC CELT patients from 
the Mayo model (solid line), Royal Free model (dotted line) and 
European model (dashed line) over five years 
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Table 5.7 summarises the prognostic factors included in each on the three PSC 
prognostic models9 • All three models use information on patient age, bilirubin levels, 
albumin levels and the presence or absence of ascities, to predict survival. In addition 
to these, the Mayo model uses additional information on gender, prothrombin time and 
oedema score, whereas the European model uses information on the presence or 
absence of gastrointestinal bleeding. 
In each of the three models a different modelling approach has been used. The Mayo 
model uses data from one time point (the last study visit) to predict survival in the 
absence of transplantation, the objective of this model was to estimate survival in the 
absence of transplantation in patients with end-stage PSC. The Royal Free and 
9 The PSC Mayo model variables are the ones included in the model presented in this thesis (Table 5.2 
and 5.3) and not the ones included in the published models. 
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European models differed from the Mayo model in their objectives: they aimed to 
predict short-term prognosis for PBC patients at any stage of their disease via updated 
covariates, both models utilising information from several visits in a person-interval 
model and a time dependent Cox model, respectively. 
Table 5.7 Variables used in the PBC Mayo, Royal Free and European 
prognostic models 
PBC Mayo Royal Free European 
Age ./ ./ ./ 
Bilirubin ./ ./ ./ 
Albumin ./ ./ ./ 
Ascities ./ ./ ./ 
Gender ./ 
Prothrombin time ./ 
Oedema ./ 
Gastrointestinal bleeding ./ 
The correlation between regression coefficients was not available from the authors of 
either the Royal Free or European prognostic models; therefore it was not possible to 
compare model uncertainty across models after accounting for correlations. However, 
the standard errors for the regression coefficients were available for all three prognostic 
models. The methods described in Section 5.5 above are applied to the Royal Free 
and European models in order to estimate model parameter uncertainty and compare 
the degree of uncertainty with that from the PSC Mayo model. 3,000 simulations are 
run for each model, regression coefficients converged to the mean prior to 3,000 
simulations. The results are shown in Figure 5.11 below. 
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Figure 5.11 Mean non-transplant (shadow) survival (solid line) with 95% CI 
(blue shaded areas) estimated from a) the Royal Free model and b) 
the European model using Monte Carlo simUlations for 81 PBC 
CELT patients - using the standard errors (se) of the regression 
coefficients to account for model parameter uncertainty 
a) The Royal Free model 
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Table 5.8 presents a summary of the estimates of non-transplant survival, the expected 
survival gain over five years and the 95% CI represent the respective model parameter 
uncertainty for PSC CELT patients using the PSC Mayo, Royal Free and European 
prognostic models. It can be seen by comparing Figures 5.7, 5.11 a and 5.11 b and from 
Table 5.8 that the model uncertainty is much larger for the PSC Mayo model than for 
the Royal Free and European models. When the latter two models are used, there is 
evidence of a survival gain after transplantation that is not apparent from the Mayo 
model. Despite this, the average survival gain after transplantation is remarkably 
similar for all three models, with gains ranging slightly between 23 and 24 months. The 
choice of model from which non-transplant survival is estimated does not therefore give 
rise to inconsistent estimates of the effect of transplantation, but does produce large 
differences in the amount of uncertainty surrounding these. 
Table 5.8 Summary of model parameter uncertainty for non-transplant 
survival over five years and the survival gain after liver 
transplantation for 81 PSC CELT patients from three prognostic 
models (PSC Mayo, Royal Free and European) 
Non-transplant survival Survival gain 
(95% CI) (95% CI) 
PSC Mayo Model 2.47 1.93 
(0.27 to 4.81) (-0.38 to 4.13) 
Royal Free Model 2.43 1.97 
(0.98 to 3.99) (0.41 to 3.42) 
European Model 2.45 1.95 
(2.21 to 2.74) (1 .66 to 2. 19) 
The variation in the degree of model uncertainty for the three prognostiC models is 
surprising and could have arisen for many reasons including: the number of patients on 
which each prognostiC model was derived, the amount of uncertainty explained by 
each model, the number and nature of the prognostiC factors selected for each model, 
or the type of model fitted. Each of these possible reasons is explored in more detail 
below. 
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5.7.1 Number of Patients on which each Prognostic Model was Derived 
When prognostic models are derived on larger patient cohorts, less uncertainty is likely 
to arise in the model estimates, in comparison with models derived from smaller 
cohorts. More precisely, if a large number of patients die during follow-up, the 
coefficients of the prognostic model are more accurately estimated (that is, their 
standard errors are smaller) than if the model had been evaluated on a smaller cohort, 
or in a cohort where few deaths had occurred. 
A published prognostic model derived from a small sample would result in outcomes 
being estimated with less precision and this would be reflected by the standard errors 
of the model regression coefficients. A published prognostic model applied to an 
alternative cohort would use the simulation techniques described in this chapter to 
account for prognostic model uncertainty. 
The sample sizes for the three PSC prognostic models and the proportion of deaths 
per cohort were similar (European model: 248 patients - 49% died, Royal Free model: 
289 patients - 40% died, Mayo model: 312 patients - 44% died). Given that the 
confidence limits for model uncertainty were largest for the PSC Mayo model and 
smallest for the European model, the results do not conform to this hypothesis, 
meaning that sample size is not the reason for the variation in model uncertainty. 
It is possible that other characteristics of the patient cohort affected the accuracy. For 
instance, if the patient population is a relatively homogeneous sub-sample of PSC 
patients, the estimated coefficients may be more precisely estimated than had they 
been estimated on the full (Le. more heterogeneous) PSC population. Whether such 
estimates can be validly generalised to the general population of patients with PSC is 
unclear, but this consideration is independent of the calculated standard errors. 
5.7.2 The Amount of Uncertainty Explained by each Prognostic Model 
The standard errors of the coefficients included in the Mayo model - where uncertainty 
is greatest, may be comparatively larger than the standard errors for the other two 
models. To explore the variability in uncertainty levels between models, the ratio of the 
regression coefficient to the standard error (Regression coefficienUStandard error) was 
calculated for each variable in the PSC Mayo, Royal Free and European models. The 
ratios, which are equivalent to the z-statistic, are presented in Table 5.9, the larger the 
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ratio, the smaller the amount of uncertainty for a specific variable, and the greater the 
association between the variable and survival. 
Table 5.9 
Age 
Bilirubin 
Albumin 
Ascities 
Gender 
Prothrombin 
Oedema: 0.5 
Oedema: 1 
Ratio of regression coefficients to standard errors (regression 
coefficient/standard error) for prognostic model variables: PBe 
Mayo, Royal Free and European models 
PBe Mayo Royal Free European 
2.96 5.00 3.64 
7.65 7.92 9.73 
4.31 5.26 4.47 
0.86 3.61 6.62 
2.59 
1.67 
1.93 
2.06 
Gastrointestinal bleeding 3.10 
Generally, the ratios of regression coefficient to standard errors were much higher for 
the variables included in the European Model and Royal Free models than for the PBC 
Mayo model; ratios were less than 3.5 for six of the variables in the Mayo model, 
whereas no ratios were less than 3.5 for the other two models. Additionally, the ratios 
were much lower for the PBC Mayo models than that for the Royal Free and European 
models, for each of the four variables that were common to all four models (bilirubin, 
albumin, age and ascities). Bilirubin levels were the most significant predictors of 
survival across all three models and had a higher level of significance for the European 
model in comparison with the PSC Mayo model and Royal Free model. 
The results presented in Table 5.9 support the evidence presented in Figures 5.7 and 
5.11 that there is more parameter uncertainty in the PBC Mayo model than the 
European model and Royal Free model. However, based upon the results presented in 
the table, it is not possible to conclude that survival estimates from the European model 
will show less uncertainty than estimates from the Royal Free model, where uncertainty 
is least for bilirubin and ascities in the European model and for age and albumin in the 
Royal Free model. 
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5.7.3 The Number and Nature of the Prognostic Factors 
A total of seven variables were fitted in the PBC Mayo model and variables were 
included regardless of level of statistical significance. In contrast, the European and 
Royal Free models only included variables that were statistically significant. This is an 
important consideration, since the standard error of the predicted risk score is directly 
related to the square root of the sum of the squared standard errors for each 
coefficient1o. Adding more factors may increase or decrease this model uncertainty, 
dependent on how predictive the prognostic factor is. However, non-significant 
predictive factors would be expected to have larger standard errors (and hence greater 
variation) than significant factors, and including only significant terms can lead to 
narrow (and quite probably, artificially narrow) CI. 
The PSC Mayo model was refitted in order to compare uncertainty across models 
when only significant variables were included, using the 5% significance level as a cut 
off for significant variables. Figure 5.12 shows the non-transplant survival curve for the 
refitted Mayo model if non-significant variables (ascities and prothrombin time) are 
excluded from the model. The 95% CI is smaller than that when prothrombin time and 
ascities are included in the model (95% CI: 0.16 to 2.78 years excluding prothrombin 
time and ascities compared with -0.36 to 4.13 years when these variables were 
included), and now suggests that transplantation is a beneficial treatment of choice for 
patients with end-stage PBC. The mean transplant survival gain over five years is 
slightly shorter (1.47 years) than when prothrombin time and ascities are included in 
the model (1.93 years). Further model details are presented in Appendix A5.1. 
10 The relationship is: Standard Error(predicted risk score) = ..J sum of squared model regression coefficient 
standard error + 2*sum of all model regression coefficient covariances. Since the latter term is not 
available or not included here the Standard Error (predicted risk score) =..J sum of squared model 
regression coefficient standard error. 
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Figure 5.12 Mean non-transplant (shadow) survival (solid line) with 95% CI 
(blue shaded areas) estimated from the PBC Mayo model 
(excluding ascities and prothrombin time) using Monte Carlo 
simulations for 81 PBC CELT patients - using the standard errors 
(se) of the regression coefficients to account for model parameter 
uncertainty 
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Given that the number of variables was higher in the Mayo model than both the 
European and Royal Free models, a third version of the PBC Mayo model was fitted 
where the variables included in the model were limited to the four variables common to 
all three PSC prognostic models: bilirubin, age, albumin and ascities. Variables were 
included in the model regardless of level of significance, though only ascities was non-
significant at the 50/0 level (p = 0.064, Appendix A5.1). Figure 5.13 shows that, in 
comparison with the original Mayo model, model uncertainty has decreased, the 
survival gain after transplantation is now 1.39 years (95% CI: 0.18 to 2.95 years) - the 
gain is slightly less than when including prothrombin time, gender and oedema (1.93 
years [95% CI: -0.36 to 4.13 years]). 
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Figure 5.13 Mean non-transplant (shadow) survival (solid line) with 95% CI 
(blue shaded areas) estimated from the PBC Mayo model 
(including bilirubin, albumin, age and ascities) using Monte Carlo 
simulations for 81 PBC CELT patients - using the standard errors 
(se) of the regression coefficients to account for model parameter 
uncertainty 
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The results from the two alternative PBC Mayo prognostic models demonstrate how 
the number of variables included in the model, and the way that variables are selected, 
can influence the level of model parameter uncertainty. Researchers should be aware 
that if variables are included in a model, regardless of level of significance, it is likely to 
increase the level of model uncertainty. However, just because a variable is not 
statistically significant does not mean that it is not clinically meaningful, and several 
studies have shown that there is a relationship between the variables included in the 
PBC Mayo model (bilirubin, albumin, prothrombin time, age, gender, oedema scores 
and ascities) and liver disease severity/survival [See: Hughes et ai, 1992; Kamath et 
ai, 2001]. It is therefore defendable to include non-significant variables in our PBC 
Mayo prognostiC model, as although they are insignificant here, they have been shown 
to be statistically Significant in other studies. 
5.7.4 The Type of Model Fitted 
Both the Royal Free and European models make use of repeated measures of patient 
and clinical characteristics over time and these models allow for these changes over 
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the study period. Hughes et aI, fit a person interval model in which a series of intervals 
are defined [Hughes et aI, 1992]. The first interval begins at the point where a patient 
visits the Royal Free hospital for treatment for end stage liver disease and ends two 
years after that time point or at time of death if sooner. The second interval begins at 
the hospital visit that follows the end of the first interval and ends two years after that 
time point or at point of death if sooner. This process continues for the duration of the 
study, and each patient's follow up is defined by the number of intervals for which there 
are available data. By contrast, the authors of the European model use a time 
dependent Cox PH model in which the first interval starts at first study visit and ends 
immediately prior to the second study visit, at which time the next interval begins and 
so on. Unlike the Royal Free model, no follow-up information is lost as interval lengths 
are not fixed. The authors of the Royal Free model state that 81 % of total follow-up 
information and 93% of deaths are captured in their model, with the remainder 
occurring outside of the defined two-year intervals. This is likely to be a contributing 
factor to the increased model uncertainty in the Royal Free model in comparison with 
the European model. 
In contrast, the PBC Mayo prognostic model includes data only on the final study visit. 
This type of model was chosen because the ultimate aim of the CELT study was to 
compare transplant survival with non-transplant survival and clinical information was 
only collected at one pre-transplant time point in the CELT study. 
5.7.5 Summary of Possible Contributors to Uncertainty Levels 
In summary, sample size and the number of deaths per study do not appear to be 
contributing factors that influence the levels of model parameter uncertainty across the 
three PBC prognostic models. However, the level of uncertainty of individual model 
variables and the number of variables included in the model contribute to the increased 
uncertainty levels for the PBC Mayo model over the Royal Free and European models. 
Additionally, the person specific interval model fitted to the Royal Free cohort appears 
to be a contributing factor to the additional uncertainty in this model over the European 
model. 
5.8 PROGNOSTIC MODEL CRITERIA - CHOOSING A PROGNOSTIC MODEL 
In the CELT study a series of prognostic models existed that could be used to estimate 
non-transplant survival: AlD (2 models), PBC (3 models), PSC (2 models). In Chapter 
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2, six selection criteria were outlined (Box 5.2) and these criteria were applied in the 
selection of prognostic models in the main CELT analysis. 
Box 5.2 Selection Criteria applied in the main CELT study when selecting a 
disease specific prognostic model to estimate non-transplant 
survival 
These criteria state that models should: 
• be validated on both internal and external data sets (Criterion 1) 
• be based on adequate samples of patients (Criterion 2) 
• for each variable fitted in the model the number of events, in this case deaths, 
should be in the ratio of one explanatory variable for every 10 or more deaths 
(Criterion 3) 
• the variables included in the model should make sense clinically (Criterion 4) 
• the model should be applied to appropriate cohorts (Criterion 5) 
• the cohort should include UK patients (Criterion 6) 
Criteria 1 to 5 were originally suggested by Altman and Royston [Altman & Royston, 
2000] and formed the basis of the model selection process. The most appropriate 
prognostic models were then selected in the main CELT analysis across a series of 
steps. In the first step, any model failing three of the first five criteria was defined as 
being statistically invalid, and was then discarded. The second step, for those models 
that appeared to be statistically valid, was to incorporate models where the historical 
cohort included UK patients (Criterion 6). Longworth and colleagues applied Criterion 
1 to 6 in their CELT analysis. This resulted in the selection of the Beclere model for 
AlD patients, an average of the European and the Royal Free models for PBC patients 
and the International model for PSC patients [Longworth et aI, 2003]. 
Based on the work on prognostic model parameter uncertainty, detailed in this chapter, 
it does not seem unreasonable to propose a seventh selection criterion, where the 
lower the level of uncertainty the better the model at predicting survival. Thus, in 
addition to Criteria 1 to 6, it could be proposed to add Criterion 7, which states that a 
model should: 
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• display the least amount of parameter uncertainty (in comparison with other 
appropriate models) (Criterion 7) 
Table 5.10 sets out the seven selection criteria for the three PSC prognostic models. 
The first six Criteria are either met ("Yes") or are not met ("No"), whereas Criterion 7 
ranks the models by their amount of parameter uncertainty ("1" being the least amount 
of uncertainty, "3" the most uncertainty). Clearly, the ideal model would meet the first 
six Criteria and contain the least amount of uncertainty. None of the PSC prognostic 
models displayed clear statistical superiority over the other models (Criteria 1 to 5), 
although the Royal Free model was not validated on an external data set. The PSC 
Mayo model was not based on UK patients and is thus eliminated from the model 
selection process. 
Table 5.10 Seven prognostic model selection criteria applied to the European, 
Royal Free and PBC Mayo prognostic models 
European Model Royal Free Model PBC Mayo Model 
Criterion 1 Yes No Yes 
Criterion 2 Yes Yes Yes 
Criterion 3 Yes Yes Yes 
Criterion 4 Yes Yes Yes 
Criterion 5 Yes Yes Yes 
Criterion 6 Yes Yes No 
Criterion 7* 1 2 3 
* See Figure 5.7 and 5.11 
For the remaining two prognostic models it can be seen clearly from Figure 5.11 that 
the European model displays the least amount of model parameter uncertainty 
(Criterion 7) and would therefore be selected as the most appropriate model for 
predicting non-transplant survival. However, just because a model, such as the PSC 
Mayo prognostic model displays a large amount of uncertainty, does not necessarily 
mean that it is a bad model. This chapter has already discussed possible causes of 
increased parameter uncertainty. In the case of the inclusion of non-significant 
variables in prognostic models (increasing uncertainty), this chapter argued for their 
inclusion in prognostic models - a statistically insignificant variable may be clinically 
meaningful. Although it may be intuitive to select a model with the least amount of 
uncertainty, explanations may exist that explain that additional uncertainty. A 
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prognostic model should not be excluded from the selection process if the additional 
parameter uncertainty could be attributed to the inclusion of clinically meaningful 
variables that are not necessarily statistically significant. A model displaying a large 
amount of parameter uncertainty will not necessarily give inaccurate survival estimates; 
all three PSC models give similar estimates of non-transplant survival (Table 5.8). 
5.9 DISCUSSION 
5.9.1 Historical Cohorts or Prognostic Models - Which are Preferable when 
Person Specific Historical Data are Available? 
In the main CELT analysis no patient specific non-transplant data were available, for 
comparison with data from a transplant cohort; therefore, disease specific published 
prognostic models were applied to estimate survival in the absence of transplantation. 
The patient specific historical data from the Mayo cohort became available at a later 
date. 
But what if historical data had been available to use in the CELT study? If this was the 
case, the authors of the main CELT analysis would probably have used the approach 
described in Section 5.3 to estimate non-transplant survival and the survival gain from 
transplantation. Cox PH regression models would have been used to adjust for 
differences between cohorts. This is a more conventional approach to use. Yet, why 
not fit a prognostic model to the historical data, and use the methods described in 
Sections 5.5 and 5.6 to adjust for model uncertainties? Again I suspect convention 
would be the reason that the technique of adjusting for model parameter uncertainty 
might not be used. However the Kaplan-Meier survival results presented in Section 
5.3.4 assume that the estimated regression coefficients are accurate and thus fail to 
account for any uncertainty around these estimates (The 95% CI in Figure 5.4 depict 
cohort uncertainty alone). Information is available on the regression coefficients and 
their standard errors for the Cox PH model applied in Section 5.3, and model 
uncertainty still exists, and so it should be allowed for, this would increase the 
uncertainty around mean estimates 11. 
11 Allowing for parameter uncertainty in the Cox PH model applied to the Mayo cohort (Section 5.3) 
increase CI from 2.4 to 2.9 years to 0.6 to 4.8 years, in the same way as allowing for parameter 
uncertainty increased CI when the PSC Mayo model is applied to the CELT cohort (CI increased from 2.2 
to 2.8 years to 0.3 to 4.8 years (Table 5.6). 
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5.9.2 Problems with Historical Data 
Uncertainties in model predictions arise in part due to the variability of patient 
characteristics between the prognostic model cohort and the cohort the prognostic 
model is fitted to. This chapter has described an approach for adjusting for this 
uncertainty. However, there are other considerations that need to be acknowledged 
when applying a historical model to a concurrent data set that will affect the accuracy of 
the prognostic model predictions. Firstly, there will be changes in clinical practice over 
time, which may improve patient prognosis in the absence of transplantation. Secondly, 
there may be advances in medicine over time, which may again improve patient 
prognosis or prolong the occurrence of end-stage liver disease. Thirdly, there is 
uncertainty in the model estimates due to differences in practice between countries; 
patients with PSC in the UK may be treated differently to those in the US. The first two 
aspects would result in an underestimation of survival in the absence of 
transplantation, whereas the third could result in either an under or overestimation of 
survival in the absence of transplantation. 
It is impossible to measure how these sources of uncertainty could effect model 
predictions. However, it is important to acknowledge their existence as they add to the 
degree of uncertainty in the model predictions. 
5.9.3 Model Parameter Uncertainty 
In the liver transplant example used here, there was no evidence of a statistically 
significant survival gain from transplantation after adjusting for the standard errors and 
correlation coefficients of the regression coefficients for the PBC Mayo model. Had the 
standard errors, in this example, been smaller then the uncertainty surrounding the 
estimates of survival in the absence of transplantation would have been smaller, and it 
is possible that there would have been some evidence of a survival benefit. 
In Section 5.6, Monte Carlo simulations incorporated parameter uncertainty using 
information on the standard errors and the correlation between regression coefficients. 
Overall, there was little correlation between variables, although some variables were 
highly correlated, for example age and sex (Table 5.5). Had the correlation between 
variables been larger, the change in the amount of uncertainty after allowing for the 
correlations would have been more noticeable. In contrast, if the regression variables 
had been independent of each other, i.e. the correlation between coefficients was zero; 
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the uncertainty surrounding the survival estimates would be the same as when the 
standard errors alone are adjusted for. 
5.9.4 Variation in the Amount of Model Parameter Uncertainty 
Often, adding non-significant factors in to the model will increase the model 
uncertainty, since in general, a greater uncertainty occurs around non-significant 
variables than significant ones. The inclusion of clinically meaningful variables could be 
more justifiable if the variables included had been shown to be important in other 
studies within that country. Thus, for the US Mayo model the inclusion of clinically 
significant variables within the US setting could be justified. However, if several studies 
from several other countries had found a particular covariate to be clinically meaningful 
but there was no evidence from the US, in the case of the Mayo model, there could be 
argument for inclusion of the clinically meaningful variable. However, the inclusion of 
clinically meaningful variables in prognostiC models should be considered carefully and 
involve discussions with clinical experts before making decision on whether to include 
or exclude a variable. 
There are no clear recommendations as to what the best approach is for the inclusion 
of variables in mathematical models, although it is generally recognised that statistical 
significance should not be the sole basis of this [Collett, 1994; Altman & Royston, 2000; 
Bradburn et aI, 2003]. Therefore, variables were included in the PBC Mayo model that 
shared a commonality between both the Mayo and CELT cohorts and were included in 
the model regardless of the significance level. 
5.9.5 Further Model Parameter Uncertainty 
A further area of uncertainty that is specific to the Cox PH model has not been 
accounted for here, namely the uncertainty in the baseline survival estimator. For any 
time dependent Cox PH regression model the baseline survival is assumed fixed and 
therefore constant over the period of the model [Collett, 1994]. Therefore authors of 
published prognostiC models provide no information on the uncertainty in baseline 
survival estimates. In fact baseline survival estimates are correlated with the regression 
coefficients and when modelling uncertainty in these estimates it is assumed that a 
change in the coefficients would alter the baseline survival estimates. Further 
exploration of model parameter uncertainty that accounts for uncertainties in the 
baseline survival coefficients could be the basis of future work. 
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5.9.6 Generalisability 
In this chapter a Cox PH model was used to illustrate methods to adjust for model 
parameter uncertainty using Monte Carlo techniques. These techniques can easily be 
adapted to other model forms, from the basic linear regression model to the Weibull 
model, using the same process described above and detailed in Appendix AS.2. 
The simulation techniques presented in this chapter to adjust for parameter uncertainty 
are relatively simple and easy to apply. In fact, the command to generate the 
simulations in the statistical computer package S-PlUS meant that no additional 
computer programming was required for this analysis [S-PlUS 6, 2001]. As 
demonstrated in this chapter, a simple pre-existing function for the S-PlUS computer 
package (rmvnorm) was used to generate 3,000 sets of regression model coefficients 
that were then applied to the CELT cohort in order to estimate non-transplant survival. 
Using this one function, it was possible to incorporate uncertainty from the standard 
errors and correlation between regression coefficients. Alternative computer packages 
could also have been used for this analysis, for example EXCEL/Crystal Ball software, 
or the Bayesian software package BUGS [Decisioneering, Inc, 1994; Spiegelhalter et 
aI, 1999]. 
What is required by authors of future prognostic models is an additional table providing 
the reader with the correlation coefficients of the regression coefficients. Providing the 
reader with this additional information would give potential users the opportunity to 
obtain more realistic estimates of uncertainty and journal editors ought to ensure that 
this is done. The limits imposed by journals on overall reporting space, tables and 
figures will inevitably prove an obstacle to providing potential users with this 
information, but since many journals now have internet sites, the additional information 
could be obtained via these sites. 
It is accepted that the likely reason for variation in the levels of uncertainty across three 
prognostiC models used in this chapter, i.e. number of covariates and type of model 
fitted, could be specific to this example. Potential variation in other prognostiC models 
might be explained by variations in sample size or the proportion of events per model. 
Therefore, reasons for the variation in uncertainty between models should be explored 
on a case by case basis. 
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It is important that the prognostic model is representative of the cohort it is being 
applied to; if it is not representative then it will not estimate the desired outcome. An 
extreme example of this would be fitting a published prognostic model for estimating 
survival derived from a cohort of heart transplant patients to predict survival in a cohort 
of liver transplant patients. Therefore, it is much more important to apply a realistic 
prognostic model with a large amount of uncertainty than a less realistic model with a 
small amount of uncertainty. 
5.10 CONCLUSIONS 
In this chapter a Monte Carlo simulation technique has been presented and this 
technique may be used to incorporate model parameter uncertainty in to outcome 
estimates, for example survival estimates. It is recommended that future studies of 
health care technologies should incorporate model parameter uncertainty in to 
estimates when using prognostic modelling techniques to estimate outcomes. 
Based upon the results from one model, it is unclear whether additional information on 
the correlations between regression coefficients will have any significant impact on 
model parameter uncertainty and it is recommended that future work is carried out to 
establish this. Guidelines set by the National Institute for Health and Clinical Excellence 
(NICE) state that decision makers should "know about the uncertainty associated with 
clinical and cost-effectiveness information" [NICE, 2004]. Therefore, it is recommended 
that the additional uncertainty from the correlation between regression coefficients 
should be incorporated in to model parameter uncertainty, in order to provided further 
knowledge about uncertainty. 
A large amount of model parameter uncertainty was demonstrated around the PSC 
Mayo prognostic model and the survival gain from transplantation over a five-year 
period was shown to be statistically non-significant. However, a survival gain from 
transplantation was evident if model uncertainty was excluded from the estimates of 
the survival gain post transplantation, or when alternative PBC prognostic models were 
applied to the CELT data. 
Estimates of non-transplant survival and the survival gain up to five years after 
transplantation were compared across three PSC prognostic models, after allowing for 
model parameter uncertainty. All three models gave a similar average non-transplant 
survival estimate; however, the model uncertainty around these estimates differed 
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across models, was greatest for the PSC Mayo model and smallest for the European 
model. 
Chapter 5 also considered whether levels of uncertainty around prognostic models 
could be used to influence the choice of prognostic model, when more than one model 
exists. If all other model choice considerations are equal, models with a smaller amount 
of uncertainty are preferable to models with a large amount of uncertainty. However, it 
is recommended that when using levels of uncertainty to choose between prognostic 
models consideration should be given as to why one model may display more 
uncertainty to another model. If obvious explanations exist, for example a model 
including non-statistically significant variables, though clinically meaningful ones, is 
likely to display more uncertainty than one that includes only statistically significant 
variables; this model should not necessarily be excluded from the model selection 
process. It is important that decision makers are presented with information on the 
survival gain that incorporates the uncertainty around prognostic model parameter 
estimates in order to make an informed decision about new or existing treatments or 
technologies, for example liver transplantation. 
This chapter has begun to apply Monte Carlo simulation methods to estimate some of 
the uncertainty around prognostic model estimates. Chapter 6 moves on to describe 
methods for estimating a further area of prognostic model uncertainty when estimating 
individual patient outcomes from a prognostic model. 
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ESTIMATING INDIVIDUAL PATIENT OUTCOMES FROM 
PROGNOSTIC MODELS AND 
SURROUNDING THE OUTCOMES 
6.1 INTRODUCTION 
THE UNCERTAINTY 
In the absence of observed data on non-transplant survival, it is proposed that the 
prognostic models applied in the main CELT study [Longworth et ai, 2003] are used to 
estimate non-transplant survival over the extended CELT study period of five years. All 
the published prognostic models applied to the CELT cohort are Cox PH models and 
are specific to one of three liver disease groups: AlD, PSC or PSC. The prognostic 
models are used to obtain patient specific estimates of non-transplant survival, QAl Ys 
and costs and subsequently patient level estimates of the survival, QAl Y and cost gain 
from transplantation. Non-transplant QAl Y and cost estimates clearly depend on a 
patient's expected survival time. 
A particular feature of the GEL T non-transplant cost estimates is that each patient's 
study cost will depend not only on the time for which the patient is predicted to survive, 
but whether or not the patient was predicted to survive for the complete five-year study 
period. Empirical evidence suggests that patients who die require additional resources 
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(and thereby incur additional cost) toward the end of their lives. Consequently, an 
adjustment was made to the non-transplant costs for patients who were predicted to 
die during the study period. In the main CELT study the costs in the month prior to 
death were estimated at patient level using a linear regression model, based upon 
patient age and liver disease group. However, if these costs are to be applied, then it is 
necessary to know which patients are going to die during the study period. 
Altman and Royston state that "our ability to provide informative prognosis at the 
individual level ... is almost always limited" [Altman & Royston, 2000]. For the majority 
of studies it is not necessary to estimate individual patient outcomes, because 
outcomes are observed for all individuals participating in the study. However, in some 
situations, for example, the prognosis of cancer patients or patients with end-stage 
organ failure, the estimated outcome can influence the choice of treatment or help 
families and patients come to terms with their illnesses and it becomes necessary to 
predict individual patient outcomes [Henderson et ai, 2001]. Additionally, individual 
estimates of patient outcomes may aid in allocating "the effective use of limited health 
care resources" [Henderson et ai, 2001]. Moreover, the estimation of individual patient 
outcomes only arises when survival is estimated over a fixed time period, such as a 
five-year period. If the study objective is to estimate lifetime costs, effects, or costs and 
effects, it would not be necessary to estimate outcomes at an individual level, as all 
patients will die. 
To summarise, the analytical need to predict individual patient outcomes can be 
generalised to studies where the following conditions apply: 
• observed information on patient outcomes are unavailable and prognostic 
models are utilised to estimate patient outcomes and 
• outcomes are to be estimated over a fixed study period and 
• individual outcome estimates are needed, for example to: 
- estimate the survival, QAl Y or costs at the patient level 
- estimate the survival, QAl Y or cost gain at the patient level 
make an adjustment to costs, or HRQl data for a time period prior to 
death 
If it were possible to predict the lifetime survival of patients from published prognostic 
models, then it would also be possible to state, at any particular time point, which 
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patients were alive and which were dead. However, for some diseases or treatments 
(including liver transplantation) the authors of prognostic models tend to provide 
information to estimate survival over a fixed time period. For example, the original 
versions of the European and PSC Mayo prognostic models for predicting survival in 
patients with PBC publish information for estimating survival to eight years and seven 
years, respectively [Christensen et aI, 1985; Dickson et aI, 1985]. 
One reason that authors of published prognostic models do not always give enough 
information to predict the time of later deaths is because survival predictions at later 
time points have more uncertainty around them than at earlier time points. This is a 
well-known limitation of the Cox PH regression model and arises through the manner in 
which the estimation is formulated. The regression equation bases the survival 
estimate at any time on the estimated hazard, which is the probability of death among 
patients who remain alive and under observation. Since few patients remain under 
observation at the later time points (the majority having previously died or having been 
censored), the estimate of the hazard (and consequently survival) at later times is 
imprecise. In these situations, methods are needed to predict individual patient 
outcomes. 
Suppose that we are conducting a study where we need to use prognostic models to 
estimate individual patient outcomes, and we have chosen a prognostic model, which 
we then apply to a cohort of patients to estimate their survival over a fixed time period. 
For example, in the CELT study we might choose to apply the PBC Mayo prognostic 
model (Chapter 5, Table 5.2 & 5.3) to a cohort of patients with end-stage PSC to 
estimate their survival in the absence of transplantation over a five-year period. 
Assuming that the model we are applying is a Cox PH model, it is possible to obtain 
individual estimates of the probability of surviving over a series of time points, where 
the probability of surviving to anyone time point will range between zero and one. 
These probabilities can then be plotted over time and an individual's mean survival 
time can be calculated from the area under their resultant survival curve (Chapter 5, 
Section 5.4). The predicted survival over the duration of the five-year study period, for 
the PBC CELT patients, ranged from 0.13 years to 4.93 years, depending on the 
individual's prognosis. Given that each of the patients has a predicted mean survival 
time of less than five years; one might (naively) assume that all patients die during the 
study period. If this were true, a death cost would then need to be added to all patients 
if the study was also estimating costs. 
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However, the nature of the Cox PH prognostic model is such that survival estimates will 
always range from slightly greater than zero to slightly less than the final study time 
point, e.g. slightly less than five years. Thus, no single patient can have a predicted 
survival time greater than the last time point of interest (e.g . five years) when applying 
a Cox PH prognostic model to a cohort of patients over a fixed time period. In addition 
to survival estimates over the fixed time period, information is available on the 
probability of survival at the last time point of interest (e.g. five years) and it is possible 
to estimate the proportion of patients who survive to the end of the study by taking the 
average survival probability for the cohort at the final time point. The average survival 
probability, when applying the PSC Mayo model to the PSC CELT cohort over a five-
year period is 0.315, thus 31.5% of PSC CELT patients are expected to survive for at 
least five years. 
It is therefore clear that the predicted survival (calculated from the area under the 
survival curve) over a fixed time period does not itself tell us whether the patient would 
survive the study period or not. Therefore, survival probabilities at the fixed time point 
of interest can be used to estimate patient outcomes, rather than assuming the death 
of all patients within a fixed study period . 
Suppose that a patient has an expected survival length of 4.93 years and a 0.98 
probability of survival at five years. Given this information, we might revise our belief 
that this patient died at 4.93 years, and instead assume that they survived the full five-
year study period. It is reasonable to prefer this logic over the above argument, as the 
patient had only a two per cent chance of death at five years. We might next consider 
another patient who had a survival probability of 0.85 at five years (15% probability of 
death at five years) and an estimated survival length of 4.58 years and decide that this 
patient probably survived to five years, and alter their estimated survival accordingly. 
This process can be repeated for the whole cohort of patients and will result in the 
selection of a proportion of patients who, based on their survival probabilities at five 
years, would probably have survived the full study period. Altering these patients' 
survival lengths would increase the mean survival time for the cohort. Any additional 
outcome estimates that were dependent upon survival , for example QAl Ys and costs 
would also change for those patients assumed to survive the full study period . 
At some point it will become necessary to decide what the cut off survival probability is, 
when using the approach described above. In other words, at what probability X do we 
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say, patients with a probability less than X will die, and those with a probability greater 
than X will live? The choice of this probability will typically be based on empirical 
evidence. 
This chapter focuses on introducing a series of methods for estimating patient 
outcomes, and the uncertainty around the patient outcome estimates, after using 
prognostic models to estimate survival. At the fixed time point of interest we wish to 
know, not only the proportion of patients surviving, but which patients survive. In the 
particular instance of the CELT study, this information is needed in order to assign 
individual patient costs to patients who die in the month prior to death and to estimate 
the patient specific survival, QAl Y and cost gains from liver transplantation over a five-
year period. 
This chapter is divided in to a further five sections. Section 6.2 presents an overview of 
methods for estimating individual patient outcomes, identified in the transplant literature 
review, previously presented in Chapter 3. Section 6.3 introduces the PSC CELT 
cohort used throughout this chapter to estimate individual patient outcomes in the 
absence of transplantation. Methods for estimating patient outcomes and the 
uncertainty surrounding the outcome estimates are discussed in Section 6.4, where a 
preferred method is recommended. In the CELT study patient outcome estimates 
impacted on non-transplant QAl Y and cost estimates, therefore, Section 6.5 
investigates how the prediction of individual patient outcomes, and outcome 
uncertainty, effects non-transplant QAl Y and cost estimates. The final section of this 
chapter (Section 6.6) will discuss the implications of the methods introduced here and 
consider their implementation outside the field of transplantation. 
6.2 A BRIEF OVERVIEW OF THE ESTIMATION OF INDIVIDUAL PATIENT 
OUTCOMES IN SOLID-ORGAN TRANSPLANTATION STUDIES 
In this section, we return to the results of the solid organ transplant literature review of 
cost, effectiveness and cost-effectiveness studies, first presented in Chapter 3. The 
review considered how issues of uncertainty were dealt with in non-RCT studies and 
identified further issues of statistical uncertainty, one of which was estimating individual 
patient outcomes in the absence of observed data. Four of the 158 studies included in 
the review used Cox PH prognostic models to estimate survival in the absence of 
observed data [Bonsel et aI, 1990; Christensen et aI, 1999; longworth, et aI, 2003; 
Longworth et aI, 2003a]. Of these studies, two compared survival, with and in the 
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absence of transplantation, at patient level [Christensen et aI, 1999; Longworth et aI, 
2003]. Additionally, three of the 158 studies (one of which also used prognostic 
models) included in the review made an adjustment to costs for a time period prior to 
death [Van Enckevort et aI, 1997; Anyanwu et aI, 2002; Longworth et aI, 2003]. 
However, Van Enckevort et a/ and Anyanwu et a/ estimated the lifetime costs of lung 
transplantation, where all patients will eventually die [Van Enckevort et aI, 1997; 
Anyanwu et aI, 2002]. 
The third of the three papers that adjusted for costs in the final period of life was the 
main CELT study, which estimated the cost-effectiveness of liver transplantation over a 
2.25 year study period [Longworth et aI, 2003]. The CELT study also estimated the 
survival, QAl Y and cost gain of liver transplantation on a per patient basis. In the main 
CELT study, non-transplant costs were assumed to be constant over time with an 
adjustment made for costs in the month prior to death for patients assumed to die 
within the 2.25 year study period1. The published CELT paper fails to present details of 
how individual patients were estimated to survive or die within the 2.25 year study 
period [Longworth et aI, 2003]. However, from personal involvement in the CELT study, 
I can state that the cut off length for survivors were selected by examining the expected 
survival times for each prognostic model and assuming that patients surviving for two 
years or more survived the full 2.25 year study period. For some of the prognostic 
models in the CELT study no patients' expected non-transplant survival time was 
greater than two years, in these situations the cut-off time was decreased in 0.25 year 
increments until at least one patient survived until the end of the study. For example, in 
the main AlD CELT analysis the survivors were selected according to whether their 
predicted survival, estimated by applying the Beclere prognostic model to the AlD 
CELT patients, was greater than 1.75 years or not. Yet the AlD model used in the 
sensitivity analysis selected survivors with an expected survival time greater than two 
years. The selection process was not based on information available from the 
prognostic model, nor from any other source of data. Given that this method is 
essentially arbitrary it will not be considered further in this chapter. 
Christensen and colleagues also used Cox PH prognostic models to estimate survival, 
with and in the absence of liver transplantation and computed the patient level survival 
gain from transplantation over a six-month period [Christensen et aI, 1999]. Two 
1 The choice of a one month adjustment period was based on an examination of costs on the waiting list 
for liver transplantation observed in the main eEL T study (see Appendix A2.2). 
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prognostic models were applied to a series of patients; the first estimated their survival 
over six months without transplantation and the second estimated their survival with 
transplantation. The authors did not estimate patient level outcomes at six months. 
Although they do not estimate individual patient outcomes, O'Brien et al use 
extrapolation techniques to estimate cohort survival over a 20-year period, both with 
and in the absence of heart transplantation [O'Brien et aI, 1987]. The authors used 
three different extrapolation models; linear extrapolation, Weibull survival model and 
the exponential survival model, to extrapolate transplant survival beyond a five-year 
observed period. However, this is extrapolating survival at the cohort level and not the 
individual patient level. Additionally, it is not possible to apply a survival model 
approach, such as fitting a Weibull model, to the estimated survival from the Cox PH 
prognostic model without making some inference about the survival outcome of, at 
least a proportion of, patients. Fitting a survival model requires a proportion of patients 
to have the event of interest and this returns to the problem of how to allocate the 
proportion who survive and the proportion who die. 
It is concluded that none of the studies that were identified in the solid organ transplant 
literature review use adequate methods for estimating individual patient outcomes. 
Therefore, after presenting details of the PSC CELT data set, this chapter will present 
three possible methods for estimating individual patient outcomes over a fixed study 
time period. Each of the three methods will utilise the limited information available from 
three PBC prognostic models for estimating non-transplant survival. 
6.3 ESTIMATES OF NON-TRANSPLANT SURVIVAL FOR THE PBC CELT 
COHORT 
As in the previous chapter, a sub-cohort of 81 CELT patients with end-stage PBC will 
be used to illustrate a series of three proposed techniques for estimating individual 
patient outcomes in the absence of liver transplantation. All three PBC prognostic 
models; European model, PBC Mayo model and Royal Free model, which were 
described in Chapter 5, will be applied to the 81 PSC patients to estimate their survival 
in the absence of transplantation over a five-year period. The three techniques for 
estimating individual patient outcomes will be set out in full for the PSC Mayo model 
and summarised for the European and Royal Free models. 
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After applying the three prognostic models, the mean non-transplant survival over the 
five-year study period, prior to estimating individual patient outcome was: 
• 2.47 years - PSG Mayo model 
• 2.45 years - European model 
• 2.50 years - Royal Free model 
Mean survival estimates are similar across the three models, differing by approximately 
three weeks between the European model and the Royal Free model. 
6.4 METHODS FOR PREDICTING INDIVIDUAL PATIENT OUTCOMES 
In this section, three methods for estimating individual patient outcomes are 
considered. The average non-transplant survival and the average number of survivors, 
together with their 95% GI, are presented for each method. 
All three methods utilise information on the probability of survival at the final study time 
point, in the GEL T study this is the expected non-transplant survival probability at five 
years. The first method described in this section uses information on the mean 
probability of survival for a cohort of patients at the final time point of a study. 
Subsequent techniques account for patient specific information available after applying 
a prognostic model to a cohort of patients. 
6.4.1 Predicting Individual Patient Outcomes: Probability of Survival Equivalent 
for all Patients, Random Selection of Survivors (Method 6.4.1) 
In the absence of any information on patient mortality, a reasonable starting point 
would be to assume that each patient has an equal chance of survival or death: 
(Probability or survival = Probability of death = 0.5) 
However, it is unlikely that the researcher has no expectations about the proportion of 
survivors in their cohort. Possible sources of information on the likely outcome of 
patients may come from expert opinions, published information, or alternative data 
sources. In this chapter, information from published prognostic models is utilised, in 
order to estimate survival and patient outcomes over a five-year period. Information on 
the mean probability of survival at five years, for the PSG GEL T cohort, after applying 
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the PSC Mayo prognostic model is used as a starting point. The mean probability of 
survival at five years is 0.315 for the 81 PSC CELT patients. 
The mean survival probability can be expressed statistically by assuming that the 
probability of survival follows a binomial distribution, where the probability of an 
individual patient surviving to five years is 0.315. Formally, this probability is written as 
PSi = 0.315, where i = 1 to 81 refers to the patient identifier. A random number 
generator is used to simulate the expected outcome for each individual patient in a 
cohort. This random number generator produces a number, either zero or one, for each 
patient. A survival prediction can be generated for each of the 81 cases in the PSC 
CELT cohort by assuming that the occurrence of a one denotes that the individual will 
survive the full study period without transplantation and a zero denotes a patient who 
will die within the five-year study period. 
The following computer syntax is used in S-PLUS [S-PLUS 6, 2001] to simulate this 
process: 
rbinom(81, 1, 0. 3 15) 
For one simulation run, a series of estimated events for each of the 81 PSC patients 
are obtained, as illustrated below: 
0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0, 1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0, 
0,0,0,0, 0,0,0,1,0, 0,1,1,0,0,1,0,1,0,1,1,1,0,0,0,0, 0, 0, 0,1,0,1,0,0,0,1, 
1,0,0,0,1,0,1,0,0,0,0 
The number and proportion of survivors in the cohort can then be calculated. For the 
simulation run presented above, the number of survivors equals 22, giving an 
estimated five-year survival of 27% (for this simulation run the percentage of survivors 
is lower than the "true" percentage of 31.5%). 
It is assumed that all estimated survivors survive the full study period and have a 
survival length of five years. The survival length for patients predicted to die is 
estimated by applying the PSC Mayo prognostic model to the PSC CELT cohort. The 
mean non-transplant survival length for the PSC CELT cohort can then be estimated 
from the area under the Kaplan-Meier survival curve. 
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Method 6.4.1 is illustrated in Appendix A6.1 for the PBC CELT cohort for one 
simulation run. Table A6.1 shows the expected survival lengths for the PBC CELT 
cohort, the predicted survival outcomes for one simulation run and the corresponding 
expected survival times. 
The 22 predicted survivors were assumed to have an expected survival length of five 
years and the 59 predicted deaths an estimated non-transplant survival length 
calculated using the PBC Mayo prognostic model. The Kaplan-Meier survival curve for 
81 patients is shown in Figure 6.1, using the results from one simulation run. The mean 
survival length, estimated from the area under the curve is 3.0 years. 
Figure 6.1 
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Kaplan-Meier survival curve for 81 CELT PBC patients where 
expected individual patient survival is predicted assuming the 
probability of survival is equivalent for all patients, random 
selection of survivors (p = 0.315)1 
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1 Results from one simulation run 
To generate uncertainty surrounding the estimates of the percentage of expected non-
transplant survivors, or the mean non-transplant survival length, more than one 
simulation is necessary. A total of 1,000 simulations were run in order to measure the 
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uncertainty around the predicted percentage of survivors in the cohort, and the mean 
survival time for the cohort. One thousand simulations were found to be sufficient to 
obtain convergence to the mean percentage of survivors and mean survival lengths. 
The proportion of patients surviving, and the mean survival times, were recorded for 
each of the 1,000 simulations. The 50th percentile of the 1,000 simulated outcomes 
represents the mean percentage of survivors, and the 50th percentile of the estimated 
survival times represents the mean survival length for the cohort across all simulations. 
The 2.5th and 97.5th percentiles represent the 95% CI. 
Method 6.4.1 measures two areas of uncertainty. Firstly, the patients who are assumed 
to survive to five years are varied between simulation runs. This allows many possible 
permutations of patients selected as survivors and patients selected as deaths. 
Secondly, the proportion of patients expected to survive will vary by simulation run, 
although across the 1,000 runs it will average out at approximately 31.5%. In fact, the 
mean proportion of survivors over the 1,000 simulation runs was 31 % (95% CI: 17% to 
34%). If a larger number of simulations had been run, say 10,000 simulations, the 
mean proportion would have converged further to the 31.5%, set by using a binomial 
distribution with p = 0.315. 
The mean survival time across 1,000 simulations is 3.08 years (95% CI: 2.74 to 3.39 
years). This is approximately nine months greater than the mean survival time from the 
PBC Mayo prognostic model prior to estimating patient outcomes (Mean = 2.47 years). 
This result is expected, because approximately 31 per cent of the simulated patients 
have their expected survival time extended to five years. 
However, the method described above ignores information related to individual 
patient's survival lengths. To illustrate what I mean by this, let us take five patients for 
whom information is available on expected survival times from a prognostic model 
(Table 6.1). Method 6.4.1 has been applied to these five patients to simulate their 
survival outcomes and their revised expected survival lengths, over a five-year study 
period. 
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Table 6.1 
Patient 
A 
B 
C 
D 
E 
Predicting Individual Patient Outcomes 
Results from one simulation run for predicting patient outcome for 
five hypothetical patients (Applying Method 6.4.1) 
Predicted survival time Simulated Revised survival 
(estimated from a patient outcome time after simulation 
prognostic model) 
0.13 years Died 0.13 years 
4.93 years Survived 5.00 years 
0.25 years Survived 5.00 years 
4.88 years Died 4.88 years 
2.50 years Died 2.50 years 
Patient A had a prognostic model survival time, prior to simulation of expected 
survivors, of 0.13 and for this simulation run was expected to die. This appears to be a 
reasonable estimate, based on patient A's prognostic model survival time. The 
outcome estimate of survival for patient B also appears to be a reasonable estimate, as 
their prognostic model survival estimate, prior to simulation, is 4.93 years. However, 
patient C has a pre-simulation survival estimate of 0.25 years yet is simulated as 
expecting to survive five years in the absence of transplantation and patient D a 
survival length of nearly five years is expected to die. Patient E survival estimate is 2.5 
years and is an expected death. 
This anomaly has arisen as a result of attempting to apply a group-level probability of 
0.315 to each of the individual patients. On average each patient will be predicted to 
survive in 315 of the simulations and be predicted to die in 685 simulations, when 
performing 1,000 simulations and assuming an overall cohort survival probability of 
0.315. However, from examining the expected survival times prior to simulation it 
appears unrealistic to assume that patients Band D will only survive in 31.5% of 
simulations; it is expected that they will survive in a higher proportion of simulation runs 
than patients A, C and E. Likewise, based on their expected survival lengths, it is 
expected that patients A and C die in more simulation runs than patients B, D and E. 
Method 6.4.1 will give an accurate estimate of the mean proportion of survivors 
because the five-year survival probability is based on available prior information 
relating to survival outcome. However, Method 6.4.1 will overestimate the mean 
survival length. To understand why, let us return to the five example patients detailed in 
Table 6.1. Prior to simulating patient outcomes, the mean survival time for these five 
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patients is 2.54 years. Suppose that in the first simulation run patient B is selected as 
the only survivor, meaning that their survival time over a five-year study period is now 
assumed to be five years. The mean survival for the cohort increases slightly to 2.55 
years. In a second simulation run patient A is predicted as the only survivor and their 
survival time is assumed to be five years, increasing the mean survival time for the 
cohort by approximately one-year, to 3.51 years. 
Thus for anyone simulation run, if a survival rate of 31.5% is assumed to apply to any 
individual patient (regardless of their prognosis), then on average 31.5% of the cohort 
will be randomly selected as survivors. Further, a proportion of these patients will have 
a poor prognosis with a short predicted non-transplant survival time (e.g. one-year). 
The individual patient survival times for the simulated survivors are set to five years 
and the randomly selected patients with short survival times will increase the mean 
survival time to being longer than what it might have been, had the original prognostic 
model predicted survival times been accurate. 
In summary, we have assumed that the probability of any individual patient surviving 
for five years is 0.315. We have then used a random number generator to define 
whether each person survived until five years or not and estimated the individual's 
survival time to be equal to either five years (if they were defined as having lived), or to 
their originally predicted survival time (if they were defined as having died). This 
simulation process was repeated to allow the uncertainty in the process to be 
estimated. Method 6.4.2 illustrates how extra available information can be incorporated 
in to the estimation of patient outcomes. 
6.4.2 Predicting Individual Patient Outcomes: Selecting the N2 Patients with the 
Longest Survival Times as Survivors (Method 6.4.2) 
The second method proposed in this chapter for estimating patient level outcomes 
attempts to customise the predicted outcome to the patient, rather than to assume the 
chances of surviving five years are the same for every individual. The method that is 
set out here assumes that information is available regarding the average proportion of 
survivors for a cohort. 
The mean probability of survival, in the absence of transplantation, at five years can be 
converted in to the average number of survivors by multiplying the study sample size 
2 N is the average number of survivors at the end of the fixed study period. 
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by the mean survival probability. The mean probability of survival at five years for the 
81 PSC CELT patients, estimated using the PBC Mayo model, is 0.315 (95% CI: 0.247 
to 0.383). The mean expected number of survivors at five years is therefore: 
81xO.315 = 26 patients3 
The 95% CI for the expected number of survivors is calculated in a similar way and 
ranges from 20 patients (81xO.247 = 20) to 31 patients (81xO.383 = 31). 
Expected non-transplant survival estimates are available for each patient after applying 
the PBC Mayo prognostic model to the PSC CELT cohort. It seems reasonable to use 
this information when selecting the survivors for the cohort. On average, 26 patients 
survive, and it is assumed that the 26 patients with the longest survival times, over the 
five-year study period, survive to five years and the remaining 55 patients with shorter 
survival times die during the study period. Appendix A6.1 Table A6.2 illustrates the 
selection process for the PBC CELT cohort assuming the 26 patients with the longest 
survival times survive. The mean non-transplant survival time for the PBC CELT 
cohort, estimated from the area under the Kaplan-Meier survival curve, is 2.59 years. 
To allow for uncertainty in the estimated number of survivors, the analysis is repeated 
using one-way sensitivity analysis. Two sensitivity analysis are performed, firstly using 
the lower 95% confidence limit for the probability of surviving to five years (N = 20) and 
secondly the upper limit (N = 31), giving a 95% CI for survival of 2.48 years to 2.70 
years. 
One of the drawbacks of this method is that its predicted outcomes are deterministic, 
and do not allow any uncertainty in the selection of cases estimated to survive or die. 
Survival outcome priority is given to the cases with the highest survival times, and 
although this is not an unreasonable assumption to make, it does not allow for a 
random element, where cases with a poor survival probability survive longer than 
expected, or those with a good survival probability suffer some form of complication 
and die unexpectedly. Thus, although the mean survival estimates from this method 
will be more accurate than those from Method 6.4.1, there is likely to be some extra 
3 Given that is not feasible to have 0.1 of a patient numbers have been rounded up to the next whole 
number. 
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uncertainty due to chance, which if not allowed for, would result in artificially narrow CI. 
The final method in this section uses techniques to adjust for this uncertainty. 
6.4.3 Predicting Individual Patient Outcomes: Probabilistic Sensitivity Analysis 
(Method 6.4.3) 
The final method considered in this section uses probabilistic sensitivity analysis (PSA) 
to incorporate uncertainty in individual outcome estimates. In PSA, statistical 
distributions are assigned to parameters of interest and Monte Carlo simulations 
subsequently run to re-estimate both the outcome of interest and the uncertainty 
around it [Ooubilet et aI, 1985; Critchfield et aI, 1986]. PSA is a useful method to use in 
economic evaluations, where there is often significant parameter uncertainty behind 
generated outcomes. 
In this section, each patient's expected non-transplant survival probability at five years, 
estimated from the PSC Mayo model, will be utilised in PSA to assign an individual 
patient outcome distribution. Each patient's outcome will be assumed to follow a 
binomial distribution. 
Table 6.2 presents expected non-transplant survival probabilities, at five years, for 
three hypothetical patients. Each patient's outcome is assumed to follow a binomial 
distribution and 1,000 simulations are run for each of the three patients to predict 
individual patient outcomes. Over the course of 1,000 simulations patient A, who has a 
predicted survival probability of 0.09, will on average survive in 90 of the simulations 
and will die in the remaining 910. Patient S on the other hand will, on average, be 
expected to survive in 500 out of 1,000 simulations, and likewise patient C is expected 
to survive in 980 of the simulations. 
Table 6.2 
Patient 
A 
B 
C 
Illustration of the expected number of survival outcomes and death 
outcomes for three patients over a series of 1,000 simulations 
Expected Average number of times Average number of 
survival predicted to survive times predicted to die 
probability 
0.09 90 910 
0.50 500 500 
0.98 980 20 
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PSA can be run in the S-PlUS statistical package, and the S-PlUS syntax, below, will 
generate a set of survival outcomes for 81 PSC CELT patients. Each patient's five-year 
non-transplant survival probability is used to estimate patient outcomes, where survival 
probabilities are based on estimates from the PSC Mayo prognostic model at five 
years. 
res <- numeric (81) 
for(i in 1:81) res[i) <- rbind(l, 1, ProbSy[i)) 
Prob5y is the data field which contains the predicted survival probabilities for each of 
the 81 individual PSC patients at five years. Appendix A6.1 presents an illustration of 
the PSA method for one simulation run in further detail. 
A total of 1,000 simulations are run in order to measure the uncertainty in the predicted 
patient outcomes and the proportion of patients surviving. One thousand simulations 
were found to be sufficient to obtain convergence to the mean percentage of survivors 
and mean survival lengths. The mean survival length from 1,000 simulation runs was 
2.60 years (95% CI: 2.46 to 2.75 years) and the mean proportion of survivors was 32% 
(95% CI: 25% to 40%). 
The 95% CI for the mean proportion of survivors and mean survival lengths are virtually 
identical to those for Method 6.4.2. The slight difference in mean outcome and survival 
estimates between Methods 6.4.2 and 6.4.3 are due to the PSA method allowing for 
the genuine uncertainty in the selection of patients who survive the full study period or 
die during the study period. 
6.4.4 Summary of Three Methods for Estimating Individual Patient Outcomes: 
PBC CELT Cohort - PBe Mayo Model 
Table 6.3 summarises the mean proportion of survivors, and the mean survival 
estimates, for the three alternative methods for predicting individual patient outcomes, 
for the PSC CELT cohort after applying the PSC Mayo prognostic model to estimate 
non-transplant survival. Method 6.4.1 assumes that each patient has the same survival 
probability, set as the mean probability of survival at five years (p = 0.315 for the PSC 
Mayo model). The method of assuming that the probability of survival was equivalent 
for all patients (random selection of survivors) gave a mean survival estimate of 3.06 
years. Method 6.4.1 will always overestimate the mean survival time because this 
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method does not account for individual patient information on survival and randomly 
allocates the proportion of survivors over the entire cohort. 
Method 6.4.2 utilises information on the probability of survival at five years and selects 
the N patients with the longest survival times as survivors. Method 6.4.2 will give a 
more accurate estimate of the mean survival than Method 6.4.1 but does not allow for 
the random selection of survivors by chance (the patients with the longest survival 
times are always selected as survivors). Whereas, Method 6.4.3 allows for the random 
selection of survivors using a PSA approach. Method 6.4.3 and 6.4.2 result in similar 
mean survival estimates, but the 95% CI for Method 6.4.3 are slightly wider, reflecting 
the genuine uncertainty allowed for using this method. 
Table 6.3 Mean percentage of PBC CELT non-transplant survivors and mean 
survival (95% CI) after applying three methods for predicting 
patient outcome - PBC Mayo model 
Method Mean percentage Mean survival 
of survivors time in years 
Method 6.4.1: Probability of survival 31% 3.06 
equivalent for all patients, random selection (17% to 34%) (2.74 to 3.39) 
of survivors (p = 0.315) 
Method 6.4.2: Selecting the N patients with 32% 2.59 
the longest survival times as survivors (25% to 38%) (2.48 to 2.70) 
(N = 26) 
Method 6.4.3: Probabilistic Sensitivity 32% 2.59 
Analysis (25% to 40%) (2.46 to 2.75) 
6.4.5 Summary of Three Methods for Estimating Individual Patient Outcomes: 
PBC CELT Cohort - European and Royal Free Models 
As a further demonstration of the proposed methodology for estimating individual 
patient outcomes, the same three methods, described above, were used to predict 
individual patient outcomes, in the absence of transplantation, for 81 PSC CELT 
patients using two alternative prognostiC models. The European prognostic model and 
the Royal Free prognostiC model are applied to the PSC CELT cohort to predict their 
non-transplant survival over a five-year study period. 
191 
Chapter 6 Predicting Individual Patient Outcomes 
To apply Method 6.4.1, the mean non-transplant survival probability at five years was 
calculated. The mean survival probability at five years was 0.333 for the European 
model and 0.323 for the Royal Free model. Therefore, for Method 6.4.1, where the 
probability of survival was equally likely for each of the 81 PSC CELT patients, the 
mean survival was 3.19 years when applying the European model and 3.20 years 
when applying the Royal Free model (Table 6.4 and 6.5). 
The 95% CI around mean survival probabilities at five years were 0.26 to 0.40 for the 
European model and 0.25 to 0.39 for the Royal Free model. To estimate the expected 
number of survivors at five years (Method 6.4.2), the mean proportion of survivors at 
five years was multiplied by the total sample size and rounded to the nearest whole 
number. The expected number of survivors was similar for the European and Royal 
Free models; 27 (95% CI: 21 to 33 patients) and 27 (95% CI: 21 to 32 patients), 
respectively. After applying Method 6.4.2 to predict individual patient outcomes the 
mean survival times were 2.64 (European model) and 2.74 (Royal Free model). 
Survival estimates were similar across the three prognostiC models, with mean non-
transplant survival estimates differing by only 0.15 years between the PSC Mayo model 
and the Royal Free model. 
The same pattern in mean survival estimates can be seen across all three prognostic 
models, with Method 6.4.1 producing mean survival estimates that are approximately 
0.5 years greater than estimates for Methods 6.4.2 and 6.4.3 for all three models. 
Method 6.4.2 and Method 6.4.3 produce similar mean survival estimates, but with wider 
CI for the PSA method, which captures outcome uncertainty at the individual level, 
across all three prognostiC models (Table 6.3 to 6.5). 
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Table 6.4 Mean percentage of PBC CELT non-transplant survivors and mean 
survival (95% CI) after applying three methods for predicting 
patient outcome - European model 
Method Mean percentage Mean survival 
of survivors time in years 
Method 6.4.1: Probability of survival 33% 3.19 
equivalent for all patients, random (22% to 43%) (2.88 to 3.52) 
selection of survivors (p = 0.333) 
Method 6.4.2: Selecting the N patients with 33% 2.64 
the longest survival times as survivors (26% to 41%) (2.56 to 2.74) 
(N = 27) 
Method 6.4.3: Probabilistic Sensitivity 33% 2.63 
Analysis (27% to 40%) (2.52 to 2.75) 
Table 6.5 Mean percentage of PBC CELT non-transplant survivors and mean 
survival (95% CI) after applying three methods for predicting 
patient outcome - Royal Free model 
Method Mean percentage of Mean survival 
survivors time in years 
Method 6.4.1: Probability of survival 32% 3.20 
equivalent for all patients, random (21% to 42%) (2.92 to 3.50) 
selection of survivors (p = 0.323) 
Method 6.4.2: Selecting the N patients with 32% 2.74 
the longest survival times as survivors (25% to 39%) (2.64 to 2.84) 
(N = 27) 
Method 6.4.3: Probabilistic Sensitivity 32% 2.72 
Analysis (26% to 40%) (2.61 to 2.85) 
6.4.6 Overall Summary 
Method 6.4.1 uses Monte Carlo simulations to estimate individual patient outcomes 
and assumes the probability of survival is equivalent for all patients. This method 
should not be used to estimate individual patient outcomes because it does not utilise 
patient specific information and will overestimate survival. Applying Method 6.4.1 within 
the CELT study WOUld, in turn, result in an underestimation of the survival gain from 
liver transplantation over five years. 
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Method 6.4.2 selects the N patients with the longest estimated survival times as 
survivors, where N is the estimate of the average number of survivors at the end of the 
study period. Method 6.4.3 uses individual patient survival probabilities in a PSA to 
estimate survival outcomes. Both Method 6.4.2 and 6.4.3 allow for individual patient 
information on the probability of survival at five years, and both produce similar mean 
estimates. Method 6.4.3 is recommended here as it allows for the additional uncertainty 
in the selection of the patients who survive, whereas Method 6.4.2 does not allow for 
this uncertainty. 
However, some researchers may prefer Method 6.4.2 to the PSA method due to the 
potential additional work load when conducting a PSA analysis for a similar mean 
estimate with slightly wider CI. The conclusions from comparing the difference in 
survival between two cohorts of patients are unlikely to differ in the majority of studies, 
were Method 6.4.2 selected rather than Method 6.4.3, when estimating individual 
patient outcomes. However, if the difference in survival approached statistical 
significance then researchers might draw different conclusions had they selected PSA 
over Method 6.4.2 or visa versa. It should be pointed out that the PSA analysis that 
incorporated outcome uncertainty took less than five minutes to run. Additionally, one 
of the advantages of PSA is that, alongside individual patient outcome uncertainty, 
other sources of uncertainty can also be incorporated (for example, prognostiC model 
parameter uncertainty and outcome uncertainty can be incorporated within the same 
analysis); this topic will be returned to briefly in Section 6.7 and explored further in 
Chapter 7. 
In conclusion, PSA is recommended here as the preferred method for estimating 
individual patient outcomes from a prognostic model, over a fixed time period because 
it allows for patient level uncertainty and can combine other sources of uncertainty 
within a single PSA run. 
6.5 THE IMPACT OF OUTCOME UNCERTAINTY ON NON-TRANSPLANT 
SURVIVAL, QALY AND COST ESTIMATES 
So far, this chapter has investigated the impact of estimating individual patient 
outcomes and outcome uncertainty on survival. In many studies, survival is not the sole 
outcome of interest. For example, the CELT study was concerned with estimating 
survival, QAl Ys and costs with, and in the absence of, transplantation and non-
transplant QAl Y and cost estimates were dependent upon non-transplant survival 
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estimates. Therefore, this section investigates how allowing for the uncertainty in 
outcome estimates impacts upon non-transplant QAl Y and cost estimates. 
As in the previous section, the PSC Mayo, European and Royal Free prognostic 
models were each applied to 81 PSC CELT patients to estimate their survival in the 
absence of liver transplantation. 
For each of the three PSC prognostic models (PSC Mayo, European and Royal Free) 
1,000 PSA simulations (Method 6.4.3) were run to allow for prognostic model outcome 
uncertainty. For each simulation run the mean survival time, expected number of 
survivors, QAl Ys and costs in the absence of transplantation are calculated. One 
thousand simulations were found to be sufficient to obtain convergence to the mean 
percentage of survivors and mean survival lengths. 
Non-transplant HRQl was measured using the EQ-5D and each PSC patient's last 
observed HRQl score pre-transplant was assumed to remain constant over time, until 
time of death. At time of death HRQl was assumed to be zero. Non-transplant QAl Ys 
were estimated by multiplying the expected non-transplant survival time by the last 
observed pre-transplant EQ-5D score. 
Individual patient average daily costs were estimated from cost data collected on the 
CELT patients prior to transplant and predicted for the same patients in the absence of 
transplantation using a three-part mode~. The first part of the model predicts whether 
each patient incurs a (non-zero) daily cost (Equations 6.1 and 6.2). If a non-zero cost is 
predicted the second part of the model is used to predict what that cost would be 
(Equation 6.3); otherwise, a daily cost of zero is assigned to the patient. Finally, a 
death cost is added on for patients who are predicted to die during the study (Equation 
6.5). 
4 The method of estimating non-transplant costs, described here, models costs more completely than the 
approach used in the main eEL T analysis [Longworth 8t aI, 2003]. In the main eEL T analysis individual 
patient average daily costs on the waiting were used to estima~e non-transplant cos~s and these were 
assumed constant over time until the month prior to death, Equation 6.5 was then applied to predict costs 
in the month prior to death. 
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The model used to predict whether a cost arises is: 
Logit(Probability of incurring daily costs) = lop = 
1.70 x log10(bilirubin) + 0.082 x age 
- 1.51 x ascities present - 4.78 
Equation 6.1 
The probability of incurring daily costs is calculated by applying Equation 6.2 
Probability of incurring daily costs = exp(lop) 
1 + exp(lop) 
Equation 6.2 
For patients who are predicted to have a cost, the value of this cost in UK pounds is 
predicted by the model: 
Expected daily loge cost = E[loge (C)] = 
1.84 + 1.31 x female + 0.68 x ascities present 
Equation 6.3 
Finally, the probability of incurring a daily cost is multiplied by the expected daily cost to 
obtain the predicted cost per day in the absence of transplantation (Equation 6.4). 
Predicted cost per day = 
[ exp(lop) ]x({exP(E[IOge(C)h}X3.51) 1 + exp(lop) 
Equation 6.4 
The retransformation of log transformed data results in an estimation of the geometric 
mean rather than the arithmetic mean [Graham et aI, 1988]. Duan proposed the 
smearing estimate which corrects for bias in taking the exponential the log transformed 
costs to obtain the arithmetic mean cost rather than the geometric mean cost [Duan, 
1983]. The smearing estimate is calculated by summing the exponential of the 
residuals for the log transformed ordinary least squares model (Equation 6.3) and 
taking the average over the total number of observations in the sample (N = 81 in this 
chapter). The smearing estimate for Equation 6.3 is 3.51, and is applied when 
retransforming the log daily cost estimates back in to UK pounds in order to obtain an 
unbiased estimate of expected daily costs. 
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The five year costs in the absence of transplantation for survivors were calculated by 
multiplying the predicted daily cost on the waiting list by 1,826 days (five years). For 
patients who were predicted to die within the five-year period, an adjustment was made 
to the non-transplant costs by adding on additional costs in the final month of life: 
Costs in the month prior to death (£) = 
(101.6 x age) - 1,676.4 
Equation 6.5 
The total non-transplant costs for each patient, was then calculated using Equation 6.6. 
Total non-transplant costs (£) 
= (Predicted daily cost on waiting list x [Predicted 
survival time (in days) - 30]) 
+ Cost in the month prior to death 
(if patient predicted to die within five years) 
OR 
= Predicted daily cost on the waiting list x 1,826 
(if patient predicted to survive five years) 
Equation 6.6 
The mean total non-transplant costs for the PSC CELT cohort were then estimated for 
each of the three PSC prognostic models and are presented in Table 6.6 with the mean 
percentage of survivors at five years, the mean survival estimates and mean QAl Ys for 
the three PSC prognostic models. The means and 9So/0 CI were derived from the soth, 
2.Sth and 97.Sth percentiles of the one thousand simulations. 
Mean survival, QAl Y and cost estimates and the widths of the 9So/0 CI were similar 
across the three prognostic models, with survival and QAl Y estimates being lowest for 
the Mayo model and highest for the Royal Free model. 
To compare the impact of accounting for outcome uncertainties at the individual level, 
non-transplant survival, QAl Y and cost were also estimated for Method 6.4.2 which 
selected the N patients with the longest estimated survival times (Table 6.7)5. 
5 When comparing the results from Table 6.6 with Table 6.7 it should be born in mind that Method 6.4.2 
and Method 6.4.3 (PSA) are presenting slightly different summary measures which could explain the 
disparity in mean costs between methods. Method 6.4.2 presents cohort mean survival, QAL Y and cost 
estimates with confidence intervals estimated from cohort mean from two sensitivity analysis. PSA 
produces 1,000 estimates of the cohort mean survival, QAL Y and cost and summarises the mean and 
9S% CI from the SOth, 2.Sth and 97.Sth percentiles of the simulated means. 
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A comparison of the QAL Y and cost estimate between Method 6.4.2 and PSA (Method 
6.4.3) shows that, like survival estimates, allowing for prognostic model outcome 
uncertainty slightly increases the uncertainty around non-transplant QAL Y and cost 
estimates (Table 6.8) 
Table 6.6 Mean percentage of survivors, survival, QAl Ys and total non-
transplant costs (95% Cis) over five years for 81 PBe eEL T 
patients estimated by the PBe Mayo, European or Royal Free 
prognostic models: using PSA (Method 6.4.3) to incorporate 
prognostic model outcome uncertainty 
PBe Mayo Model European Model Royal Free Model 
Mean percentage of 32 33 32 
survivors (25 to 40) (27 to 40) (26 to 40) 
Mean survival in 2.59 2.63 2.72 
years (2.46 to 2.75) (2.52 to 2.75) (2.61 to 2.85) 
Mean QAL Ys in 1.34 1.40 1.45 
years (1.26 to 1.44) (1.33 to 1.48) (1.38 to 1.54) 
Mean non-transplant £82,178 £80,951 £81,631 
costs (£'s) (£77,512 to £88,358) (£77,057 to £85,551) (£77,442 to £86,608) 
Table 6.7 Mean percentage of survivors, survival, QAl Ys and total non-
transplant costs (95% Cis) over five years for 81 PBe eEL T 
patients estimated by the PBC Mayo, European or Royal Free 
prognostic models: using Method 6.4.2 to incorporate prognostic 
model outcome uncertainty 
PBe Mayo Model European Model Royal Free Model 
Mean percentage of 32 33 32 
survivors (25 to 38) (26 to 41) (25 to 39) 
Mean survival in 2.59 2.64 2.74 
years (2.48 to 2.70) (2.56 to 2.74) (2.64 to 2.84) 
Mean QAL Ys in 1.28 1.35 1.41 
years (1.22 to 1.33) (1.30 to 1.42) (1.35 to 1.48) 
Mean non-transplant £78,929 £74,545 £80,118 
costs (£'s) (£75,369 to £80,990) (£72,079 to £77,254) (£77,734 to £83,178) 
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Table 6.8 A Comparison of 95% CI Widths for Non-Transplant QAL Y and 
Cost Estimates for the PSC Mayo model, European Model and 
Royal Free Model after applying Method 6.4.3 (PSA) and Method 
6.4.2 
95% CI Widths 
PSC Mayo European Royal Free 
Model Model Model 
Non-transplant Method 6.4.3 (PSA) 0.18 0.15 0.16 
QAlYs Method 6.4.2 0.11 0.12 0.13 
Non-transplant Method 6.4.3 (PSA) £10,846 £8,494 £9,166 
costs Method 6.4.2 £5,621 £5,175 £5,444 
6.6 DISCUSSION 
The published prognostic models used in the CELT study did not provide enough 
information to estimate "lifetime" patient survival. Additionally, the prognostic models 
did not provide information as to who was alive or dead at a fixed prior time point (five 
years). Therefore, this chapter has presented methodology that can be used to account 
for uncertainties that arise from applying Cox PH prognostic models to estimate 
survival, QAl Ys and costs in the absence of observed data for a cohort of patients over 
a fixed time period. 
6.6.1 Alternative Approaches to Estimating Individual Patient Outcomes 
Three alternative approaches have been presented in this chapter that can be applied 
to survival estimates in order to estimate individual patient outcomes. An alternative 
approach that was excluded from Section 6.4 was to fit a mathematical model, for 
example, a linear regression model, to the prognostic model estimates at either the 
cohort or patient level, in order to extrapolate survival beyond the study time period. 
However, this involves fitting prognostic models to prognostic models. This will 
inevitably increase the amount of uncertainty in the estimation process. Therefore, 
methods that utilised information from prognostic models were focused upon. 
A further method for estimating individual patient outcomes, excluded from this chapter, 
was to treat the unknown outcome as missing data. This approach was used recently 
by Oostenbrink and colleagues who apply missing data techniques to cost data, where 
costs information is incomplete for a proportion of patients [Oostenbrink et aI, 2003; 
Oostenbrink & AI, 2005). 
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Missing data techniques assume that data are either missing completely at random 
(MCAR) or MAR [Little & Rubin, 1987; Little, 1993]. MCAR occurs when the missing 
data are independent of observed and unobserved data, in other words the missing 
data occurs in an entirely random fashion. Data are said to be MAR if the values of the 
variable(s) which contain the missing data are not a sub-sample of the sampled 
observations but are a random sample of variables that depend on the values of 
observed variable(s). 
It would be inappropriate to apply missing data techniques to estimate individual patient 
outcomes in the absence of transplantation in the CELT study. To use imputation 
techniques, a proportion of patients in the cohort should be known to have had an 
observed death and a proportion known to survive to the end of the study. This was not 
the case when predicting non-transplant survival, where outcomes were missing for all 
patients in the cohort. It was considered inappropriate to combine the non-transplant 
cohort with the transplant cohort as if they were two separate data sets, or to combine 
the non-transplant cohort with patients who were listed for transplant within the CELT 
study but who did not receive transplantation. The reasons in each case are that the 
MAR assumption is violated. In the first scenario, the transplant cohort are a sub-
sample of the combined cohort of transplant and non-transplant patients. In the second 
scenario, the "non-transplant" patients were on the waiting list long enough for a 
suitable organ to become available and are a sub-sample of patients on the waiting list. 
6.7 CONCLUSIONS 
This chapter has addressed an issue of methodological uncertainty by presenting and 
comparing three alternative methods for estimating individual patient outcomes. PSA 
uses individual patient survival probabilities to estimate survival outcomes and is the 
recommended method for estimating the uncertainty around individual patient outcome 
estimates derived from prognostic models. This approach is selected over a 
deterministic approach where the N patients with the longest survival times are 
selected as survivors (Method 6.4.2). Both PSA and Method 6.4.2 gave a similar mean 
percentage of survivors and survival estimates, however, PSA gave wider (but more 
realistic) CI owing to the extra uncertainty it allowed for. 
In the CELT study, outcome uncertainty had little impact on survival, cost and QAlY 
estimates and increased the uncertainty around non-transplant estimates slightly and 
did not differ noticeably for the three PBC prognostic models. Each patient's expected 
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outcome is dependent on their expected survival time over the fixed study period, 
therefore, it follows that any estimates of patient outcomes and survival times should 
incorporate both prognostic model parameter uncertainty, using the methods presented 
in Chapter 5 and uncertainty around the outcome estimates, using PSA. The impact of 
both prognostic model parameter uncertainty and outcome uncertainty on survival, 
QAl Y and cost estimates can then be investigated. A further source of prognostic 
model uncertainty occurs when a series of equally appropriate prognostic models can 
be applied to a cohort of patients. 
Additionally, CELT non-transplant costs are also estimated from a three-part prognostic 
model and the parameters from each part of the prognostic model are also subject to 
parameter uncertainty. Therefore, the impact of parameter uncertainty, in the three-part 
cost model, on cost estimates should also be investigated. Thus, Chapter 7 goes on to 
combine prognostic model parameter (both survival models and cost models), outcome 
and model selection uncertainties with cohort uncertainties using PSA analysis. 
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COLLECTIVELY MEASURING MULTIPLE SOURCES OF 
UNCERTAINTY RELATED TO THE USE OF A 
PROGNOSTIC MODEL INSTEAD OF AN OBSERVED 
NON-TRANSPLANT COHORT 
7.1 INTRODUCTION 
Prognostic models can be applied to estimate control group survival, and subsequently 
QAL Ys and costs, in the absence of information from an observed control group. 
However, it is inevitable that uncertainty in survival, QAL Y and cost estimates will exist 
when applying a prognostic model to a cohort of patients. In Chapters 5 and 6, 
simulation methods have been presented that can be applied in order to incorporate 
three sources of uncertainty in prognostic model estimates. Firstly, when published 
prognostic models are used to estimate control group survival, the prognostic model's 
parameters are themselves estimates and the uncertainty that exists therein should be 
incorporated in to survival, QAL Y and cost estimates. Secondly, when more than one 
prognostic model is available as a basis for estimating survival, uncertainty exists as to 
whether the selected model is the most appropriate choice. Finally, uncertainty occurs 
when estimating the individual patient outcomes in the control group. 
202 
CHAPTER 7 PROGNOSTIC MODEL UNCERTAINTY 
This thesis has not yet examined the impact of multiple sources of prognostic model 
uncertainty on survival, QAl Y and cost estimates in the absence of observed 
information from a control group. Nor has this thesis incorporated parameter 
uncertainties from the three-part cost model applied to estimate non-transplant costs 
(Chapter 6, Section 6.5). 
In health economics it has historically been recommended that analysts allow for 
uncertainty by selecting a base case scenario for the main analysis, which is based on 
the most plausible parameter values. These values should then be varied in a series of 
sensitivity analyses "to examine the robustness over a range of altemative values" 
[Drummond et aI, 1997]. 
Only 20 of the 40 solid organ transplantation studies reviewed in Chapter 3 varied 
parameter values, all of which used deterministic one-way sensitivity analysis. In one-
way analysis, parameter values are varied one at a time and the effect of varying the 
values on the overall analysis is examined. However, one-way sensitivity analysis does 
not allow for possible interdependences between variables, where varying one 
parameter has an impact on the values of other parameters. 
One-way sensitivity analysis was used in the main CELT analysis to vary the choice of 
prognostic model for estimating non-transplant survival, QAl Ys and costs [Longworth 
et aI, 2003]. However, intuitively, this does not appear to be the most appropriate 
technique to allow for prognostic model parameter uncertainty, or to allow for the 
uncertainty in the individual patient outcome estimates. Additionally, non-transplant 
cost and QAl Y estimates will be dependent upon individual patient outcome 
predictions and estimated survival in the absence of transplantation and a series of 
one-way sensitivity analyses would not allow for these interdependencies between 
parameter values. 
It is inappropriate to use one-way or mUlti-way sensitivity analysis to examine 
prognostic model parameter uncertainty. Briggs recommends using PSA to allow for 
parameter uncertainty in economic evaluations [Briggs, 2001]. Further, NICE guidelines 
on economic evaluations in health technology assessments recommend PSA to allow 
for parameter uncertainties in model estimates [NICE, 2004]. PSA was first introduced 
in Chapter 6 as the preferred method for estimating individual patient outcomes and the 
uncertainty around outcome estimates. 
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PSA will be used in Chapter 7 to examine the impact of prognostic model uncertainties 
on estimates of non-transplant survival, QAl Ys and costs over a five-year study period, 
for a series of CELT study patients. An advantage of applying PSA to the CELT study 
will be to incorporate the interdependencies between survival and outcome estimates, 
between survival and QAl Y estimates and between survival and cost estimates. Whilst 
the PSA technique presented in this chapter is not original, its application to organ 
transplantation and to these specific sources of uncertainty is. 
Section 7.2 summarises the three sources of prognostic model uncertainty mentioned 
above within the context of estimating non-transplant survival in the CELT study. 
Section 7.3 presents non-transplant survival, QAl Y and cost estimates prior to 
incorporating uncertainties from prognostic models. Following this, the estimated non-
transplant survival, QAl Ys and costs over five years are presented for a cohort of 81 
PSC patients using the European prognostic model to estimate survival. Section 7.4 
examines the effects of prognostic model uncertainties using PSA on non-transplant 
survival, QAl Y and cost estimates for the PSC CELT cohort after applying the 
European prognostic model. Section 7.5 discusses techniques for combining a series 
of prognostic models within PSA, as a solution to incorporating uncertainty in the 
choice of prognostic models, when more than one model exists. The section then 
compares non-transplant survival, QAl Y and cost estimates for three PSC prognostic 
models (European, Royal Free and PSC Mayo models) after allowing for prognostic 
model uncertainties. The difference between four sets of results and the implications of 
the results for decision makers and the transplant community will be discussed in 
Section 7.6. 
7.2 SOURCES OF PROGNOSTIC MODEL UNCERTAINTY IN THE CELT STUDY 
In the CELT study, non-transplant survival was estimated by applying published Cox 
PH prognostic models to patient and clinical information from transplant patients; this 
information was collected at time of transplantation. Using the information at point of 
transplant, it was possible to estimate the transplant patients' survival had they not 
received a liver transplant. The three main sources of prognostic model uncertainty 
when estimating non-transplant survival in the absence of an observed control group 
are presented below. 
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7.2.1 Prognostic Model Parameter Uncertainty 
Incorporating the standard errors of regression coefficients in to the estimate of non-
transplant survival gives a more accurate estimate of model uncertainty (Chapter 5). Of 
the seven published prognostic models considered in the main CELT study, six 
provided the standard errors of the regression coefficients. Anand et al did not provide 
information on the standard errors of the regression coefficients for the Birmingham 
AlD model [Anand et aI, 1987]. Prognostic model parameter uncertainty was not 
incorporated in to the published CELT analysis [Longworth et aI, 2003]. 
In Chapter 5 it was shown that allowing for prognostic model parameter uncertainty 
increased the amount of uncertainty around survival estimates. Therefore, it is 
expected that allowing for parameter uncertainty will also increase the uncertainty 
around non-transplant QAl Y and cost estimates. 
7.2.2 Selection Uncertainty: Choosing a Prognostic Model 
A series of prognostic models existed for each of the three liver disease groups 
included in the main CELT analysis: AlD (2 models), PBC (3 models) and PSC (2 
models). Chapter 5 set out a series of seven selection criteria, to be applied to the 
alternative prognostic models (Section 5.8). Criteria 1 to 6 were applied in the main 
CELT paper, which resulted in the selection of the AlD Seclere model, an average of 
the PBC European model and PSC Royal Free model and the PSC International model 
in the main analysis [Longworth et aI, 2003]. As pointed out in Chapter 2, although the 
justification of model choice appeared reasonable, one can never be totally sure that 
the best model has been selected; therefore, the alternative models (AlD Birmingham, 
PSC Mayo, and PSC Mayo) were applied in one-way sensitivity analysis. 
The ih criterion states that a prognostic model should display the least amount of 
parameter uncertainty (in comparison with other models) and was first proposed in 
Chapter 5 as an additional selection criterion for a reliable prognostic model. A model 
displaying the least amount of uncertainty in the survival estimates should, 
consequently, show less uncertainty in the subsequent cost and QAl Y estimates. 
Additionally, Chapter 5 also recommended that researchers explore whether there is 
an explanation as to why a prognostic model displays more uncertainty than a 
comparable model. For example, the inclusion of non-significant clinically meaningful 
variables in a model is likely to increase model uncertainty in comparison with a model 
that excluded non-significant variables. Therefore, it was recommended that criterion 7 
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should not be included as an additional selection criterion and any explanation for the 
increase in model parameter uncertainty should be considered when choosing an 
appropriate model. 
Chapter 5 discussed methods for selecting an appropriate model, rather than 
combining alternative models. Therefore, Section 7.7 revisits this problem to discuss 
whether it is possible to incorporate prognostic model choice uncertainty in a PSA. 
7.2.3 Individual Patient Outcome Uncertainty 
In the CELT study, prognostic models are applied to the CELT transplant cohort in 
order to estimate each patient's survival, QAl Y and costs in the absence of 
transplantation. Survival, QAl Y and cost gains from transplantation are estimated at 
the patient level, thus making it necessary to estimate individual patient outcomes over 
the fixed study period. Additionally, it was assumed that non-transplant costs would 
vary in the month prior to death and that these costs could be estimated individually for 
patients based on their age at listing and their type of liver disease. 
In Chapter 6, a PSA method was introduced for estimating individual patient outcomes 
and the uncertainty around the outcome estimates, this method was also omitted in the 
original CELT study. Allowing for individual outcome uncertainty resulted in an increase 
in the uncertainty around survival estimates. Chapter 6 showed that allowing solely for 
individual patient outcome uncertainty increased the uncertainty around non-transplant 
QAl Y and cost estimates. 
7.2.4 Summary 
All three sources of prognostic model uncertainty mentioned above have an impact on 
survival, QAl Y and cost estimates. For example, the choice of prognostic model could 
influence any decisions made regarding the treatment of end-stage liver disease. In 
addition to this, it is important to allow for any interdependencies between survival, 
QAl Y and cost estimates and between estimated survival and survival outcomes, 
highlighting the importance of incorporating all prognostic model uncertainties within a 
PSA. Further, the three-part model for predicting non-transplant costs is subject to 
model parameter uncertainty, and allowing for this will further increase the uncertainty 
around cost estimates. Thus, cost model parameter uncertainty should also be 
incorporated within the PSA. 
206 
CHAPTER 7 PROGNOSTIC MODEL UNCERTAINTY 
7.3 ESTIMATING NON-TRANSPLANT SURVIVAL, QAL Y AND COSTS FOR THE 
PBC CELT COHORT -IGNORING PROGNOSTIC MODEL UNCERTAINTIES 
As in Chapters 5 and 6, a cohort of 81 patients with end-stage PBC who received a 
liver transplant will be used to illustrate the impact of prognostic model uncertainty on 
non-transplant survival, QAl Y and cost estimates over a five-year study period. 
Section 7.3 presents details of the non-transplant survival, QAl Y and cost estimates 
prior to incorporating prognostic model uncertainties. 
7.3.1 Prognostic Models Considered for the PBC CELT Cohort 
Three alternative prognostic models were available for estimating non-transplant 
survival over five years in PBC patients; the European model, the Royal Free model, 
and the PBC Mayo model. These models have been introduced previously in Chapter 
5, and Table 5.4 summarised the patient and clinical characteristics needed to predict 
survival in the absence of transplantation for each of the three prognostic models. All 
three models use patient age, bilirubin levels, albumin and the presence or absence of 
ascities to predict survival. However, the European model uses additional information 
on the presence or absence of gastrointestinal bleeding and the PBC Mayo model uses 
additional information on gender, prothrombin time and oedema scores. 
7.3.2 Estimating Non-Transplant Outcomes (Survival, QAlYs and Costs) at the 
Patient level 
Once a suitable prognostic model has been identified, the predicted survival time, 
during the study period, is estimated for each individual patient by plotting the patient 
specific survival probabilities over time and calculating the area under the curve. Non-
transplant QAl Ys are estimated by multiplying the expected survival time by the last 
observed pre-transplant EQ-5D score. 
Individual patient average daily costs are estimated from cost data collected on the 
CEl T patients prior to transplant and predicted for the same patients in the absence of 
transplantation using a three-part model (Chapter 6, Section 6.5). The total non-
transplant costs for patients who died were calculated by multiplying their estimated 
survival in days (minus 30 days)1, by their estimated daily cost on the waiting list and 
adding this to their expected cost in the month prior to death. For patients who survived 
, An adjustment was made to the expected non-transplant costs of patients predicted to die for the 30 day 
period prior to death. 
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the full five-year study period their expected daily cost was multiplied by 1,B26 days 
(five years). 
7.3.3 Estimating the Overall Mean Non-Transplant Outcomes (Survival, QALYs 
and Costs) with no Allowance for Model Uncertainty (Step 1) 
In order to estimate non-transplant survival, QAl Ys and costs we need to select a 
prognostic model that can be used as a base case. This model should be the most 
appropriate to apply to the PBC CELT cohort and will be selected using the six 
selection criteria set out in Chapter 5, Section 5.B (Box 5.2). The PBC Mayo model is 
not based on UK patients (Criterion 6) and is thus eliminated from the selection 
process. 
After the exclusion of the PBC Mayo model two prognostic models remained: the Royal 
Free model and the European model. The European model met all six selection 
criteria, whereas the Royal Free model had not been validated on internally and 
extemal data sets (Chapter 5: Table 5.10). Therefore, in this chapter the European 
model is selected as the base case in preference to the Royal Free model because it 
meets all six selection criteria. 
The European prognostic model is applied to the CELT cohort to estimate non-
transplant survival over five years. The mean probability of survival to five years in the 
absence of transplantation for the CELT cohort as a whole was 0.333. Thus, the 
expected number of non-transplant survivors at five years is 0.333xB1 = 27 patients. 
Each patient's expected survival is then calculated from the area under the predicted 
survival curve. The survival times are extended to five years for the 27 patients with the 
longest survival. 
The expected non-transplant survival, QAl Ys and costs are presented in Figure 7.1, 
with 95% bootstrapped Cis to represent cohort uncertainty. One thousand bootstrap 
replicates were sufficient for convergence of non-transplant survival, QAl Y and cost to 
the mean estimate. On average, patients are expected to survive 2.63 years in the 
absence of transplantation. After adjusting for HRQl, the quality adjusted survival 
decreases to approximately 16 months (1.34 years). The mean predicted costs over 
five years in the absence of transplantation are £74,420. Figure 7.1 also presents the 
mean QAl Y and cost estimates for each of the 1,000 bootstrap replicates. 
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The non-transplant survival, QAL Ys and cost estimates will form the base case 
scenario, prior to adjusting for prognostic model uncertainties. 
Figure 7.1 
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1.34 (1.06 to 1.65) 
Costs (95% CI) 
£74,420 (£63,872 to £85,067) 
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7.4 COMBINING PROGNOSTIC MODEL UNCERTAINTIES FOR THE 
EUROPEAN MODEL USING PSA - PARAMETER AND PATIENT OUTCOME 
UNCERTAINTY 
This thesis has now presented methods to estimate individual patient survival on the 
basis of prognostic models, and this, together with the approach set out in Section 
7.3.2 allows the estimation of total patient costs and QAl Ys. The PSA approach 
provides a framework within which prognostic model parameter uncertainty and 
individual outcome uncertainty can be incorporated in to survival estimates. This 
chapter will now proceed to incorporate this uncertainty, thus enabling the comparison 
of non-transplant survival, CAL Y and cost results with and without the inclusion of 
prognostic model uncertainties. 
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The European prognostic model has been selected as the base case model for 
estimating non-transplant survival, QAL Ys and costs over five years for a cohort of 
PSC patients (Step 1). Figure 7.1 presented mean non-transplant survival, QAL Y and 
cost estimates over five years with 95% bootstrapped CI showing cohort uncertainty 
prior to incorporating prognostic model uncertainties. In this section, prognostic model 
uncertainties will be incorporated in to survival, QAL Y and cost estimates over a series 
of three further steps. 
7.4.1 Adding in Prognostic Model Parameter Uncertainty to Cohort Uncertainty 
(Step 2) 
Monte Carlo simulations are applied to simulate the regression coefficients for the 
European prognostic models to allow for prognostic model parameter uncertainty. 
Through the central limit theorem, regression coefficients are assumed to follow a 
normal distribution; Table 7.1 presents the mean and standard error estimates for each 
of the parameters in the European prognostic model. 
Table 7.1 Regression coefficients (and standard errors) for the European 
prognostic model 
European Model* 
Age in years 0.04 (0.011) 
Log 10(Bilirubin) 2.53 (0.260) 
Albumin -0.09 (0.019) 
Ascities present 1.39 (0.210) 
Gastrointestinal bleeding 0.65 (0.210) 
.. 
* Variables should be standardised before coefficients are applied (Age In years - 55, log10 bilirubin 1.53, 
Albumin - 34.3) 
One thousand Monte Carlo simulations are run to allow for prognostic model parameter 
uncertaintl and for each of the 1,000 simulation runs 1,000 bootstrap replicates are 
run to account for cohort uncertainty. This resulted in a total of one million simUlations. 
After each simulation run, the cohort mean non-transplant survival, QAL Ys and costs 
are estimated. The 50th percentile of the 1,000,000 simulated results represents the 
2 The number of simulations for parameter uncertainty was reduced from 3,000 (Chapter 5) owing to 
computational constraints. For each simulation run 1,000 bootstrap replicates were run to allow for ~hort 
uncertainty. Figure 5.6 (Chapter 5) shows that the majority of parameters converge to the mean pnor to 
1,000 runs. 
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mean survival time, QAL Ys or costs across all simulations and the 2.5th and 97.5th 
percentiles represent the 95% confidence limits. 
Figure 7.2 presents non-transplant survival, QAL Y and cost estimates with 95% Clover 
five years, after incorporating both prognostic model parameter uncertainty and cohort 
uncertainty. The mean survival, QAL Y and cost estimates are approximately the same 
as those presented in Figure 7.1 - when prognostic model parameter uncertainty is 
ignored. Mean survival estimates differ by approximately one week, QAL Y estimates 
are identical and cost estimates differ by approximately £600. Mean survival, QAL Y 
and cost estimates would tend further towards the mean estimates presented in Figure 
7.1 if the number of simulations were increased. 
Figure 7.2 
II) 
>-~ 
C 
1\1 
0. 
II) 
c: 
~ 
c: 
0 
c: 
'C 
!!! 
1\1 
E 
., 
Uj 
Mean predicted non-transplant survival, QAL Ys and costs over five 
years for 81 PBC patients: applying the European prognostic 
model - Incorporating cohort and prognostic model parameter 
uncertainty· 
2.5 
2 
1.5 
.5 
o 
o 25 
• 
• 
50 75 100 125 150 
Estimated non-transplant costs (in £10oos) 
Survival in years (950/0 CI) 
2.65 (2.13 to 3.18) 
QAL Vs (95% CI) 
1 .35 (1. 03 to 1.71) 
Costs (95% CI) 
£75,019 (£59,677 to £91,649) 
175 200 
• Figure shows results from 1,000 randomly selected simulations only 
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As expected, incorporating prognostic model parameter uncertainty in to non-transplant 
survival, QAL Y and cost estimates increased the uncertainty around mean survival, 
QAL Y and costs, shown by the increase in the width of the CI between Figure 7.2 and 
Figure 7.1 where only cohort uncertainty was allowed for. 
Figure 7.2 also presents a plot of the mean non-transplant QALY and cost estimates3 . 
The figure shows that mean non-transplant costs increase linearly with increasing 
QALYs. 
7.4.2 Adding in Individual Patient Outcome Uncertainty to Cohort Uncertainty 
and Prognostic Model Parameter Uncertainty (Step 3) 
The third step expands on Step 2 and incorporates cohort uncertainty, prognostic 
model parameter uncertainty and individual patient outcome prediction uncertainty. 
Individual patient outcomes are assumed to follow binomial distributions with expected 
survival probabilities at five years ranging between zero and one. 
As with Step 2, one million simUlations are run to account for cohort uncertainty, 
prognostic model parameter and individual patient outcome uncertainty and the results 
(Figure 7.3) are compared with those from Steps 1 and 2. Mean non-transplant 
survival, QAL Y and cost estimates are slightly higher after incorporating cohort 
uncertainty, prognostic model parameter uncertainty and outcome uncertainty in to the 
prognostic models, in comparison with mean estimates after adjusting for prognostic 
cohort uncertainty and model parameter uncertainty (Figure 7.2) or cohort uncertainty 
alone (Figure 7.1). As explained in Chapter 6, by incorporating individual patient 
outcome uncertainty, the 27 patients with the longest survival times are no longer 
selected as survivors, rather individual patient survival probabilities at five years are 
used to predict survival. This random selection process will result in patients with 
shorter predicted survival times selected as surviving to five years and this will result in 
an increased mean survival for the cohort (Chapter 6 Section 6.4.1). The increased 
survival has an impact on the mean costs and QAL Y estimates, which also increase 
because patients are surviving slightly longer. 
3 Figures 7.2 to 7.10 presents mean CAL Y and cost estimates for a random selection of 1.0~ simulations 
of the 1.000.000 simulations run (one estimate is randomly selected from each of the Simulation runs that 
allow for parameter uncertainty. One million points were not plotted owing to computational constraints). 
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Figure 7.3 Mean predicted non-transplant survival, QALYs and costs over five 
years for 81 PBC patients: applying the European prognostic 
model - Incorporating cohort, prognostic model parameter and 
outcome uncertainty* 
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2.73 (2.19 to 3.30) 
QAL Ys (95% CI) 
1.40 (1.06 to 1.77) 
Costs in £ (95% CI) 
£77,833 (£61,368 to £96,982) 
* Figure shows results from 1,000 randomly selected simulations only 
Incorporating outcome uncertainty in to non-transplant survival, QAL Y and cost 
estimates increases the uncertainty around mean estimates slightly, in comparison with 
the uncertainty when incorporating cohort and prognostiC model parameter uncertainty. 
After incorporating outcome uncertainty the CI widths for survival, QAL Y and costs are 
1.19 years, 0.71 years and £35,614 in comparison with widths of 1.05 years, 0.68 
years and £31,972 when incorporating cohort uncertainty and model parameter 
uncertainty. 
7.4.3 Adding In Uncertainty in Non-Transplant Cost Estimates to Cohort 
Uncertainty, Prognostic Model Parameter Uncertainty and Individual 
Patient Outcome Uncertainty (Step 4) 
It has already been stated that individual patient estimates of QAL Ys and costs depend 
on the predicted survival times. Furthermore, cost estimates depend upon outcome 
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predictions, where additional costs in the month prior to death are incorporated in to 
non-transplant cost estimates. Both death costs and daily costs on the waiting list are 
estimated at the patient level using regression models and, as with the prognostic 
models, these models are subject to parameter uncertainty. Therefore, the final step 
incorporates prognostic model uncertainties (cohort, parameter and outcome) and 
parameter uncertainties in the individual patient cost predictions. The impact of these 
uncertainties on the survival, cost and QAl Y predictions is examined and compared 
with the results from Step 1 to 3. In this final step the incorporation of cost model4 
uncertainty affects only the non-transplant cost estimates; survival and QAl Y estimates 
are independent of costs and remain unchanged from those in Step 3. 
As with the prognostic model parameters, regression coefficients for cost estimates are 
assumed to follow a normal distribution. The means and standard errors for the 
regression coefficients for whether daily costs are incurred (yes/no), predicted daily 
costs (if incurred) and costs in the month prior to death (where the patient has been 
predicted to die) are presented in Table 7.2. 
Table 7.2 Regression coefficients (and standard errors) for the three models 
used to estimate non-transplant costs 
Daily Cost Loge Daily Cost in the 30 days 
Incurred (YIN) Cost prior to death 
Constant -4.78 (3.32) 1.84 (0.66) -1,676.4 (1,493.41) 
Age 0.08 (0.05) N/a 101.6 (18.65) 
Ascities present -1.51 (0.80) 0.68 (0.44) N/a 
Gender: female N/a 1.31 (0.69) N/a 
Log10(Bilirubin) 1.70 (0.85) N/a N/a 
N/a - not applicable 
Figure 7.4 presents mean non-transplant survival, QAl Y and cost estimates, with 95% 
CI, over five years for the PBC CELT cohort after adding cost model parameter 
uncertainties to cohort, prognostic model parameter and outcome uncertainties. As 
mentioned above, Figure 7.4 shows that the non-transplant survival and QAl Y 
estimates and their 95% Cis are the same as those presented in Figure 7.3 (Step 3) as 
the additional uncertainty allowed for only impacts on costs. 
4 The cost model applied in this chapter is the same model as described in Chapter 6 (Equations 6.1 to 
6.6). 
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Figure 7.4 Mean predicted non-transplant survival, QAL Ys and costs over five 
years for 81 PBC patients: applying the European prognostic 
model - Incorporating cohort, prognostic model parameter, 
outcome and cost model parameter uncertainty* 
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Estimated non-transplant costs (in £1000s) 
Survival in years (95% CI) 
2.73 (2.19 to 3.30) 
QALYs (95% CI) 
1.40 (1.06 to 1.77) 
Costs in £ (95% CI) 
£58,696 (£5,509 to £484,257) 
* Figure shows results from 1,000 randomly selected simulations only 
The first thing to note about the cost estimates is that, as with the survival, QAL Y and 
cost estimates after allowing for prognostic model parameter uncertainty, after allowing 
for cost model parameter uncertainty the Cis around cost estimates have increased 
substantially. The Cis around cost estimates are much wider than those presented for 
mean costs in Step 3 (CI width: £35,614), where the CI is now over £440,000 wider. 
Figure 7.5 illustrates how the uncertainty in each part of the three part cost model has 
increased after allowing for model parameter uncertainty, uncertainty estimates are 
compared with those after allowing for cohort uncertainty alone, for each of the three 
parts of the prognostic model. The increase in the uncertainty around each of the three 
parts of the cost model has increased the overall uncertainty in the total non-transplant 
co t estimates (Table 7.3) 
215 
PROGNOSTIC MODEL UNCERTAINTY 
.5 Cost distributions, incorporating cohort uncertainties (a to c) and predictive cost model parameter uncertainty (d to f) 
Distributions after accounting for cohort uncertainties 
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Table 7.3 95% bootstrapped CI for cohort uncertainty and 95% CI after 
allowing for cost model parameter uncertainty for each of the three 
parts of the cost prediction model 
95% bootstrap CI for 95% CI for cost model 
cohort uncertainty parameter uncertainty 
Probability of incurring costs 0.85 to 0.90 0.01 to 1.00 
Expected daily costs £102 to £124 £15 to £784 
Expected costs in the month £3,766 to £4,105 £294 to £7,575 
prior to death 
Expected total costs over five £63,872 to £85,067 £5,509 to £484,257 
years 
The second thing to note is that the mean non-transplant cost estimates for each 
prognostic model are approximately £20K less than the estimates when cost model 
uncertainty remained unaccounted for. 
The main cause of the change in mean non-transplant costs is the decrease in the 
probability of patients incurring a daily cost. The probability of incurring a daily cost on 
the transplant list is estimated using a binary logistic regression model, where the 
probability of incurring a daily cost ranges between zero and one. Prior to allowing for 
cost uncertainties the mean probability of incurring a daily cost was 0.88 (95% 
bootstrap CI: 0.85 to 0.90). After incorporating cost model parameter uncertainties the 
probability of incurring a daily cost ranged between zero and one across simulations, 
with a mean estimate of 0.82. Figures 7.5a and 7.5d illustrate how the probability 
distribution of incurring costs changes after allowing for cost model parameter 
uncertainty. 
The expected mean daily costs (Chapter 6, Equation 6.3) prior to allowing for cost 
model uncertainty was £114 and was similar to the mean costs (£112) after uncertainty 
was accounted for. However, like the probability of incurring costs, distributions were 
markedly different pre and post adjustment for cost model uncertainty (Pre 95% 
bootstrap CI: £102 to £124; Post 95% CI: £15 to £784). Figures 7.5b and 7.5e illustrate 
how the distribution of expected daily costs changes after allowing for cost model 
parameter uncertainties. 
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Prior to allowing for prognostic model parameter uncertainty the mean daily cost 
estimates, derived by multiplying the probability of incurring a cost by the estimated 
daily cost, was £98 (95% bootstrap CI: £89 to £106). After allowing for cost model 
parameter uncertainty the average probability of incurring a cost has decreased and 
the expected daily cost has remained approximately the same. Thus, the mean daily 
cost (the probability of incurring a cost multiplied by the estimated daily cost) decreases 
to £59 (95% CI: £0 to £637). This results in the mean daily cost estimate being lower, 
by approximately £40 per day, after accounting for cost model uncertainty, and this in 
turn reduces the mean total non-transplant costs over five years5. 
7.4.4 Summary 
Figure 7.6 illustrates the effects of accounting for cohort uncertainty, prognostic model 
parameter uncertainty, outcome uncertainty and cost model parameter uncertainty 
(Steps 1 to 4) on mean survival and cost estimates6 . The incorporation of prognostic 
model parameter and outcome uncertainty increases the uncertainty around non-
transplant survival, QAl Y and cost estimates. Additionally, the incorporation of cost 
model parameter uncertainty markedly increases the uncertainty around non-transplant 
cost estimates, because the method used to estimate costs in the absence of 
transplantation proved to be subject to a large amount of uncertainty. 
The three-part model that was chosen to predict non-transplant costs was the best 
fitting model for the PSC CELT data, yet the model failed to accurately predict non-
transplant costs. All three parts of the model were derived from CELT patients and the 
variables selected for inclusion in the model were statistically significant predictors of 
costs in the CELT cohort (p ~ 0.05). Had we used an external model (had one existed) 
or included non-significant variables in the model, then the uncertainty around the non-
transplant cost estimates could have been even greater than that presented in Figure 
7.4. 
5 For example, a patient surviving for 365 days will have estimated total costs of £35,770, assuming costs 
are incurred at a constant rate of £98 a day (excluding death costs) when cost model uncertainty is not 
accounted for and a total cost of £21,535, assuming costs are incurred at a constant rate of £59 a day 
~excluding death costs) when cost model uncertainty is accounted for. 
QAL Y estimates are not shown; the only uncertainty that impacted on the QAL Y estimates was that from 
the prognostiC models. Therefore, the pattern of uncertainty is exactly the same pattern as for survival 
estimates. 
218 
CHAPTER 7 PROGNOSTIC MODEL UNCERTAINTY 
Figure 7.6 Mean non-transplant a) survival and b) cost estimates with 95% Cis for the four stages of prognostic model uncertainty for 81 
PBC CELT patients using the European model 
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Decision makers should be presented with non-transplant estimates that incorporate 
model parameter uncertainty (prognostic model and cost model) and outcome 
estimation uncertainty in addition to cohort uncertainty, in order to make an informed 
decision regarding non-transplant cost and effectiveness estimates. 
7.5 SELECTION UNCERTAINTY: CHOOSING A PROGNOSTIC MODEL 
Thus far, this chapter has examined the effects of patient cohort uncertainty, prognostic 
model parameter uncertainty, prognostic model outcome uncertainty and cost model 
parameter uncertainty on non-transplant survival, QAL Y and costs, for one of three 
prognostic models. This section considers methods for allowing for uncertainties in the 
choice of prognostic models within PSA. 
The most obvious way of combining the results from a series of prognostic models is to 
combine the original data sets for the three models and refit a prognostic model based 
upon the combined data [Sutton et aI, 1998]. The original data were sought for the 
three prognostic models, though were only provided for the PBC Mayo model, 
therefore this approach could not be used. 
Another alternative would be to apply the Bayesian methods referred to in Chapter 5 
for dealing with model selection/structural uncertainty [Draper, 1995, Kang, 2000], 
which is the uncertainty that arises when selecting the mathematical structure of the 
model. These methods involve running "repeated analysis utilising different models and 
specifying prior probabilities of different models across this model space" [Briggs, 
2000]. These methods also require the original data and therefore, can not be used 
here to account for model choice uncertainty. 
In the absence of the original data, a meta-analytical approach, pooling the estimates 
from the regression coefficients and baseline survival/hazards to obtain an "averaged" 
prognostic model, might be considered. However, this is an inappropriate method to 
use because the choice of mathematical structure of the variables may differ between 
models. For example, the European model's variables are standardised prior to model 
fit and the PBC model and Royal Free model are not standardised. Further, the 
"averaged" coefficients and baseline survival/hazard estimates do not themselves 
produce meaningful survival estimates. Each individual prognostic model may contain 
a different combination of variables, as is the case for the three PBC models. Variables 
that are common to the prognostic models are not necessarily collected using the same 
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units, for example bilirubin is collected in mg/dl for the PSC Mayo model and IJmol/l for 
the European and Royal Free data sets. It is also important to recognise that some 
models may transform variables on to another scale, for example, a loge scale, 
whereas other models may transform variables on to a log10 scale or not transform the 
data at all. 
Therefore, rather than combining the results from the three models within a PSA, it is 
felt more appropriate to present separate estimates of non-transplant survival, QAl Ys 
and costs for each of the three prognostic models. Therefore, this section presents 
survival, QAl Y and cost estimates over five years for the PSC Mayo and Royal Free 
models after adjusting for cohort uncertainty, (prognostic and cost) model parameter 
uncertainty and prognostic model outcome uncertainty (Steps 1 to 4). The results from 
the European prognostic model are repeated in this section to aid the comparability of 
the uncertainty in non-transplant survival, QAl Y and cost estimates across the three 
PSC prognostic models. 
Figures 7.7 to 7.10 present the mean survival, QALY and cost estimates over five 
years for 81 PSC CELT patients, for the PSC Mayo and Royal Free models, after 
accounting for prognostic model and cost model uncertainties (Steps 1 to 4). The first 
thing to note is that the pattern of increasing uncertainty is the same across all three 
prognostic models, where CI for survival, QAl Y and cost estimates: 
• increase noticeably after allowing for Cox PH model parameter uncertainty 
(Step 2) and 
• increase marginally after the additional incorporation of outcome uncertainty 
(Step 3) and 
• cost estimates increase substantially after the additional incorporation of cost 
model parameter uncertainty (Step 4) 
Uncertainty in greatest when the PSC Mayo model is used to estimate non-transplant 
survival and is least when the European model is used. Although the PSC Mayo model 
displays more uncertainty than other models, this does not mean that it is a poor 
model: all three PSC prognostic models give similar mean non-transplant survival 
estimates over five years. 
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Figure 7.7 Mean predicted non-transplant survival, QALYs and costs over five years for 81 PBC patients: applying a) the European b) 
the PBC Mayo model and c) the Royal Free model - Incorporating cohort uncertainty 
a) European Model b) PBC Mayo Model b) Royal Free Model 
2.5 2.5 2.5 
• 2 .. 2 .. 2 
>- >- >- .. ' ~ ..J ." ~ I-I ~ --I 15 C c: ~ 1.5 ~ 1.5 · . . .. .+ .... +", .. · " " t! ~ co , .,. l: -;> § '. . c: ". !! 0 1 .. ".'. 1 -. . c: 1 . ~ , j .' . "tJ "tJ 
.! .. 
E 
. co iii 
~ Iii 
• .:J .5 
il 
w 5 W .5 
0 0 0 T I I 
0 25 50 75 100 125 150 175 200 0 25 50 75 100 125 150 175 200 0 25 50 75 lOa 125 150 175 200 
Esbmaled non-Iranoplant cosls (on £10(05) Esllma1l!ld non-transplant costs (In £1(005) l sllmalM non-transplant cost. (In £ 1000s) 
Survival in years (95% CI) Survival in years (95% CI) Survival in years (95% CI) 
2.63 (2.22 to 3.05) 2.60 (2.24 to 3.05) 2.74 (2.34 to 3.13) 
QAL Ys (95% CI) QALYs (95% CI) QAL Ys (95% CI) 
1.34 (1.06 to 1.65) 1.29 (1.04 to 1.60) 1.41 (1. 1 3 to 1.71) 
Costs (95% CI) Costs in £ (95% CI) Costs in £ (95% CI) 
£74,420 (£63,872 to £85,067) £78,849 (£67,277 to £90,718) £80,107 (£69,831 to £90,387) 
- ---- - -- ---
222 
CHAPTER 7 PROGNOSTIC MODEL UNCERTAINTY 
Figure 7.8 Mean predicted non-transplant survival, QALYs and costs over five years for 81 PBC patients: applying a) the European b) 
the PBC Mayo model and c) the Royal Free model - Incorporating cohort and prognostic model parameter uncertainty* 
a) European Model b) PBC Mayo Model c) Royal Free Model 
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Figure 7.9 Mean predicted non-transplant survival, QALYs and costs over five years for 81 PBC patients: applying a) the European b) 
the PBC Mayo model and c) the Royal Free model - Incorporating cohort and prognostic model parameter and outcome 
uncertainty* 
a) European Model b) PBC Mayo Model c) Royal Free Model 
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Figure 7.10 Mean predicted non-transplant survival, QAL Ys and costs over five years for 81 PBC patients: applying a) the European b) 
the PBC Mayo model and c) the Royal Free model - Incorporating cohort and prognostic model parameter and outcome 
uncertainty and cost model parameter uncertainty* 
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7.6 DISCUSSION 
In Chapter 3 the difficulties in selecting an appropriate observed non-transplant control 
group with which to compare the effectiveness, costs or cost-effectiveness of solid 
organ transplantation were discussed. In the absence of observed data from a control 
group, the approach adopted by several transplant studies, including the CELT study, 
was to use a prognostic model to estimate survival, QAl Ys or costs in the absence of 
transplantation. Given that it is necessary to estimate non-transplant outcomes, it is 
natural that there will be some degree of uncertainty relating to these estimates in 
comparison with predictions from an observed cohort of non-transplant patients. This 
chapter has shown that it is possible to allow for this uncertainty using PSA. 
7.6.1 Cost-Effectiveness Studies in Liver Transplantation: Choice of Control 
Group 
A total of eight studies in the solid organ transplant literature review (including the main 
CELT study) attempted to measure the cost-effectiveness of liver transplantation. 
Three of these eight studies used a current comparator group. Burroughs et a/ used a 
cohort of patients with end-stage cirrhosis who were treated for complications at the 
same centre as the transplant patients [Burroughs et ai, 1992]. The comparator cohort 
is likely to be of a different case mix to the transplant cohort and is likely to contain 
patients who are not eligible for transplantation. It is not clear how these potential 
differences between groups could affect the study results, as patient's clinical details 
are not supplied in the paper. Caution should also be applied to the interpretation of the 
paper by Manjo and colleagues, where it would be difficult to generalise the results, as 
the transplant cohort consists of only four patients [Manjo et ai, 2000]. Finally, Williams 
et aI's study is likely to exaggerate the effects of transplantation [Williams et aI, 1987]. 
The transplant cohort is selective and contains patients who survive for at least six 
months post transplant, although their non-transplant cohort met listing criteria for 
transplantation, they consist only of patients who died prior to transplant. None of these 
three studies acknowledge the likely biases from their choice of study design. 
The remaining five studies used modelling techniques to estimate the cost-
effectiveness of liver transplantation [Bonsel et aI, 1990; Sarasin et aI, 1998; Farinati et 
aI, 2001; Sagmeister et aI, 2002; Longworth et aI, 2003], and two of these five studies 
used prognostic models to estimate, what would have been, non-transplant survival 
[Bonsel et aI, 1990; Longworth et aI, 2003]. However, none of the five studies 
incorporated model parameter uncertainty in to cost-effectiveness estimates. 
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Thus, to date, decision makers have been unable to make a completely informed 
decision about the cost-effectiveness of liver transplantation, as the selection of the 
non-transplant control cohort is likely to give biased estimates or the decision makers 
have not been presented with full information on the uncertainty around cost-
effectiveness estimates. 
7.6.2 Reliability of Cost Estimates 
Non-transplant cost estimates were heavily dependent upon the survival estimates 
from the prognostic model. Cost estimates were influenced by both survival length, as 
estimated from the prognostic model and estimated outcome, where costs increased in 
the month prior to death. Therefore, this chapter also explored the impact of both 
prognostic model uncertainties and non-transplant cost model parameter uncertainties, 
predicted from a three-part model. 
The most striking result to be raised from this piece of research is the amount of 
uncertainty that should properly be attributed to the method for estimating non-
transplant costs. In both the main CELT study and here it was assumed that non-
transplant costs could be estimated based on the costs of patients on the waiting list. 
Non-transplant costs were estimated on a per patient basis and assumed to be 
constant over time until the month prior to death. In the main CELT analysis each 
patient's average daily cost on the waiting list was used to estimate non-transplant 
costs over time. However, this approach did not allow for uncertainty in the cost 
predictions, therefore the method for estimating non-transplant costs adapted here 
modelled costs more completely than the approach used in the main CELT analysis 
[Longworth et ai, 2003]. 
The three-part modelling approach for estimating non-transplant costs adopted in this 
chapter is not necessarily the only model solution for estimating costs in the absence of 
transplantation and other approaches may produce more reliable estimates. For 
example, a model that incorporates more detailed information relating to the individual 
change in costs over time on the waiting list, may give more accurate predictions than 
the model used here, which uses the individual average daily cost on the waiting list. 
Alternative approaches to modelling daily costs could be explored by using a Bayesian 
approach to model structural uncertainty [Draper, 1995]. However, the cost models that 
have been used here are ones that best fit the CELT data, and the variables selected 
in the models are ones that were found to be significant predictors of costs for the 
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CELT cohort. Despite this the model estimates were subject to a large amount of 
model parameter uncertainty. Decision makers should be presented with mean non-
transplant cost estimates with 95% CI that include the parameter uncertainty around 
the cost model in order to highlight how poor the estimates of non-transplant costs are. 
The final area of concern relating to cost estimates was how allowing for cost model 
parameter uncertainty changed the mean non-transplant cost estimates. It is generally 
assumed that mean estimates remain constant and the degree of uncertainty around 
them varies. Therefore, decision makers make policy implications based on mean 
estimates and the information on uncertainty is used to make decisions about whether 
further research is needed (value of information analysis) [Claxton, 1999]. Given that 
the best estimate of a statistic (e.g. mean cost) is the observed mean cost from the 
original data, it can be seen that the best estimate of the mean cost estimated from a 
prognostic model should be derived using the mean regression coefficients. Therefore, 
it is recommended that decision makers make choices about the clinical or cost-
effectiveness of treatments or technologies using a base case scenario based upon 
mean survival, QAl Y and cost estimates prior to allowing for any uncertainties. Mean 
survival, QAl Y, cost or cost-effectiveness estimates that incorporate uncertainties 
should then be presented separately and these can be used to inform decisions 
regarding whether further research should be undertaken. 
7.6.3 Cost-Effectiveness of Liver Transplantation 
The aim of Chapters 5 to 7 was to propose methods for estimating uncertainty around 
prognostic model estimates and to demonstrate the effects of this uncertainty on 
survival, QAl Y and cost estimates. Therefore, the impact of prognostic model 
uncertainties on the cost-effectiveness of liver transplantation in the UK was not 
examined. 
Had one of the objectives of this thesis been to estimate the cost effectiveness of liver-
transplantation over a five-year period after incorporating prognostic model 
uncertainties it would have been necessary to make assumptions about transplant 
resource use and HRQL. Survival information post transplant, was routinely collected 
and available at each of the six centres participating in the CELT study, and was 
obtained from each centre for the extended five-year study period. However, resources 
were unavailable to the CELT study for obtaining information on HRQl and resource 
use information from 2.25 years post assessment to five years post assessment. 
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Hence, estimation techniques are needed in order to estimate transplant HRQl and 
costs for the extended study period, drawing upon information from the CELT study. 
A full PSA analysis would incorporate all uncertainties in to the estimation of the cost-
effectiveness of liver transplantation in the UK over a five-year period, but was beyond 
the scope and focus of this thesis. 
7.6.4 Incorporating Other Sources of Uncertainty in to PSA 
This chapter has focused on presenting methods for measuring the impact of 
prognostic model uncertainty on non-transplant survival, QAl Y and cost estimates in 
the absence of information from an observed control group. Uncertainty from 
prognostic models occurs in addition to standard sources of uncertainty, for example 
assigning distributions around unit costs or HRQl estimates, and this analysis can be 
extended further to incorporate these sources of uncertainty within a full PSA. 
One source of prognostic model uncertainty we were unable to incorporate in to the 
PSA analysis was model choice uncertainty. In principle, it should be possible to 
combine the regression coefficients and baseline survival/hazard estimates in to one 
"average" prognostic model, providing that the original data are available for all three 
models. Insufficient information was available for all three PSC models to produce an 
average model. Therefore, a series of three deterministic one-way sensitivity analyses 
(scenario analysis) were presented, one for each prognostiC model, which incorporated 
prognostic model uncertainties. It is recommended that the results for all three 
scenarios be presented to decision makers. 
7.7 CONCLUSIONS 
This is the first time that PSA has been used to describe uncertainty around prognostiC 
model estimates and, more specifically, uncertainty in non-transplant survival, QAl Y 
and cost estimates in liver transplantation. Although mean survival, QAL Y and cost 
estimates were robust across three PSC prognostiC models the uncertainty around 
these estimates varied by prognostiC model. 
Allowing for prognostic model uncertainty increased the amount of uncertainty around 
mean survival, QAl Y and cost estimates, in comparison to estimates where only cohort 
uncertainty is accounted for. Individual patient outcome uncertainty had only a small 
impact on non-transplant survival, QAl Y and cost estimates. In contrast parameter 
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uncertainty from the three-part cost model only impacted on non-transplant cost 
estimates and greatly increased the uncertainty around the mean cost estimates. 
Additionally, cost model parameter uncertainty changed the mean cost estimates by 
over £20K in comparison with mean cost estimates prior to accounting for cost model 
uncertainties. It is recommended that further research in to the repeatability of these 
results to other data sets and models be explored in further detail. Furthermore, 
decision makers should be presented with mean survival, QAL Y, cost or cost-
effectiveness estimates prior to allowing for any uncertainties (base case scenario) and 
subsequently presented with estimates that allow for uncertainties such as model 
parameter uncertainties (and the uncertainty around them). 
Intuitively, a prognostic model displaying the least amount of uncertainty might be an 
appealing choice of model, in comparison with models that display a greater amount of 
uncertainty. However, this thesis has already argued that a model displaying a large 
amount of parameter uncertainty will not necessarily give inaccurate survival estimates, 
with uncertainty being attributed to a number of factors including; the number of 
parameters in the model, the Uustifiable) inclusion of non-significant variables, the type 
of model fitted (structural form), sample size and the number of events. The only 
"justification" for excluding one of the three PSC prognostic models, the PSC Mayo 
model, was that it was not based on a cohort of UK patients. 
Decision makers should be presented with survival, QAL Y and cost estimates that 
account for the uncertainty that arises from using prognostic models, in the absence of 
information from an observed cohort. Additionally, when more than one prognostic 
model exists, scenario analysis should be undertaken and estimates provided for each 
of the prognostic models and each set of estimates should allow for prognostic model 
uncertainties. 
This thesis has identified and explored two areas of uncertainty identified as issues 
important within an economic evaluation in liver transplantation and generalisable to 
other economic evaluations in health care (selecting an appropriate method for 
estimating mean total costs in the presence of censoring and measuring uncertainties 
from prognostic models). Chapter 8 will summarise the findings of this thesis and 
explore the wider implications of these findings within the transplant community, for 
researchers and decision makers. 
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CONCLUSIONS 
8.1 INTRODUCTION 
When conducting an economic evaluation it is important to identify all possible sources 
of uncertainty (sampling variation, methodological uncertainty, extrapolation and 
generalisability, model parameter, model structure and model process) and present 
information about these uncertainties to decision makers. Providing full details of these 
uncertainties and their effects on the health care technology under evaluation will 
enable decision makers to reach an informed decision and make informed 
recommendations on the need for further research. 
The aim of this thesis was to explore some methodological issues for measuring 
uncertainties in economic evaluations. The issues explored here were identified as 
important concerns in the potential extension of an economic evaluation in liver 
transplantation over a five-year study period. A review of the literature of solid~rgan 
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transplant studies confirmed that the uncertainties identified in the CELT study were 
issues that were not addressed adequately in other solid organ transplant studies. 
This thesis has focused on two separate issues of methodological, model parameter 
and model uncertainties, namely: 
• the selection of an appropriate method for estimating mean total costs in the 
presence of censoring (methodological uncertainties) 
• the measurement of uncertainty around survival, QAl Y and cost estimates 
derived from prognostic models in the absence of observed data (model 
parameter, model selection and methodological uncertainties) 
This final chapter will summarise the main findings of this thesis and discuss the 
implications of these findings within solid-organ transplantation. This chapter will also 
discuss how the methods and guidance given in this thesis contribute to health 
services research and its value to decision makers. 
8.2 ISSUES OF UNCERTAINTY IN SOLID-ORGAN TRANSPLANTATION 
STUDIES 
Chapter 2 presented an overview of the results of an economic evaluation in liver 
transplantation in the UK over a 2.25 year study period (the CELT study) [Longworth et 
aI, 2003]. The cost-effectiveness of liver transplantation was evaluated for three liver 
disease groups: AlD, PSC and PSC. 
Survival, HRQl and resource usage were observed for the transplant cohort from point 
of assessment to 2.25 years post assessment. In the absence of data from an 
observed cohort of non-transplant patients with end-stage liver failure, prognostic 
models were used to estimate the transplant patients' non-transplant survival, had they 
not received a transplant. 
The incremental QAl Y gain from liver transplantation over 2.25 years was 
approximately six months across all disease groups. However, the cost-effectiveness 
of liver transplantation in the UK differed by disease groups. The cost-effectiveness of 
liver transplantation was most likely to be acceptable in patients with PSC (Mean ICER: 
£21 K), then PSC (Mean ICER: £29K) and least likely to be acceptable for AlD patients 
(Mean ICER: £4BK). 
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Longworth et al suggested extending the analysis over a longer time frame so that the 
mid to long term benefits of liver transplantation could be measured. Therefore, a 
proposed extension to the CELT study time frame from 2.25 years to five years was 
considered. The proposed extended time frame raised two areas of concern: selecting 
an appropriate method for estimating mean total costs in the presence of censoring 
and measuring uncertainties around prognostic model estimates. 
Solid organ transplantation is currently considered to be the treatment of choice for 
patients with end-stage organ failure, despite having never been the subject of an ReT. 
In the absence of this gold standard evaluation (a situation which seems likely to 
remain), researchers seeking to evaluate the effectiveness, costs or cost-effectiveness 
of solid organ transplantation need to be especially careful to select a comparator 
group for transplanted patients that would appear to give the most reliable approach 
and that considers representativeness, comparability and sample size in particular. 
Chapter 3 described alternatives to the RCT study design which could be applied to 
studies in solid organ transplantation in order to assess their effectiveness, costs or 
cost-effectiveness. The use of quasi-experimental control groups, intervention delay 
cohorts, historical cohorts, case-control studies, before and after studies, expert 
opinions and modelling techniques were considered as possible methods to create 
comparisons for evaluating the medical management of end-stage organ failure in 
comparison with transplantation. However, all of the comparator groups listed above 
were either unrepresentative of the general population, not comparable to the 
transplant cohort, or were unlikely to be of sufficiently large sample size to draw 
conclusions from. 
Chapter 3 confirmed that the two uncertainty issues identified in the CELT study were 
not adequately addressed within other effectiveness, cost and cost-effectiveness 
studies in solid organ transplantation. Virtually all of the 158 studies included in the 
literature review in Chapter 3 failed to acknowledge any of the inherent problems 
relating to the choice of an appropriate non-transplant control group or to perform any 
form of sensitivity analysis to allow for any sources of uncertainty in the study. The 
literature review also confirmed the importance of providing guidance for estimating 
mean study costs, where only three out of 33 studies attempted to adjust for censoring 
when estimating mean study costs. The remaining 30 studies failed to give sufficient 
detail to establish whether censoring was an issue and it was assumed that it would be 
for a proportion of the thirty studies. Further, none of the studies that used prognostic 
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models to estimate non-transplant survival accounted for uncertainty in prognostic 
model estimates. These two concerns were not unique to the CELT study and were 
generalisable to other solid organ transplant studies. 
8.3 GUIDANCE ON METHODS FOR ESTIMATING MEAN TOTAL COSTS IN THE 
PRESENCE OF CENSORING - METHODOLOGICAL UNCERTAINTY 
Censored data can be a problem in all health care research studies, it occurs when a 
proportion of patients in a cohort do not have the event of interest (e.g. death) and 
have incomplete follow up data for the study period. Although well established methods 
exist to account for censored survival data it is inappropriate to directly apply these 
methods to censored cost or QAl Y estimates. 
A review of the literature identified 12 methods that can be applied to censored cost 
data to estimate mean study costs in the presence of censoring: ignoring censoring, 
ignoring censored cases, Kaplan-Meier cost method, Cox PH cost method, the 
partitioned Cox cost method [Lipscomb et ai, 1998], Lin's methods with either KCH or 
unknown cost history (UCH) [Lin et ai, 1997], the weighted cost method with KCH or 
UCH [Bang & Tsiatis, 2000], Lin's regression method with KCH or UCH [Lin, 2000] and 
Carides' regression method [Carides et ai, 2000]. To date no review of all existing 
methods for estimating mean total costs in the presence of censoring exists. Therefore, 
this thesis sought to review these methods and to offer guidance in the selection of 
appropriate methods for estimating mean study costs in the presence of censoring. 
The 12 methods identified in the literature review were compared across four different 
censoring mechanisms - random censoring, end-of-study censoring, informative 
censoring and partial censoring - by simulating the censoring mechanisms from a 
complete cohort of patients included in the CELT study. Methods were also compared 
across differing levels of censoring ranging from light censoring (10% of data censored) 
to heavy censoring (80% censored). Finally, the accuracy of mean cost estimates was 
compared across different interval lengths for the six methods where the study time 
period can be divided in to smaller interval lengths (weighted cost method [KCH], Lin's 
regression method [KCH], Lin's method [KCH], partitioned Cox cost method, Carides' 
method and Lin's method [UCH]). The aim was to establish whether the choice of 
interval length affected the accuracy of the mean cost estimates for each of the six 
methods. 
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Chapter 4 included three methods that have serious shortcomings in estimating mean 
total costs in the presence of censoring: the Kaplan-Meier method (estimates were 
almost four times greater than the observed mean cost for the "complete" data set prior 
to censoring [£36,045]), Cox cost method (estimates approximately twice as high as 
the observed estimate) and partitioned Cox cost method (estimates at least £10K lower 
than the observed estimate). Yet anecdotal evidence suggests that these methods are 
still commonly used. As demonstrated here and elsewhere, application of the Kaplan-
Meier method, Cox cost method or partitioned Cox cost method will result in serious 
bias when estimating mean costs affected by censoring. For this reason, it was felt 
important to investigate and address this issue in depth, in order to ascertain how well 
12 proposed methods work in various circumstances. 
Chapter 4 identified a further three methods that gave poor estimates of mean study 
costs when resources were not incurred in the final period of the study: Lin's method 
(UCH), Carides' method and the weighted cost method (UCH). It is recommended that 
these three methods should not be applied when costs are not incurred at the end of 
the study period of interest. This scenario is most likely to occur when economic 
evaluations are subject to partial censoring and is therefore more likely in economic 
evaluations designed to collect costs at specific time points during the study or when 
costs are collected at one time point during the study period. For example, a study may 
be designed to collect costs every six months, thus a patient dying in month eight will 
have a six-month cost but censored costs for month seven onwards or a study may be 
designed to collect cost data over a two year period and survival data over a four year 
period, therefore cost data are censored from the end of year two to the end of year 
four. The scenario is less likely to occur for treatment specific interventions, though 
potentially costs might not be incurred at the end of the study period when the majority 
of resource use is incurred at the beginning of the study period with few resources 
occurring later on in the study i.e. liver transplantation, surgical interventions and 
service interventions. 
It was surprising that the method of ignoring censoring was one of the more accurate 
methods for estimating mean total costs. The technique of ignoring censoring produced 
fairly accurate estimates of mean total costs and standard errors when censoring was 
restricted to the end of the study period (end-of-study censoring restricted to the final 
six months of the study and partial censoring). The accuracy of this method could be 
due to the nature of the CELT dataset, where on average larger costs were incurred 
235 
Chapter 8 Conclusions 
earlier in the study period at the point of the transplant operation and stabilised in the 
later end of the study period. Assuming that these results are generalisable to other 
solid organ transplantation studies, the cost and cost effectiveness estimates 
presented by the 30 studies identified in Chapter 3 (that potentially ignored the issue of 
censoring) are likely to result in more accurate mean estimates than if they had chosen 
an inappropriate method for accounting for censoring (For example the Kaplan-Meier 
method). 
Selecting the interval length that resulted in the best mean cost estimate and 
comparing the estimates across all 12 censoring methods showed that Lin's method 
(KCH) with small interval lengths gave the most accurate estimate of mean study costs 
across all censoring mechanisms and levels. Therefore, based upon the results of the 
CELT study, it is recommended that in the presence of censored cost data Lin's 
method with short interval lengths (KCH) is used to estimate mean study costs in the 
presence of censoring. 
The majority of methods that gave reliable mean cost estimates were poor at 
estimating the standard error. In order to obtain accurate estimates of both the mean 
and standard error, the results of Chapter 4 suggest Lin's method (KCH) with small 
interval lengths and the weighted cost method (KCH) give the most accurate estimates 
of both. Lin's method (KCH) and the weighted cost method (KCH) performed well 
across all censoring mechanisms and levels. 
8.3.1 Implications - Censoring Methodology 
Bodies issuing guidance on the evaluation of health care technologies do not currently 
offer advice on methods for estimating mean total costs in the presence of censoring 
[See: Drummod & Jefferson, 1996; NICE, 2004; CADTH, 2006]. Based upon the 
results of one study it is recommended that Lin's method (KCH) with small interval 
lengths be used to estimate mean total costs in the presence of censoring. Lin's 
method (KCH) gave accurate estimates of both the mean study costs and their 
uncertainty. 
The weighted cost method (KCH) also gave accurate estimates of the mean study 
costs and its standard error, but when dividing the study period up in to smaller 
intervals it is not obvious how to select the interval length that achieves the most 
accurate cost and standard error estimates. Comparing estimates across interval 
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lengths, the weighted cost method gave the most accurate estimates using interval 
lengths of six months for random and end-of-study censoring and three months for 
partial and informative censoring. However, for two monthly interval lengths there was 
a loss of information when estimating the Kaplan-Meier survival probabilities. With 
CELT survival measured in monthly units and choosing two monthly interval lengths an 
event can only occur at one of two time points (month one or month two). This choice 
of interval lengths thus results in less accurate estimates of survival over time. 
Therefore, it is suggested that further research is undertaken to establish whether it is 
possible to create a formula for selecting interval lengths for the weighted cost method 
(KCH) that result in the most accurate estimate of mean study costs. 
Under random, end of study and informative censoring due to good health the accuracy 
of methods for estimating mean total costs in the presence of censoring (excluding 
na·(ve methods: Kaplan-Meier, Cox cost, partitioned Cox cost, ignoring censoring and 
complete costs) varied by approximately £3K. It could be argued that a £3K difference 
around the "true" mean estimate is a small difference and it is immaterial which method 
is used to estimate mean costs (Observed mean CELT study cost = £36,045). 
Variation increased under informative censoring due to ill health and partial censoring 
(ignoring estimates for Lin's method (UCH), the weighted cost (UCH) and Carides' 
method under 80% partial censoring) to between £4K to £8K and could now be argued 
to be a meaningful difference in variation across methods. These differences are 
specific to the CELT study and the variation across methods depends upon the type of 
censoring mechanism. If the mean cost of transplantation had been lower, for example 
£20K, a £3K difference between methods might be regarded as meaningful. Given that 
the variation across methods is influenced by censoring mechanism and the expected 
"true" mean cost would impact on the importance given to the magnitude of the 
variation across methods it is recommended that Lin's method KCH with small interval 
length be used to estimate mean total costs in the presence of censoring. 
The recommendations on the selection of an appropriate method for estimating mean 
total costs in the presence of censoring are based on observations from one cost-
effectiveness study. The CELT study was most likely to be subject to end-of-study 
censoring and had a distinct pattern of cumulative costs over time. Other solid organ 
transplant studies are likely to observe a similar resource usage pattern over time, it is 
assumed that the recommendations given in this thesis are generalisable to other solid 
organ transplant studies estimating mean costs in the presence of censoring. 
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However, the methods that produced the most accurate estimate of mean total costs 
i.e. Lin's method KCH with small intervals, might not give the most accurate estimates 
of mean costs in other data sets where the pattern of resource use differs to that 
observed in the CELT study. Each of the non-na·ive methods for estimating mean total 
costs (Lin's methods KCH and UCH, weighted cost methods UCH and KCH, Lin's 
regression methods UCH and KCH and Carides' method), apply Kaplan-Meier survival 
probability weights to costs. 
Lin's method KCH weights mean costs per interval by the Kaplan-Meier probability of 
survival in each interval, with mean costs in later intervals weighted lower than mean 
costs in earlier intervals. If a study observed an increase in resource usage over time, 
for example in studies of chronic conditions, then lower weights will be applied to the 
higher costs at the end of the study which could result in an underestimation of mean 
costs. Similarly, cost estimates from a study observing a constant resource use pattern 
over time, for example a drug treatment, may also be underestimated. 
Lin's method UCH and Carides' methods use a similar process and weight cost 
estimates by the probability of dying, where the largest weights occur in intervals with 
the greatest probability of death. Finally, the weighted cost methods and Lin's 
regression methods weight costs by the inverse of the Kaplan-Meier survival 
probability, with reverse censoring, thus inflating costs, with a higher level of inflation 
applied to costs in the later intervals of a study.1 Therefore, the weighted cost method 
and Lin's regression method with UCH might overestimate mean cost estimates in 
studies where costs increase over time (chronic conditions) or studies with constant 
resource patterns over time (drug treatments) by over inflating costs at the end of the 
study period. 
The above discussion speculates as to how mean total cost estimates could be 
affected by alternative patterns of resource use to those observed for in the CELT 
study, i.e. resource use patterns for chronic conditions and drug treatments, and it is 
important to investigate these hypotheses with further research. 
1 If cost histories are known the study period is divided into several intervals and costs will be given a 
larger inflation rate in the later part of each interval in comparison to earlier parts of the interval. 
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8.4 PROGNOSTIC MODEL UNCERTAINTIES MEASURING MODEL 
PARAMETER, MODEL STRUCTURE AND METHODOLOGICAL 
UNCERT ANITIES 
To date none of the published solid organ transplant studies that applied prognostic 
models to estimate non-transplant survival, and subsequently QAl Ys or costs, 
incorporated uncertainties in the prognostic model estimates. Chapters 5 to 7 
presented simulation methods for estimating the uncertainty around these estimates, 
demonstrating that it is possible to account for uncertainties in prognostic models. 
Published prognostic models can be applied in studies to predict patient outcomes (Le. 
survival, QAL Ys and costs) in the absence of observed data or in situations where 
researchers wish to model the likely implications of a change in a current treatment 
policy or the introduction of a new policy. Prognostic models were applied to CELT 
study patients in order to estimate, what would have been, their survival in the absence 
of liver transplantation. 
Prognostic models are subject to various types of model uncertainty (parameter, 
structure and methodological process) and Chapters 5 to 7 present PSA techniques 
that account for prognostic model parameter and outcome uncertainties. Chapters 5 
and 7 also considered ways of selecting the appropriate prognostic model, when more 
than one model exists. The remainder of this section considers the methodological 
contributions of the simulation techniques proposed in this thesis to account for model 
parameter uncertainty, selection (structural) uncertainty and methodological 
uncertainty. 
8.4.1 Model Parameter Uncertainty 
Prognostic models are subject to model parameter uncertainty and Chapter 5 proposed 
a Monte Carlo simulation technique to allow for this uncertainty when estimating 
survival from Cox PH models. The Monte Carlo method uses information from 
prognostic model regression coefficients and their standard errors to measure model 
parameter uncertainty. The method can be applied to any mathematical model to 
estimate parameter uncertainty, provided that information on the standard errors of 
(and correlation between) regression coefficients are given. In Chapter 7 the Monte 
Carlo technique was also applied to a three-part regression model for estimating non-
transplant costs to measure the parameter uncertainty around cost estimates, 
alongside prognostic model parameter uncertainty. 
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Further work should be carried out to establish whether it is important to adjust for 
correlations between regression coefficients when accounting for prognostic model 
parameter uncertainties. The only prognostic model where it was possible to 
incorporate correlations between regression coefficients was the PBC Mayo model, 
where the original Mayo model data were available. The results showed that allowing 
for correlations between regression coefficients for the PBC Mayo model had little 
noticeable impact on the uncertainty around prognostic model estimates in comparison 
with estimates where only information on the standard errors of regression coefficients 
was used. However, guidelines set by NICE state that decision makers should "know 
about the uncertainty associated with clinical and cost-effectiveness information" 
[NICE, 2004]. Therefore, it is recommended that the additional uncertainty from the 
correlation between regression coefficients should be incorporated in to model 
parameter uncertainty, in order to provided further knowledge about uncertainty, 
provided that this information is available. 
None of the published prognostic models used to estimate non-transplant survival in 
the CELT study provided information on the correlation or covariance matrix for 
prognostic model regression coefficients. Therefore, in order for this extra uncertainty 
to be incorporated in to survival estimates it is advised that authors of future prognostic 
models provide an additional table with the correlation coefficients of the regression 
coefficients. Providing the reader with this additional information would give potential 
users the opportunity to obtain more realistic estimates of uncertainty and joumal 
editors ought to ensure that this is done. 
Both Chapter 5 and 7 demonstrated that the incorporation of prognostiC model 
parameter uncertainty impacts on the CI around mean outcome estimates, where the 
greater the amount of uncertainty in the prognostic model, the larger the amount of 
uncertainty around mean estimates. This was demonstrated in Chapter 5, where the 
PBC Mayo model, which had a larger amount of uncertainty in its parameters than the 
Royal Free and European models, displayed a larger amount of uncertainty around 
mean non-transplant survival estimates than the other two models. All three prognostic 
models gave similar mean non-transplant survival estimates. 
Additionally, this thesis has raised three issues regarding the accuracy of non-
transplant cost estimates. Firstly, it raises questions about the appropriateness of 
assuming non-transplant costs remain constant over time, except for a period prior to 
240 
Chapter 8 Conclusions 
death. The main CELT study was not the only organ transplant study to assume that 
non-transplant costs remained constant over time [Bonsel et al. 1990a; Van Enckevort 
et al. 1997; Anyanwu et al. 2002]. Therefore, it appeared reasonable to assume that 
costs remained constant over time in the CELT study. It is perhaps more realistic to 
assume that non-transplant costs vary over time, and further work should be carried 
within the area of transplantation to explore the pattern of costs over time using time 
dependent modelling techniques. For example, resource use information was collected 
for the CELT study on a daily basis, making it possible to calculate CELT study costs 
on a daily basis. Modelling daily costs over time would establish whether assumptions 
about alternative rates of change in costs reflect non-transplant resource use more 
accurately. It is therefore suggested that future economic evaluations in solid organ 
transplantation should investigate these issues further. 
Secondly, the large amount of uncertainty around modelled non-transplant cost 
estimates raises concerns about whether other models might fit the data better than the 
three-part model applied in Chapters 6 and 7. Alternative approaches to modelling daily 
costs could be explored using methods that allow for model structure uncertainty [See: 
Draper, 1995]. 
The final area of concern was the effect of cost model parameter uncertainty on mean 
estimates, where mean non-transplant cost estimates decreased by £20K after 
allowing for cost model parameter uncertainty. It is generally assumed that mean 
estimates remain constant and only the degree of uncertainty around them varies, 
however this thesis showed that this assumption does not always hold true. It is 
recommended that decision makers make choices about the clinical or cost-
effectiveness of treatments or technologies using a base case scenario based upon 
mean survival, QAl Y and cost estimates prior to allowing for any uncertainties. Mean 
survival, QAl Y, cost or cost-effectiveness estimates that incorporate uncertainties 
should then be presented separately and these can be used to inform decisions 
regarding whether further research should be undertaken. This supports 
recommendations made by Claxton that decision makers make policy implications 
based on mean estimates and the information on uncertainty is used to make decision 
about whether further research is needed using value of information analysis [Claxton, 
1999]. 
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8.4.2 Model Selection Uncertainty 
Three prognostic models were available for estimating non-transplant survival in 
patients with end-stage liver failure. The derivation of these three prognostic models is 
subject to model process uncertainty, where three independent research teams chose 
alternative modelling approaches (fixed time or time dependent models), and had 
different variable selection criteria (Chapter 5). This resulted in three altemative 
prognostic models that contained different combinations of variables for estimating 
survival. All three prognostic models gave similar mean estimates when applied to the 
CELT cohort. Chapter 7 considered whether it was possible to merge the regression 
parameters from the three prognostic models in to one model and concluded that it was 
more appropriate to present separate estimates of non-transplant survival, QAl Ys and 
costs for each prognostic model. Therefore, in the absence of original prognostic model 
data, when more than one appropriate prognostic model exists, scenario analysis that 
presents the results from all alternative prognostic models is recommended. 
8.4.3 Methodological Uncertainty 
The analytic need to estimate individual patient outcomes will generally be specific to 
studies where: 
• observed information on patient outcomes are unavailable and prognostic 
models are utilised to estimate patient outcomes; 
• outcomes are to be estimated over a fixed study period; 
• individual outcome estimates are needed, for example to: 
- estimate the survival, QAl Y or costs at the patient level; 
- estimate the survival, QAl Y or cost gain at the patient level; and, 
- make an adjustment to costs, or HRQl data for a time period prior to 
death. 
In the CELT study, the published prognostic models did not provide enough information 
to estimate "lifetime" patient survival. Additionally, they did not provide information as to 
who was alive or dead at a fixed prior time point (five years). Therefore, Chapter 6 
presented three alternative methods for estimating individual patient outcomes and the 
uncertainty around them: 
• 
assumes the probability of survival is equivalent for all patients, with survivors 
selected randomly 
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• assumes the N patients with the longest expected survival times are the 
survivors, where N is the expected number of survivors in the cohort 
• PSA 
PSA was recommended for estimating individual patient outcomes, as it accounted for 
patient level information relating to expected outcome and allowed for uncertainty in 
individual patient outcome estimates. 
As outlined above, there are circumstances in which a researcher will want to estimate 
individual patient outcomes from a Cox PH prognostic model, and to date, no study has 
attempted to formalise these methods. Therefore this thesis has made a contribution to 
the methodology by providing three alternative methods for estimating individual patient 
outcomes, with PSA being the preferred method. 
8.4.4 Implications - Measuring Prognostic Model Uncertainties 
PSA often purports to reflect the true uncertainty in clinical and cost-effectiveness 
studies. This thesis highlights that in the absence of an observed control group there 
are more uncertainties than are normally recognised in traditional cost-effectiveness 
studies, in which data from a control cohort are traditionally observed. PSA is able to 
incorporate the additional uncertainty from using prognostic models to estimate control 
group outcomes in the absence of observed data alongside more traditional forms of 
uncertainty, for example uncertainty in unit cost or HRQl estimates. 
8.5 FURTHER RESEARCH IN TO UNCERT AINTV 
This thesis has focused on providing guidance in the selection of a method for 
accurately estimating mean total costs in the presence of censoring and presenting 
methods for measuring uncertainty around prognostic models. In the course of 
exploring these issues other areas of uncertainty in censoring, prognostic modelling 
and within the CELT study were highlighted. This section presents these issues in 
further detail. 
8.5.1 Further Issues of Censoring in QAL V, Cost or Cost-effectiveness Studies 
It is assumed that the recommendation of using Lin's method (KCH) with small interval 
lengths is generalisable to all solid organ transplantation studies that are subject to 
censored cost data. However, it is recommended that further research is undertaken to 
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establish whether these recommendations can be generalised to health care research 
studies. 
HRQl is typically measured at one or more fixed time points during a study, patients 
may chose not to respond at particular time points and thus HRQl data could have a 
higher likelihood of informative censoring than resource use data. Given that the 
censoring mechanism may differ to that for resource use data caution is advised in 
generalising the results shown here to QAl Y. Further work should also be conducted 
to establish the generalisability of the results to censored QAl Y and cost-effectiveness 
data. Additional, future work should focus on accurate estimates of both the mean and 
the standard error because decision makers are advised to give advice on the 
necessity of further research, based upon the uncertainty around clinical and cost-
effectiveness estimates. 
Any method that accounts for censoring in cost-effectiveness studies should allow for 
the correlation between QAl Y and cost data and a number of researchers have 
proposed methods that account for this when estimating the cost-effectiveness of 
treatments in the presence of censoring [Willan & Lin, 2001; Backhouse et aI, 2002; 
Willan et aI, 2002; Willan et aI, 2003; Heitjan et aI, 2004; Willan et aI, 2004]. Therefore, 
any future research that compares the accuracy of methods for estimating the cost-
effectiveness of health technologies should allow for these methods. 
8.5.2 Further Issues of Model Uncertainty 
This thesis focused upon methodology for estimating the uncertainty around the Cox 
PH prognostic models with the parameter uncertainty around non-transplant cost 
estimates presented in Chapter 7. A further area of model uncertainty that could also 
be explored in more detail is the uncertainty around HRQl estimates. It was decided to 
focus on the uncertainty around Cox PH and cost models because conventional PSA 
typically allows for uncertainty in HRQl estimates. However, it is important to bring to 
the readers attention that utility estimates are also subject to model parameter and 
model structure uncertainty. 
The EQ-SO was used in the main CELT analysis to estimate non-transplant HRQl, and 
subsequently, utility values and QAl Ys. Utility estimates for the EQ-SO were derived by 
applying an algorithm to each patient's EQ-SO responses. The algorithm for estimating 
utilities from EQ-SO responses was originally derived by Oolan by fitting a general least 
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squares regression model, i.e. a prognostic model, to a cohort of responders to the EQ-
SO [Oolan, 1997]. Thus, the EQ-SO algorithm consists of a set of regression 
coefficients derived from a prognostic model and these regression coefficients are 
subject to model parameter uncertainty. The Monte Carlo simulation techniques, 
presented in Chapter S, could have been applied to the CELT cohort to account for 
model parameter uncertainty using information on the standard errors (and correlation) 
from the regression coefficients. Any future PSA analysis of the CELT data that 
attempts to account for all sources of uncertainty should allow for the model 
uncertainties in EO-SO utility estimates. Further, all clinical and cost-effectiveness 
studies of health care technologies that wish fully incorporate uncertainties and who 
have used the EQ-SO should consider applying Monte Carlo simulation methods to 
EQ-SO model parameters to allow for EQ-SO model parameter uncertainty. 
Further, utility estimates can also be subject to model structure/selection uncertainty. 
For example, the CELT study patients complete two HRQl questionnaires the EQ-SO 
and the SF-36. It is possible to derive patient utilities from both of these instruments2 . 
Several authors have compared the utility values of the SF-60 with the EQ-SO and 
concluded that the instruments give different utility values [See: McOonough et aI, 
200S; Stavern et aI, 200S]. The SF-60 is ineffective at describing health states at the 
lower end of the utility scale (close to zero) and the EQ-SO is ineffective at the upper 
end of the scale (close to one) [Longworth & Bryan, 2003; Brazier et al. 2004]. 
Instrument selection was not considered in this thesis, which focused on prognostic 
model selection process, an area of uncertainty that has not previously been 
considered by other researchers. However, the main CELT analysis estimated the 
cost-effectiveness of liver transplantation over 2.2S years using both the EQ-SO (main 
analysis) and the SF-60 (sensitivity analysis) [Longworth et aI, 2003]. 
8.5.3 Other Issues of Uncertainty 
This thesis has approached the issue of statistical uncertainty from a standard 
frequentist point of view, thus all the methods and issues dealt with, within this thesis, 
use frequentist methods. An alternative approach would have been to consider the use 
of Bayesian methods in the estimation of uncertainty within the CELT study and 
methods exist for accounting for uncertainty in health care research studies within a 
Bayesian framework [See: Spiegelhalter et aI, 2004]. None of the methods identified for 
2 Brazier et al derived a preference based measure from the SF-36, known as the SF-60 [Brazier et ai, 
2002]. A scoring system is assigned to six of the questions in the 36 item instrument and, as with the EQ-
50 a value of one represents full health and zero death. 
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estimating mean costs in the presence of censoring used Bayesian analysis, therefore 
it was not applicable to focus on Bayesian methods here. However, it would have been 
possible to develop Bayesian techniques when estimating prognostic model uncertainty 
and these techniques could be developed in future research. 
The focus of this thesis was to identify an appropriate method for estimating average 
costs in the presence of censoring and presenting methodology for estimating 
uncertainty around prognostic model estimates. Therefore, this thesis did not focus on 
the overall cost-effectiveness of liver transplantation for the CELT study over a five-
year study period, nor did it conduct a full PSA that allowed for all possible sources of 
uncertainty that arose within the CELT study. 
8.6 IMPLICATIONS FOR THE COST-EFFECTIVENESS OF LIVER 
TRANSPLANTATION 
As already stated in this chapter, the aim of this thesis was to explore the 
methodological issues of measuring uncertainties in economic evaluations. Therefore, 
the impact of prognostic model uncertainties on the cost-effectiveness of liver 
transplantation in the UK was not estimated. However, this section examines how 
allowing for prognostiC model uncertainties might affect cost-effectiveness estimates for 
liver transplantation and the likely impact on policy decisions. 
Survival information post transplant was routinely collected and available at each of the 
six centres participating in the CELT study, and was obtained from each centre for the 
extended five-year study period. Thus, it was possible to estimate the survival gain 
from transplantation over five-years after adjusting for model parameter uncertainty in 
the non-transplant estimates. In Chapter 5 the survival gain from transplantation over 
five years was estimated at 1.9 years for PSC patients, and after adjusting for 
prognostic model parameter uncertainty varied from -0.4 years to 4.1 years across the 
three prognostic models. This analysis could be expanded further to include the 
uncertainty in estimating non-transplant outcomes over five years. Chapter 7 showed a 
slight increase in the uncertainty in non-transplant survival estimates after incorporating 
prognostiC model parameter uncertainty and outcome uncertainty into survival 
estimates in comparison to uncertainty that incorporated prognostic model parameter 
uncertainty. Therefore, it is expected that after allowing for this the mean survival gain 
would remain at approximately 1.9 years and the uncertainty around the survival gain 
would increase slightly compared to the results shown in Chapter 5. 
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Although survival information was routinely collected, no resources were available (to 
the CELT study) to obtain information on HRQl or resource use for 2.25 to five years 
post assessment. Hence estimation techniques were needed to estimate transplant 
HRQl and costs for the extended study period, drawing upon information from the 
CELT study. It is likely that the assumption of constant HRQl over time assumed in the 
non-transplant HRQl estimates would also be applied to transplant HRQl between 
2.25 and five years. Therefore, I would expect to observe an increase in transplant 
QAl Y over those observed to 2.25 years in the CELT study with a smaller increase in 
non-transplant QAl Ys at five years. Thus, there is likely to be a QAl Y gain in favour of 
transplantation at five years. After adjusting for prognostic model uncertainties there is 
likely to be an increase in the uncertainty around the incremental QAl Ys compared to 
estimates at 2.25 years. I would expect a similar range of uncertainty in the QAl Y gain 
from transplantation to that observed for the survival gain over five years for PSC 
patients (-0.4 to 4.1 years) with possible evidence of a negative QAl Y gain in favour of 
non-transplant patients to a large positive gain of 4 years or more in favour of 
transplantation. 
Figure 4.9 illustrated how cumulative CELT study costs remained fairly constant in the 
later part of the 2.25 year study period. This pattern is likely to continue over a five year 
period where patients are stable and typically seen at outpatient appointments every 
six to twelve months, therefore the mean costs of transplantation are not expected to 
increase very much compared to those observed at 2.25 years. In contrast, individual 
patient non-transplant costs are expected to increase cumulatively over time. 
Therefore, I would expect a reduction in the incremental costs of transplantation, which 
could be cost-saving, and a large increase in the level of uncertainty around cost 
estimates, which would range from cost saving in favour of non-transplantation to cost 
saving in favour of transplantation, after allowing for prognostic model and cost model 
uncertainty. 
An increase in the QAl Y gain and a reduction in the incremental costs would result in a 
decrease in the incremental cost effectiveness of transplantation over five years. Thus, 
the mean ICER for AlD patients could drop below the £30K NHS benchmark indicating 
transplantation as a beneficial treatment for AlD patients over five years. The mean 
ICER for PBC and PSC patients were both less than £30K at 2.5 years (Chapter 2) and 
it is expected that they would drop further below the £30K benchmark. Furthermore, 
allowing for prognostic model and cost model uncertainties would increase the amount 
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of variation around ICERs considerably compared to the variation estimated at 2.25 
years in the original CELT study. After allowing for prognostic model and cost model 
uncertainties I would expect that bootstrapped estimates of the ICERs to cover all four 
quadrants of the incremental cost-effectiveness plane, with the majority of ICERs 
showing liver transplantation as a cost-effective treatment over five years and a very 
small proportion showing non-transplantation to be less costly and more beneficial than 
transplantation. 
Thus, the methods presented in this thesis for measuring uncertainty in cost-
effectiveness studies are likely to substantially increase the degree of uncertainty in 
cost-effectiveness estimates. However, I would not expect these results to alter the 
current decision to fund liver transplantation. Liver transplantation is accepted as the 
treatment of choice for patients with end stage liver failure and it is believed to be 
beneficial and to improve patients HRQl, although acknowledged as a costly 
procedure [Burton & Heyse, 1985]. A cost-effectiveness study of lung-transplantation in 
The Netherlands suggested that lung transplantation was beneficial and improved 
HRQl but was very expensive [van Enckevort, TenVergert et al. 1998]. As a result of 
the Dutch study the Dutch Health Care insurance board and Dutch Minister of Health 
Affairs chose to include lung-transplantation in the countries health benefit package 
[Ouwens et al. 2003]. 
8.7 CONCLUDING COMMENTS 
This thesis focused upon two issues of statistical uncertainty that arose as a result of 
the potential extension of the study period in an economic evaluation in liver 
transplantation. By addressing these two issues of uncertainty this thesis has aided the 
transplant community by enabling future studies in solid organ transplantation to obtain 
more accurate estimates of survival, QAl Y and cost outcomes. When study 
observations are subject to censoring, the guidance provided in this thesis on 
censoring methods will enable more accurate estimates of transplant costs, and the 
uncertainty around them. This thesis has also highlighted the importance in 
acknowledging the difficulties in selecting an appropriate non-transplant control group. 
The methodology presented in this thesis for estimating uncertainty around non-
transplant survival, QAl Y and costs estimated from prognostiC models should be 
applied to any solid organ transplant study that uses prognostiC models in the absence 
of observed non-transplant data. In presenting the uncertainty around non-transplant 
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estimates the transplant community will be presented with a truer picture of the 
uncertainty around non-transplant survival, QAL Y and cost estimates. This, in tum, will 
enable a more realistic picture of the uncertainty around the survival and QAL Y gains 
and the cost differences and aid decision makers in implementing policy decisions 
regarding solid organ transplantation. 
This thesis has also raised questions about the credibility of the results from previous 
studies that assumed non-transplant costs could be estimated from the transplant 
experience of patients on the waiting list. Chapter 7 showed that there was a large 
amount of uncertainty around non-transplant cost estimates and raised questions about 
the accuracy of estimating non-transplant costs in this way. It is important that future 
economic evaluations in solid organ transplantation address this issue and this should 
result in more credible estimates of the cost-effectiveness of solid organ transplantation 
in the future. 
This thesis has contributed to the methodology and guidance in health care research 
studies by offering guidance on selection of appropriate method for estimating mean 
study costs in the presence of censoring. Further, this thesis has contributed to the 
research field by presenting simulation methods for estimating uncertainty around 
prognostic model estimates and presenting a PSA approach for estimating individual 
patient outcomes (and uncertainty) over a fixed study time period estimated from Cox 
PH prognostic models. 
This thesis identified two previously unexplored issues of uncertainty that can arise in 
clinical and cost-effectiveness studies in health care technologies. By exploring these 
issues and offering guidance on techniques and presenting methodology for estimating 
uncertainties this thesis will enable decision makers to have more confidence in clinical 
and cost-effectiveness estimates and present them with a more complete picture of 
uncertainty around these estimates. A more accurate picture of the uncertainty around 
effectiveness, cost and cost-effectiveness estimates can, in turn, inform value of 
information analysis, which can be used to inform decision makers of the need for 
further investigation in to health care services [Claxton, 1999]. Thus, decisions in to the 
need for future research depend upon accurate estimates of the uncertainty around 
clinical or cost-effectiveness estimates of health care technologies and this thesis has 
provided methodology that contributes to a more precise estimate of this uncertainty. 
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APPENDIX A2.1 ATTRIBUTING CELT ASSESSMENT COSTS FOR NON. 
TRANSPLANT PATIENTS ACROSS THE TRANSPLANT COHORT 
Patients who were assessed but not listed for transplantation, who were listed for 
transplantation and died on the waiting list, or who were removed from the waiting list prior to 
transplantation, were excluded from the main GEL T analysis. The reason for the exclusion of 
these patients was that their QAl Ys and costs would be the same with and without the 
transplant programme. The exception to this is the assessment costs, which are attributable to 
the transplant programme. Rather than ignoring these costs, they are attributed across the 
transplant patients as set out below. 
Table A2.1.1 lists the number of patients who were excluded from the main GEL T analysis 
because they were assessed and not listed, removed from the waiting list, or died on the waiting 
list. Forty seven per cent of AlD patients who were assessed did not receive a transplant during 
the study period; the majority of these patients were not listed for transplantation. The 
percentage of assessed patients who did not receive a transplant during the GEL T study is 
much lower for the PSG (34%) and PSG (36%) groups in comparison with the AlD group. 
Table A2.1.1 Number of patients assessed in the CELT analysis by disease group 
ALD PBC PSC 
Total number assessed 155 122 70 
Transplanted patients 82 81 45 
Patients not listed for transplant 55 28 17 
Patients removed from the waiting list 9 5 3 
Patients who died on the waiting list 9 8 5 
The PSG group will be used to illustrate how the assessment costs for excluded patients were 
attributed to PSG transplant patients. The total assessment costs to the transplant programme 
that arose from 25 patients with end-stage PSG who were assessed but did not receive a liver 
transplant during the GEL T study was £206,137 (Table A2.1.2). The total assessment cost for 
excluded patients was then divided by the number of transplant patients (N = 45) to give a value 
of £4,581. This value (£4,581) is then added to each transplant patients total study costs, thus 
attributing the assessment costs for patients who did not receive a transplant during the GEL T 
study period over the transplant patients. 
Table A2.1.2 Total assessment costs for PSC patients who did not receive a liver 
transplant 
N Total assessment costs 
PSG patients not listed for transplantation 17 £122,247 
PSG patients removed from the waiting list 3 £15,690 
PSC patients who died on the waiting list 5 £68,200 
Total 25 £206,137 
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APPENDIX A2.2 ESTIMATING COSTS PRIOR TO DEATH 
The CELT study team hypothesised that the cost of end-stage liver disease would increase in 
the month prior to death. To establish whether the hypothesis was true, the cost infonnation 
from 44 CELT patients with end-stage liver disease who died on the waiting list was examined. 
Costs were examined over the waiting list period in monthly intervals from month of death, back 
in time, until point of listing. The median time on the waiting list for the 44 patients prior to death 
was two months (Range 1 to 14 months). 
The cohort of patients who died on the waiting list included patients with liver diseases other 
than AlD, PBC or PSC, in order to maximise the number of patients included in this exercise. 
The majority of patients were male and over three quarters of the sample were classified as 
elective cases (Table A2.2.1). 
Table A2.2.1 Demographic characteristics of the 44 CELT patients who died on the 
liver transplant waiting list 
Mean age in years (SD) 51 (11.1) 
Males (%) 28 (64%) 
Liver disease (%): 
AlD 9 (20%) 
PBC 8 (18%) 
PSC 5 (11 %) 
Other diseases 22 (50%) 
Elective cases (%) 34 (77%) 
Table A2.2.2 details the mean and median costs per month from point of death, back in time, 
towards point of listing. Both mean and median costs were highest in the month immediately 
prior to death (30 days immediately prior to transplant). The differences between the mean and 
median costs per month show that the cost data is highly skewed. Therefore, non-parametric 
tests were used to test for statistical differences in costs between months one and two, months 
two and three, and months three and four. Median costs in the month prior death were 
significantly higher than costs two months prior to death (p = 0.049). However, there was no 
evidence of a significant differences in costs between months two and three, or months three 
and four prior to death (p = 0.738, P = 0.791, respectively). 
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Table A2.2.2 Mean and median monthly costs on the waiting list from time of death 
N Mean cost Median cost 
In 30 days immediately prior to transplant 44 £3,893 £2,476 
30-60 days prior to transplant 22 £2,555 £203 
60-90 days prior to transplant 14 £1,549 £50 
90-120 days prior to transplant 11 £903 £99 
A linear regression model was then fitted to the cost data to predict cost of treatment for end-
stage liver disease in the month prior to death. The model was fitted to the 44 patients with end-
stage liver diseases who died on the waiting list. Age, gender, disease group1, type of transplant 
(emergency or elective) and centre were considered in the model to adjust for case mix. 
Variables were excluded from the model if they were non-significant predictors of cost at the 5% 
level (p-value). 
Table A2.2.3 presents the results of the regression model. Costs in the month prior to death 
increased with age, and were higher for emergency cases than for elective cases. Patients with 
parenchymal liver diseases (this group includes AlD patients) were more likely to have higher 
costs than other disease groups. Disease group, transplant centre, and the constant term was 
not statistically significant and was removed from the model. 
Table A2.2.3 Results of regression model for predicting costs in the month prior to 
death 
Regression coefficient Standard error t-value P-value 
Age in years 101.6 18.65 5.45 < 0.001 
Elective Base* 
Emergency 13,453.2 2,562.25 5.25 < 0.001 
Parenchymal Base* 
Fulminent -15,350.7 3,013.17 -5.10 < 0.001 
Cholestatic -1,676.4 1,493.41 -1.12 0.272 
Other -1,940.3 2,292.40 -0.85 0.405 
* Sase case scenano ,L Adjusted R - 0.744 Root MSE - 3,653.30 
The model presented in Table A2.2.3 was used to adjust the non-transplant costs for CELT 
patients not expected to survive for the full 2.25 year study period. 
1 Disease group 1 = parenchymal (indudes ALD), 2 = fulminant, 3 = cholestatic (includes PSC, PSC), 4 = 
other 
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APPENDIX A3.1 LITERATURE REVIEW SEARCH STRATERGY 
A list of search terms are presented in sections A3.1, A3.2 and A3.3. Section A3.1 presents a 
list of terms relating to organ transplantation and Section A3.2 a list of search terms relating to 
the seven organs included in this review. Section A3.3 lists the search terms applied in order to 
identify different types of study. Potentially relevant studies included at least one term from each 
of the three lists (A3.1, A3.2 and A3.3) in the abstract, title or keywords. 
Al.1 
Al.2 
e.g. "transplant" AND "kidney" AND "cost-utility" 
e.g. "graft" AND "lung" AND "mortality" 
Transplantation 
Graft 
Grafting 
Transplant 
Transplantation 
Transplants 
Transplant organs 
Bowel 
Cardiac 
Heart 
Heart-Lung 
Hepatic 
Intestinal 
Intestine 
Kidney 
Liver 
Lung 
Pancreas 
Pancreatic 
Renal 
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A3.3 Type of study 
Benefits 
Benefits and costs 
Charges 
Cost 
Cost analysis 
Costs and benefits 
Costs and cost analysis 
Cost-benefit analysis 
Cost-benefit data 
Cost-effective 
Cost-effectiveness 
Cost measures 
Cost-utility 
Cost-uti lities 
Costing 
Death rate 
Expenses 
Mortality 
Outcome 
Pricing 
Quality of life 
Survival 
Surviving 
Utilities 
Utility 
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APPENDIX A3.2 SOLID ORGAN TRANSPLANTATION LITERATURE REVIEW 
This appendix lists the references for 202 articles included in the literature review detailed in 
Chapter 3. Articles are listed by organ. 
Heart Transplantation 
Bocchi EA, Bellotti G, et ai, (1996) Mid-term results of heart transplantation, cardiomyoplasty, 
and medical treatment of refractory heart failure caused by idiopathic dilated cardiomyopathy. 
Journal of Heart and Lung Transplantation; 15(7): 736-745 
Bortman G, Delgardo D, et ai, (1999) Analysis of quality of life before and after heart 
transplantation. Transplantation Proceedings; 31 (6): 2555 
Buxton MJ, Acheson R, et ai, (1985) Costs and benefits of the heart transplant programme at 
Harefield and Papworth hospitals. Department of Health and Social Security; Report No. 12: 
HMSO 
Caine N, Sharples LD, et ai, (1990) Prospective study comparing quality of life before and after 
heart transplantation. Transplantation Proceedings; 22(4): 1437-1439 
Caine N, Sharples LD, et ai, (1996) Measurement of health-related quality of life before and 
after heart-lung transplantation. Journal of Heart and Lung Transplantation; 15 (10): 1047-1058 
Clark DA, Stinson EB, et ai, (1971) Cardiac Transplantation in Man: VI. Prognosis of patients 
selected for cardiac transplantation. Annals of Internal Medicine; 75(1); 15-21 
Cope JT, Kaza AK, et ai, (2001) A cost comparison of heart transplantation versus alternative 
operations for cardiomyopathy. Annals of Thoracic Surgery; 72(4): 1298-1305 
Cotrufo M, Romano G, et ai, (2005) Treatment of extensive ischemic cardiomyopathy: quality of 
life following two different surgical strategies. European Journal of Cardio-Thoracic Surgery; 
27(3): 481-487 
Evangalista LS, Moser D, et ai, (2004) Functional status and perceived control influence quality 
of life in female heart transplant recipients. Journal of Heart and Lung Transplantation; 23(3): 
360-367 
Fisher DC, Lake KD, et ai, (1995) Changes in health-related quality of life and depression in 
heart transplant recipients. Journal of Heart and Lung Transplantation; 14(2): 373-381 
Gajarski RJ, Towbin JA, Garson A, (1996) Fontan palliation versus heart transplantation: a 
comparison of charges. American Heart Journal; 131(6): 1169-1174 
Grady KL, Jalowiec A, White-Williams C, (1996) Improvement in quality of life in patients with 
heart failure who undergo transplantation. Journal of Heart and Lung Transplantation; 15(8): 
749-757 
Haberman S, (1980) Heart transplants: putting a price on life. Health and Social Service 
Journal; 90(4700): 877-879 
Hellinger FJ. (1982) An analysis of a public programme for heart transplantation; Journal of 
Human Resources; 17(2): 307-313 
Hummel et a', (2000) How expensive is heart transplantationn (HTX) when compared with 
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patients. Journal of Heart and Lung Transplantation; 19(1): 44 
Jones BM, Taylor F, et ai, (1992) Longitudinal study of quality of life and psychological 
adjustment after cardiac transplantation. Medical Journal of Australia; 157(1): 24-26 
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Lietz K, John R, et aI, (2004) Outcomes in cardiac transplant recipients using allografts from 
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criteria. Journal of the American College of Cardiology; 43(9): 1553-1561 
Mai FM, McKenzie FM, Kostuk WJ, (1990) Psychosocial adjustment and quality of life following 
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Turnbull BW, Brown BW, Hu M, (1974) Survivorship analysis of heart transplant data. Journal of 
the American Statistical Association; 69(345): 74-80 
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APPENDIX Al.l FURTHER DETAILS ON THE 158 STUDIES INCLUDED IN THE 
LlTERTURE REVIEW; BY ORGAN 
Sections A3.3.1 to A3.3.7 summarise the results of the literature review presented in Chapter 3 
in further detail. Results are presented by organ: heart (A3.3.1), intestine (A3.3.2), kidney 
(A3.3.3), liver (A3.3.4), lung (A3.3.5), pancreas (A3.3.6) and pancreas-kidney (A3.3.7). Each 
section presents a general overview of the studies reviewed and gives further comments in 
detail by type of study: survival, HRQL, cost or cost-effectiveness. A summary of the studies 
included in this review is also summarised in tabular fashion by organ. 
Al.l.1 Heart Transplantation 
A total of 26 studies compared heart transplantation with a non-transplant comparator group 
(Table A3.1 a to A3.1 c). Seven (27%) of studies used a quasi-experimental control group and 
the remainder of the studies compared transplantation with outcomes on the waiting list prior to 
transplantation. Quasi-experimental control groups were: Coronary Artery Bypass Grafting 
(CABG), mitral valve repair, left ventricular reconstruction, cardiomyoplasty, Fontan palliation, 
ventricular resection, and medical treatment of end-stage heart failure. Only one study matched 
quasi-experimental and transplant patients in terms of disease characteristics [Shum-Tim, 
1999], though a further study did acknowledge that the control cohort might bias the results, as 
some of the patients in the control group did not have end-stage heart failure [Cope et a', 2001]. 
Survival (Table Al.1 a) 
Five studies focused on comparing survival with and without transplantation. Four studies 
compared transplantation with survival on the waiting list whilst the fifth study compared 
transplant survival with a quasi-experimental comparator group. The study presented by Clark 
and colleagues is likely to exaggerate the effect of survival after transplantation as two of the 14 
patients in the waiting list group were removed from the waiting list due to stabilisation or 
improvement; in order to maintain an "intention to treat" approach these two patients should 
have remained in the comparator group for the analysis [Clarket a', 1971]. The most thorough 
survival study compared transplant survival with survival on the waiting list for heart 
transplantation using a series of statistical models [Turnbull et a', 1974]. Turnbull and 
colleagues proposed a series of alternative statistical techniques to allow for biases in using an 
intervention delay cohort of waiting list patients, however their approach assumes patients are 
not given transplants selectively, which is unlikely to be the case. 
Two of the four studies that addressed both survival and HRQL had a sample sizes of less than 
30 patients. The results from these two studies should be interpreted with caution as they may 
not be powered to detect a statistical difference between groups. The other study of note in this 
series of papers evaluated the costs and benefits of the UK heart transplant programme [Buxton 
et a', 1985]. Buxton and colleagues used the methods suggested by Turnbull et a', to allow for 
1 A simultaneous heart-lung transplant study is included within this group of studies [Caine et ai, 1996) 
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potential biases when comparing a cohort of heart transplant patients with a cohort of non-
transplant patients awaiting transplantation [Turnbull et aI, 1974]. In addition to this the authors 
also consider a series of functions for extrapolating the survival data beyond the observed study 
period (linear, Weibull & exponential) [O'Brien et aI, 1987]. Buxton's study presents costs for the 
transplant programme but does not compare these costs with a non-transplant cohort of 
patients. 
HRQL (Table A3.1b) 
Over half of the heart transplant studies reporting HRQL (62%) compared patients with and 
without transplantation, with one study comparing the HRQL of heart-lung transplantation 
[Caine et aI, 1996; O'Brien et aI, 1988]. A total of 12 studies compared HRQL with and without 
transplantation. Two studies compared HRQL after transplantation with a quasi-experimental 
control group. The remaining 10 HRQL studies compared transplantation pre and post 
transplant, three of whom used an unpaired comparisons design, measuring HRQL at one time 
point only, and seven used a paired comparison, evaluating HRQL at a series of time points pre 
and post transplant. 
The studies by Bortman et al and Packa et al will be subject to recall bias as transplanted 
patients were asked to value their pre-transplant HRQL several months after transplantation 
[Packa et aI, 1989; Bortman et aI, 1999]. One HRQL study asked experts to value patient's 
HRQL before and after transplantation using an unvalidated HRQL instrument [Mai et aI, 1990]. 
Costs & Cost-effectiveness (Table A3.1c) 
Five studies evaluated the costs or cost-effectiveness of heart transplantation in comparison 
with either quasi-experimental or intervention delay groups. Of note amongst these studies is 
one that consisted of a sample of one patient, a 25 year old male [Haberman 1980]. A series of 
hypothesised scenarios were considered for this patient, including transplantation, survival 
without transplantation for two years and immediate death. The cost-effectiveness of heart 
transplantation was then estimated for this patient. The results are unlikely to be generalisable 
to the population, where the average heart transplant patient is unlikely to be a 25-year old 
male. 
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Table Al.1a Summary of the literature review results for heart transplantation (N = 9 survival or survival and HRQL studies) 
Study Type of study Comparator Statistical If modelling Was censoring Type of Sensitivity Type of Small sample size 
group modelling used was allowed for, if censoring analysis sensitivity for either treatment 
(YIN) uncertainty C or CE study? method (YIN) analysis or comparator 
allowed for? used group (N < 30) 
Bocchi et al Survival Quasi N N/a N/a N Greater than 30 
Clark et al Survival Intervention N N/a N/a N Less than 30 
Hellinger et al Survival Intervention N N/a N/a N Greater than 30 
Leitz et al Survival Intervention N N/a N/a N Greater than 30 
Turnbull et al Survival Intervention Y N N/a Y One-way Greater than 30 
Buxton et at Survival & HRQL Intervention Extrapolate N N/a Y One-way Greater than 30 
Cotrufo et al Survival & HRQL Quasi N N/a N/a N Greater than 30 
Fisher et al Survival & HRQL Before & After N N/a N/a N Less than 30 
Shum-Tim et al Survival & HRQL Quasi N N/a N/a N Less than 30 
Three papers were published for this study: Buxton et aI, 1985; Caine et aI, 1990; O'Brien et aI, 1987 HRQL - Quality of life Intervention - Intervention delay waiting list cohort 
Quasi - Quasi-experimental N/a - Not applicable 
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Table Al.1b Summary of the literature review results for heart transplantation (N = 12 HRQL studies) 
Study Type of study Comparator Statistical If modelling Was censoring Type of Sensitivity Type of Small sample size 
group modelling used was allowed for, if censoring analysis sensitivity for either treatment 
(YIN) uncertainty C or CE study? method (YIN) analysis or comparator 
allowed for? used group (N < 30) 
Bortman et at HRQL Before & After N N/a N/a N Greater than 30 
Caine et at HRQL Before & After Last value N N/a N Greater than 30 
carried forward 
Evangalista et at HRQL Cross section N N/a N/a N Greater than 30 
Grady et at HRQL Before & After N N/a N/a N Greater than 30 
Jones et at HRQL Before & After N N/a N/a N Greater than 30 
Mai et at HRQL Expert opinion N N/a N/a N Less than 30 
Packa et at HRQL Before & After N N/a N/a N Greater than 30 
Rector et at HRQL Cross section N N/a N/a N Greater than 30 
Riether et at HRQL Before & After N N/a N/a N Greater than 30 
Shih et at HRQL Before & After N N/a N/a N Less than 30 
Walden et af HRQL Quasi N N/a N/a N Less than 30 
Wu et at HRQL Quasi N N/a N/a N Less than 30 
Two papers were published for this study: Caineet aI, 1996; O'Brien et aI, 1988 J "Two papers were published for this study: Walden et aI, 1989; Walden et al. 1994 
HRQL - Health related quality of life Quasi - Quasi-experimental N/a - Not applicable 
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Table A3.1c Summary of the literature review results for heart transplantation (N = 5 cost or cost-effectiveness studies) 
Study Type of study Comparator Statistical If modelling Was censoring Type of Sensitivity Type of Small sample size 
group modelling used was allowed for, if censoring analysis sensitivity for either treatment 
(YIN) uncertainty C or CE study? method (YIN) analysis or comparator 
allowed for? used group (N < 30) 
Hummel et al Cost Before & After N N/a N N Greater than 30 
Cope et al Cost-effectiveness Quasi N N/a N N Less than 30 
Gajarski et al Cost-effectiveness Quasi N N/a N N Greater than 30 
Haberman et al Cost-effectiveness Intervention (P) Y N N/a Y One way Less than 30 
Van-Hout et al Cost-effectiveness Intervention Simulation N N/a N Greater than 30 
model 
I 
Intervention - Intervention delay waiting list cohort P - paired comparison with and without transplantation N/a - Not applicable 
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A3.3.2 Intestine Transplantation 
Intestinal transplantation is an alternative treatment to parenteral nutrition (PN) for patients with 
chronic intestinal failure. Only two studies were identified that compared transplantation with a 
non-transplant alternative for intestinal transplantation (Table A3.2). The first study, comprising 
three papers looked at HRQL using two approaches: a) HRQL before and after transplantation, 
b) compared the HRQL of listed patients on PN (an alternative treatment to transplantation) with 
HRQL after transplantation. In both cases the number of patients per group was ten or less. 
The second study explored the cost-effectiveness of intestinal transplantation and again used 
two approaches a) a combination of historical data from a prognostic model and an intervention 
delay group b) intervention delay waiting list data only [Longworth et a', 2003a]. The two 
approaches produce very different results and the authors acknowledge that there is likely to be 
bias using the second approach as sicker patients are given priority of healthier patients for 
transplanted organs. However, the first approach does rely on the validity of the prognostic 
model, which the authors acknowledge has not been validated, and does not incorporate model 
parameter uncertainty. 
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Table AJ.2 Summary of the literature review results for intestinal transplantation (N = 2 studies) 
Study Type of study Comparator Statistical If modelling Was Type of Sensitivity Type of Small sample 
group modelling used was censoring censoring analysis (YIN) sensitivity size for either 
(YIN) uncertainty allowed for, method used analysis treatment or 
allowed for? if C or CE comparator 
study? group (N < 30) 
DiMartini et a/ HRQL 1. Before & After N N/a N/a N Less than 30 
2. Quasi 
Longworth et a/ Cost-effectiveness 1. Intervention & Y N Y Lin Y One-way Less than 30 
historical 
2. Intervention N N/a Y Lin Less than 30 
Three papers were published for this study: DiMartini et aI, 1998; Rovera et aI, (1998); Rovera et aI, (1998a) 
Quasi - Quasi-experimental N/a - Not applicable 
HRQL - Health related quality of life Intervention - Intervention delay waiting list cohort 
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A3.3.3 Kidney Transplantation 
Dialysis is an alternative therapy for patients with end-stage renal failure and many of the 
studies identified in the review of kidney transplant studies compare transplantation with 
dialysis. In total 64 studies were identified that compared kidney transplantation with alternative 
treatments for kidney failure, 53 (83%) of which compared transplantation with dialysis, the 
remaining 11 compared kidney transplantation with an intervention delay cohort of waiting list 
patients. Of the 64 studies identified ten (16%) focused on survival, 25 (39%) on HRQL, nine 
(14%) costs only and 20 (31%) were cost-effectiveness studies (Table A3.3a to A3.3d). 
Survival (Table A3.3a) 
Four of the ten kidney transplant studies that address survival do not adjust for differences in 
case mix, using Cox PH models, between the non-transplant control group and the kidney 
transplant cohort. All six of the studies that do adjust for case mix differences between groups 
use Cox proportional hazard models to do so. However, only one study matched transplant 
patients with a quasi-experimental control group of listed patients undergoing dialysis, by time 
spent on the waiting list, prior to analysis [Schaubel et aI, 1995]. In two of the studies the effect 
of kidney transplantation is likely to be exaggerated, in favour of transplantation, because 
transplant patients must survive for either one year [Djamali et aI, 2003] or five years [Thomson 
et aI, 1989] before being included in the study. 
HRQL (Table A3.3b) 
Nine (35%) of the 26 HRQL studies performed a paired analysis of HRQL pre and post 
transplantation (before and after study), and the remaining studies compared HRQL post 
transplant with a quasi-experimental dialysis group. Only one study adjusted for difference in 
case mix between the quasi-experimental control group and the transplant group before 
comparing HRQL [Evans et aI, 1985]. Two studies selected a quasi-experimental dialysis group 
of patients on dialysis who were listed for transplantation [Jofre et aI, 1998; Fujisawa et aI, 
2000]. These two studies have more comparable control groups than other studies using quasi-
experimental control groups as they considered only patients who had developed end-stage 
kidney failure (patients with end-stage failure become eligible for transplantation), whereas 
other studies included patients who were not considered for transplant. 
One before and after study will be subject to recall bias as patients were asked to recall their 
pre-transplant HRQL after transplantation [Koch & Muthny, 1991; Muthny & Koch, 1991]. 
Costs (Table A3.3c) 
All nine cost studies compare transplantation with a quasi-experimental group of dialysis 
patients. In all but one study the dialysis cohort consists of a group of observed patients, 
Loupez-Neblina et al compare transplantation with simulated cohort of 50 dialysis patients 
[Loupez-Neblina et aI, 1999]. 
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Table A3.3a Summary of the literature review results for kidney transplantation (N = 10 survival studies) 
Study Type of study Comparator Statistical If modelling Was censoring Type of Sensitivity 
group modelling used was allowed for, if censoring analysis 
(YIN) uncertainty C or CE study? method (YIN) 
allowed for? used 
Bonal etat Survival Quasi Cox N Nla N 
Chantler at at Survival Quasi N N/a Nla N 
Ojamali et al Survival Quasi Cox N N/a N 
Jacobson et al Survival Quasi N N/a N/a N 
McDonald at at Survival Intervention Cox N N/a N 
Nishimura at al Survival Quasi Cox N N/a N 
Ost et al Survival Quasi N N/a N/a N 
Schaubel et al Survival Quasi Cox N N/a N 
Thomson at al Survival Quasi N N/a N/a N 
Wolfe etal Survival Intervention Cox N N/a N 
Two papers were published for this study: McDonald & Ross, 2002; McDonald & Craig, 2004 
Nla - Not applicable 
Intervention - Intervention delay waiting list cohort 
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Type of Small sample 
sensitivity size for either 
analysis treatment or 
comparator group 
(N < 30) 
Greater than 30 
Greater than 30 
Greater than 30 
Greater than 30 
Greater than 30 
Greater than 30 
Greater than 30 
Greater than 30 
Greater than 30 
Greater than 30 
Quasi - Quasi-experimental 
Table A3.3b Summary of the literature review results for kidney transplantation (N = 25 HRQL studies) 
Study Type of study Comparator group Statistical If modelling Was censoring Type of Sensitivity Type of Small sample 
modelling used was allowed for, if censoring analysis sensitivity size for either 
I (YIN) uncertainty C or CE study? method (YIN) analysis treatment or 
allowed for? used comparator group 
(N < 30) 
Churchill et al HRQL Quasi N N/a Nla N Greater than 30 
Devlins et al HRQL Quasi N N/a Nla N Greater than 30 
Evans eta/ HRQL Quasi Regression N N/a N Greater than 30 
Fujisawa et al HRQL Quasi N N/a N/a N Greater than 30 
Gudex HRQL Quasi N N/a N/a N Greater than 30 
Hathaway et a/ HRQL Before & After N N/a N/a N Greater than 30 
Jofr6 etal HRQL Before & After N N/a Nla N Greater than 30 
Johnson et a/ HRQL Quasi N N/a N/a N Less than 30 
Koch & Muthny HRQL 1. Before & After N N/a N/a N Greater than 30 
2. Quasi N 
Kutner et a/ HRQL Before & After N N/a N/a N Greater than 30 
Morris & Jones" HRQL Quasi N N/a N/a N Less than 30 
Parfrey et af HRQL Quasi N Nla N/a N Greater than 30 
Pari( st ar HRQL 1. Before & After N N/a Nla N Less than 30 
2. Quasi N N/a Nla N Greater than 30 
Pietrabissa et a/ HRQL Quasi N N/a Nla N Greater than 30 
Rebello et af HRQL Quasi N N/a Nla N Greater than 30 
Rodin etal HRQL Before & After N N/a Nla N Greater than 30 
Russell st a/ HRQL Before & After N N/a Nla N Greater than 30 
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Table A3.3b Summary of the literature review results for kidney transplantation (N = 25 HRQL studies) 
Study Type of study Comparator group Statistical If modelling Was censoring Type of Sensitivity Type of Small sample 
i 
modelling used was allowed for, if censoring analysis sensitivity size for either 
(YIN) uncertainty C or CE study? method (YIN) analysis treatment or 
allowed for? used comparator group 
(N < 30) 
Churchill et a/ HRQL Quasi N N/a Nla N Greater than 30 
Devlins et a/ HRQL Quasi N N/a N/a N Greater than 30 
Evans eta/ HRQL Quasi Regression N Nla N Greater than 30 
Fujisawa et a/ HRQL Quasi N N/a N/a N Greater than 30 
Gudex HRQL Quasi N N/a Nla N Greater than 30 
Hathaway et a/ HRQL Before & After N N/a N/a N Greater than 30 
Jofr6 et al HRQL Before & After N N/a Nla N Greater than 30 
Johnson et al HRQL Quasi N N/a N/a N Less than 30 
Koch & Muthny' HRQL 1. Before & After N N/a N/a N Greater than 30 
2. Quasi N 
Kutner etal HRQL Before & After N N/a Nla N Greater than 30 
Morris & Jones'"' HRQL Quasi N N/a N/a N Less than 30 
Parfrey et af HRQL Quasi N Nla N/a N Greater than 30 
Parketaf HRQL 1. Before & After N N/a Nla N Less than 30 
2. Quasi N N/a Nla N Greater than 30 
Pletrabissa et al HRQL Quasi N N/a Nla N Greater than 30 
Rebello et af HRQL Quasi N N/a Nla N Greater than 30 
Rodin etal HRQL Before & After N N/a Nla N Greater than 30 
Russell et al HRQL Before & After N N/a Nla N Greater than 30 
-
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Study Type of study Comparator group Statistical If modelling Was censoring Type of Sensitivity Type of Small sample 
modelling used was allowed for, if censoring analysis sensitivity size for either 
(YIN) uncertainty C or CE study? method (YIN) analysis treatment or 
allowed for? used comparator group I 
(N < 30) 
I 
I 
Sayag etal HRQl Quasi N N/a N/a N Greater than 30 
Seedatetal HRQl Quasi N N/a Nla N Greater than 30 
Shih etal HRQl Before & After N N/a N/a N Greater than 30 
Simmons et al HRQl Quasi N N/a N/a N Greater than 30 
Tomosz & Piotr HRQl Quasi N N/a N/a N Greater than 30 
Waiseret al HRQl Quasi N N/a N/a N Greater than 30 
Wight et al HRQl Quasi N N/a N/a N Greater than 30 
Yoshimura et al HRQl Before & After N N/a Nla N Greater than 30 
Two papers were included for this study: Koch & Muthny, 1991; Muthny & Koch 1991 '" Two papers were included for this study: Morris & Jones, 1988; Morris & Jones, 1989 
3 Four papers were Included for this study: Parfreyat at, 1987; Parfreyet at, 1988; Parfrayet at, 1988a Parfreyat aI, 1989 
4 Two papers were Included for this study: Park at aI, 1992; Park at aI, 1996 5 Two papers were included for this study: Rebello et aI, 1998; Rebello at aI, 2000 
HRQL - Health related quality d life Intervention - Intervention delay waiting list cohort Quasi - Quasi-experimental Nla - Not applicable 
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Table A3.3c Summary of the literature review results for kidney transplantation (N = 9 cost studies) 
Study Type of Comparator Statistical 
study group modelling (YIN) 
Baltzan sf sf Costs Quasi N 
Haycox & Jones Costs Quasi N 
Lopez-Neblina at a/ Costs Quasi N 
Loubeau at a/ Costs Quasi N 
Madrigal Costs Quasi N 
Mendez at a/ Costs Quasi N 
Salonen at a/ Costs Quasi N 
Schnitzler at a/ Costs Quasi N 
Schweitzler at a/ Costs Quasi N 
Two papers were published for this study: Baltzan at at, 1996; Baltzan et at, 1997 
Nla - Not applicable 
If modelling Was censoring Type of 
used was allowed for, if censoring 
uncertainty C or CE study? method used 
allowed for? 
N/a N 
N/a N 
N/a N 
N/a N 
N/a N 
N/a N 
N/a N 
N/a N 
N/a N 
Intervention - Intervention delay waiting list cohort 
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Sensitivity Type of Small sample 
analysis sensitivity size for either 
(YIN) analysis treatment or 
comparator group I 
! (N < 30) 
I 
N Greater than 30 . 
N Greater than 30 
I 
N Greater than 30 I 
N Greater than 30 
N Greater than 30 
N Greater than 30 
N Greater than 30 
N Greater than 30 
N Greater than 30 
Quasi - Quasi-experimental 
~ 
Table A3.3d Summary of the literature review results for kidney transplantation (N = 20 cost-effectiveness studies) 
Study Type of study Comparator Statistical If modelling Was censoring Type of Sensitivity Type of Small sample size 
group modelling used was allowed for, if censoring analysis sensitivity for either treatment 
(YIN) uncertainty C or CE study? method (YIN) analysis or comparator 
allowed for? used group (N < 30) 
Aranzabal et a/ Cost-effectiveness Quasi N N/a N N Greater than 30 
Bloomers et a/ Cost-effediveness Quasi N N/a N N Greater than 30 
Croxson & Ashton Cost-effectiveness Quasi Markov N N/a Y One-way Greater than 30 
De By etal Cost-effectiveness Quasi N N/a N N Greater than 30 
DeWit et al Cost-effectiveness Quasi Markov N N/a Y One-way Greater than 30 
Eggars Cost-effediveness Quasi N N/a N Y One-way Greater than 30 
Gamer & Dardis Cost-effediveness Quasi Y N Y Lin Y One-way Greater than 30 
Jassal at al Cost-effectiveness Quasi Markov N N/a (Lifetime) Y One-way Greater than 30 
Kal6eta/ Cost-effediveness Intervention Extrapolate N N/a Y Discount Greater than 30 
rate 
I 
I 
Kaminota at al Cost-effectiveness Quasi Y N N/a (Lifetime) Y One-way Greater than 30 
Kar1berg' Cost-effectiveness Quasi N N/a N Y One-way Greater than 30 
Krakauer Cost-effectiveness Quasi Cox N N N Greater than 30 
Laupacls et af Cost-effediveness Intervention Extrapolate N N N Greater than 30 
Ludbrook Cost-effectiveness Quasi Markov N N Y One-way Greater than 30 
Matas & Schnitzler Cost-effectiveness Quasi Markov N N N Greater than 30 
Ohi eta/ Cost-effectiveness Quasi N N/a Y Lin N Greater than 30 
Roberts et a/ Cost-effectiveness Quasi Modelling N N/a (Lifetime) N Greater than 30 
Sasso etal Cost-effectiveness Quasi N N/a N N Greater than 30 
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Study Type of study Comparator Statistical 
group modelling 
(YIN) 
Tousignant et al Cost-effectiveness Quasi N 
Whiting et al Cost-effectiveness Quasi Markov 
Two papers were included for this study: Karlberg, 1992; Kar1berg & Nyberg, 1995 
Qu.I- Qu.Hxperimental N/a - Not applicable 
If modelling Was censoring Type of 
used was allowed for, if censoring 
uncertainty C or CE study? method 
allowed for? used 
N/a N 
N N/a 
Laupacis et ai, 1993; Laupacis et ai, 1996 
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Sensitivity Type of Small sample size 
analysis sensitivity for either treatment 
(YIN) analysis or comparator 
group (N < 30) 
N Less than 30 
Y One-way Greater than 30 
Intervention -Intervention delay waiting list cohort 
A3.3.4 Liver Transplantation 
A total of 27 studies were identified as comparing survival, HRQL, costs or cost-effectiveness of 
non-transplant versus transplant cohorts: three survival, 14 compared HRQL, two costs and 
eight reported cost-effectiveness analYSis (Table A3.4a to A2.4d). 
Survival (Table A3.4a) 
Of the three survival stUdies only one used a prognostic model to estimate survival in the 
absence of transplantation. The prognostic model was based on historical patients with end 
stage liver disease and was applied to the transplant patients, using information from their 
experience on the waiting list, to estimate survival in the absence of transplantation 
[Christensen et ai, 1999; Liemann Garcia et ai, 2001]. The other two survival studies used a 
quasi-experimental comparator group consisting of patients receiving an alternative treatment 
for end-stage organ failure [Llovet et ai, 1999; Shabahang et aI, 2002]. 
HRQL (Table A3.4b) 
Over half (ten) of the HRQL studies used a before and after approach for the comparison of 
HRQL with and without transplantation. Seven of these stUdies excluded patients who did not 
respond at all time points during a study or those who died before the study was completed, 
making these studies biased towards healthier patients. However, Payne et al and Younossi et 
ai, who both used a time series approach to measuring HRQL, included patient information up 
to the time point a patient dropped out of the study [Payne et ai, 1996; Younossi et aI, 2000]. 
The remaining studies used an unpaired comparator approach and all included survivors. 
Costs (Table A3.4c) 
Rufat and colleagues cost study uses cost incurred on the waiting list for liver transplantation to 
estimate costs in the absence of transplantation, whereas Batra uses a quasi-experimental 
alternative treatment group [Rufat et ai, 1999; Batra, 2001]. Of the two studies only Rufat et al 
conduct one-way sensitivity analysis on the assumptions they make in the cost analysis. 
Cost-effectiveness (Table A3.4c) 
Over half of the cost-effectiveness studies used modelling techniques to estimate costs and 
effects with and without transplantation, with all but one study conducting one-way sensitivity 
analysis. 
The remaining three cost-effectiveness studies used a quasi-experimental comparator group. 
Burroughs et al used a cohort of patients with end-stage cirrhosis who were been treated for 
complications at the same centre as the transplant patients [Burroughs et a', 1992]. The 
comparator cohort is likely to be of a different case mix to the transplant cohort and is likely to 
contain patients who are not eligible for transplantation. It is not clear how these potential 
differences between groups could affect the results as patients clinical details are not supplied 
in the paper. Caution should also be applied to the interpretation of the paper by Manjo and 
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colleagues where it would be difficult to generalise the results as the transplant cohort consists 
of only four patients [Manjo et aI, 2000]. Finally, Williams et a/ study is likely to exaggerate the 
effects of transplantation [Williams et aI, 1987]. The transplant cohort is selective and contains 
patients who survive for at least six months post transplant, whilst although their non-transplant 
cohort met listing criteria for transplantation they included patients who died in the six month 
period preceding transplantation. 
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Table Al.4a Summary of the literature review results for liver transplantation (N = 3 survival studies) 
Study Type of study Comparator group Statistical If modelling Was censoring Type of Sensitivity Type of Small sample 
modelling used was allowed for, if censoring analysis sensitivity size for either 
(YIN) uncertainty C or CE study? method (YIN) analysis treatm ent or 
allowed for? used comparator group 
(N < 30) 
Christensen et al Survival Combined historical PM N N/a N Greater than 30 
& Intervention 
Llovet et al Survival Quasi Cox N N/a N Greater than 30 
Shabahang et al Survival Quasi N N/a N/a N Greater than 30 
- - - - - -
-
Two papers were published for this study: Christensen et aI, 1999; Liemann Garcia et aI, 2001 Quasi - Quasi-experimental PM - Prognostic model N/a - Not applicable 
303 
Table A3.4b Summary of the literature review results for liver transplantation (N = 14 HRQL studies) 
Study Type of study Comparator group Statistical If modelling Was censoring Type of Sensitivity Type of Small sample 
modelling 
used was allowed for, if censoring analysis sensitivity size for either (YIN) 
uncertainty C or CE study? method (YIN) analysis treatment or 
allowed for? used comparator group 
(N < 30) 
Belle et al HRQL Before & After N N/a N/a N Greater than 30 
Cole et al HRQL Before & After N N/a N/a N Greater than 30 
De Bona et al HRQL Cross section N N/a N/a N Greater than 30 
Gross et al HRQL Before & After N N/a N/a N Greater than 30 
Karam et al HRQL Before & After N N/a N/a N Greater than 30 
Kober et al HRQL Cross section N N/a N/a N Greater than 30 
Levy et al HRQL Cross section N N/a N/a N Greater than 30 
O'Carroll et al HRQL 1. Before & After N N/a N/a N Greater than 30 
2. Cross section Less than 30 
Payne et al HRQL Before & After N N/a N/a N Greater than 30 
Price et al HRQL Cross section N N/a N/a N Greater than 30 
Riether et al HRQL Before & After N N/a N/a N Greater than 30 
Tarter et a( 1988 HRQL Before & After N N/a N/a N Less than 30 
Tarter et aI, 2001 HRQL Before & After N N/a N/a N Greater than 30 
Younossi et al HRQL Before & After N N/a N/a N Greater than 30 
-
HRQL - Health related quality of life Quasi - Quasi-experimental N/a - Not applicable 
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Table A3.4c Summary of the literature review results for liver transplantation (N = 10 cost or cost-effectiveness studies) 
Study Type of study Comparator group Statistical If modelling Was censoring Type of Sensitivity Type of Small sample 
modelling used was allowed for, if censoring analysis sensitivity size for either 
(YIN) u ncertai nty Cor CE study? method (YIN) analysis treatment or 
allowed for? used comparator group 
(N < 30) 
Batra Costs Quasi N N/a N N Greater than 30 
Rufat et al Costs Intervention N N/a N Y One way Greater than 30 
BonseletaP Cost-effectiveness Combined historical PM N N N Greater than 30 
& Intervention 
Burroughs et at Cost-effectiveness Quasi N N/a N N Less than 30 
Farinati et at Cost -effectiveness Quasi N N/a N N Less than 30 
Longworth et at Cost-effectiveness Combined historical PM N N/a Y One way Greater than 30 
& Intervention 
Majno et al Cost-effectiveness Quasi Markov N N/a Y One way Greater than 30 
Sagmeister et at Cost-effectiveness Intervention Markov N N/a Y One-way Greater than 30 
Sarasin et at Cost -effectiveness Quasi Decision N N/a Y One-way Greater than 30 
Williams et at Cost -effectiveness Historical N N/a N N Less than 30 
--'--- - -
Four papers were published for this study: Bonselet ai, 1900; Bonsel et aI, 1900a; Bonsel et aI, 1900b; Bonsel et ai, 1992 
2 Five papers were published for this study: Longworth et ai, 2003; Longworth & Bryan, 2003; Ratcliffe et aI, 2001; Ratcliffe et ai, 2002; Young et ai, 2003 
Intervention -Intervention delay waiting list cohort Quasi - Quasi-experimental PM - Prognostic model Nla - Not applicable 
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A3.3.5 Lung Transplantation 
Lung transplantation is accepted as a treatment of choice for some patients with end-stage lung 
failure, where either single or double lung transplantation can occur. The literature review 
identified 16 studies that compared lung transplantation with a non-transplant cohort; two 
studies looked at survival alone, 11 were HRQL studies and three were cost-effectiveness 
studies of lung transplantation (Table A3.5). 
Survival (Table A3.5) 
Of the two survival studies, one used a time dependent non-parametric survival model to 
compare survival with and in the absence of transplantation [Hosenpud et aI, 1998] The second 
study used a modelling approach to estimate non-transplant and transplant survival up-to five 
years, adjusting for demographic and clinical characteristics [Liou et aI, 2001]. The latter study 
did not consider allowing for model parameter uncertainties. 
HRQL (Table A3.5) 
In four studies the authors compared a non-transplant cohort with a transplant cohort at a single 
time point (cross sectional study) and eight studies used a before and after comparison of 
HRQL with and without transplantation (one study used both a cross sectional and before and 
after approach [Cohen et aI, 1998]). All of the studies that used a before and after approach 
ignored patients with incomplete HRQL profiles over time and patients who died during the 
study. 
Cost-effectiveness (Table A3.5) 
All three cost-effectiveness studies compare lung transplantation with an intervention delay 
group of waiting list patients over the lifetime of the study cohort, in all three studies data are 
extrapolated beyond the observed study period. The authors use various statistical modelling 
techniques including the declining exponential function (DEALE) method and the Wei bull model 
to extrapolate survival beyond the study period. 
Ramsey and colleagues extrapolate costs based on the monthly cost on the waiting list, which 
varies by time post-listing [Ramsey et aI, 1995]. Van Enckevort et al use a slightly more 
sophisticated approach; they extrapolate transplant and non-transplant costs based on the 
average per patient weekly cost at the end of the observed post-transplant follow-up period or 
time spent on the waiting list [Van Enckevort et aI, 1997]. The Dutch study of Van Enckevort 
and colleagues also make an adjustment to both transplant and non-transplant costs in the 
three months prior to death. Anyanwu et aI, state that they use the same approach as Van 
Enckevort to estimate the lifetime costs of lung transplantation and a non-transplant cohort of 
patients in the UK [Anyanwu et aI, 2002]. 
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TableA3.5 Summary of the literature review results for lung transplantation (N = 16 studies) 
Study Type of study Comparator Statistical If modelling Was censoring Type of Sensitivi Type of Small sample size 
group modelling used was allowed for if C censoring ty sensitivity for either treatment 
(YIN) uncertainty or CE study? method analysis analysis or comparator 
allowed for? used (YIN) group (N < 30) 
Hosenpud et al Survival Intervention Non- N Nla N Greater than 30 
parametric 
Liou et al Survival Quasi Cox N N/a N Greater than 30 
Busschbach et al HRQL Before & After N Nla N/a N Less than 30 
Cohen etal HRQL Before & After N Nla N/a N Greater than 30 
Cross section N Nla N/a N Less than 30 
Gross et a/ HRQL Before & After N N/a N/a N Less than 30 
Kugler et a/ HRQL Before & After N Nla N/a N Greater than 30 
Lanuza et al HRQL Before & After N N/a N/a N Less than 30 
Limbos et a/ HRQL Cross section N Nla N/a N Less than 30 
Limbos et a/ HRQL Cross section N N/a N/a N Greater than 30 
MacNaughton et a/ HRQL Before & After N N/a N/a N Less than 30 
Shih et al HRQL Before & After N N/a N/a N Less than 30 
Staverm et a/ HRQL Cross section N N/a N/a N Less than 30 
Vermeulen et al HRQL Before & After N Nla N/a N Less than 30 
Anyanwu et af Cost-effectiveness Intervention Extrapolate N Nla N Greater than 30 
Ramseyetaf Cost-effectiveness Intervention Extrapolate N N (Lifetime) N Less than 30 
Van Enkevort et ar Cost-effectiveness Intervention Extrapolate N N (Lifetime) N Greater than 30 
Two papers were published for this study: Venneulen et al, 2003: Vermeulen et ai, 2004 I. Two papers were published for this study: Anyanwu et ai, 2001: Anyanwu et ai, 2002 
S Three papaa were published for this study. Ramseyet ai, 1998: Ramseyet ai, 1995: Ramseyet ai, 1995a 
4 SIx papers were published for this study: AJet ai, 1998; Groen et ai, 2004; TenVergertet ai, 1998: TenVergertet al, 2001; van Enckervortet ai, 1997: van Enckervort et ai, 1998 
HRQl- Health related quality d life Intervention - Intervention delay waiting list cohort control group Quasi - Quasi-experimental Nla - Not applicable 
~n7 
A3.3.6 Pancreas Transplantation 
A total of three studies compared pancreas transplantation with a non-transplant control group 
(Table A3.6). One HRQL study compared transplantation with dialysis on the waiting list 
[Piehlmeier et aI, 1992), one HRQL study compared transplant patients' treatment on the 
waiting list with their post-transplant experience [Johnson et aI, 1990] and a cost-effectiveness 
study compared transplantation with treatment for diabetes mellitus [Kiberd & Larson, 2000]. 
308 
Table Al.6 Summary of the literature review results for pancreas transplantation (N = 3 studies) 
Study Type of study Comparator Statistical If modelling Was Type of Sensitivity Type of Small sample 
group modelling used was censoring censoring analysis (YIN) sensitivity size for either 
I 
(YIN) uncertainty allowed for, method used analysis treatment or 
allowed for? if Cor CE comparator group 
study? (N < 30) 
Johnson et a/ HRQL Before & After N N/a N/a N Less than 30 
Piehlmeier et a/ HRQL Quasi N N/a N/a N Greater than 30 
Kiberd & Larson Cost -effectiveness Quasi Markov N N (Lifetime) Y One-way Greater than 30 I 
I 
HRQL - Health related quality of life Intervention - Intervention delay waiting list cohort Quasi - Quasi-experimental N/a - Not applicable 
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A3.3.7 Simultaneous Pancreas Kidney Transplant (SPK) 
A total of 20 studies were identified that compared SPK with either kidney transplant alone, 
haemodialysis, or an intervention delay (waiting list) control group, with five studies comparing 
SPK with more than one control group. These studies are detailed in Tables A3.7a to A3.7c 
below. 
Survival (Table A3.7a) 
All three survival studies made adjustments for case mix factors. However, none of the three 
studies looking at survival and HRQL adjusted for case mix factors. These three studies all 
compared simultaneous pancreas-kidney transplantation with kidney transplant alone. In 
addition to this Secchi and colleagues also compared the survival and HRQL of SPK patients 
with a group of haemodialysis patients [Secchi et aI, 1991] and Stratta et aI, compared HRQL 
pre and post transplant [Stratta et aI, 1993]. 
HRQL (Table A3.7b) 
A total of ten studies compared HRQL with and without transplantation: five studies compared 
HRQL pre and post transplant, two compared SPK with a quasi-experimental (haemodialysis) 
control group, and six studies compared SPK with kidney transplant alone. Only one paper 
matched SPK recipients by gender, age and year of transplant [Sureshkumar et aI, 2002]. Milde 
and colleagues comparison of HRQL pre and post SPK is subject to recall bias as patients are 
asked to recall what their HRQL was before they had a transplant [Milde et aI, 1995]. The study 
does not give details of how long after transplantation patients are asked about their HRQL. 
Two studies used more than one comparator group. 
Cost and Cost-Effectiveness (Table A3.7c) 
The cost study of Cosimi et aI, gives scant details of their methodology and present only the 
average charges of transplantation in comparison with kidney transplant alone [Cosimi et aI, 
1988]. Of the three cost-effectiveness studies, two use a modelling approach, one over a 
patient's lifetime [Holohan, 1996] and the other over a five year period [Douzdjian et aI, 1998; 
Douzdjian et aI, 1999]. The remaining cost-effectiveness study uses observed data to compare 
transplantation with a quasi-experimental control group [Frank et aI, 2004]. 
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Table Al.7a Summary of the literature review results for simultaneous pancreas-kidney transplantation (N = 6 survival or HRQL and survival studies) 
Study Type of study Comparator Statistical If modelling Was Type of Sensitivity Type of Small sample 
group modelling used was censoring censoring analysis (YIN) sensitivity size for either 
(YIN) uncertainty allowed for, method used analysis treatm ent or 
allowed for? if C or CE comparator group 
study? (N < 30) ! 
Cheung et al Survival Kidney alone Y (for age) N N/a N Greater than 30 
Reddy et al Survival Kidney alone Cox N N/a N Greater than 30 I 
Venstrom et al Survival Intervention Cox N N/a N Greater than 30 I 
Nathan et al Survival & HRQL Kidney alone N N/a N/a N Less than 30 
Secchi et a/ Survival & HRQL 1 Kidney alone N N/a N/a N Less than 30 
2 Quasi N N/a N Greater than 30 
Stratta et at Survival & HRQL 1 Kidney alone N N/a N/a N Greater than 30 
2 Before & After N N/a N Greater than 30 
Two papers were published for this study: Secchi et aI, 1991; Secchi et aI, 1998 ' Two papers were published for this study: Stratta et aI, 1993; Stratta et aI, 1993a 
HRQL - Health related quality of life Intervention - Intervention delay waiting list cohort Quasi - Quasi-experimental Nla - Not applicable 
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- -- - - - -- - - --
---------- .. -- ---- --------- ------- - -- - - ----- -- -- ~ -- - - -- - - 'L -- - - .-- - - - - -- - - ,-- - ---- - -------. 
Study Type of study Comparator group Statistical If modelling Was Type of Sensitivity Type of Small sample 
modelling used was censoring censoring analysis (YIN) sensitivity size for either 
allowed for. 
(YIN) uncertainty ifCorCE method used analysis treatment or 
allowed for? study? comparator group 
(N < 30) 
Adanget et a/ HRQL Before & After N N/a N/a N Less than 30 
esmaties et a/ HRQL Quasi N N/a N/a N Greater than 30 
Gaber eta/' HRQL Before & After N N/a Nla N Less than 30 
I 
, Gross etar HRQL 1 Kidney alone N N/a N/a N Greater than 30 
I 2 Quasi N N/a Nla N Greater than 30 
I 3 Intervention N N/a Nla N Less than 30 
Kiebert at al HRQL Kidney alone N N/a N/a N Greater than 30 
Matas etal HRQL Kidney alone N N/a N/a N Greater than 30 
Milde at al HRQL 1 Kidney alone N N/a Nla N Greater than 30 
2 Before & After N N/a N/a N Greater than 30 
Nakache at af HRQL Kidney alone N N/a N/a N Less than 30 
Piehlmelr et ar HRQL Before & After N N/a Nla N Greater than 30 
Cross section 
Sureshkumar at 8/ HRQL Kidney alone N N/a Nla N Less than 30 
- -
Three papers were published for this study: Gaber et ai, 1994; Hathaway et ai, 1994a; Hathaway et ai, 1994b 
2 Three papers were published for this study: Gross & Zehrer, 1993; Grosset ai, 1995; Zehrer & Gross, 1994 3 Two papers were published for this study: Nakache et aI, 1989; Nakache et aI, 1994 
• Two papers were published for this study: Plehlmeieret ai, 1991; Piehl meier et aI, 1996 HRQL - Health related quality of life Intervention - Intervention delay waiting list cohort 
au ... - Quall-expertmental Nla - Not applicable 
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" 
- - - - - - - - - - - - - - -- - - - - - - - -- - .- --- - - - -- - - -- - -" -- -----1- ---- ---- , -
Study Type of study Comparator Statistical If modelling Was Type of Sensitivity Type of Small sample 
group modelling used was censoring censoring analysis (YIN) sensitivity size for either 
(YIN) uncertainty allowed for, method used analysis treatment or 
allowed for? if C or CE comparator group 
study? (N < 30) 
Cosimi et al Costs Kidney alone N N/a N N Less than 30 
Douzdjian et al Cost-effectiveness 1 Kidney alone Markov N N Y One-way Greater than 30 
2 Quasi Markov N N Y One-way Greater than 30 
Frank et al Cost-effectiveness Quasi N N/a N Y One-way Less than 30 
Holohan Cost-effectiveness Kidney alone Modelling N N (Lifetime) Y One-way Greater than 30 
Two papers were published for this study: Douzjian et aI, 1998; Douzjian et aI, 1999 Intervention - Intervention delay waiting list cohort Quasi - Quasi-experimental N/a - Not applicable 
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APPENDIX A4.1 LITERATURE REVIEW SEARCH STRATERGY FOR IDENTIFYING 
STUDIES CONSIDERING CENSORED COST METHODOLOGY 
A literature review was conducted in order to identify existing methods for estimating mean total 
study costs in the presence of censored data. The follOwing databases were searched: Ovid 
Medline [Ovid, 2005]. BIDS Social Science database [BIDS, 2005], NHS EED [Centre for 
Review and Dissemination, 2005] and OHE HEED [OHE HEED, 2005]. A list of search terms is 
presented in Table A4.1.1; any term listed in the first column of the table was combined with the 
search terms listed in the second column of the table. 
Table A4.1.1 Search terms used to identify censored cost methods 
The following terms: Were combined with: 
Censor Cost 
Censors Costs 
Censored Costing 
Censoring 
Incomplete Cost 
Costs 
Costing 
Missing Cost 
Costs 
Costing 
The titles and abstracts of articles that were identified in the literature review were scanned and 
a total of 30 articles were obtained and read to establish whether they contained methodology 
for estimating mean total study costs in the presence of censoring. A further three artides were 
added to the review from the reference list of reviewed articles, giving a total of 33 articles. 
Of the 33 articles that were obtained and read: 
14 (42%) were rejected as they did not contain original methodology 
Four (12%) were rejected as they treated censoring as a missing data problem 
Two (6%) were rejected as methods dealt with censoring of CAL Y data 
Six (18%) were rejected as methods dealt with censoring of cost-effectiveness data 
Seven (21 %) were accepted as they contained original methods for estimating mean study 
costs in the presence of censoring. 
The seven articles that were accepted listed a possible 12 methods for estimating mean total 
costs in the presence of censoring. Three articles were identified by Ovid, one by both Ovid and 
NHS EED, and the remaining three articles from the reference lists of other articles. 
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APPENDIX A4.2 CENSORED COST RESULTS 
Tables A4.2.1 to A4.2.15 present mean total costs and standard errors for each of the 12 
censoring methods under different levels of censoring and different censoring mechanisms. In 
each table the difference between the estimated mean and observed mean, and the estimated 
standard error and the observed standard error, are presented. Tables A4.2.1 to A4.2.9 also 
present the sampling standard error (SSE) - the variation in the mean results across 5,000 
simulations. The smaller the SSE the more consistent the method is at predicting the mean total 
cost estimate. 
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Table M.2.1 Random censoring (10% censored data) 
Mean total cost Difference in Means Mean Standard Difference in SE SE SSE 
(Estimated - Observed) Ranking Error (SE) (Estimated - Observed) Ranking 
CELT .... ults £36,045 1,517 
eo.t H'-forI .. Known 
WK: Weighted costs £35,311 -734 7 1,510 -7 1 407 
RK: Un's regression £37,184 1,139 8 1,047 -470 9 298 
LK: Lin's method £33,785 -2,260 9 1,327 -190 5 214 
PC: Partitioned Cox £20,321 -15,724 10 345 -1,172 10 120 
Cost Histories Unknown 
C: Carides £36,145 100 4 1,295 -222 7 550 
IC: Ignoring Censoring £35,359 -686 6 1,500 -17 2 233 
LU: Lin's method £36,071 26 1 1,557 40 3 545 
RU: Un's regression £35,863 -182 5 1,134 -383 8 530 
WU: Weighted costs £35,968 -77 3 1,723 206 6 616 
CC: Complete cases £35,981 -64 2 1,671 154 4 413 
Cox: Cox regression £69,266 33,221 11 2,708 1,191 11 1,241 
KM: Kaplan-Meier £133,752 97,707 12 11,651 10,134 12 2,323 
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Table M.2.2 Random censoring (30% censored data) 
Mean total cost Difference in Means Mean Standard Difference in SE SE SSE 
(Estimated - Observed) Ranking Error (SE) (Estimated - Observed) Ranking 
!SLT ..... £36,045 1,517 
CMt HIaIot1_ Known 
WI<: Weighted costs £35,219 -826 7 1,505 -12 1 485 
,RK: Un's regression £35,951 -94 3 997 -520 9 462 
LK: Lin's method £33,597 -2,448 9 1,335 -182 4 362 
PC: Partitioned Cox £20,795 -15,250 10 405 -1,112 10 213 
Coat HIstories Unknown 
C: carides £36,179 134 4 1,538 21 2 1,044 
IC: Ignoring Censoring £34,263 -1,782 8 1,469 -48 3 361 
LU: Un's method £36,052 7 1 1,780 263 6 1,027 
RU: Lin's regression £35,809 -236 6 1,200 -317 7 981 
WU: Weighted costs £35,972 -73 2 1,742 225 5 650 
CC: Complete cases £36,256 211 5 1,892 375 8 967 
Cox: Cox regression £68,594 32,549 11 2,915 1,398 11 1,838 
KM: Kaplan-Meier £136,791 100,746 12 12,347 10,830 12 3,881 
- -
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Table A4.2.3 Random censoring (50% censored data) 
Mean total cost Difference In Means Mean Standard Difference in SE SE SSE 
(Estimated - Observed) Ranking Error (SE) (Estimated - Observed) Ranking 
CELT ...... £36,045 1,517 
Co8t HIstotI_ Known 
WK: Weighted costs £33,333 -2,712 8 1,529 12 1 1,729 
RK: Un's regression £34,730 -1,316 6 949 -568 7 554 
LK: Un's method £33,373 -2,672 7 1,307 -210 5 479 
PC: Partitioned Cox £21,385 -14,660 10 505 -1,012 10 303 
Coat HIstories Unknown 
C: Carides £36,173 128 2 1,988 471 6 1,692 
IC: Ignoring Censoring £33,072 -2,973 9 1,437 -80 3 430 
LU: Un's method £35,952 -93 1 2,198 681 8 1,633 
RU: Un's regression £35,534 -511 4 1,464 -53 2 1,472 
WU: Weighted costs £35,619 -416 3 1,725 208 4 2,412 
CC: Complete cases £36,571 526 5 2,336 819 9 1,397 
Cox: Cox regression £67,836 31,791 11 3,123 1,606 11 2,194 
KM: Kaplan-Meier £140,485 104,440 12 13,210 11,693 12 5,134 
-
319 
Table M.2.4 End-of-Study censoring (10% censored data, censored from 1.75 years) 
Mean total cost Difference in Means Mean Standard Difference in SE SE SSE 
(Estimated - Observed) Ranking Error (SE) (Estimated - Observed) Ranking 
I eEL T results £36,045 1,517 
, 
Cost Histories Known 
WK: Weighted costs £35,078 -967 7 1,505 -12 2 1,267 
RK: Lin's regression £37,866 1,821 8 1,076 -441 7 50 
LK: Lin's method £33,882 -2,163 9 1,804 -433 6 35 
PC: Partitioned Cox £21,385 -14,656 10 506 -1,011 10 146 
Cost Histories Unknown I 
C: Carides £36,408 363 5 1,284 -233 5 496 
IC: Ignoring Censoring £35,983 -62 2 1,514 -3 1 45 
LU: Lin's method £36,391 346 4 1,552 35 3 480 
RU: Lin's regression £36,059 14 1 1,030 -487 8 454 
WU: Weighted costs £35,898 -147 3 2,016 499 9 1,060 
CC: Complete cases £36,794 749 6 1,694 177 4 50 
Cox: Cox regression £69,583 33,538 11 2,573 1,056 11 100 
KM: Kaplan-Meier £133,339 97,294 12 11,440 9,923 12 1,855 
- -
_.- -
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Table A4.2.5 End-of-Study censoring (30% censored data, censored from 1.75 years) 
Mean total cost Difference in Means Mean Standard Difference in SE SE SSE 
(Estimated - Observed) Ranking Error (SE) (Estimated - Observed) Ranking 
CELT results £36,045 1,517 
Cost Histories Known 
WK: Weighted costs £35,838 -207 4 1,549 32 3 1,809 
RK: Lin's regression £37,785 1,740 8 1,072 -445 8 64 
LK: Lin's method £33,248 -2,797 9 1,471 -46 4 3,512 
PC: Partitioned Cox £21,389 -14,656 10 506 -1,011 10 302 
Cost Histories Unknown 
C: Carides £36,414 369 6 1,493 -24 2 946 
IC: Ignoring Censoring £35,935 -110 2 1,511 -6 1 39 
LU: Lin's method £36,368 323 5 1,736 219 5 938 , 
RU: Lin's regression £36,074 29 1 1,167 -350 6 894 
WU: Weighted costs £35,886 -159 3 1,993 476 9 2,005 
CC: Complete cases £36,718 673 7 1,930 413 7 29 
Cox: Cox regression £69,512 33,467 11 2,563 1,046 11 109 
KM: Kaplan-Meier £135,678 99,633 12 11,417 9,900 12 321 
- - -
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Table M.2.6 End-of-Study censoring (50% censored data, censored from 1.75 years) 
Mean total cost Difference in Means Mean Standard Difference in SE SE SSE 
(Estimated - Observed) Ranking Error (SE) (Estimated - Observed) Ranking 
eEL T results £36,045 1,517 
Cost Histories Known 
WK: Weighted costs £35,861 -184 5 1,506 -11 2 4 
RK: Lin's regression £36,122 77 1 1,033 -484 6 1,084 
LK: Lin's method £34,305 -1,740 9 1,387 -130 3 2,077 
PC: Partitioned Cox £22,345 -13,700 10 2,178 661 8 673 
Cost Histories Unknown 
C: Carides £36,495 424 7 1,864 347 5 1,407 
IC: Ignoring Censoring £35,866 -179 4 1,507 -10 1 42 
LU: Lin's method £36,421 375 6 2,071 554 7 1,451 
RU: Lin's regression £36,170 -125 2 1,379 -138 4 1,272 
WU: Weighted costs £35,895 -150 3 2,478 961 10 1,450 I 
CC: Complete cases £35,037 -1,008 8 2,340 823 9 73 
Cox: Cox regression £69,409 33,364 11 2,548 1,031 11 123 
KM: Kaplan-Meier £160,124 124,079 12 14,291 12,774 12 482 
--
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Table A4.2.7 End-of-Study censoring (10% censored data, censored from 1.25 years) 
Mean total cost 
I 
Difference in Means Mean Standard Difference in SE SE SSE 
(Estimated - Observed) Ranking Error (SE) (Estimated - Observed) Ranking 
eEL T results £36,045 1,517 
Cost Histories Known 
WK: Weighted costs £35,689 -356 7 1,630 113 3 3,102 
RK: Lin's regression £36,253 208 5 1,031 -486 9 1,090 
LK: Lin's method £33,798 -2,247 9 1,352 -165 4 303 
PC: Partitioned Cox £21,501 -14,544 10 2,138 621 10 210 
Cost Histories Unknown 
C: Carides £36,129 84 4 1,292 -225 5 493 
IC: Ignoring Censoring £35,975 -70 3 1,514 -3 1 39 
LU: Lin's method £36,042 -3 1 1,545 28 2 491 
RU: Lin's regression £36,063 18 2 1,035 -482 8 482 
WU: Weighted costs £35,742 -303 6 1,770 253 6 3,144 
CC: Complete cases £36,739 694 8 1,931 414 7 35 
Cox: Cox regression £69,559 33,514 11 2,570 1,053 11 164 
KM: Kaplan-Meier £135,861 99,816 12 11,506 9,989 12 345 
- -
- ~- '-- ~- --
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Table A4.2.8 End~f-Study censoring (30% censored data, censored from 1.25 years) 
Mean total cost Difference in Means Mean Standard Difference in SE SE SSE 
I 
(Estimated - Observed) Ranking Error (SE) (Estimated - Observed) Ranking 
eEL T results £36,045 1,517 
Cost Histories Known 
WK: Weighted costs £35,865 -180 6 1,507 -10 3 69 
RK: Lin's regression £36,183 138 5 1,095 -422 7 2,576 
LK: Lin's method £33,844 -2,201 9 1,077 -440 8 7 
PC: Partitioned Cox £21,611 -14,434 10 2,129 612 10 317 
Cost Histories Unknown 
C: Carides £36,163 118 4 1,517 0 1 939 
IC: Ignoring Censoring £35,859 -186 7 1,508 -9 2 56 ; 
LU: Lin's method £36,094 49 2 1,750 233 5 942 
RU: Lin's regression £36,048 3 1 1,182 -335 6 904 
WU: Weighted costs £35,986 -59 3 1,975 458 9 919 
CC: Complete cases £36,661 616 8 1,687 170 4 64 
Cox: Cox regression £69,368 33,323 11 2,540 1,023 11 239 
KM: Kaplan-Meier £132,631 96,586 12 11,302 9,785 12 485 
- ----- -- -
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Table M.2.10 Informative censoring - Too ill (10th percentile of EQ5D distribution, 13% censored) 
Mean total cost Difference in Means Mean Standard Error (SE) Difference in SE SE Ranking 
(Estimated - Observed) Ranking (Estimated - Observed) 
eEL T results £36,045 1,517 
Cost Histories Known 
WK: Weighted costs £32,696 -3,349 7 1,549 32 2 
RK: Lin's regression £34,317 -1,728 3 990 -527 9 
LK: Lin's method £31,589 -4,456 9 1,278 -239 7 
PC: Partitioned Cox £19,662 -16,383 10 288 -1,229 10 
Cost Histories Unknown 
C: Carides £35,120 -925 1 1,345 -172 5 
IC: Ignoring Censoring £31,897 -4,148 8 1,439 -78 3 
LU: Lin's method £34,866 -1,179 2 1,740 223 6 
RU: Lin's regression £22,575 -2,470 4 1,078 -439 8 
WU: Weighted costs £33,492 -2,553 6 1,647 130 4 
CC: Complete cases £33,560 -2,485 5 1,495 -22 1 
Cox: Cox regression £72,596 36,551 11 4,245 2,728 11 
KM: Kaplan-Meier £136,841 100,796 12 13,720 12,203 12 
- --
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Table M.2.9 End-of-Study censoring (50% censored data, censored from 1.25 years) 
I 
Mean total cost Difference in Means Mean Standard Difference in SE SE SSE 
(Estimated - Observed) Ranking Error (SE) (Estimated - Observed) Ranking 
eEL T results £36,045 1,517 
Cost Histories Known 
WK: Weighted costs £35,713 -332 7 1,493 -24 2 280 
RK: Lin's regression £36,092 47 3 1,083 -434 6 2,642 
LK: Lin's method £33,405 -2,640 9 1,404 -113 4 2,485 
PC: Partitioned Cox £21,933 -14,112 10 557 -960 9 2,589 
Cost Histories Unknown 
C: Carides £36,081 36 2 1,926 409 5 1,512 
IC: Ignoring Censoring £35,744 -301 6 1,502 -15 1 62 
LU: Lin's method £36,096 51 4 2,135 618 7 1,576 
RU: Lin's regression £36,076 31 1 1,421 -96 3 1,424 
WU: Weighted costs £35,931 -114 5 2,525 1,008 11 1,476 
CC: Complete cases £34,931 -1,114 8 2,333 816 8 98 
Cox: Cox regression £69,174 33,129 11 2,512 995 10 280 
KM: Kaplan-Meier £159,605 123,560 12 14,381 12,864 12 625 
- - - -
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Table M.2.10 Informative censoring - Too ill (10th percentile of EQ5D distribution, 13% censored) 
Mean total cost Difference in Means Mean Standard Error (SE) Difference in SE SE Ranking 
(Estimated - Observed) Ranking (Estimated - Observed) 
CELT results £36,045 1,517 
Cost Histories Known 
WK: Weighted costs £32,696 -3,349 7 1,549 32 2 
RK: Un's regression £34,317 -1,728 3 990 -527 9 
LK: Lin's method £31,589 -4,456 9 1,278 -239 7 
PC: Partitioned Cox £19,662 -16,383 10 288 -1,229 10 
Cost Histories Unknown 
C: Carides £35,120 -925 1 1,345 -172 5 
IC: Ignoring Censoring £31,897 -4,148 8 1,439 -78 3 
LU: Lin's method £34,866 -1,179 2 1,740 223 6 
RU: Lin's regression £22,575 -2,470 4 1,078 -439 8 
WU: Weighted costs £33,492 -2,553 6 1,647 130 4 
CC: Complete cases £33,560 -2,485 5 1,495 -22 1 
Cox: Cox regression £72,596 36,551 11 4,245 2,728 11 
KM: Kaplan-Meier £136,841 100,796 12 13,720 12,203 12 
- - --
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Table A4.2.11 Informative censoring - Too ill (20th percentile of EQ5D distribution, 31 % censored) 
Mean total cost Difference in Means Mean Standard Error (SE) Difference in SE SE Ranking 
(Estimated - Observed) Ranking (Estimated - Observed) 
eEL T results £36,045 1,517 
Cost Histories Known 
WK: Weighted costs £28,526 -7,519 8 1,482 -35 2 
RK: Un's regreSSion £30,475 -5,570 6 849 -668 9 
LK: Lin's method £29,032 -7,013 7 1,197 -320 6 
PC: Partitioned Cox £20,075 -15,970 10 280 -1,237 10 
Cost Histories Unknown 
C: Carides £33,896 -2,149 1 1,459 -58 3 
IC: Ignoring Censoring £26,794 -9,251 9 1,348 -169 4 
LU: Lin's method £33,560 -2,485 2 2,041 524 8 
RU: Lin's regression £31,031 -5,014 3 1,237 -280 5 
WU: Weighted costs £30,759 -5,286 5 1,847 330 7 
CC: Complete cases £30,977 -5,068 4 1,494 -23 1 
Cox: Cox regression £74,468 38,423 11 5,295 3,778 11 
KM: Kaplan-Meier £145,445 109,400 12 16,644 15,127 12 
-- -
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Table A4.2.12 Informative censoring - Too well (80th percentile of EQ5D distribution, 21% censored) 
i Mean total cost Difference in Means Mean Standard Error (SE) Difference in SE SE Ranking 
(Estimated - Observed) Ranking (Estimated - Observed) 
eEL T results £36,045 1,517 
Cost Histories Known 
WK: Weighted costs £34,409 -1,636 4 1,524 7 1 
RK: Lin's regression £36,315 270 1 1,013 -507 10 
LK: Lin's method £33,008 -3,037 9 1,284 -233 6 
PC: Partitioned Cox £20,244 -15,801 10 3,215 1698 11 
Cost Histories Unknown 
C: Carides £35,131 -914 2 1,538 -21 2 
IC: Ignoring Censoring £33,671 -2,374 8 1,493 -24 3 
LU: Lin's method £34,753 -1,292 3 1,747 230 5 
RU: Lin's regression £34,300 -1,745 6 1,230 -287 7 
WU: Weighted costs £34,160 -1,885 7 1,847 330 8 
CC: Complete cases £34,401 -1,644 5 1,624 107 4 
Cox: Cox regression £64,998 28,953 11 1,985 468 9 
KM: Kaplan-Meier £130,421 94,376 12 11,244 9,727 12 
- --
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Table A4.2.13 Informative censoring - Too well (90th percentile of EQ5D distribution, 14% censored) 
Mean total cost Difference in Means Mean Standard Error (SE) Difference in SE SE Ranking 
(Estimated - Observed) Ranking (Estimated - Observed) 
CELT results £36,045 1,517 
Cost Histories Known 
WK: Weighted costs £35,627 -418 3 1,482 -35 2 
RK: Lin's regression £37,630 1,585 8 1,065 -452 9 
LK: Lin's method £33,850 -2,193 9 1,397 -120 5 
PC: Partitioned Cox £20,284 -15,761 10 321 -1,196 11 
Cost Histories Unknown 
C: Carides £36,405 360 2 1,432 -85 4 
IC: Ignoring Censoring £35,182 -863 7 1,520 3 1 
LU: Lin's method £35,885 -160 1 1,670 153 6 
RU: Lin's regression £35,259 -786 5 1,150 -367 8 
WU: Weighted costs £35,201 -844 6 1,780 263 7 
CC: Complete cases £35,328 -717 4 1,593 76 3 
Cox: Cox regression £70,863 34,818 11 2,516 999 10 
KM: Kaplan-Meier £132,764 96,719 12 11,321 9,804 12 
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Table M.2.14 Partial censoring - One time resource collection (collected 2.25 years after the CELT study first began, 80% censored) 
Mean total cost Difference in Means Mean Standard Error (SE) Difference in SE SE Ranking 
(Estimated - Observed) Ranking (Estimated - Observed) 
CEl T results £36,045 1,517 
Cost Histories Known 
WK: Weighted costs £34,359 -1,676 2 1,543 26 1 
RK: Lin's regression £35,615 -430 1 999 -518 6 
LK: Lin's method £33,503 -2,542 4 1,232 -285 3 
PC: Partitioned Cox £22,765 -13,280 7 758 -759 9 
Cost Histories Unknown 
C: Carides £10,117 -25,928 8 365 -1,152 10 
IC: Ignoring Censoring £34,120 -1,925 3 1,460 -57 2 
LU: Lin's method £9,361 -26,684 9 871 -646 7 
RU: Lin's regression £42,119 6,704 6 2,917 1,400 11 
WU: Weighted costs £8,369 -27,676 10 1,104 -413 4 
CC: Complete cases £42,195 6,150 5 2,027 510 5 
Cox: Cox regression £64,272 28,227 11 2,171 654 8 
KM: Kaplan-Meier £141,108 105,063 12 12,824 11,307 12 
L-
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Table M.2.15 Partial censoring - Fixed resource collection (collected 2.25 years after the end of recruitment at each centre, 15% censored) 
Mean total cost Difference in Means Mean Standard Error (SE) Difference in SE SE Ranking 
(Estimated - Observed) Ranking (Estimated - Observed) 
CELT results £36,045 1,517 
Cost Histories Known 
I WK: Weighted costs £35,991 -54 2 1,502 -15 3 
I RK: Lin's regression £37,912 1,867 7 1,079 -438 8 
lK: Lin's method £33,924 -2,121 8 1,290 -227 6 
PC: Partitioned Cox £20,199 -15,846 10 84 -1,433 11 
Cost Histories Unknown 
C: Carides £37,699 1,654 6 1,233 -284 7 
IC: Ignoring Censoring £36,035 -10 1 1,517 0 1 
LU: Lin's method £37,585 1,540 5 1,506 -11 2 
RU: Lin's regression £37,194 1,149 =3 1,060 -457 9 
WU: Weighted costs £31,456 -4,589 9 1,463 -54 4 
CC: Complete cases £37,194 1,149 =3 1,655 138 5 
Cox: Cox regression £69,374 33,629 11 2,588 1,071 10 
KM: Kaplan-Meier £132,074 96,029 12 11,290 9,773 12 
- ---------'----- - - - ---
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APPENDIX A4.3 RESULTS FROM KENDALL'S CONCORDANCE STATISTIC 
Kendall's concordance statistic is a measure of the agreement between several sets of 
rankings. Given that the test is measuring agreement a significant p-value (p S 0.05) indicated 
that the sets of rankings agree with each other, whereas a p-value > 0.05 indicates that the 
ran kings differ. For the eEL T data a significant p-value indicates that the ordering of the 
accuracy of the mean (or standard error) in the presence of censoring does not differ, and a 
non-significant p-value indicates that the accuracy of methods does differ. 
Table A4.3.1 presents the results from comparing the rahkings of the mean (or standard error) 
estimates across different censoring mechanisms, or censoring levels, using Kendall's 
concordance statistic. The following comparisons were made firstly across the rankings for the 
mean estimates and secondly across the rankings for the standard error estimate: 
• random censoring: comparing rankings for mean estimates at 10%, 30% and 50% 
• end of study censoring (1.75 years): comparing rankings for estimates at 10%, 30% and 50% 
• end of study censoring (1.25 years): comparing rankings for estimates at 10%, 30% and 50% 
• informative censoring: too ill (10th and 20th percentiles) and too well (80th and 90th percentiles) 
• Informative censoring: too ill (10th and 20th percentiles) 
• informative censoring: too well (80th and 90th percentiles) 
• partial censoring: one time (80%), varied by centre (15%) 
• 10% censoring: random, end of study (1.75 years), end of study (1.25 years), informative too ill 
(1 Oth percentile) 1, informative too well (90th percentile) 1, partial (varied by centre) 1 
• 30% censoring: random, end of study (1.75 years), end of study (1.25 years), informative too ill 
{20th percentile)2, informative too well {80th percentile)2 
• 50% censoring: random, end of study (1.75 years), end of study (1.25 years) 
, Although Informative censoring levels and partial censoring levels are slightly greater than 10% they have 
been induded in this comparison duded I this 
2 Although Informative censoring levels are slightly greater than 30% they have been in n 
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Table A4.3.1 Results from applying Kendall's Concordance across censoring 
mechanisms or censoring levels to compare agreement In a) mean 
rankings and b) standard error rankings 
Mean Standard error 
Kendall's p-value Kendall's p-value 
concordance concordance 
statistic statistic 
Random censoring 0.93 0.001 0.84 0.003 
End of study censoring (1.75 years) 0.89 0.002 0.89 0.002 
End of study censoring (1.25 years) 0.94 0.001 0.82 0.004 
Informative censoring (all levels) 0.89 <0.001 0.92 <0.001 
Informative censoring: too ill 0.97 0.030 0.95 0.034 
Informative censoring: too well 0.90 0.049 0.97 0.030 
Partial censoring 0.83 0.074 0.89 0.052 
10% censoring 0.67 <0.001 0.85 <0.001 
30% censoring 0.79 <0.001 0.88 <0.001 
50% censoring 0.82 0.004 0.90 0.002 
Table A4.3.2 presents the. results after comparing the rankings for the accuracy of the mean 
estimates with the rankings for the accuracy of the standard error estimates for each individual 
censoring mechanism by level. 
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Table A4.3.2 Results from applying Kendall's Concordance for individual censoring 
mechanisms by censoring levels to compare agreement between mean 
rankings and standard error ran kings 
Kendall's concordance p-value 
statistic 
Random censoring 10% 0.81 0.082 
Random censoring 30% 0.69 0.196 
Random censoring 50% 0.69 0.172 
End of study censoring 1.75 years 10% 0.78 0.103 
End of study censoring 1.75 years 30% 0.82 0.082 
End of study censoring 1.75 years 50% 0.75 0.122 
End of study censoring 1.25 years 10% 0.83 0.078 
End of study censoring 1.25 years 30% 0.77 0.113 
End of study censoring 1.25 years 50% 0.75 0.125 
Informative censoring: too ill 101n percentile (13%) 0.72 0.144 
Informative censoring: too ill 20th percentile (31 %) 0.78 0.106 
Informative censoring: too well 8dh percentile (21 %) 0.76 0.115 
Informative censoring: too well 9dh percentile (14%) 0.83 0.075 
Partial censoring: one time (80%) 0.81 0.087 
Partial censoring: varied by centre (15%) 0.87 0.060 
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DIVIDING THE STUDY PERIOD INTO ALTERNATIVE INTERVAL 
LENGTHS WHEN ESTIMATING MEAN STUDY COSTS (AND 
STANDARD ERRORS) IN THE PRESENCE OF CENSORING 
The weighted cost method (KCH), Lin's regression method (KCH), Lin's method (KCH), 
partitioned Cox cost method, Carides' method and Lin's method (UCH) required the study time 
interval to be divided into smaller intervals, in order to estimate mean study costs in the 
presence of censoring. The accuracy of mean (and standard error) estimates was compared 
across different choices of interval length. For the weighted cost method (KCH), Lin's regression 
method (KCH) and the partitioned Cox method mean cost estimates were compared for interval 
lengths of 2, 3, 6, and 12 months; for Lin's method (KCH), Carides method and Lin's method 
(UCH) mean cost estimates were compared for interval lengths of 1, 2, 3, 6 and 12 months. The 
accuracy of methods was examined for five alternative censoring mechanisms: 
• 10% random censoring 
• 10% end of study censoring (1.75 years) 
• 13% informative censoring too ill (10th percentile) 
• 14% informative censoring too well (90th percentile) 
• 15% partial censoring (fixed time resource collection). 
The results are presented in Tables A4.4.1 to A4.4.6 below. In each table the interval length thaI 
gives the most accurate estimate of mean total costs are printed in blue, for each censoring 
mechanism. Thus, for the weighted cost method (Table A4.4.1) under 10% random censoring, 
dividing the study period into six monthly interval lengths, the most accurate estimates of mear 
total costs. Interval lengths that gave the least accurate mean cost estimate are printed in rec 
for each censoring mechanism. 
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interval lengths of 2, 3, 6, and 12 months 
Mean cost Difference in Standard Difference In 
Means· error SE* 
eEL T results £36,045 1,517 
2 monthly Intervals 
10% random £46,238 10,193 1,8n 360 
10% end of study (1.75 years) £48,270 12,225 1,918 401 
13% informative: too ill £42,946 6,901 1,860 343 
14% informative too well £47,136 11,091 1,997 480 
15% partial: fixed time £48,278 12,233 1,982 465 
3 monthly intervals 
10% random £35,311 -734 1,510 -7 
10% end of study (1.75 years) £35,078 -967 1,505 -12 
13% informative: too ill £32,695 -3,349 1,549 32 
14% informative too well £35,627 -418 1,482 -35 
15% partial: fixed time £35,991 -54 1,502 -15 
6 monthly Intervals 
10% random £36,133 88 1,691 174 
10% end of study (1.75 years) £36,518 473 1,665 148 
13% informative: too ill £30,994 -5,051 1,650 133 
14% informative too well £34,556 -1,489 1,721 204 
15% partial: fixed time £36,497 452 1,680 163 
12 monthly Intervals 
10% random £35,723 -322 1,592 75 
10% end of study (1.75 years) £35,553 -492 1,621 104 
13% informative: too ill £29,474 -6,571 1,533 16 
14% informative too well £32,769 -3.276 1,583 66 
15% partial: fixed time £35,953 -92 1,507 -10 
* Estimated - Observed 
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Table A4.4.2 Lin's regression method (KCH) mean and standard error estimates for 
interval lengths of 2, 3, 6, and 12 months 
Mean cost Difference in Standard Difference in 
Means* error SE* 
eEL T results £36,045 1,517 
2 monthly intervals 
10% random £45,980 9,935 1,116 -401 
10% end of study (1.75 years) £46,722 1o,6n 1,142 -375 
13% infonnative: too ill £40,238 4,193 926 -591 
14% infonnative too well £42,835 6,790 969 -548 
15% partial: fixed time £46,n5 10,730 1,145 -372 
3 monthly intervals 
10% random £37,184 1,139 1,047 -470 
10% end of study (1.75 years) £37,866 1,821 1,076 -441 
13% infonnative: too ill £34,462 -1,583 989 -528 
14% infonnative too well £37,640 1,595 1,067 -450 
15% partial: fixed time £37,912 1,867 1,079 -438 
6 monthly intervals 
10% random £36,707 662 1,012 -505 
10% end of study (1.75 years) £37,203 1,158 1,033 -484 
13% infonnative: too ill £34,897 -1,148 962 -555 
14% infonnative too well £37,433 1,388 1,039 -478 
15% partial: fixed time £37,257 1,212 1,035 -482 
12 monthly Intervals 
10% random £39,013 2,968 1,140 -377 
10% end of study (1.75 years) £39,255 3,210 1,152 -365 
13% infonnative: too ill £39,008 2,963 1,119 -398 
14% infonnative too well £39,847 3,802 1,173 -344 
15% partial: fixed time £39,398 3,263 1,155 -362 
* Estimated - Observed 
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Table A4.4.3 Lin's method (KCH) mean and standard error estimates for interval 
lengths of 1, 2, 3, 6, and 12 months 
Mean cost Difference in Standard Difference In 
Means· error S~ 
eEL T results £36,045 1,517 
1 monthly intervals 
10% random £36,017 
-28 1,535 18 
10% end of study (1.75 years) £36,009 
-36 1,519 2 
13% infonnative: too ill £33,977 -2068 1,563 46 
14% infonnative too well £36,382 337 1,539 22 
15% partial: fixed time £36,062 -17 1,430 -87 
2 monthly intervals 
10% random £34,602 -1,443 1,318 -199 
10% end of study (1.75 years) £34,644 -1,401 1,329 -188 
13% infonnative: too ill £32,296 -3,749 1,272 -245 
14% infonnative too well £34,952 -1,093 1,313 -204 
15% partial: fixed time £34,813 -1,232 1,380 -137 
3 monthly Intervals 
10% random £33,785 -2,260 1,327 -190 
10% end of study (1.75 years) £33,882 -2,163 1,084 -433 
13% infonnative: too ill £31,589 -4,456 1,278 -239 
14% infonnative too well £33,852 -2,193 1,397 -120 
15% partial: fixed time £33,924 -2,121 1,290 -227 
6 monthly Intervals 
10% random £31,688 -4,357 1,274 -243 
10% end of study (1.75 years) £31,905 -4,140 1,283 -234 
13% infonnative: too ill £28,903 -7,142 1,210 -307 
14% infonnative too well £31,726 -4,319 1,298 -219 
15% partial: fixed time £31,946 -4,099 1,272 -245 
12 monthly Intervals 
10% random £29,212 -6,833 1,212 -305 
10% end of study (1.75 years) £29,578 -6,467 1,224 -293 
13% infonnative: too ill £26,3n -9,668 1,143 -374 
14% infonnative too well £29,130 -6,915 1,230 -287 
15% partial: fixed time £29,619 -6,426 1,181 -338 
• Estimated - Observed 
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Table A4.4.4 Partitioned Cox cost method mean and standard error estimates for 
interval lengths of 2, 3, 6, and 12 months 
Mean cost Difference in Standard Difference in 
Means* error SE* 
eEL T results £36,045 1,517 
2 monthly intervals 
10% random £19,240 
-16,805 112 -1,405 
10% end of study (1.75 years) £19,115 -16,930 100 -1,417 
13% informative: too ill £18,697 -17,348 106 -1,411 
14 % informative too well £19,031 -17,014 101 -1,416 
15% partial: fixed time £19,194 -16,854 103 -1,414 
3 monthly intervals 
10% random £20,321 -15,724 345 -1,172 
10% end of study (1.75 years) £21,385 -14,660 506 -1,011 
13% informative: too ill £19,662 -16,383 288 -1,229 
14% informative too well £20,284 -15,761 321 -1,196 
15% partial: fixed time £20,199 -15,846 84 -1,433 
6 monthly intervals 
10% random £21,969 -14,076 79 -1,436 
10% end of study (1.75 years) £21,651 -14,394 76 -1,441 
13% informative: too ill £21,421 -14,624 81 -1,436 
14% informative too well £22,113 -13,932 81 -1,436 
15% partial: fixed time £21,729 -14,316 79 -1,438 
12 monthly intervals 
10% random £24,198 -11,847 192 -1,325 
1 0% end of study (1 .75 years) £23,439 -12,606 180 -1,337 
13% informative: too ill £23,403 -12,642 88 -1,429 
14 % informative too well £24,236 -11,809 84 -1,433 
15% partial: fixed time £23,533 -12.512 81 -1,436 
* Estimated - Observed 
339 
Table A4.4.S Carides' method mean and standard error estimates for interval lengths of 
1, 2, 3, 6, and 12 months 
Mean cost Difference in Standard Difference in 
Means* error SE* 
eEL T results £36,045 1,517 
1 monthly intervals 
10% random £36,122 77 1,294 -223 
10% end of study (1 .75 years) £36,091 46 1,283 -234 
13% informative: too ill £34,451 -1,594 1,319 -198 
14% informative too well £35,450 -595 1,319 -198 
15% partial: fixed time £36,874 829 1,267 -250 
2 monthly intervals 
10% random £36,907 862 1,313 -204 
10% end of study (1.75 years) £36,854 809 1,300 -217 
13% informative: too ill £35,029 -1,016 1,374 -143 
14% informative too well £36,381 336 1,423 -94 
15% partial: fixed time £37,670 1,625 1,335 -182 
3 monthly intervals 
10% random £36,145 100 1,295 -222 
10% end of study (1.75 years) £36,408 363 1,284 -233 
13% informative: too ill £35,120 -925 1,345 -172 
14% informative too well £36,405 360 1,432 -85 
15% partial: fixed time £37,699 1,654 1,233 -284 
6 monthly intervals 
10% random £36,091 46 1,283 -234 
10% end of study (1.75 years) £36,659 813 1,306 -211 
13% informative: too ill £35,029 -1,016 1,346 -171 
14% informative too well £36,380 335 1,360 -157 
15% partial: fixed time £37,682 1,637 1,271 -246 
12 monthly intervals 
10% random £36,823 778 1,351 -166 
10% end of study (1.75 years) £36,869 824 1,343 -174 
13% informative: too ill £34,553 1,492 1,272 -245 
14 % informative too well £36,379 334 1,386 -131 
15% partial: fixed time £37,689 1,644 1,309 -208 
* Estimated - Observed 
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Table A4.4.6 Lin's method (UCH) mean and standard error estimates for interval 
lengths of 1, 2, 3, 6, and 12 months 
Mean cost Difference in Standard Difference in 
Means* error SE* 
eEL T results £36,045 1,517 
1 monthly Intervals 
10% random £36,096 51 1,553 36 
10% end of study (1 .75 years) £36,107 62 1,541 24 
13% informative: too ill £34,638 -1,407 1,591 74 
14 % informative too well £35,341 -704 1,672 155 
15% partial: fixed time £36,877 832 1,610 93 
2 monthly intervals 
10% random £36,539 494 1,561 44 
10% end of study (1 .75 years) £36,576 531 1,549 32 
13% informative: too ill £34,620 -1,425 1,612 95 
14% informative too well £34,682 -363 1,658 141 
15% partial: fixed time £37,419 1,374 1,553 36 
3 monthly Intervals 
10% random £36,071 26 1,557 40 
10% end of study (1 .75 years) £36,391 346 1,552 35 
13% informative: too ill £34,866 -1,179 1,740 223 
14% informative too well £35,885 -160 1,670 153 
15% partial: fixed time £37,985 1,940 1,493 -24 
6 monthly intervals 
10% random £36,640 595 1,579 62 
10% end of study (1 .75 years) £36,659 614 1,559 42 
13% informative: too ill £34,698 -1,347 1,642 125 
14 % informative too well £35,759 -286 1,598 81 
15% partial: fixed time £37,518 1,473 1,545 28 
12 monthly intervals 
10% random £36,597 552 1,613 96 
10% end of study (1.75 years) £36,699 654 1,603 85 
13% informative: too ill £34,179 -1,866 1,687 170 
14 % informative too well £35,806 -239 1,758 241 
15% partial: fixed time £37,541 1,496 1,596 79 
* Estimated - Observed 
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APPENDIX AS.1 RESULTS FOR A SERIES OF COX PH MODELS FinED TO THE 
PBC MAYO COHORT 
This appendix presents further results of a series of Cox PH models fitted to the PSC Mayo 
data. 
AS.1.1 Cox PH Model Fitted to the Combined PBC Mayo (N = 312) and PBC CELT (N = 81) 
data sets 
Table A5.1.1 presents the Cox PH results for the model presented in Section 5.3.4. 
Table AS.1.1 Regression coefficients and standard errors for a combined PBC Mayo 
cohort and PBC CELT cohort Cox PH model 
Regression coefficients Standard Error Z p-value 
Age 0.03 0.01 3.25 0.001 
Gender: female -0.51 0.24 -2.15 0.032 
Ascities present 0.26 0.21 1.22 0.220 
Loge(bilirubin) 0.77 0.10 7.47 < 0.001 
Loge(prothrombin time) 0.70 0.56 1.24 0.210 
Oedema score 0.5 0.39 0.22 1.78 0.075 
Oedema score 1 0.45 0.24 1.90 0.057 
Albumin -0.65 0.18 -3.57 < 0.001 
Study: CELT cohort 3.04 0.41 7.36 < 0.001 
Likelihood ratio test = 270 on 9 Degrees of Freedom (OF), p < 0.001 
The results of the proportionality test are detailed in Table A5.1.2, variables should have a non-
significant p-value (p > 0.05) should the proportionality assumption hold. 
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Table AS.1.2 PH results for the for a combined PBC Mayo cohort and PBC CELT cohort 
Cox model 
X12 p-value 
Age 3.77 0.052 
Gender: female 0.09 0.760 
Ascities present 0.29 0.594 
loge(bilirubin) 0.95 0.329 
loge(prothrombin time) 1.06 0.304 
Oedema score 0.5 0.89 0.345 
Oedema score 1 3.67 0.056 
Albumin 0.16 0.689 
Study: CEl T cohort 0.85 0.355 
AS.1.2 Cox PH Model Fitted to the Combined PBC Mayo (N = 312) data sets 
The regression coefficients for the Cox PH model are presented in the main text in Tables 5.2 
and 5.3. Table A5.1.3 presents the proportionality tests for the Cox PH results for the model 
presented in Section 5.4. 
Table AS.1.3 PH results for the for the PBC Mayo cohort Cox model 
X1
2 p-value 
Age 1.05 0.305 
Gender: female 0.04 0.837 
Ascities present 0.55 0.458 
loge(bilirubin) 1.68 0.195 
loge(prothrombin time) 0.00 0.979 
Oedema score 0.5 1.46 0.228 
Oedema score 1 3.66 0.056 
Albumin 0.06 0.811 
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AS.1.3 Cox PH Model Fitted to the PBC Mayo (N = 312) data sets - excluding 
prothrombin time and ascities 
Table A5.1.4 presents the Cox PH results for the model presented in Section 5.7.3; excluding 
non-significant variables from the PSC Mayo model (prothombin time and ascities). 
Table AS.1.4 Regression coefficients and standard errors for the PBe Mayo cohort Cox 
PH model (excluding prothrombin time and ascities) 
Regression coefficients Standard Error Z p-value 
Age 0.03 0.01 3.08 0.002 
Gender: female -0.60 0.25 -2.40 0.016 
Loge(bilirubin) 0.91 0.11 8.07 < 0.001 
Oedema score 0.5 0.44 0.23 1.89 0.059 
Oedema score 1 0.67 0.24 -2.82 0.049 
Albumin -0.97 0.21 -4.67 < 0.001 
Likelihood ratio test = 245 on 6 OF, P < 0.001 
The results of the proportionality test are detailed in Table A5.1.5. 
Table AS.1.S PH results for the for the PBe Mayo cohort Cox model (excluding 
prothrombin time and ascities) 
X\2 p-value 
Age 0.59 0.442 
Gender: female 0.14 0.708 
Loge(bilirubin) 0.96 0.327 
Oedema score 0.5 1.63 0.201 
Oedema score 1 3.53 0.060 
Albumin 0.00 0.999 
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AS.1.4 Cox PH Model Fitted to the PBC Mayo (N = 312) data sets - including bilirubin, 
albumin, age, and ascities 
Table AS.1.6 presents the Cox PH results for the model presented in Section S.7.3; induding 
variables that were common to the PSC Mayo model, Royal Free model, and European model 
(bilirubin levels, albumin levels, age, and ascities). 
Table AS.1.6 Regression coefficients and standard errors for the PBC Mayo cohort Cox 
PH model (including bilirubin, albumin, age, and ascities) 
Regression coefficients Standard Error Z p-value 
Age 0.03 0.01 3.80 < 0.001 
Ascities present 0.37 0.20 1.86 0.064 
Loge(bilirubin) 0.94 0.11 8.43 < 0.001 
Albumin -0.96 0.21 -4.67 < 0.001 
Likelihood ratio test = 237 on 4 OF, P < 0.001 
The results of the proportionality test are detailed in Table AS.1.7. 
Table AS.1.7 PH results for the for the PBC Mayo cohort Cox model (including bilirubin, 
albumin, age and ascities) 
X12 p-value 
Age 1,19 0.276 
Ascities present 0.02 0.87S 
Loge(bilirubin) 1.74 0.187 
Albumin 0.03 0.860 
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APPENDIX AS.2 S-PlUS COMPUTER CODE FOR ADJUSTING FOR MODEL 
PARAMETER UNCERT AlNY 
AS.2.1 S-PlUS Code for adjusting for model parameter uncertainty - using standard 
errors 
This appendix presents the relevant S-PlUS code for obtaining 3,000 Monte Carlo simulations 
in order to adjust for model uncertainty using published information from Cox PH models on 
regression coefficients and standard errors [S-PlUS 6, 2001]. 
The regression coefficients for the log transformation of serum bilirubin, serum albumin, 
oedema scores 0.5 (oedema present without diuretics or oedema resolved by diuretics), 
oedema score 1 (oedema present despite diuretics), presence of ascities, female gender, 
patient age and the log transformation of prothrombin time were: 0.87, -0.93, 0.45, 0.52, 0.19, -
0.64,0.027, and 1.10 and their standard errors were: 0.112, 0.215, 0.234, 0.252, 0.221, 0.250, 
0.009, and 0.660, respectively. rmvnorm is a function in S-PlUS for simulating randomly 
generated multivariate normal distributions. In the case of measuring model parameter 
uncertainty the mean is set to be the value of the regression coefficients from the prognostic 
model and the standard deviation is set at the standard error of the regression coefficients. The 
number of simulations run was 3,000. 
Mayo <- rmvnorm(3000, mean = c(0.87, -0.93, 0.45, 0.52, 0.19, -0.64, 
0.027, 1.10), sd = c(0.112, 0.215, 0.234, 0.252, 0.221, 0.25, 0.009, 
0.66)) 
The risk score for the CELT population is derived by fitting each of the 3,000 Monte Carlo 
simulated data sets to the PSC CELT data, using the following S-PlUS command: 
RS <- PBCCELT %*% t(Mayo) 
where PBCCELT is a vector of the serum bilirubin score, serum albumin, oedema, ascities, 
gender, age, and prothrombin time for the 81 CELT patients with end-stage PSC, andMayo is a 
vector of the 3,000 simulated regression coefficients after applying the command rmvnorm. The 
adjusted risk score is then obtained: 
RSadj <- RS - 2.41 
ExpSurv <- exp(RSadj) 
The next step is to obtain estimates for the baseline survival probabilities of surviving to time 
point t for each individual in the CELT cohort for each of the 3,000 Monte Carlo simulations. The 
baseline survival probabilities were presented in Table 5.3 and are applied to the CELT cohort 
at three monthly intervals from 3 months to 60 months. 
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ProbSurv3m <- 0.9l7"ExpSurv 
ProbSurv6m <- 0.835" ExpSurv 
ProbSurv9m <- 0.782" ExpSurv 
ProbSurv12m <- 0.734" ExpSurv 
ProbSurv15m <- 0.686" ExpSurv 
ProbSurv18m <- 0.644" ExpSurv 
ProbSurv2lm <- 0.644" ExpSurv 
ProbSurv24m <- 0.632" ExpSurv 
ProbSurv27m <- 0.547" ExpSurv 
ProbSurv30m <- 0.547" ExpSurv 
ProbSurv33m <- 0.547" ExpSurv 
ProbSurv36m <- 0.489" ExpSurv 
ProbSurv39m <- 0.489" ExpSurv 
ProbSurv42m <- 0.489" ExpSurv 
ProbSurv45m <- 0.489" ExpSurv 
ProbSurv48m <- 0.489" ExpSurv 
ProbSurv5lm <- 0.462" ExpSurv 
ProbSurv54m <- 0.462" ExpSurv 
ProbSurv57m <- 0.435" ExpSurv 
ProbSurv60m <- 0.379" ExpSurv 
The mean probability of survival to time point t is then estimated for the CELT cohort for each of 
the 3,000 Monte Carlo simulated data sets. 
CohortMeanSPOm <- rep(l, 3000) 
CohortMeanSP3m<- round (apply (ProbSurv3m, 2, mean) , 6) 
CohortMeanSP6m<- round (apply (ProbSurv6m, 2, mean) , 6) 
CohortMeanSP9m<- round (apply (ProbSurv9m, 2, mean) , 6) 
CohortMeanSP12m <- round (apply (ProbSurv12m, 2, mean) , 6) 
CohortMeanSP15m <- round (apply (ProbSurv15m, 2, mean) , 6) 
CohortMeanSP18m <- round (apply (ProbSurv18m, 2, mean) , 6) 
CohortMeanSP2lm <- round (apply (ProbSurv2lm, 2, mean) , 6) 
CohortMeanSP24m <- round (apply (ProbSurv24m, 2, mean) , 6) 
CohortMeanSP27m <- round (apply (ProbSurv27m, 2, mean) , 6) 
CohortMeanSP30m <- round (apply (ProbSurv30m, 2, mean) , 6) 
CohortMeanSP33m <- round (apply (ProbSurv33m, 2, mean) , 6) 
CohortMeanSP36m <- round (apply (ProbSurv36m, 2, mean) , 6) 
CohortMeanSP39m <- round (apply (ProbSurv39m, 2, mean) , 6) 
CohortMeanSP42m <- round (apply (ProbSurv42m, 2, mean) , 6) 
CohortMeanSP45m <- round (apply (ProbSurv45m, 2, mean) , 6) 
CohortMeanSP48m <- round (apply (ProbSurv48m, 2, mean) , 6) 
CohortMeanSP51m <- round (apply (ProbSurv51m, 2, mean) , 6) 
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CohortMeanSP54m <- round (apply (ProbSurv54m, 2, mean), 6) 
CohortMeanSP57m <- round (apply (ProbSurv57m, 2, mean), 6) 
CohortMeanSP60m <- round (apply (ProbSurv60m, 2, mean), 6) 
Finally the estimated mean CELT PSC survival in the absence of transplantation is obtained for 
each of the 3,000 Monte Carlo simulations from the area under the survival curve [Collett, 
1994]. 
ExpNonTxSurv <- (3*CohortMeanSP3m)+(3*CohortMeanSP6m)+ 
(3*CohortMeanSP9m) + (3*CohortMeanSP12m) + (3*CohortMeanSP 15m)+ 
(3*CohortMeanSP18m) + (3*CohortMeanSP21m) + (3*CohortMeanS P24m)+ 
(3*CohortMeanSP27m) + (3*CohortMeanSP30m) + (3*CohortMeanS P33m)+ 
(3*CohortMeanSP36m) + (3*CohortMeanSP39m) + (3*CohortMeanS P42m)+ 
(3*CohortMeanSP45m) + (3*CohortMeanSP48m) + (3*CohortMeanS P51m)+ 
(3*CohortMeanSP54m) + (3*CohortMeanSP57m) + (3*CohortMeanS P60m)+ 
((CohortMeanSPOm - CohortMeanSP3m) *1.5)+ 
((CohortMeanSP3m - CohortMeanSP6m) *1.5)+ 
((CohortMeanSP6m - CohortMeanSP9m) *1.5)+ 
((CohortMeanSP9m - CohortMeanSP12m) *1.5)+ 
((CohortMeanSP12m - CohortMeanSP15m) *1.5)+ 
((CohortMeanSP15m - CohortMeanSP21m) *3)+ 
((CohortMeanSP21m - CohortMeanSP24m) *1.5)+ 
((CohortMeanSP24m - CohortMeanSP33m) *4.5)+ 
((CohortMeanSP33m - CohortMeanSP48m) *7.5)+ 
((CohortMeanSP48m - CohortMeanSP54m) *3)+ 
((CohortMeanSP54m - CohortMeanSP57m) *1.5)+ 
((CohortMeanSP57m - CohortMeanSP60m) *1.5) 
The mean area under the curve is equivalent to the sdh percentile of the distribution 
ExpNonTxSurv, i.e. the mean of the 1,SOO and 1,S01th observations when the 3,000 Monte 
Carlo simulations are ordered smallest to largest. 
(Sort(ExpNonTxSurv)) [1500] 
And the 9S% percentile CI is equivalent to the 2.Sh and the 97.Sth percentiles 
(Sort(ExpNonTxSurv)) [75] 
(Sort(ExpNonTxSurv)) [2925] 
Finally the number of life years gained can be obtained by subtracting the mean expected 
survival length in the absence of transplantation (ExpNonTxSurv) from the mean CELT survival 
to five-years post-liver transplantation (4.4 years or S3 months). 
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ExpSurvGain <- 53 - ExpNonTxSurv 
(Sort(ExpSurvGain)) [1500] 
(Sort(ExpSurvGain)) [75] 
(Sort(ExpSurvGain)) [2925] 
AS.2.2 S-PLUS code for adjusting for model parameter uncertainty - using 
standard errors and the correlation matrix 
There is no additional programming required in order to adjust for the correlation between 
regression coefficients and the standard errors of the regression coefficients. All that is needed 
is some extra information on the correlation matrix of the regression coefficients, when running 
the rmvnorm function in S-PLUS. 
The correlation matrix for the Mayo model is presented in Table 5.5 in Chapter 5, lets call this 
matrix "Mayo. cor" 
1.00 -0.19 -0.03 0.05 0.09 0.19 0.39 -0.79 
-0.19 1.00 -0.07 -0.09 0.10 -0.19 0.01 0.33 
-0.03 -0.07 1.00 0.85 -0.38 -0.45 -0.36 -0.24 
0.05 -0.09 0.85 1.00 -0.51 -0.52 -0.31 -0.30 
Mayo.cor = 
0.09 0.10 -0.38 -0.51 1.00 -0.00 -0.38 -0.30 
0.19 -0.19 -0.45 -0.52 -0.00 1.00 0.82 -0.04 
0.39 0.01 -0.36 -0.31 -0.38 0.82 1.00 -0.01 
-0.79 0.33 -0.24 -0.30 -0.30 -0.04 -0.01 1.00 
This extra information was added to rmvnorm and, as before, 3,000 simulations were run. 
Mayo <- rmvnorm(3000, mean = c(O.87, -0.93, 0.45, 0.52, 0.19, -0.64, 
0.027, 1.10), cov = Mayo.cor, sd = c(0.112, 0.215, 0.234, 0.252, 
0.221, 0.25, 0.009, 0.66)) 
The process described in section A5.2.1 is then repeated in order to obtain the survival gain 
after transplantation and the probabilities of surviving to time point t, with 95% Cis for model 
parameter uncertainty. 
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APPENDIX AS.1 FURTHER DETAILS OF THREE METHODS FOR ESTIMATING 
INDIVIDUAL PATIENT OUTCOMES 
This Appendix describes how Methods 6.4.1 to 6.4.3 are applied to a cohort of patients in order 
to estimate individual patient outcomes (Chapter 6, Section 6.4). The PSC Mayo prognostic 
model will be applied to 81 PSC CELT patients to estimate, what would have been, their 
survival and survival outcome in the absence of liver transplantation over a five-year period. 
Methods are illustrated for one of the simulation runs. 
A.S.1.1 Method S.4.1: Probability of Survival Equivalent for all Patients, Random 
Selection of Survivors (p = 0.315) 
Table A6.1 presents non-transplant survival estimates for 81 PSC CELT patients, using the 
PSC Mayo model to predict survival over five years. Survival estimates are first presented prior 
to allowing for patients survival. Table A6.1 also presents the expected survival outcomes for 
the 81 patients for one simulation run, where each patient has a 31.5% probability of being 
selected as surviving to five years. Finally, the table presents each patient's individual survival 
time, after adjusting the survival times for patients expected to survive for five years. 
The Kaplan-Meier survival curve for this simulation run is presented in Chapter 6 (Figure 6.1) 
and the mean survival time for the cohort is 3.0 years. 
AS.1.2 Method S.4.2: Selecting the n Patients with the Longest Survival Times as 
Survivors (n = 2S) 
The mean expected number of survivors at five years for the PSC CELT cohort is 26. The 26 
patients with the longest survival times are assumed to survive the full five-year study period. 
Table A6.2 shows which patients would be expected to survive to five years and presents their 
adjusted survival times, where survivors have an expected survival length of five years and 
deaths a survival length equivalent to their predicted survival from the PSC Mayo prognostic 
model. 
Figure A6.1 presents the Kaplan-Meier survival curve after selecting the 26 patients with the 
longest survival times as survivors. The mean survival time for the cohort after applying Method 
6.4.2 is 2.59 years. 
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Figure A6.1 
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Kaplan-Meier survival curve for 81 CELT PBC patients where expected 
individual patient survival is predicted assuming the 26 patients with the 
longest survival times survive (Method 6.4.2) 
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A6.1.3 Method 6.4.3: Probabilistic Sensitivity Analysis (PSA) 
Table A6.3 presents the results from one PSA simulation run. Each patient's predicted outcome 
is estimated using information from the expected non-transplant survival probability at five 
years. As with the previous two methods, survivors have an expected survival length of five 
years and deaths a survival length equivalent to their predicted survival from the PSC Mayo 
prognostic model. 
Figure A6.2 presents the Kaplan-Meier survival curve after applying PSA for one simulation run. 
The mean survival time for the cohort after applying Method 6.4.3 is 2.70 years. 
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Figure A6.2 Kaplan-Meier survival curve for 81 eEL T PBe patients where expected 
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individual patient survival is predicted using PSA to predict individual patient 
outcomes 1 (Method 6.4.3) 
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1 Results from one simulation run 
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Table A6.1 
Patient 10 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
Estimating individual survival outcomes for 81 eEL T PBe patients assuming that the probability of survival equivalent for all patients, 
random selection of survivors (p = 0.315) 
pac Mayo estimated Simulated patient Estimated survival Patient 10 PSC Mayo estimated Simulated patient Estimated survival 
survival length outcome length survival length outcome length 
3.42 0 3.42 41 1.73 0 1.73 
1.72 S 5.00 42 2.45 0 2.45 
3.19 0 3.19 43 0.45 S 5.00 
2.99 0 2.99 44 0.56 0 0.56 I 
2.17 0 2.17 45 2.89 0 2.89 
4.32 0 4.32 46 1.30 S 5.00 
4.92 S 5.00 47 0.27 S 5.00 
0.47 0 0.47 48 0.85 0 0.85 
0.12 0 0.12 49 0.78 0 0.78 
0.19 0 0.19 50 1.60 S 5.00 
3.01 0 3.01 51 4.53 0 4.53 
2.13 0 2.13 52 0.22 S 5.00 
4.61 0 4.61 53 4.27 0 4.27 
3.80 S 5.00 54 1.40 S 5.00 
4.62 S 5.00 55 0.54 S 5.00 
1.27 0 1.27 56 2.82 S 5.00 
4.24 0 4.24 57 0.70 0 0.70 
3.52 S 5.00 58 0.16 0 0.16 
0.91 0 0.91 59 0.28 0 0.28 
2.85 0 2.85 60 2.10 0 2.10 
0.13 0 0.13 61 4.67 0 4.67 
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Table A6.1 (continued)Estimating individual survival outcomes for 81 CELT PBC patients assuming that the probability of survival equivalent for all 
patients, random selection of survivors (p = 0.315) 
Patient 10 PSC Mayo estimated Simulated patient Estimated survival Patient 10 PSC Mayo estimated Simulated patient Estimated survival 
survival length outcome length survival length outcome length 
22 4.23 0 4.23 62 2.75 0 2.75 
23 0.21 S 5.00 63 3.96 0 3.96 
24 2.93 0 2.93 64 3.47 S 5.00 
25 0.70 0 0.70 65 3.32 0 3.32 
26 1.54 0 1.54 66 4.06 S 5.00 
27 0.13 0 0.13 67 0.44 0 0.44 
28 0.53 0 0.53 68 4.49 0 4.49 
29 3.95 0 3.95 69 1.68 0 1.68 
30 4.84 0 4.84 70 4.63 S 5.00 
31 3.40 S 5.00 71 4.45 S 5.00 
32 4.38 0 4.38 72 0.37 0 0.37 
33 2.03 S 5.00 73 2.79 0 2.79 
34 4.13 0 4.13 74 2.15 0 2.15 
35 3.73 0 3.73 75 4.06 S 5.00 
36 1.29 0 1.29 76 0.73 0 0.73 
37 2.60 0 2.60 77 0.22 S 5.00 
38 0.77 0 0.77 78 1.06 0 1.06 
39 0.16 0 0.16 79 2.66 0 2.66 
40 3.42 0 3.42 80 3.14 0 3.14 
81 3.54 0 3.54 
-
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Table A6.2 Estimating individual survival outcomes for 81 CELT PBC patients assuming that the 26 patients with the longest survival times survive (PBC 
Mayo prognostic model) 
Patient 10 PBC Mayo estimated Simulated patient Estimated Patient 10 PBC Mayo estimated Simulated patient Estimated survival 
survival length outcome survival length survival length outcome length 
1 3.42 S 5.00 41 1.73 0 1.73 
2 1.72 0 1.72 42 2.45 0 2.45 
3 3.19 0 3.19 43 0.45 0 0.45 
4 2.99 0 2.99 44 0.56 0 0.56 
5 2.17 0 2.17 45 2.89 0 2.89 
6 4.32 S 5.00 46 1.30 0 1.30 
7 4.92 S 5.00 47 0.27 0 0.27 
8 0.47 0 0.47 48 0.85 0 0.85 
9 0.12 0 0.12 49 0.78 0 0.78 
10 0.19 0 0.19 50 1.60 0 1.60 
I 
11 3.01 0 3.01 51 4.53 S 5.00 
12 2.13 0 2.13 52 0.22 0 0.22 
13 4.61 S 5.00 53 4.27 S 5.00 
14 3.80 S 5.00 54 1.40 0 1.40 
15 4.62 S 5.00 55 0.54 0 0.54 
16 1.27 0 1.27 56 2.82 0 2.82 
17 4.24 S 5.00 57 0.70 0 0.70 
18 3.52 S 5.00 58 0.16 0 0.16 I 
19 0.91 0 0.91 59 0.28 0 0.28 
20 2.85 0 2.85 60 2.10 0 2.10 
21 0.13 0 0.13 61 4.67 S 5.00 
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Table A6.2 (continued)Estimating individual survival outcomes for 81 CELT PBC patients assuming that the 26 patients with the longest survival times 
survive (PBC Mayo prognostic model) 
Patient 10 PBC Mayo estimated Simulated patient Estimated Patient 10 PBC Mayo estimated Simulated patient Estimated survival 
survival length outcome survival length survival length outcome length 
22 4.23 S 5.00 62 2.75 0 2.75 
23 0.21 0 0.21 63 3.96 S 5.00 
24 2.93 0 2.93 64 3.47 S 5.00 
25 0.70 0 0.70 65 3.32 0 3.32 I 
26 1.54 0 1.54 66 4.06 S 5.00 
27 0.13 0 0.13 67 0.44 0 0.44 
28 0.53 0 0.53 68 4.49 S 5.00 
29 3.95 S 5.00 69 1.68 0 1.68 
30 4.84 S 5.00 70 4.63 S 5.00 
31 3.40 0 3.40 71 4.45 S 5.00 
32 4.38 S 5.00 72 0.37 0 0.37 
33 2.03 0 2.03 73 2.79 0 2.79 
34 4.13 S 5.00 74 2.15 0 2.15 
35 3.73 S 5.00 75 4.06 S 5.00 
36 1.29 0 1.29 76 0.73 0 0.73 
37 2.60 0 2.60 77 0.22 0 0.22 
38 0.77 0 0.77 78 1.06 0 1.06 
! 39 0.16 0 0.16 79 2.66 0 2.66 
40 3.42 S 5.00 80 3.14 0 3.14 
81 3.54 S 5.00 
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Table A6.3 Estimating individual survival outcomes for 81 CELT PBC patients using information from the individual patient survival 
probabilities from the PBC Mayo prognostic model to estimate survival (Method 6.4.3: PSA) 
Patient PSC Mayo survival PSC Mayo Simulated Estimated Patient PSC Mayo survival PSC Mayo Simulated Estimated 
10 probability at five estimate patient survival length 10 probability at five estimate patient survival length 
years survival length outcome years survival length outcome 
1 0.48 3.42 S 5.00 41 0.11 1.73 0 1.73 
2 0.11 1.72 0 1.72 42 0.24 2.45 0 2.45 
3 0.42 3.19 S 5.00 43 0.01 0.45 0 0.45 
4 0.37 2.99 0 2.99 44 0.002 0.56 0 0.56 
5 0.19 2.17 0 2.17 45 0.34 2.89 S 5.00 
6 0.76 4.32 S 5.00 46 0.05 1.30 0 1.30 
7 0.97 4.92 S 5.00 47 0.000 0.27 0 0.27 
8 0.001 0.47 0 0.47 48 0.01 0.85 0 0.85 
9 0.000 0.12 0 0.12 49 0.01 0.78 0 0.78 
10 0.000 0.19 0 0.19 50 0.09 1.60 0 1.60 
11 0.37 3.01 0 3.01 51 0.83 4.53 S 5.00 
12 0.18 2.13 0 2.13 52 0.000 0.22 0 0.22 
13 0.86 4.61 S 5.00 53 0.74 4.27 S 5.00 
14 0.59 3.80 S 5.00 54 0.06 1.40 0 1.40 
15 0.86 4.62 S 5.00 55 0.002 0.54 D 0.54 
16 0.05 1.27 0 1.27 56 0.32 2.82 D 2.82 
17 0.73 4.24 S 5.00 57 0.01 0.70 D 0.70 
18 0.51 3.52 S 5.00 58 0.000 0.16 D 0.16 
19 0.02 0.91 0 0.91 59 0.000 0.28 0 0.28 
20 0.33 2.85 0 2.85 60 0.17 2.10 D 2.10 
-
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Table A6.3 (continued)Estimating individual survival outcomes for 81 CELT PBC patients using information from the individual patient survival 
probabilities from the PBC Mayo prognostic model to estimate survival (Method 6.4.3: PSA) 
Patient PSG Mayo survival PSG Mayo Simulated Estimated Patient PSG Mayo survival PSG Mayo Simulated Estimated 
10 probability at five estimate patient survival length 10 probability at five estimate patient survival length 
years survival length outcome years survival length outcome 
21 0.000 0.13 0 0.13 61 0.88 4.67 S 5.00 
22 0.73 4.23 S 5.00 62 0.31 2.75 0 2.75 
23 0.000 0.21 0 0.21 63 0.64 3.96 0 3.96 
24 0.35 2.93 0 2.93 64 0.50 3.47 S 5.00 
25 0.01 0.70 0 0.70 65 0.46 3.32 0 3.32 
26 0.08 1.54 0 1.54 66 0.68 4.06 S 5.00 
27 0.000 0.13 0 0.13 67 0.001 0.44 0 0.44 
28 0.002 0.53 0 0.53 68 0.82 4.49 S 5.00 
29 0.64 3.95 S 5.00 69 0.10 1.68 S 5.00 
30 0.94 4.84 S 5.00 70 0.87 4.63 S 5.00 
31 0.48 3.40 S 5.00 71 0.81 4.45 0 4.45 
32 0.78 4.38 S 5.00 72 0.000 0.37 0 0.37 
33 0.16 2.03 0 2.03 73 0.32 2.79 0 2.79 
34 0.70 4.13 0 4.13 74 0.18 2.15 S 5.00 
35 0.57 3.73 0 3.73 75 0.68 4.06 S 5.00 
36 0.05 1.29 0 1.29 76 0.01 0.73 0 0.73 
37 0.28 2.60 S 5.00 77 0.000 0.22 0 0.22 
38 0.01 0.77 0 0.77 78 0.03 1.06 0 1.06 
39 0.00 0.16 0 0.16 79 0.29 2.66 0 2.66 
40 0.48 3.42 0 3.42 80 0.41 3.14 0 3.14 
81 0.52 3.54 S 5.00 
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Chapter 6 Predicting Individual Patient Outcomes 
the PSC Mayo prognostic model is used as a starting point. The mean probability of 
survival at five years is 0.315 for the 81 PSC CELT patients. 
The mean survival probability can be expressed statistically by assuming that the 
probability of survival follows a binomial distribution, where the probability of an 
individual patient surviving to five years is 0.315. Formally, this probability is written as 
PSi = 0.315, where i = 1 to 81 refers to the patient identifier. A random number 
generator is used to simulate the expected outcome for each individual patient in a 
cohort. This random number generator produces a number, either zero or one, for each 
patient. A survival prediction can be generated for each of the 81 cases in the PSC 
CELT cohort by assuming that the occurrence of a one denotes that the individual will 
survive the full study period without transplantation and a zero denotes a patient who 
will die within the five-year study period. 
The following computer syntax is used in S-PlUS [S-PlUS 6, 2001] to simulate this 
process: 
rbinorn{81, 1, 0.315) 
For one simulation run, a series of estimated events for each of the 81 pse patients 
are obtained, as illustrated below: 
0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0, 1,0,0,0,0, 1,0,0,0,0,0,0,0, 1,0, 1,0,0, 
0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,0,1, 1, 1,0,0,0,0,0,0,0, 1,0, 1,0,0,0, 1, 
1,0,0,0,1,0,1,0,0,0,0 
The number and proportion of survivors in the cohort can then be calculated. For the 
simulation run presented above, the number of survivors equals 22, giving an 
estimated five-year survival of 27% (for this simulation run the percentage of survivors 
is lower than the "true" percentage of 31.5%). 
It is assumed that all estimated survivors survive the full study period and have a 
survival length of five years. The survival length for patients predicted to die is 
estimated by applying the PSC Mayo prognostic model to the pse eEL T cohort. The 
mean non-transplant survival length for the pse eEL T cohort can then be estimated 
from the area under the Kaplan-Meier survival curve. 
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